CONCORD BIOTECH

ANNUAL REPORT 2024-25

CONCORD BIOTECH
CELEBRATING
25TH
ANNIVERSARY













Innovate in cells...
Impact the world





Our Approach To Reporting

At Concord Biotech Limited, we are dedicated to reporting the financial and non-financial performance of our Company in compliance with the regulatory requirements of the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It offers a comprehensive and detailed overview of our business performance, showcasing how we manage our various stakeholders and create shared value through our corporate governance strategy and risk management, stakeholder engagement, and sustainability initiatives.

Frameworks and Guidelines

The content and structure of this Annual Report are aligned with the regulatory requirements of NSE and BSE listings, as well as SEBI compliances. We are dedicated to adopting best practices in corporate reporting to promote transparency and enhance stakeholder engagement.

Scope and Boundary

This Annual Report comprises all the relevant aspects of the operations of Concord Biotech Limited. It also consists of the desired statutory disclosures and audited annual financial statements for the year ended 31st March 2025.

Assurance

Concord Biotech Limited's Board of Directors and its Committees have thoroughly reviewed the Report, ensuring its materiality, accuracy, and balance of disclosures. The Board opted not to seek independent assurance for the Report beyond the annual financial statements.

Corporate Overview

Innovate in cells... Impact the world 01

Statement From The Chairman's Desk 04

About Concord Biotech Limited 06

What makes us unique 08

Message From The Joint Managing Director 10

Key Performance Indicators 12

The evolving landscape 14

Risk management 16

Our value creation model 18

Intellectual Capital 20

Manufactured Capital 22

Financial Capital 24

Human Capital 25

Natural Capital 26

Social & Relationship Capital 28

Our Esteemed Board 32

Management Reports

Director's Report 36

Corporate Governance Report 54

Business Responsibility & Sustainability Reports 73

Financial Statements

Standalone Statements 115

Consolidated Statements 176

In an era where the environmental impact of industries is under intense scrutiny, prioritising sustainable innovation has become more crucial than ever. It is no longer a desirable add-on but a core necessity for corporations.

Fermentation-based pharmaceuticals- a revolutionary approach that embodies sustainability without compromising efficacy.

Fermentation-based API production leverages the natural metabolic processes of microorganisms. These microorganisms are engineered to produce complex molecules that can be used as APIs.

Fermentation is a sustainable and efficient method for producing a wide range of valuable compounds. It generates fewer harmful byproducts, operates under milder conditions, and utilizes cost-effective raw materials.

The process is highly scalable, enabling rapid production of large quantities of target molecules. Moreover, fermentation is capable of generating complex and biologically active compounds such as antibiotics, enzymes, and other specialized molecules that are essential in various industries. These advantages position fermentation as a key technology for advancing cleaner and smarter production solutions.



EMBRACE THE FUTURE OF SUSTAINABLE INNOVATION!

At Concord, we have strategically positioned our business on the sustainability platform and have diligently worked for over more than a quarter century to cultivate our expertise and competencies in biotechnology.

As we journeyed. . .


...we progressively created and scaled capacities that have cleared multiple stringent global regulatory audits such as the USFDA, EU GMP, WHO, MFDS (Korea), ANVISA (Brazil), FDCA , TMDA (Tanzania), DPML, United Arab Emirates Ministry of Health and Prevention, NMRA , FDA (Philippines), The Republic of Yemen and PMDA Japan.

...we established a strong presence across the complex fermentation value chain to create a wide product portfolio of 30+ fermentation-based APIs and close to 100 approved Formulation products across markets.

...we widened our global footprint to 70+ countries, including regulated markets and catering to 250+ customers.

...and we graduated to a podium position in the complex biotechnology space.

While we recognise it was a difficult choice and an even more demanding journey, the results were undoubtedly worth the challenges and transformative experiences along the way.



As we reaffirm our dedication to widening our capabilities in fermentation-based APIs and formulations, we realise that our penchant for excellence will not just be a step forward in advancing medical success; it's a leap toward a healthier planet and thriving communities!



STATEMENT FROM THE **CHAIRMAN'S DESK**

Our strategic initiatives, focused on enhancing our commercialised APIs and pipeline products through our expertise in precision fermentation and injectable formulations, are crucial to our long-term growth. **These efforts not only secure our sustained success but also play a significant role in advancing global healthcare standards.**



SUDHIR VAID, *Chairman*

DEAR STAKEHOLDERS,

As we celebrate Concord Biotech's 25th anniversary, I am filled with immense pride and gratitude for the remarkable journey we have undertaken in the biotechnology field.

OVER the past quarter-century, our unwavering commitment to innovation and excellence has driven us to attain unparalleled expertise in the fermentation process, enabling the development of groundbreaking new products and continuous process improvements. These achievements have not only propelled us to the forefront of the global fermentation industry but have also solidified our leadership position.

We have built a legacy of scientific advancement and industry leadership that will continue to inspire and guide us in the future. As we draw to a close a significant milestone in our journey, we reflect with profound pride and satisfaction on our accomplishments while looking forward to an even more promising future.

In this context, I am privileged to share our progress and the vision that drives us forward, framed around key themes that emphasises our global presence and the broader industry landscape and define our path.

The Global Biotechnology sector is thriving

The global biotechnology sector is experiencing rapid growth, driven by advancements in biotechnological research and development. Valued at approximately US$ 1.38 trillion in 2023, the market is projected to reach around US$ 4.25 trillion by 2033, expanding at a compound annual growth rate (CAGR) of 11.8%. This growth is fuelled by increasing investments in R&D, the rising prevalence of chronic diseases, and the growing demand for personalised medicine. Key areas of innovation include genetic engineering, bio-pharmaceuticals, synthetic biology, and bio-based solutions aimed at enhancing human health, food security, and environmental sustainability. The integration of AI-driven drug discovery, CRISPR gene-editing, and sustainable bio-manufacturing is reshaping the industry, enabling faster drug development and more precise medical treatments. As a result, the biotechnology sector is poised to play a crucial role in addressing global healthcare challenges and advancing future healthcare standards.

At Concord, we are pleased to have established a strong presence in this dynamic ecosystem, utilising state-of-the-art scientific advancements to compete globally. Our international collaborations and expanding footprint across geographies exemplify our commitment to being one of the leading players in this transformative sector.

Trends shaping the Global Fermentation Industry

The global fermentation industry in the pharmaceutical sector is undergoing significant changes driven by several key trends. Precision fermentation technology is becoming increasingly important, allowing for the efficient production of complex biological molecules essential for next-generation bio-therapeutics. The integration of artificial intelligence and machine learning is optimising fermentation processes, improving yields, and reducing costs. Investment in fermentation technology is increasing, with significant funding directed towards research and development. Strategic partnerships between pharmaceutical companies and academic institutions are fostering innovation and expanding capabilities. Regulatory support and government initiatives promoting renewable resources and reducing carbon footprints are also shaping the industry's future.

At Concord, we are proactively addressing this gap. The recent investments in Palvella Therapeutics, Inc., a company incorporated in the USA, establish a partnership to produce rare dermatological pharmaceuticals. This strategic collaboration with other industry stakeholders will position us to meet the increasing demand and ensure our leadership in this wave of consolidation.

We have further strengthened our presence in the U.S. through the incorporation of Stellon Biotech Inc., which

will focus on the marketing, distribution, and commercialization of Concord Biotech's pharmaceutical and biotech products in the U.S. market. Stellon will manage end-to-end commercial operations, including warehousing, inventory planning, order processing, customer service, and regulatory compliance.

Additionally, we incorporated Concord Lifegen Limited as a wholly owned subsidiary to further strengthen our domestic marketing, sales, and distribution capabilities for pharmaceutical products. This move will allow us to establish a sharper market focus, enhance customer engagement, and create a stronger brand presence in India.

Biotechnology is a priority sector for governments globally

Governments around the world are increasingly recognising the potential of biotechnology to propel both economic and environmental advancement. In the United States, initiatives such as the National Biotechnology and Bio-manufacturing Initiative facilitate funding opportunities and encourage innovation. Domestically, India's Bioe3 policy and increased budgetary allocations indicate robust support for the biotechnology sector. This governmental support acts as a favourable impetus for our progress. We actively engage with policymakers to ensure our growth aligns with national priorities, enabling us to leverage available incentives and make meaningful contributions to a sustainable bio-economy.

USA policy updates for the Indian pharma industry

Bio-Secure Act: Alongside domestic growth, the industry is also adapting to global regulatory changes, such as the U.S Bio-Secure Act, which aims to reduce dependence on foreign biotech suppliers, particularly from China. This shift, combined with the China plus one strategy, presents an opportunity for Indian pharmaceutical companies to strengthen their foothold in the U.S market by aligning with stringent quality and compliance standards.

Newly introduced US tariffs: Recent changes in U.S. trade policy have introduced new tariffs that may affect pharmaceutical exports, including those from India. While a temporary exemption was granted, future adjustments could lead to increased costs and potential disruptions. In response, companies are exploring strategies to mitigate these impacts, such as enhancing operational efficiencies and diversifying into new markets. These developments coincide with broader global shifts, including the China-plus-one strategy and the Bio-Secure Act, which are opening new avenues for growth. Concord Biotech is well-positioned to leverage these opportunities, supported by its robust manufacturing infrastructure across both API and formulation segments. Its facilities hold approvals from leading global regulatory agencies such as the U.S. FDA, EMA, and WHO, reflecting a strong commitment to quality and compliance. This reputation for reliability and excellence makes Concord a preferred partner for CDMO collaborations, enabling it to expand its global footprint and contribute meaningfully to the evolving pharmaceutical landscape.

Expanding to elevate care

In this context, our strategic initiatives, such as strengthening our pipeline of APIs driven by our expertise in precision fermentation and formulations, particularly injectables, ensure long-term growth and contribute to advancing future healthcare standards globally.

Our precision fermentation platform is producing numerous promising candidates to support this commitment to innovation and expansion further. I am particularly enthusiastic that we received approvals from the US FDA to market Teriflunomide Tablets, 7 mg and 14 mg, for the treatment of relapsing forms of multiple sclerosis in the United States. This is an important addition to our portfolio and underscores our commitment to bringing high-quality therapies to global markets. These innovations exemplify our dedication to translating scientific advancements into tangible impacts. Moreover, Concord has more than 10 products in the pipeline, which are planned to be commissioned in the next 5-7 years.

Expanding formulation horizon through injectable

We are broadening our formulation capabilities with a dedicated emphasis on injectables. The worldwide demand for injectable bio-pharmaceuticals, including vaccines, monoclonal antibodies, and gene therapies, is experiencing substantial growth, propelled by their efficacy and precision. We have significantly invested in advanced sterile manufacturing facilities to address this demand. Our recently commissioned injectable line will augment our product offerings, capitalising on Concord's fermentation expertise and establishing us as a reputable partner in providing life-saving treatments on a global scale.

In closing

As I reflect on our journey, I recognise that Concord is strategically positioned for a promising future within a dynamic global biotechnology landscape. Our successes are built upon three fundamental pillars: innovation, collaboration, and purpose. Therefore, in light of these challenges, I firmly assert that our integrated model and strategic focus on domestic and emerging markets empower us to adeptly navigate volatility. We are building a lasting legacy rooted in advancing human health, fostering sustainability, and creating enduring value for all stakeholders.

To our shareholders, I extend my gratitude for your trust; to our employees, your commitment propels us forward; and to our clients, I appreciate your enduring confidence during these challenging times. Collectively, let us confront the future with resilience, pragmatism, and steadfast optimism, for I am convinced that our best days lie ahead.

Yours Sincerely,

SUDHIR VAID
Chairman



ABOUT **CONCORD BIOTECH LIMITED**

Our Excellence, Built on Over 25 Years of Relentless Dedication, Leads the Way in Fermentation-based APIs and Formulations

Concord Biotech Limited (Concord) is a biopharmaceutical company driven by research and innovation. Since its inception in 2000, Concord has transformed from a single-product entity into a comprehensive solution provider, excelling in the production of Active Pharmaceutical Ingredients (APIs) through fermentation, semi-synthetic processes, and finished formulations. Today, Concord delivers a wide range of products across diverse therapeutic segments.

Based in Ahmedabad, India, we run four advanced manufacturing facilities in Gujarat, driven by a team of skilled and experienced professionals. Through deep technical expertise, capital-intensive investments, optimal scale, regulatory clearances and efficient plant design, we have built formidable entry barriers-overcoming complex industry challenges and establishing fermentation capabilities that are difficult to replicate. This strategic differentiation has earned us a leadership position in India and globally.

Vision

Create products through the Biotechnology route and Service offerings that enrich the lives of people by continually building on our expertise in Biotechnology.

Mission

We strive to be a global power in the field of biotechnology-based products through research and development to create sustainable earnings growth and to establish long-term business success. We continue to reinforce our commitment to safety, health, and the environment. We endeavour for an environment where creativity and effectiveness are encouraged with the technologies for the niche market.

A Shade of Excellence in Numbers

100+
Approved formulation products across markets
Approved formulation products across markets

5+
ANDAs approved for products from our facilities


Shared Values

Driving **Continuous Progress**
We constantly explore new processes, research, and concepts while adopting cutting-edge technologies, which fuels our pursuit of long-term success.

Setting **Global Standards**
We adhere to the highest standards, fulfilling customer expectations and improving their quality of life.

Excellence **at Core**
We are attaining business excellence from research to final product delivery by harnessing teamwork in a time-bound manner.

Our **Foundation**
We showcase result-oriented actions both at the individual and team levels, which forms the foundation of our work culture.



Our **Moral Compass**
We maintain the highest moral and ethical standards, prioritising honesty in both personal and professional conduct.

Leading **the Way**
We recognise the importance of sensitivity, compassion, and kindness towards our people, business associates, and society.

Dedicated **to Deliver**
We perform our duties with exemplary moral responsibility and accountability across all functions with a solution-finding mindset.

5+
Molecules for which we hold a 20% plus market share globally

37.8%
Revenue contribution from top 10 customers in FY25

27%
Return on Capital Employed

What makes us unique?


Presence in every step of the fermentation value chain

At Concord, we are a global leader in fermentation-based API manufacturing, excelling in this specialised field with unparalleled expertise. Our end-to-end capabilities span the entire complex fermentation value chain, ensuring seamless execution from R&D to commercialisation.

Our integrated fermentation value chain significantly enhances efficiency, quality, and supply chain resilience throughout the entire process, facilitating seamless transitions from laboratory research to large-scale production. This system not only reduces costs and accelerates time-to-market but also ensures consistent compliance with regulatory standards.

Furthermore, it nurtures innovation, improves profit margins, and provides a substantial competitive advantage. Additionally, the integration of these processes promotes sustainability by minimising waste and enhancing energy efficiency, thereby effectively meeting market demands and regulatory compliance.

Our integrated presence across the fermentation value chain:



Our Key Strengths in the Value Chain



- **In over 25 years of experience developing and producing specialised, complex molecules.**
- **Fermentation capacity of 1250 m^3 across two advanced API facilities.**
- **Product portfolio of more than 30+ fermented-based APIs.**
- **Considerable market share in the global immunosuppressants, oncology and anti-infectives.**

High entry barriers

Over the years, we have created entry barriers that protect our market share and profitability by deterring competitors from entering the market.

Our fermentation-based API vertical presents high barriers to entry.

- The complex nature of the sector
- Advanced technical skills restrict many from entering the field
- Substantial financial investment is needed for extensive infrastructure
- Difficulty in scaling operations limits entry to even major players
- Long gestation period

We leverage our strong capabilities to excel in the fermentation-based API field, characterised by:

- A diverse portfolio across various therapeutic areas
- Scaled manufacturing facilities with a consistent regulatory compliance record
- Flexible plant configurations ensuring robust operational efficiency

We further up the ante through our:

- Backward integration to the KSM level
- Regulatory approvals for global markets
- Creating a wide range of fermentation-based APIs.

Superior position in the fermentation-based API business

We are a leading player in the Active Pharmaceutical Ingredient (API) sector, with specialized expertise in fermentation-based APIs across key therapeutic areas including immunosuppressants, oncology, anti-infectives, and antifungals. Our strong product portfolio leverages niche expertise and backward integration for Key Starting Materials (KSMs), ensuring efficiency and quality. Our focus on expanding wallet share with existing customers and increasing our global presence highlights our growth strategy. Led by industry veterans and committed to innovation, we have become a trusted leader in biotechnology, providing high-quality APIs that enhance medicine efficacy and promote a healthier future.

Wide range of product portfolio

Our diverse range of fermentation products gives us a competitive edge globally. Covering various therapeutic areas, it showcases our advanced fermentation technologies and innovative formulations. This strong offering, paired with top-notch manufacturing facilities, ensures quality, scalability, and compliance with international regulations. By meeting healthcare needs, we offer high-quality, cost-effective solutions, establishing us as a trusted partner and leader in the pharmaceutical industry, exceeding competitors in global demands.

Expansive Global presence

Our global presence offers a key advantage, serving over 250+ customers in 70+ countries with our APIs and formulations. This expands our market reach, diversifies revenue, provides varied resources, fosters collaboration, enhances brand recognition, and builds resilience against market fluctuations. It also streamlines distribution, accelerates regulatory approvals, and shares innovative practices across regions.

We supply formulations primarily in India through government and corporate hospitals, while in the US and emerging markets in Asia, Africa, and Latin America, we rely on distributor collaborations. Our APIs are supplied exclusively to pharmaceutical companies worldwide under a B2B model. Our strong focus on product quality and diverse offerings through an extensive global network allows us to meet client needs globally.



MESSAGE FROM THE **JOINT MANAGING DIRECTOR**

As we transition into fiscal year 2026, Concord is well-positioned for accelerated growth, supported by our enhanced capabilities, strategic investments, and **steadfast commitment to innovation and sustainability**



DEAR SHAREHOLDERS,

It is with great pleasure that I present the key highlights of Concord's performance for FY25. This year has witnessed substantial strategic advancements, notable operational achievements, and a steadfast commitment to sustainable growth. These factors position us favourably to attain our long-term objective of establishing ourselves as a market leader in fermentation-based active pharmaceutical ingredients (APIs) and formulations. I am pleased to outline our significant accomplishments and the promising focus areas we have identified for the current year and the future.

ANKUR VAID, *Joint Managing Director & CEO*

Financial performance

In FY25, our revenue from operations was ₹1,200.1 crore, exemplifying a remarkable 18% year-over-year growth. Our profitability remained healthy as evidenced by our EBITDA margin standing at 42.1%, and an increase of 21% in profit after tax (PAT) to ₹371.6 crore, accompanied by a PAT margin enhancement of 70 basis points to 31.0%. Furthermore, as of 31st March 2025, our debt-free status has significantly strengthened our financial position, enabling us to confidently pursue strategic growth opportunities.

From Vision to Value, across every milestone

Our journey of transforming strategic intent into measurable outcomes reflects our substantial achievements during FY25. I am pleased to share the significant progress we have made. Our unwavering commitment to innovation, sustainability, regulatory excellence, and the expansion of our global presence has been instrumental in shaping our success. These initiatives not only reinforce our leadership within the industry but also establish a robust foundation for sustainable growth and long-term value creation.

Broader horizon, diminishing concentration

In FY25, we made significant strides in diversifying our market presence and reducing customer concentration. Our formulation business saw robust growth, with revenues rising by 38% year-on-year for the full year ended March 2025, driven by strong acceptance across domestic, emerging and regulated markets. We expanded our sales and marketing team to over 200 members, enabling deeper market penetration in India and opportunistic forays into regulated markets. Simultaneously, our API business grew with new customer acquisitions and strengthened relationships with existing partners. By targeting niche markets with complex, fermentation-based products, we steadily increased our global market share while reducing reliance on a concentrated customer base, ensuring sustainable and diversified revenue streams.

Launching our state-of-the-art Injectable facility

In FY25, we commissioned a state-of-the-art injectable facility at Valthera, beginning commercial production in Q4 FY25. This marks a key step in expanding our portfolio to include injectables alongside in-house API production. The plant will initially launch several products targeting the domestic market, with plans for emerging markets in FY26. This vertical strengthens Concord's position as a fully integrated player (**API + oral + injectable formulations**) while capitalising on the tender-driven growth opportunities.

Unlocking new opportunities

The Contract Development & Manufacturing Organisation (CDMO) segment emerged as a key growth driver for Concord in FY25. Initially viewed as a long-term opportunity, the increasing industry interest and growing number of inquiries have prompted us to reposition CDMO as a medium-term growth engine. We are actively engaging with potential partners and exploring collaborations with large innovators and established generic companies. Our expertise in fermentation-based APIs, complex formulations, and high-value products positions us as a reliable CDMO partner. Our proactive approach ensures we are well-placed to capitalise on this growing opportunity.

Strategic investment in U.S-based Company: A new horizon

In line with our strategy to forge meaningful global partnerships, we invested in Palvella Therapeutics Inc., a U.S-based biotechnology company focused on rare genetic skin diseases. This investment, made in FY25, aligns with our long-term growth objectives and paves the way for a collaborative partnership centred on the manufacturing and commercialisation of QTORIN, a therapy designed to address high unmet medical needs in dermatology. By strengthening our relationship with Palvella, we aim to expand our footprint in global markets and enhance our supply chain for innovative, high-value products.

Building on our momentum, we have further reinforced our presence in the United States through the incorporation of Stellon Biotech Inc. This newly established entity will spearhead the marketing, distribution and commercialization of Concord Biotech's pharmaceutical and biotech products in the U.S. Stellon will manage end-to-end commercial operations including warehousing, inventory planning, order processing, customer service, and regulatory compliance, while maintaining our uncompromising standards of quality and adherence to regulatory frameworks. It also opens avenues for strategic collaborations with affiliates and third-party partners. This initiative not only marks our direct commercial entry into a key global market but also supports our broader vision of expanding market access and unlocking greater value from our product pipeline across geographies.

Emphasising Sustainability: Investing in renewable energy for the Dholka unit

Sustainability remains at the core of our business strategy. We aim to significantly lower our carbon footprint by transitioning to renewable energy sources and contributing to global climate action initiatives. In FY25, we took a significant step toward reducing our environmental impact by acquiring a 26% equity stake in Cleanmax Everglades Private Limited. This investment is dedicated to powering our Dholka plant in Gujarat with 6.6 MW wind capacity and 3.3 MW DC solar capacities. Beyond environmental benefits, this move ensures long-term financial advantages through reduced energy costs and enhanced operational efficiency, reinforcing our commitment to responsible and sustainable growth.

Update on Regulatory Compliances

Our dedication to quality and regulatory compliance was reaffirmed through successful inspections conducted by regulatory authorities. Specifically, Concord underwent an inspection by US-FDA at our Dolka API facility (Unit I). This facility has also seen successful completion of the inspection by the EU-GMP and Russian GMP. Further, inspection by EU-GMP and Saudi Food & Drug Authority (SFDA) was carried out at Valthera facility, Additionally, we obtained approval from the U.S Food & Drug Administration (USFDA) for Teriflunomide Tablets in dosages of 7mg and 14mg, thus facilitating our entry into a US$402 million market within the United States and a global market valued at US$908 million. This development significantly enhances our position within regulated markets. Our facilities remain committed to maintaining our reputation as a reliable pharmaceutical partner to global pharmaceutical companies.

A fresh perspective

The Indian pharmaceutical industry is undergoing a transformative evolution driven by the China Plus One strategy, the Bio-Secure Act, and recent United States tariff policies. The China Plus One strategy enhances India's position as a reliable alternative manufacturing hub within the global Active Pharmaceutical Ingredient (API) market. The Bio-Secure Act mitigates reliance on Chinese bio-pharmaceuticals while promoting global partnerships, consequently amplifying the demand for Indian APIs. However, the newly announced United States tariff policy may increase costs associated with Indian exports to the United States, thereby affecting profit margins.

In spite of these formidable challenges, the sector is poised to benefit from heightened global trust and investment, thereby stimulating growth and innovation. The Indian Contract Development and Manufacturing Organisation (CDMO) sector is expected to thrive as international companies seek dependable alternatives to China. This shift is likely to serve as a catalyst for India's emergence as a potential leader in the global pharmaceutical landscape, ultimately contributing to economic growth and advancements in healthcare.

Looking ahead

As we transition into fiscal year 2026, Concord is well-positioned for accelerated growth, supported by our enhanced capabilities, strategic investments, and steadfast commitment to innovation and sustainability.

I wish to express my sincere gratitude to our employees, partners, and shareholders for their continued trust and support. We are developing a stronger, more resilient Concord equipped to take the lead in the global pharmaceutical landscape.

Yours Sincerely,

ANKUR VAID
Joint Managing Director & CEO




KEY PERFORMANCE INDICATORS

Our progress is a testament to our consistent endeavors to improve our commitment to excellence


We rigorously adhere to financial discipline, embodying a firm commitment to prudent management and visionary foresight. These fundamental pillars augmented our revenue and EBITDA, reinforced by the resilience of our robust cash flow generation.

Our prudent approach to capital structure positions us favourably for pursuing our growth ambitions. Our ongoing commitment of being Debt Free coupled with generating free cash flow, provides us with the financial stability required for further expanding our business portfolio.


Performance





Profitability




Stability


NET DEBT-EQUITY RATIO
(x)
0.09
0.05
0.02
0.00
0.00
FY21
FY22
FY23
FY24
FY25


DEBT SERVICE COVERAGE RATIO (DSCR)
(x)
9.76
7.14
10.32
13.52
59.84
FY21
FY22
FY23
FY24
FY25


NETWORTH
(₹ crore)
999.37
1103.22
1290.00
1526.65
1812.72
FY21
FY22
FY23
FY24
FY25


WORKING CAPITAL
(Days)
296.65
244.46
299.25
270.65
289.30
FY21
FY22
FY23
FY24
FY25


RETURN ON EQUITY
(%)
26.55
16.64
20.06
22.00
22.00
FY21
FY22
FY23
FY24
FY25



The Evolving Landscape

Transformative trends in Biotechnology through Fermentation

The global biotechnology market, particularly through the fermentation route, is being transformed by several key trends. AI and machine learning are revolutionising drug discovery and personalised medicine, while synthetic biology and advanced biomanufacturing are enhancing bio-based material production.

Fermentation technology is driving the development of sustainable and efficient production methods for complex molecules. Personalised medicine and genomics offer tailored treatments, and advances in cell and gene therapies provide new solutions for previously untreatable conditions. Additionally, there is a growing emphasis on sustainability and green biotech, pushing companies toward eco-friendly innovations to enhance social responsibility.



INDUSTRY POSITIVES

Precision Medicine
Using genetic profiling and biomarkers to develop targeted therapies tailored to individual patients leads to more effective treatments with fewer side effects.

Artificial Intelligence (AI)
Applying AI algorithms to analyse vast datasets, optimise clinical trials, and identify potential drug targets - accelerating drug discovery like never before.

Biologics and Biosimilars
The growing prominence of biopharmaceuticals like monoclonal antibodies and gene therapies, alongside a rising focus on developing biosimilars.

Digital Health Integration
Utilising digital tools like telemedicine, wearable devices, and mobile apps to improve patient engagement and monitor treatment outcomes.

Real-World Evidence (RWE)
Integrating real-world data from diverse sources to inform drug development and post-market surveillance.

Cell and Gene Therapies
Expanding research and development of cell-based therapies, including stem cell treatments, for conditions with limited treatment options.

Patient-Centric Clinical Trials
Designing clinical trials with patient needs at the forefront, including decentralised trial models and improved patient recruitment strategies.

Emerging Markets Growth
Increased focus on expanding access to medications in emerging markets due to rising healthcare demand and growing middle class.

Sustainability Initiatives
Incorporation of eco-friendly practices throughout the drug development and manufacturing process.

Data Analytics and Big Data
Leveraging big data to gain deeper insights into disease progression, identify new drug targets, and optimise treatment strategies.

Nanobiotechnology
The application of theranostics nanoparticles enables prompt diagnosis and treatment customisation.

Liquid biopsy
The global market for liquid biopsy is expected to grow from US$4.6 billion in 2024 to US$13.1 billion by 2029.



INDUSTRY CHALLENGES

High Cost of Drug Development
Balancing innovation with affordability concerns and managing pricing pressures.

Regulatory Complexity
Navigating evolving regulatory frameworks related to drug approval, data privacy, and clinical trial design.

Healthcare Gaps
Addressing disparities in healthcare access, particularly in emerging markets.

Intellectual Property Protection
Balancing patent expirations and generic competition while ensuring innovation.



India is spurring the Biotechnology space

The 2025-26 Union Budget demonstrates a strong commitment to advancing India's biotechnology sector, with an increased allocation of ₹20,000 crore for the Department of Biotechnology (DBT). This funding will support biomanufacturing, biotech research, and innovation under the National Manufacturing Mission, which will promote 'Make in India' across all industry sizes.

OUR **STRATEGIC BLUEPRINT**

A Roadmap to Sustainable Growth

We strive to broaden our footprint, elevate our product offerings, and strengthen our presence in key markets. Our unwavering commitment to excellence permeates every facet of our strategic initiatives, ensuring we deliver value to our stakeholders while driving long-term success.



STRATEGY 1

EXPANDING OUR PRODUCT BASKET

Where we are

We are one of the leading global manufacturers of Fermentation-based APIs offering 30+ fermentation-based APIs

Our aim

We have more than 10 new API Products in pipeline that we intend to commercialise over the next five to seven years. These products focus on oncology, anti-infectives, and antibacterial treatments



STRATEGY 2

WIDENING OUR THERAPEUTIC COVERAGE

Where we are

Our product portfolio spans multiple therapeutic areas, with a particularly strong presence in immunosuppressants, anti-infectives, and oncology, driven by our expertise in fermentation-based APIs.

Our aim

We aim to diversify our offerings by positioning ourselves as a comprehensive provider of fermentation-based API products across multiple therapeutic areas. This strategy not only broadens our opportunity landscape but also strengthens our relationships with existing and potential customers, fostering sustainable growth



STRATEGY 3

EXPANDING OUR GEOGRAPHIC FOOTPRINT

Where we are

We serve 250+ customers in 70+ nations across the globe. Our global presence has been established through collaborations and tailored distribution models.

Our aim

We aim to expand our sales and distribution network globally with specialised teams, targeting key markets such as the United States, Europe, Asia, Africa, and Latin America. By intensifying marketing efforts through partnerships and distributor models, and broadening our product portfolio, we strengthen our presence and foster sustainable growth.



STRATEGY 4

STRENGTHENING OUR FORMULATION BUSINESS

Where we are

We offer 100+ products across chronic and lifestyle therapies, leveraging our oral solid dosage (OSD) delivery platform (tablets, capsules, oral suspensions). With our newly commissioned injectable plant, we are now equipped to expand our capabilities to include injectable formulations as well.

Our aim

We will continue to expand our portfolio through our own development and in-licensing to address existing and new-age lifestyle ailments. Starting with our established oral solid dosage (OSD) business, we will further broaden our formulation delivery platform to include injectables, with our injectable plant already commissioned.

Risk Management

At Concord, risk management is crucial for operational resilience and success. We identify, assess, and mitigate risks to protect our business and ensure growth. Through strong controls and constant monitoring, we aim to minimise disruptions, maintain compliance, and improve business performance.

Our risk management framework covers:



BUSINESS & FINANCIAL RISKS

Credit Risk Management

At Concord, we understand that delayed payments can cause cash flow issues affecting our financial stability.

Mitigation: To address this, we implement strong credit management practices, including monitoring receivables, setting credit limits, and conducting credit assessments. We also proactively manage Expected Credit Loss (ECL), ensuring accurate financial planning. By managing credit risk, we aim to sustain productivity and financial health while minimising operational disruptions.

Foreign Exchange Risk Management

Fluctuations in exchange rates can lead to higher Cost of Goods Sold and potentially lower profit margins. Companies may need to adjust pricing in response to these changes, making financial forecasting more challenging.

Mitigation: To address these risks, we have implemented a comprehensive foreign exchange policy. This policy guides our actions and ensures we manage foreign exchange risks effectively, maintaining financial stability and supporting our strategic objectives.

₹244.5 crore

Cash generated from operations in FY25

OPERATIONAL RISKS

Capacity Utilisation & Risk Management

Inefficient capacity utilisation raises per-unit costs as fixed costs spread over fewer units, increasing production expenses. It strains resources, leading to higher maintenance costs and possible equipment failures. Additionally, it harms customer satisfaction due to lost sales or poor service.

Mitigation: To mitigate these risks, we fill capacity with sales orders and CDMO projects, optimising resource use and ensuring customer satisfaction.

Production & Supply Chain Risk Management

Disruptions in production can stop production lines, causing delays in both production and sales, which may result in cash flow problems. Such interruptions could lead to surplus finished goods or insufficient raw materials, creating inefficient resource use, including labour and equipment. Although raw materials are abundantly available in India and other regions, macroeconomic factors can threaten their availability.

Mitigation: To address these challenges, we transport high-value finished products by air to guarantee prompt delivery.

Customer Base Diversification Risk Management

High customer concentration can increase customers' bargaining power, leading to pressure for lower prices and a greater impact from changes in customer relationships.

Mitigation: To ensure stability and growth, we are expanding our customer base by targeting new markets, enhancing marketing efforts, and leveraging data analytics. Notably, our reliance on the top 10 customers has decreased from 48.2% in FY 20-21 to 37.8% in FY 24-25, demonstrating successful diversification and a reduced dependence on a few customers.

REGULATORY RISKS

Regulatory & Compliance

Quality control failures can lead to product recalls, increased costs, and damage to our brand. Additionally, regulatory scrutiny may halt production, while patent infringements can result in costly legal issues. Delays in license renewal can cause downtime and decrease productivity. Non-compliance can result in hefty fines, restrict market access, and disrupt supply chains.

Mitigation: To mitigate these risks, we invest in compliance, training, and quality assurance. We follow SOPs for quality and regulatory compliance, foster accountability, conduct audits, and consult legal experts. We also ensure timely payments to MSME vendors for compliance.

ISO-14001 : 2015 | ISO-45001 : 2018

Certified operating facilities

INFO & TECH RISKS

Cybersecurity & Data Protection

Cybersecurity threats result in financial losses, reputational damage, operational disruptions, and data theft, increasing security costs and regulatory penalties. Loss of critical data can halt operations, causing downtime and reduced productivity. Recovery costs, legal fees, fines, and revenue loss can be substantial, while regulatory bodies may impose stricter audits, complicating operations further.

Mitigation: To mitigate risks, we have implemented cybersecurity measures such as software updates, access controls, employee training, and an incident response plan. We employ data encryption, audits, and backup systems to safeguard against attacks. Our disaster recovery plan incorporates data backups, firewalls, antivirus software, and intrusion detection. Compliance training, monitoring, and maintenance ensure ongoing protection. Employee training on disaster recovery procedures and drills promotes preparedness for potential incidents.

ADDITIONAL RISK FACTORS


Safeguarding Employee Morale & Operational Integrity

Low employee morale can reduce productivity and increase turnover. Conflicts may escalate to legal disputes, and negative posts can harm our reputation. Data breaches can lead to theft, compliance violations, and security issues.

Mitigation: To address these risks, we have adopted conflict resolution strategies, employee engagement initiatives, fair policies, and open communication. We are dedicated to reducing our carbon footprint, promoting sustainable practices, ensuring fair labour, and community engagement. A strong social media policy, access controls, monitoring, a crisis management plan and data protection measures uphold our transparency and ethics.



Our value



INPUTS

FINANCIAL CAPITAL
- Capital employed (1st April' 2025): **₹1,812.72 crore**
- Long Term Debt: **Nil**

INTELLECTUAL CAPITAL
- R&D Facilities: **API Lab & Formulation Lab**
- R&D Professionals: **180+**
- R&D Spend: **₹27 crore**

MANUFACTURED CAPITAL
- Manufacturing units: **4**
- Installed Fermentation API Capacity: **1,250m³**
- Installed Formulation OSD Capacity: **802 Mn units**
- Installed Formulation Injectable Capacity**: 13 Mn Liquid Vials, 12 Mn Dry Power Filling & 2,200 Kgs Sterile Lyophilized API**

HUMAN CAPITAL
- Team size (1st April, 2025): **1,571**
- Net addition in FY25: **194**
- Employee benefits expense FY25: **₹138.93 crore**

SOCIAL & RELATIONSHIP CAPITAL
- CSR spend in FY25: **₹6.2 crore**

NATURAL CAPITAL
- Energy consumed: **9,77,578.90 GJ**
- Water drawn: **3,85,410 KL**
- Waste generated: **2,877.57 MT**

OUR FRAMEWORK

STRENGTHS
Expertise in Fermentation Technology

Continuous Investment in R&D Driven Innovation

State-of-the-art manufacturing facilities

Commitment to the Highest Standards of Quality and Compliance

FOCUS
FERMENTATION-BASED APIS

Immunosuppressant, Oncology, Anti-bacterial, Anti-fungal, Others

FORMULATIONS & CDMO

Anti-fungal, Antibiotics, Plasma products, Transplant & Immuno, Chronic Kidney Disease, Immunology

STRATEGY
Maximise expertise in fermentation technology by engaging across all levels of the fermentation value chain

Position Concord Biotech as a leading manufacturer and supplier of fermentation-based APIs, strategically aligned with the growing potential of the global fermentation market.

Increase focus on the formulation business

Invest in transformative innovations

Expand our geographic presence in more Indian states, emerging markets, and the USA

Develop a robust product portfolio that spans various therapeutic areas

Foster a strong culture of compliance and quality

Enhance and advance a sustainable research and development platform. Broaden our customer base and expand the market reach

creation model

OUTPUTS

FINANCIAL CAPITAL
- 18% growth in Revenue
- 17% growth in EBITDA
- 21% growth in PAT


INTELLECTUAL CAPITAL
- Approved formulation products across market: 100+
- ANDAs approved for products from our facilities: 5+

MANUFACTURED CAPITAL
- **Robust volume of** API & Formulation production

HUMAN CAPITAL
- Conducive work environment
- Superior productivity

SOCIAL & RELATIONSHIP CAPITAL
- Active customers: **250+ (March 31, 2025)**

NATURAL CAPITAL
- Waste recycled: **602.577 MT**



INTELLECTUAL CAPITAL

Driving Excellence in R&D

Our commitment to research and development, coupled with our innovative mindset, drives our agility in meeting evolving demands. This dedication is reflected in our comprehensive product range, which spans various doses and advanced technologies, supported by strong regulatory expertise.

Our primary focus has always been on creating specialised products with complex processes that are difficult to replicate, presenting challenges in development and manufacturing. Embracing this philosophy, we have developed our expertise in the biotechnology sector, which is both challenging and innovative. Utilising our extensive expertise and cutting-edge technology, we maintain a leadership position in fermentation-based APIs. Our innovative research and development, combined with a commitment to sustainable practices, enables us to deliver high-quality APIs and formulations, providing a competitive advantage and long-term value to our stakeholders.

Our advanced R&D facilities, managed by a dedicated team, have developed a wide range of niche products. In the fiscal year 2025, we invested ₹27 crore in research and development initiatives, reaffirming our commitment to innovation.

Advancing API & Formulations Through Innovation

API R&D EXCELLENCE

We possess unique expertise in isolating microbial strains, inducing mutations, and selecting strains through passive methods, as well as enhancing strain properties.

Our in-house capabilities empower us to foster innovation and effectively create new active pharmaceutical ingredients.


Our state-of-the-art fermenters and pilot plant facilities ensure the efficient transition of fermentation processes from laboratory settings to large-scale commercial production.

FORMULATIONS R&D LABORATORY

By focusing on developing formulations using advanced analytical techniques, we ensure our products meet the highest standards of quality and efficacy.

Alongside, we are also focused on **enhancing patient convenience and superior efficacy.**

Development of niche **therapeutic formulations** across key segments



Key Achievements


Strategic investment in Palvella Therapeutics, Inc, a company incorporated in USA.

Investment of 26% equity in Cleanmax Everglades Private Limited for sourcing renewable energy at Dholka API Plant.

Commencement and commissioning of Injectable facility at Valthera.

Incorporation of Stellon Biotech Inc. Stellon will manage end-to-end commercial operations, in the US

Performance Highlights



Our R&D team is working on a robust pipeline of more than 10 products across different therapeutic segments of Oncology, Anti-Infectives and Anti-Fungal.



MANUFACTURED CAPITAL

Enhancing Value Through Superior Manufacturing

At Concord, we steadfastly invest in world-class manufacturing equipment, processes, and systems to cultivate a portfolio of products that not only meet but surpass customer expectations. Our unwavering commitment to exceptional value and innovation ensures that each product epitomises our dedication to manufacturing and quality excellence.

Seamless Integration for Manufacturing Mastery

Concord's core strength is rooted in its integrated manufacturing operations. Our continuous investments in cutting-edge technologies, efficient production processes, and robust operational frameworks enable us to produce reliable, high-quality products. Additionally, we ensure strict compliance with rigorous regulatory standards while maintaining the agility to meet ever-increasing market demands. In recognition of these efforts, Concord Biotech received the 2024 DET **Hurun Award** for Outstanding Contribution to India's Manufacturing Economy. The award was presented at the India Manufacturing Excellence Awards 2025, organised by Hurun India in collaboration with the Dubai Department of Economy and Tourism.









Unit I (API): Dholka, Gujarat | **112,302 sq.m:** Area of coverage | **450 m³:** Installed capacity

Unit II (Formulations): Valthera, Gujarat | **94,826 sq.m:** Area of coverage | **802 Mn units:** Installed capacity

Unit III (API): Limbasi, Gujarat | **5,96,309 sq.m:** Area of coverage | **800 m³:** Installed capacity

Unit IV (Injectables): Valthera, Gujarat | **36,441 sq.m:** Area of Coverage | Installed Capacity of **13 Mn** Liquid Vials, **12 Mn** of Dry powder filling and **2,200 kgs** of Sterile lyophilized API.

Our manufacturing vision highlights the critical importance of environmental sustainability and minimising adverse impacts. Through innovative methodologies and meticulous planning, we optimise resource consumption, reduce waste, and embrace sustainable production practices. By staying at the forefront of advancements and trends, we continually refine our practices, reinforcing our leadership in sustainability technology.

Our World-Class Manufacturing Capabilities

API

- Our API facilities are designed and operated in strict accordance with Current Good Manufacturing Practices (cGMP). They undergo inspections by various global regulatory authorities, including the USFDA, EUGMP, Japanese PMDA, Brazilian ANVISA, Korean MFDS, Russian GMP and Other Emerging Market approvals.
- Equipped with specialised clean rooms and lyophilisation capabilities, our facility enables us to maintain and cultivate various microorganisms with exceptional precision and care.
- Our advanced microbiological laboratory, staffed by well-qualified professionals, rigorously adheres to cGLP guidelines. Additionally, our facilities have been designated as an approved beneficiary of the API PLI Scheme.



FORMULATION

- Our formulation facility meets global regulatory requirements and has been inspected by USFDA, EUGMP, Japanese PMDA, Brazilian ANVISA, Korean MFDS and Other Emerging Market approvals, demonstrating our dedication to current Good Manufacturing Practices (cGMP). This enables us to manufacture a wide range of solid oral dosage forms, oral liquids, oral suspensions, and complex solid dispersions.
- We utilise advanced equipment and automation to provide innovative, targeted solutions in niche therapeutic areas. Additionally, our facilities are equipped with advanced effluent treatment plants (ETPs) designed to achieve Zero Discharge.
- We have commissioned and started injectable production at our new state-of-the-art manufacturing facility in Valthera. This milestone underscores our commitment to expanding our capabilities and delivering high-quality, innovative solutions to meet the growing demands of the healthcare industry.



Expanding Our Compliance

Concord underwent inspections by the US-FDA, EU-GMP and Russian GMP at our Dholka API facility (Unit 1).

Further, our Valthera Facility (Unit-2) underwent inspection by EU-GMP and Saudi Food & Drug Authority (SFDA).

Expanding Our Capabilities

In Q4 of FY 2025, we commissioned our injectable business as a new strategic vertical, marking a key milestone in our growth journey. This addition brings a high-value revenue stream and strengthens our capabilities in complex formulations, positioning us for long-term, profitable expansion.

FINANCIAL CAPITAL

Strategic Financial Discipline at Concord

At Concord, financial discipline is at the heart of our strategic priorities. Leveraging our strong financial position, we have seized sectoral opportunities, enhanced our product portfolio, and expanded into new markets to maximise stakeholder value.

Our prudent capital allocation practices have also fostered long-term growth prospects.

Financial Capital: A Catalyst for Growth

We view financial capital as a driving force for creating stakeholder wealth. These resources encompass the funds available to us for enhancing capacities, strengthening capabilities, streamlining processes, and producing world-class products. This ensures that our business processes remain relevant and efficient, resulting in increased productivity and yield over time while upholding the integrity of our growth narrative. Our teams have worked diligently to build a robust balance sheet, providing ample legroom to expand business operations and sustain profitable growth.

FY25 Performance: Resilient & Strategic

In Fiscal Year 2025, we demonstrated a resilient performance despite facing numerous market challenges. Our strategic initiatives, efficient management practices, and robust operational capabilities substantially contributed to our financial progress.

Strong cash flow generation

The distinguishing feature of our business operations is our capability to maintain growth in the face of external challenges, along with our diligent emphasis on working capital management, which yields robust cash flow from operations.

Net cash flow from Operations

(₹ crore)



Deleveraged position

Prudent cash management has enabled us to deleverage effectively, even amidst ongoing investments in capacity building. Over the past five years, we have invested significant amount to enhance our capacities and capabilities, yet we maintain the debt-free status. This strong financial position is a testament to our financial prudence, as our team has judiciously allocated cash generation towards capital projects.



HUMAN CAPITAL

Our Team, Our Strength

Our employees are the driving force behind our operations, fuelling our continued success. Their remarkable ingenuity, unwavering commitment, and resilient spirit have propelled us to become one of India's leading players in the biotechnology space. Our policies and practices are meticulously designed to foster an inclusive workplace where everyone feels valued and empowered.

We recognise that a diverse workforce enriches our organisational culture, broadens our outreach, and enhances our competitiveness in the pharmaceutical sector. Therefore, we strive to create an inclusive environment where employees feel valued and are encouraged to share their unique perspectives and talents. We take pride in our diverse culture, which is firmly rooted in the values of transparency, inclusion, collaboration, and excellence.

Core principles of our Talent Management

Inclusion & Growth	Learning & Development	Health & Safety	Care
We are committed to attracting top-tier talent from outside the organisation while promoting deserving team members through structured processes that drive employee motivation and organisational excellence. We deeply value and respect our employees, actively seeking their feedback to create a supportive, fair, and enriching work environment. This approach not only fosters happiness and fulfillment but also empowers our workforce to achieve their full potential, driving our collective success.	We offer comprehensive training programs aimed at enhancing employee skills and knowledge, fostering overall development, and improving career advancement prospects. Our ongoing sessions cover a diverse range of topics, including Safety Training, Technology Introduction, Environmental Awareness, Quality Management Systems (QMS), Operational Training, and Skill Upgrading.	Our EHS (Environmental, Health, and Safety) department leads the charge in fostering a safety-focused culture, ensuring that our operations do not adversely affect individuals, processes, or the environment. We conduct regular process safety risk assessments at our facilities, covering both routine and non-routine work-related hazards. To achieve this, we implement procedures such as HAZOP (Hazard and Operability Study) and HIRA (Hazard Identification and Risk Assessment).	We prioritise employee well-being by offering comprehensive benefits and consistent support. Our initiatives ensure that all team members, receive the care and resources they need to thrive.

Two units are ISO 45001 certified for Occupational Health and Safety Management Systems (OHSMS).



By fostering a **people-first culture**, we continue to empower our workforce, ensuring they grow alongside us.

NATURAL CAPITAL

Sustainability at the core of our mission

At Concord, sustainability isn't just a commitment- it's a way of life. We proactively work towards minimising our carbon footprint through responsible product stewardship, optimised resource use, proactive climate action initiatives, and adopting sustainable practices. Our comprehensive policy framework and responsible practices drive us towards achieving our ambitious sustainability objectives, reflecting our unwavering commitment to a greener future.


Cultivating Sustainable Growth

At Concord, we enhance our natural capital by committing to energy-efficient design, reducing emissions, and optimising operations. To conserve resources, we implement wastewater recycling, effluent treatment plants, and rainwater harvesting. Investing in renewable energy and effective waste management minimises our environmental impact while promoting long-term responsibility.

SUSTAINABILITY LEADERSHIP

Our vision for manufacturing centres on environmental sustainability, aiming to minimise adverse effects. Fuelled by our steadfast dedication to sustainability, we strive to lead globally in green initiatives.

At Concord Biotech, we are committed to preserving and conserving the environment, ensuring that our practices reflect our unwavering commitment to a sustainable future.



SUSTAINABLE INNOVATION PATHWAY

At Concord, we relentlessly seek eco-friendly alternatives while enhancing current processes.

Through careful planning and innovative techniques, we optimise resource consumption, reduce waste generation, and adopt sustainable production practices.

By staying abreast of the latest advancements and industry trends, we consistently refine our practices to maintain our leadership in sustainability technology.


Environmental Stewardship at Concord Biotech

At Concord, we acknowledge the significant environmental impact our operations can have on the surrounding ecosystem. Understanding this, we are dedicated to optimising energy management as a core component of our climate change strategy.

Our Energy Efficiency Measures

- ***Energy-Efficient Design:*** We have deployed energy-efficient design principles that significantly reduce energy consumption and emissions in our buildings.
- ***Sustainable Manufacturing:*** Our institutionalised sustainable manufacturing processes focus on reducing waste, recycling, and utilising agricultural materials to lower greenhouse gas (GHG) emissions from our production activities.
- ***Advanced Technologies:*** We have installed requirement-based insulation, smart thermostats, centrifugal air compressors, water chillers, and energy-efficient windows to optimise our energy usage and enhance overall efficiency.
- ***Cleaner Energy Sources:*** We have transitioned from furnace oil to natural gas for steam production, further reducing our carbon footprint and enhancing energy efficiency.
- ***Tree Planting Initiatives:*** We have carried out tree planting drives to offset the greenhouse gas emissions produced by our facilities.
- ***Investment in renewable energy:*** Concord Biotech acquired a 26% stake in Clean Max Everglades to install a hybrid renewable energy plant in Gujarat, featuring 6.6 MW wind capacity and 3.3 MWp DC solar capacity. This move ensures long-term sustainability and operational efficiency, enhances environmental responsibility, and reduces energy costs.

Energy Consumption
(GJ)



EcoVadis Bronze Medal

Concord Biotech was awarded the Bronze Medal by EcoVadis, recognizing its strong commitment to sustainable practices and responsible operations in the global biotechnology sector.

Water Management


At Concord Biotech, we are dedicated to responsible water management, recognising water as a vital shared resource. Our water management framework reflects our ongoing commitment to enhancing water use efficiency through advanced technologies and practices, alleviating pressure on shared resources by reducing our water footprint and aligning our water management practices with our broader sustainability goals to promote long-term environmental health.

Our Water Management Practices:

- ***Recycling and Reclamation:*** Institutionalising practices such as recycling, reclamation, and responsible wastewater management have significantly reduced water usage across our facilities.
- ***Effluent Treatment Plants (ETPs):*** Our ETPs are designed to achieve Zero Liquid Discharge, contributing to a substantial 90% reduction in sludge volume within our dewatering system.
- ***Green Belt Development:*** Using treated wastewater within our facilities for green belt development effectively reduces our reliance on freshwater sources.
- ***Water Recycling and Rainwater Harvesting:*** Increase the amount of treated wastewater recycled and implement rainwater collection systems to reuse water.

Our continuous dedication to water conservation and effective water management practices is evidenced by a notable reduction in water withdrawal and consumption over the past three fiscal years.

Water Withdrawal & Consumption (KL)



Waste Management

Waste management is a crucial component of Concord Biotech's sustainability strategy. We are committed to minimising waste generation and promoting responsible disposal practices throughout our operations. To achieve this objective, we have implemented a range of initiatives focused on waste reduction, recycling, and adopting circular economy principles.

Waste Management Initiatives:

- ***Recycling HDPE Bags:*** Recycling HDPE bags for ETP sludge and MEE salt while selling excess bags to recyclers.
- ***E-Waste Management:*** Transferring e-waste to authorised recyclers.
- ***Hazardous Waste Handling:*** Managing hazardous waste through reuse, recycling, or proper disposal according to legal guidelines, including selling to recyclers, co-processing, or utilising TSDF sites.
- ***ETP Sludge Management:*** Reducing the moisture content of ETP sludge by 90% using a paddle dryer before disposal.
- ***Biomedical Waste Disposal:*** Channelling biomedical waste to certified incineration facilities.
- ***Stakeholder Collaboration:*** Collaborating with stakeholders to promote environmental equity and explore circular economy possibilities.
- ***Eco-Friendly Alternatives:*** Encouraging the adoption of eco-friendly options, such as jute bags instead of plastic.
- ***Extended Producer Responsibility (EPR):*** Coordinating the waste collection strategy with the EPR requirements submitted to the Pollution Control Boards.



Industry Recognition

Concord Biotech has been recognised as a winner in the prestigious ICAI Sustainability Reporting Awards 2023-24. Our unwavering commitment to sustainability reporting and our dedication to responsible business practices have set us apart as a trailblazer in promoting these essential initiatives.

SOCIAL & RELATIONSHIP CAPITAL

Harnessing Social Capital for Long-Term Resilience

Our robust relationships with stakeholders – communities, customers, employees, and regulators – constitute our social capital. This invaluable asset fosters trust, enhances collaboration, and promotes sustainable practices, leading to more efficient operations and improved compliance. Furthermore, strong social capital drives innovation increases community engagement and strengthens long-term business resilience.

At Concord, we strengthen our social capital through impactful Corporate Social Responsibility (CSR) initiatives, benefiting local communities. We promote healthcare, education, gender equality, and environmental sustainability, ensuring holistic growth. We aim to foster long-term social and economic progress by actively engaging in rural development projects.

Our Key Interventions

GYANJYOT
Benefitting individuals from vulnerable and marginalised groups.

MORNING NUTRITION PROGRAMME
Providing nutritious meals to students at municipal schools in Dholka.

3 STEM LEARNING LABS
Supporting students in pursuing education in science, technology, engineering, and mathematics.

SPORTS SCHOLARSHIP
Awarding scholarships to promising athletes from vulnerable groups.

SCHOLARSHIP PROGRAMME
Providing educational scholarships to deserving students from underprivileged communities.

SPREADING AWARENESS THROUGH MEDIA & EDUCATIVE SEMINAR
Raising awareness through media, educational sessions, and seminars to inform and empower our community.


MOBILE MEDICAL UNITS
Delivering healthcare services to rural communities in Dholka, Valthera & Limbasi.

DONATION OF AMBULANCE/ MEDICINES
Providing ambulances and medicines to support healthcare accessibility & save lives in our community.

VISION CENTRES
Offering eye care services to individuals from vulnerable groups.

PROGRAM ON PATIENT CARE
Implementing patient care programs to enhance health outcomes and improve quality of life.

ISO Certifications
The company also received ISO-14001:2015 & ISO-45001:2018 Certifications. These certifications underscore our initiatives towards corporate social responsibility, driving a sustainable future, reducing ecological harm, and improving water quality.



CSR Spent
(₹ crore)

Empowering communities through education, healthcare, and sustainability, we drive long-term resilience with impactful CSR initiatives.
At Concord, we don't just do business...

we create lasting change!

Governance

Concord is committed to achieving sustainable and profitable growth, supported by a robust framework, comprehensive policies, and stringent ethical standards. Our Board of Directors provides strategic direction, ensuring our core values and objectives align with our operations while fostering stakeholder interests, trust and transparency.

Governance Framework

Our governance framework ensures transparency, accountability, and integrity in all decision-making processes. It outlines key policies and initiatives, guided by a distinguished Board of Directors that provides strategic direction. Comprising seasoned experts, the Board oversees critical policymaking and operational matters, prioritising the interests of the organisation and its shareholders while adhering to legal standards. The Board's diverse composition brings a range of perspectives to leadership and decision-making.

Board composition as on March 31, 2025

Category	No. of Directors	Non-Executive	Independent	Executive
Board of Directors	9	2	5	2
Audit Committee	3	0	3	0
Nomination and Remuneration Committee	3	0	3	0
Corporate Social Responsibility Committee	3	0	2	1
Risk Management Committee	3	1	1	1
Stakeholders' Relationship Committee	3	2	1	0

5
Number of Board Meetings in FY25

98%
Average attendance of Directors

Key Policies and Codes

Ensure ethical business conduct, regulatory compliance, and long-term value creation.

- Insider Trading Policy
- Dividend Distribution Policy
- Code of Practices - Fair Disclosure of UPSI
- Code of Conduct for BoD & SMPs
- Archival Policy
- Policy for Determination of Materiality
- Whistle Blower Policy
- UPSI Leak Inquiry Policy
- Succession Policy
- Risk Management Policy
- Policy to Promote Diversity of Board of Directors
- Policy on Related Party Transactions
- Policy on Material Subsidiaries
- Policy for Preservation of Documents
- Policy for Familiarisation Programme for Independent Directors
- Policy for Evaluation of the Performance of the Board of Directors
- Nomination & Remuneration Policy
- Composition of Committees
- Anti-Fraud & Anti-Corruption Policy

Governance Pillars:
Critical Aspects of Compliance & Security



DATA SECURITY

Data security is vital for protecting sensitive research, intellectual property, and patient data from cyber threats. Robust security measures also ensure regulatory compliance, safeguard innovations, and maintain public trust.

To safeguard against cyber-attacks, we implement regular data backups, utilise firewalls, antivirus software, and intrusion detection systems. Additionally, we enforce strict access controls to ensure the security and integrity of our data.



COMPLIANCE MANAGEMENT

A robust compliance management system ensures adherence to regulations, ethics, and industry best practices. Strong policies, regular audits, and employee training maintain data integrity and transparency. Effective compliance protects the company's reputation and fosters innovation within legal frameworks.

We conduct regular compliance audits to ensure adherence to all relevant regulations and maintain a dedicated compliance team to monitor regulatory changes and renew licenses promptly. Our robust tracking system manages all permits and approvals, while engagement with legal experts helps us navigate complex regulatory landscapes. Additionally, we foster a culture of compliance through regular training and awareness programs.



VALUE-CHAIN GOVERNANCE

Value chain governance plays a crucial role in ensuring not just transparency and efficiency, but also strict compliance throughout the entire journey of research, production, and distribution. By maintaining strong oversight of partnerships, suppliers, and regulatory requirements, we can uphold the highest quality and ethical standards. Moreover, effective governance serves as a catalyst for innovation, fosters sustainability, and bolsters our global competitiveness, paving the way for a brighter future in all our endeavours.

At Concord, value-chain governance ensures seamless operations from R&D to distribution, enhancing value creation and maintaining high standards of quality and compliance. We prioritise innovation, adhere to rigorous quality control, and ensure regulatory compliance through regular audits and expert engagement. Our precise supply chain management and strong stakeholder engagement foster trust and confidence. Committed to sustainability and ethical standards, we minimise our environmental footprint and uphold responsible practices, delivering high-quality products efficiently and responsibly.

Governance with Integrity, Growth with Purpose

At Concord, governance goes beyond compliance—it's about transparency, integrity, and sustainable growth, building trust and lasting value for all stakeholders.

OUR **ESTEEMED BOARD**

Sustaining our excellence quotient through Vision & Insight



MR. SUDHIR VAID
Chairman & Managing Director

Mr. Sudhir Vaid, a Biotechnologist by profession, is a technocrat turned entrepreneur. He is a dedicated Philanthropist, who has made substantial contributions to society, particularly in the areas of Health, Education, Research, Rural Development and Women Empowerment. His unwavering commitment for improving healthcare access and quality has led to numerous initiatives that benefit underserved communities. After completing his studies in Microbiology from Punjab University in 1974, he started his career in Biotechnology and moved to different domestic and multinational biotechnology-based companies till he started his own business in the year 2000. He has around 50 years of experience in the development of biopharmaceutical products, production management, marketing and strategic planning. His last job assignment was as Director-Biotechnology with Ranbaxy Laboratories where he initiated and successfully completed biotechnology green field projects. This rich experience of setting up green field projects and his risk- taking capabilities motivated him to start his own business. He established Concord in Dholka, Gujarat, in May 2000 and transformed it from a chemical facility into a biotechnology hub by producing immobilised enzymes using a recombinant strain.

As the driving force behind the company, he has made Concord grow by leaps and bounds, revolutionising Concord from a single product company to one of the global leaders in the area of fermentation-based biopharmaceuticals. He is a member of the Governing Body of Gujarat Biotechnology Research Centre and GSBTM, Government of Gujarat. He has also been appointed as Chairman of the Advisory Council of Gujarat Biotechnology University by Government of Gujarat, wherein he shares his rich experience in delivering innovative biotechnology solutions.



MR. ANKUR VAID
Joint MD & CEO

Mr. Ankur Vaid holds a Bachelor of Technology degree in Chemical Engineering from Rashtrasant Tukadoji Maharaj Nagpur University and an MBA from the Rochester Institute of Technology. He has been associated with our organisation since 2009 and possesses over18 years of experience in the pharmaceutical industry. His involvement encompasses the marketing, commercial aspects, product development, and strategic decision-making processes within our company.



MR. RAVI KAPOOR
Non-Executive Director

22+ years on the Board

Mr. Ravi Kapoor possesses a Bachelor's degree in Commerce and a Bachelor's degree in Law from Gujarat University, in addition to a Master's degree in Commerce from the same institution. Furthermore, he has acquired a Postgraduate Diploma in Intellectual Property Rights Law from the National Law School of India University in Bangalore. He is a member of the Institute of Company Secretaries of India and is duly authorised to practice as a Company Secretary. Additionally, he holds membership in the Indian Institute of Bankers and is an associate member of the All-India Management Association. He has been affiliated with the company since December 2003.



MR. RAJIV AMBRISH AGARWAL
Non-Executive Director

17+ years on the Board

Mr. Rajiv Ambrish Agarwal possesses a Bachelor of Technology degree in Chemical Engineering from Banaras Hindu University. He has been affiliated with Rare Enterprises since 2006 and serves as a nominee for RARE Trusts. His primary focus is on advancing Rare Enterprises' strategic investments across various sectors. He has expertise in both B2B and B2C business models, which contribute to Rare Enterprises' private equity portfolio. His association with the Company commenced in June 2008.

He provides strategic leadership and drives organisational success through decision-making, team management, and business expertise.



MS. BHARTI KHANNA
Independent Director

8+ years on the Board

Ms. Bharti Khanna possesses both a Bachelor's degree and a Master's degree in Pharmacy from the University of Delhi. Since January 2017, she has served as an Independent Director on our Board.

With her marketing expertise she combines strategic vision with decision-making, leading brand growth, customer engagement, and digital transformation while leveraging creativity, market insights, and cross-functional collaboration to drive competitive advantage and revenue success.

OUR **ESTEEMED BOARD** *[CONTINUED]*



MR. AMITABH THAKORE
Independent Director

8+ years on the Board

Mr. Amitabh Thakore possesses a Bachelor of Engineering degree in Mechanical Engineering from Maharaja Sayajirao University of Baroda. Additionally, he has obtained a Master of Science degree in Industrial Engineering from Lehigh University and a Postgraduate Diploma in Business Administration from the Indian Institute of Management, Ahmedabad. He has been affiliated with the Company since January 2017.

With his consulting expertise, he provides strategic guidance, leverages industry expertise, and delivers actionable insights to help clients solve complex challenges, optimise performance, and achieve sustainable growth.



MR. ARVIND AGARWAL
Independent Director

3+ years on the Board

Mr. Arvind Agarwal has a bachelor's degree in commerce from the University of Bombay. He is a retired IAS officer of Gujarat cadre, with over 35 years of experience in the Indian Administrative Service. He also acted as the Additional Chief Secretary for the industries and mines department and the environment and forests department. He has been associated with the Company since May 2022.

With his business expertise he provides strategic leadership, operational oversight, and decisive business acumen to drive organisational growth, profitability, and long-term success.



MS. JAYARAM EASWARAN

Independent Director

3+ years on the Board

Mr. Jayaram Easwaram has a postgraduate diploma in management from the Indian Institute of Management, Bangalore. He has been associated with the Company since June 2022.

With his business expertise he leverages strategic vision, financial acuity, and executive leadership to steer companies through competitive markets while maximising stakeholder value and operational efficiency.



MR. MANDAYAM CHAKRAVARTHY SRIRAMAN

Independent Director

3+ years on the Board

Dr. Mandayam Chakravarthy Sriraman has a bachelor's degree in science from Fergusson College and a master's degree in science, specialising in organic chemistry from the University of Pune. Additionally, he holds a Doctorate in chemistry from the University of Pune and a postgraduate diploma in patent law from the National Academy of Legal Studies and Research University. He has also participated in a training course for validation during API development and manufacturing conducted by the Pharmaffiliates Asia Research Foundation. He was commemorated by the American Chemical Society at its 125th anniversary as a member in good standing on 2001 and was awarded the Man of the Year in Science in 2009 for outstanding contributions to science as recognised by the American Biographical Institute. He was also awarded by the management of Camphor and Allied Products Limited for the completion of his project at the Malti-Chem Research Centre. He has been associated with the Company since June 2022.

Management Discussion & Analysis

AN ECONOMIC OVERVIEW

THE GLOBAL ECONOMY

In Fiscal Year 2024, the global economy grew moderately amid heightened geopolitical uncertainties. The International Monetary Fund reported a global GDP growth of 3.2%, matching 2023's pace. Advanced economies grew slightly faster, from 1.6% in 2023 to 1.7% in 2024, while emerging markets saw a modest slowdown, decreasing from 4.3% to 4.2%.

Inflation eased, with rates projected to fall from 9.4% in 2022 to 3.5% by 2025, allowing for a more accommodative monetary policy. Global consumer spending rose, with a projected $16.2 trillion increase by 2029, though growth slowed in developed economies while emerging markets gained. China led manufacturing, contributing 31.6% of global output, but faced challenges with a PMI of 48.8 and declining export orders. These trends reflect changing economic conditions worldwide.


Global trade remained resilient, with merchandise trade growth estimated at 2.6% for 2024, rebounding from a 1.2% decline in 2023. Digital services trade thrived, reaching US$4.25 trillion in exports in 2023, making up 13.8% of global goods and services exports.

Outlook: The global economy is set to grow at 3.3% in FY25, consistent with last year but below the 2000- 2019 average of 3.7%. This stability arises from changing monetary policies, inflation, trade policies, and geopolitical factors.

Global inflation is projected to drop to 4.2% in 2025 and 3.5% in 2026. Advanced economies may hit inflation targets sooner, though emerging markets could experience prolonged pressures. The IMF forecasts public debt will reach 100% of global GDP by 2030, highlighting the need for reforms to enhance economic resilience.

Trade and geopolitical factors continue to create uncertainty. Protectionist measures and conflicts in Europe and the Middle East will reshape global trade dynamics, presenting challenges and opportunities. Despite economic risks, strategic policy adjustments and sector resilience are expected to maintain global momentum in FY25.

Figure 1.13 Growth Outlook: Feeble and Uneven
(Percent, dashed lines are from January 2022 WEO Updated vintage)



Source: IMF staff calculations.
Note : The figure shows the projected evolution of real GDP growth for the indicated economy groups. WEO = World Economic Outlook.

Sources

https://www.imf.org/en/Publications/WEO/Issues/2025/01/17/world-economic-outlook-update-january-2025#:~:text=Growth%20on%20divergent%20paths%20amid%20elevated%20policy%20uncertainty&text=Global%20headline%20inflation%20is%20expected,emerging%20market%20and%20developing%20economies

https://www.imf.org/en/Publications/WEO/Issues/2024/10/22/world-economic-outlook-october-2024?utm

https://en.wikipedia.org/wiki/Economic_forecasting?utm

THE INDIAN ECONOMY

In FY 2024-25, India's economy showed strong growth, with real GDP increasing by []%. This was due to rising government and consumer spending and a robust rural economy. Inflation eased, with retail inflation averaging 4.9% from April to December 2024, meeting the 4% FY2025-26 target.

CPI inflation fell to 3.61% in February 2025, from 4.26% in January, due to lower food prices. CFPI also decreased from 5.97% to 3.75%, supporting consumer purchasing power and economic stability. The RBI cut the key interest rate by 25 basis points in February to improve loan rate transmission and boost economic activity. Additionally, the RBI announced a $21 billion liquidity infusion to ease lending conditions, including open market operations and a dollar-rupee buy-sell swap to address liquidity deficits caused by tax outflows and stabilise the rupee.

The services sector grew significantly, driven by strong demand and business optimism, resulting in increased hiring. This sector's growth compensated for weak manufacturing, raising the composite PMI to 58.8 in February.

The external sector remained strong, with overall exports (merchandise and services) increasing by 6% year-on-year from April to December 2024. Services exports rose by 12.8%, highlighting India's competitiveness in the global services market.

In FY2024-25, India's tax revenue significantly increased, with gross tax revenue expected at ₹38.3 lakh crore—an 11.4% rise over the previous year's revised estimates, supporting fiscal balance and developmental projects while ensuring prudence.

Outlook: India's economic outlook for the fiscal year 2025-26 remains positive, with several key indicators pointing toward sustained growth and stability. The International Monetary Fund (IMF) projects that India's GDP growth will remain at 6.5% in 2025 and 2026, which aligns with earlier projections.

The IMF projects India's headline inflation to stabilise at 4% in FY2025-26, contributing to economic stability. Additionally, the RBI's Monetary Policy Committee may implement rate cuts to stimulate economic growth further. However, potential challenges include global trade uncertainties, currency fluctuations, and a weakening Indian rupee against the U.S. dollar, which may exacerbate existing concerns.



Sources

https://www.reuters.com/world/india/indias-economic-growth-picks-up-rising-government-consumer-spending-2025-02-28/?utm

https://dea.gov.in/sites/default/files/H1-Statement%202024-25%20%28English%29.pdf

https://www.clearias.com/economic-survey-2024-25/?utm

https://pib.gov.in/PressReleasePage.aspx?PRID=2094025

https://www.india.gov.in/spotlight/union-budget-2025-2026?utm

INDUSTRY OVERVIEW

GLOBAL PHARMACEUTICAL MARKET

The pharmaceutical market grew significantly, reaching over USD 1.7 trillion in 2024, with a CAGR of 79%. Growth is driven by advancements in drug development, rising chronic diseases, and increasing demand for biologics and biosimilars.

Biologics, including monoclonal antibodies and gene therapies, boost market growth, especially in oncology and immunology. Companies invest heavily in this sector, and biosimilars gain traction in Europe and the U.S. as cost-effective alternatives.


Precision medicine, which customises treatments based on genetic and lifestyle factors, is increasingly prominent. Investments in targeted therapies are expected to exceed USD 80 billion by 2025, with rising demands driving advancements in genetic testing and biomarkers, improving therapy effectiveness. Integrating digital health with pharmaceutical R&D further fuels tech-driven healthcare solutions. By utilising AI and machine learning, companies optimise drug discovery, reduce R&D timelines, and enhance development predictions. The generative AI market in healthcare is projected to reach USD 24 billion by 2033, growing at a CAGR of 28%.

Emerging markets in Asia-Pacific, Latin America, and Africa present significant growth opportunities. Multinational companies are investing in these regions to meet rising healthcare demands for chronic disease treatments.

Government initiatives and improved healthcare infrastructure have enabled this expansion. Pharmaceutical companies are also setting up local manufacturing plants to cut costs, meet regulations, and ensure better medicine accessibility in high-potential markets.

Outlook: The sector is transforming due to heightened investments in research, technological advancements, and changing healthcare needs. Companies are focusing on innovative therapies like gene editing, cell therapies, and personalised medicine. The emphasis is on precision medicine, utilising genomics and biotechnology for targeted treatments that enhance patient outcomes with minimal side effects.

This evolution is driven by both established pharmaceutical companies and biotech startups, which attract significant venture capital to speed up innovation. Integrating AI, biotechnology, and digital health will redefine drug discovery, development, and patient care, ensuring continued growth and innovation in the industry.



Source

https://www.biospace.com/press-releases/pharmaceutical-market-size-to-surpass-usd-2-82-trillion-by-2033#:~:text=The%20pharmaceutical%20market%20has%20witnessed,prevalence%20of%20chronic-%20diseases%20worldwide.

INDIAN PHARMACEUTICAL MARKET

India's pharmaceutical industry ranks third globally in pharmaceutical production by volume and fourteenth by value, supported by a well-established domestic sector. The industry, a global leader in generics and vaccines, demonstrated robust performance in the 2024-25 financial year (April 2024–March 2025).

The industry experienced an 8.4% growth in FY25, driven by chronic therapies (e.g., cardiac – 10.8%, gastrointestinal – 10.2%, and anti-diabetics – 8%), according to Pharmarack. India's annual drug and pharmaceutical exports reached an unprecedented record of USD 30 billion in Fiscal Year 2025, bolstered by a 31% year-on-year surge in March. Exports to the United States (in value terms) increased by 14.29%, amounting to nearly USD 9 billion in FY25. In the previous fiscal year, the United Kingdom, Brazil, France, and South Africa were also leading destinations for India's pharmaceutical exports.

Foreign direct investment (FDI) inflows totalled US$ 23.04 billion from April 2000 to September 2024, supported by 100% FDI for greenfield projects. Government initiatives included a budget allocation of US$ 602.90 million for FY26 and US$ 69.76 million under the Production-Linked Incentive (PLI) scheme in the first half of FY25, according to the Indian Brand Equity Foundation (IBEF).

Sources

https://www.moneycontrol.com/news/business/india-s-pharma-exports-cross-30-billion-in-fy25-march-sees-highest-surge-12998500.html

https://www.ibef.org/news/booster-shot-as-india-s-pharma-market-grew-8-4-in-fy25-pharmarack#:~:text=The%20cardiac%20segment%20led%20with,any%20errors%20in%20the%20same.

https://www.ibef.org/industry/indian-pharmaceuticals-industry-analysis-presentation

Impact of Global Macro-Level Changes on the Indian Pharmaceutical Industry

The Indian pharmaceutical industry is undergoing a significant transformation due to several macro-level changes on the global stage. The China Plus One strategy, the Bio-Secure Act, and recent tariff policies under President Trump are reshaping the landscape, presenting both challenges and opportunities for Indian pharma companies. This section explores the impact of these changes and highlights the potential benefits for the Indian Contract Development and Manufacturing Organization (CDMO) business.

China Plus One Strategy

The China Plus One strategy has emerged as a critical response to the global supply chain disruptions caused by the COVID-19 pandemic. This strategy encourages companies to diversify their manufacturing bases beyond China to mitigate risks associated with over-reliance on a single country. India, with its robust pharmaceutical manufacturing capabilities and cost advantages, has become a preferred alternative.

India's role in the global Active Pharmaceutical Ingredient (API) market is being significantly enhanced as companies seek to establish a more resilient supply chain. The country's expertise in fermentation-based APIs and its large-scale manufacturing facilities position it as a key player in this strategic shift. This increased demand for Indian-manufactured APIs is expected to drive growth and innovation within the industry.

Bio-Secure Act

The Bio-Secure Act, aimed at reducing dependency on Chinese biopharmaceuticals, further strengthens India's position in the global market. This legislation encourages partnerships with global innovators and promotes the development of a secure and diversified supply chain. For Indian pharmaceutical companies, this presents an opportunity to expand their market presence and collaborate with international partners.

The Act also emphasises the importance of quality and compliance, areas where Indian companies have consistently excelled. With global regulatory approvals from prestigious agencies such as the US FDA, EMA, and WHO, Indian manufacturers are well-positioned to meet the stringent requirements of the Bio-Secure Act. This focus on quality assurance enhances the credibility and competitiveness of Indian biopharmaceuticals on the global stage.

US Tariff Policy

The tariff policies introduced under President Trump have added a layer of complexity to the global trade environment. These policies, aimed at protecting domestic industries, have resulted in increased costs for pharmaceutical exports to the U.S. For Indian pharma companies, this means navigating higher tariffs and potential disruptions in trade flows.

However, the Indian pharmaceutical industry has demonstrated resilience and adaptability in the face of such challenges. By leveraging cost efficiencies and exploring new markets, Indian companies can mitigate the impact of these tariffs. Additionally, the increased global trust and investment in Indian pharma, driven by the China Plus One strategy and the Bio-Secure Act, provide a buffer against the adverse effects of tariff policies.

The Rise of Indian CDMO Business

One of the most significant beneficiaries of these macro-level changes is the Indian Contract Development and Manufacturing Organization (CDMO) business. As global companies seek reliable and cost-effective alternatives to China, the demand for Indian CDMO services is expected to surge. Indian CDMOs offer a comprehensive range of services, from drug development to commercial manufacturing, making them attractive partners for international pharmaceutical companies.

The growth of the Indian CDMO sector is supported by the country's strong regulatory framework, skilled workforce, and advanced manufacturing infrastructure. These factors, combined with the strategic shifts in global supply chains, position Indian CDMOs to capture a larger share of the global market. This expansion not only drives economic growth but also enhances India's reputation as a hub for pharmaceutical innovation and excellence.

OPPORTUNITIES

The combined impact of the China Plus One strategy, the Bio-Secure Act, and Trump's tariff policies is reshaping the Indian pharmaceutical industry. While challenges such as increased tariffs pose hurdles, the overall outlook remains positive. India's enhanced role in the global API market, strengthened by strategic partnerships and a focus on quality, positions it for sustained growth.

The Indian CDMO business, in particular, stands to gain significantly from these macro-level changes. As global companies diversify their supply chains and seek reliable partners, Indian CDMOs are well-equipped to meet this demand. This strategic shift underscores India's potential to become a dominant player in the global pharmaceutical landscape, driving both economic growth and healthcare advancements.

As we navigate these changes, our commitment to delivering high-quality biopharmaceuticals remains unwavering. We will continue to leverage our strengths, embrace new opportunities, and contribute to the global healthcare ecosystem. Together, we are building a legacy of excellence and innovation that will shape the future of the Indian pharmaceutical industry.

OUTLOOK

For FY26 and beyond, revenue growth is projected at 9-11%, as per ICRA, moderated from 13-14% in FY24 due to US tariffs and regulatory pressures. As per Pharmexcil, long-term export goals are USD 130 billion by 2030 and USD 450 billion by 2047, per EY and Forbes. The Contract Research, Development, and Manufacturing Organization (CRDMO) market is set to reach USD 14 billion by 2028, per Macquarie. Challenges include tariff impacts and compliance costs.

Source:

https://www.icra.in/Research/ViewResearchReport/6249

https://www.ey.com/en_in/insights/health/what-will-it-take-for-india-to-become-a-global-pharma-powerhouse-by-2047

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/india-becoming-an-attractive-option-for-global-pharmaceutical-supply-chain-macquarie-report/articleshow/118411382.cms?from=mdr


GLOBAL API MARKET

APIs play a crucial role in modern medicine, as they form the active components in pharmaceutical formulations across various therapeutic areas, including cardiology, oncology, neurology, orthopaedics, endocrinology, pulmonology, and others.

The production of APIs involves complex processes, ranging from initial research and development (R&D) to large-scale manufacturing and stringent quality control. Additionally, APIs can be combined with other ingredients to develop medications that target multiple symptoms or conditions, enhancing therapeutic efficacy.

The global Active Pharmaceutical Ingredients (API) market is valued at approximately USD 240.8 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 6.2% during the forecast period of 2024-2030, reaching a projected USD 345.5 billion by 2030.

With continued innovation, strategic investments, and evolving healthcare needs, the API market is poised for significant growth, ensuring a steady supply of essential pharmaceutical ingredients for the development of advanced and accessible treatments worldwide.



Market Drivers

Rising Prevalence of Chronic Diseases and numbers of geriatric population

The rise of chronic diseases, an ageing global population, and lifestyle-related health issues are driving demand for effective medications, making APIs essential in drug development.

Expanding Healthcare Accessibility in Developing Economies

API market growth is driven by improved healthcare access in developing economies and rising adoption of affordable biologics and biosimilars, boosting demand and expanding the market.

Growing demand for oncology products

The rising global cancer burden is driving demand for oncology products. Pharmaceutical companies are investing heavily in innovative therapies.

Technological Advancements and R&D Investments

Advancements in medical technology, combined with substantial investments in R&D from government and private sectors, are accelerating the growth of the API market.

Rise of Personalised Medicine

As customised treatments become more prevalent, there is a rising demand for highly specific APIs, further expanding the market.

Development of Healthcare Infrastructure and Strategic Collaborations

Ongoing healthcare infrastructure development and collaboration among pharmaceutical companies, research institutions, and providers will strengthen the API market.

https://www.globenewswire.com/news-release/2024/11/19/2983486/28124/en/Active-Pharmaceutical-Ingredients-API-Global-Market-Research-2024-Biologics-and-Personalized-Therapies-Drive-Growth-in-Large-Molecule-API-Segment-Through-2030.html#:~:text=The%20global%20Active%20Pharmaceutical%20Ingredients,US%24345.5%20billion%20by%202030.

GLOBAL FERMENTATION-BASED API MARKET

The global fermentation-based Active Pharmaceutical Ingredient (API) market has been experiencing significant growth, driven by advancements in biotechnology, increasing demand for biopharmaceuticals, and a shift toward sustainable manufacturing processes.

In 2023, the API fermentation market was valued at approximately USD 61.95 billion and is projected to reach USD 96.91 billion by 2030. During the forecast period from 2024 to 2030, the market will grow at a compound annual growth rate (CAGR) of 6.8%.

Several factors have contributed to the growth of the fermentation-based API market:

- The increasing prevalence of chronic diseases and the emphasis on personalised medicine have heightened the need for biopharmaceuticals, many of which are produced through fermentation-based processes.
- Continuous developments in genetic engineering, synthetic biology, and fermentation technologies are enhancing the efficiency and cost-effectiveness of API production.


- Fermentation-based production methods are often more environmentally friendly compared to traditional chemical synthesis, aligning with the industry's move toward sustainable practices.
- Supportive government policies and initiatives aimed at bolstering healthcare infrastructure and promoting domestic manufacturing are creating a favourable environment for market growth.

The fermentation-based API market in the Asia-Pacific region is anticipated to grow significantly. This surge is attributed to the rapidly expanding pharmaceutical industries in countries like China and India, increased foreign investments in manufacturing facilities, and supportive government initiatives promoting domestic production.

In 2024, the U.S. supported fermentation-based APIs through broad biotech policies, not a single framework. FDA's Q7A guidance ensures quality for biologics like antibiotics, and the National Biotechnology and Biomanufacturing Initiative (NBBI) aims to advance U.S. biotechnology and biomanufacturing for a sustainable, safe bioeconomy, while BARDA funds biomanufacturing to localise production. The CHIPS Act's biotech grants bolster fermentation infrastructure, and EPA incentives promote sustainable processes, reducing costs for APIs like insulin.

The Indian government is actively promoting the fermentation-based market, particularly in biotechnology and pharmaceuticals, with initiatives like the Production Linked Incentive (PLI) scheme for bulk drugs and a focus on sustainable manufacturing processes.

Moreover, the BioE3 policy, approved in August 2024, boosts India's fermentation-based pharmaceutical ingredient industry. It promotes bio-based chemicals through sustainable microbial fermentation, crucial for antibiotics and biologics. The policy establishes biomanufacturing hubs and platforms to streamline scaling, reduce costs, and foster innovation, addressing challenges for Indian biotech firms. With a ₹9,197 crore Bio-RIDE scheme (2021-26), it supports R&D and infrastructure in Tier-2/3 cities, creating jobs and aiming for India's US$ 300 billion bioeconomy by 2030. Regulatory improvements and global alignment will enhance competitiveness, positioning India as a leader in eco-friendly API production in a market projected to reach US$ 285.29 billion by 2028. Success relies on continuous funding and collaboration among ministries.



https://www.verifiedmarketresearch.com/product/api-fermentation-market/?utm


THE INDIAN API MARKET

The Indian Active Pharmaceutical Ingredients (API) industry is poised for significant growth, with the market projected to reach USD 22.02 billion by 2030 from USD 14.77 billion in 2025, growing at a CAGR of 8.31%. This growth is driven by rising demand and strategic efforts to boost domestic production.

However, challenges persist, particularly due to competitive pricing and volume pressure from Chinese imports, which are impacting both domestic and export markets. Key API molecules have seen price drops of 20% to 50% over the past year, and while the sharpest declines have eased since Q2 FY25, pricing pressures remain, especially in high-volume segments.

Despite this, Indian pharmaceutical companies have maintained strong financial performance, aided by falling raw material costs, which have helped offset reduced API prices and supported healthy EBITDA margins.

Forward integration into formulations, particularly in regulated markets, has also boosted profitability by capturing more value along the supply chain. Moreover, companies with diversified product portfolios have shown greater resilience, as broader therapeutic coverage and reduced dependence on highly competitive products have helped stabilise revenues. These strategic adaptations position the Indian API industry to navigate current challenges while leveraging long-term growth opportunities.



https://www.mordorintelligence.com/industry-reports/india-active-pharmaceutical-ingredients-market

https://timesofindia.indiatimes.com/business/india-business/api-prices/-volume-growth-to-remain-weak-in-fy25/articleshow/113674553.cms

India's Competitive Advantage in the API Industry

- **Cost Competitiveness**

  India's API industry benefits from low production costs due to affordable labour, infrastructure, and operational expenses, making it a preferred manufacturing destination. Furthermore, backward integration by Indian manufacturers reduces import dependence, lowers costs, and enhances supply chain resilience.

- **Strong Manufacturing Capabilities**

  India is the world's third-largest API producer, supplying over 20% of global generic APIs. With 1,400+ WHO-GMP-certified and 700+ USFDA-approved facilities, it meets global quality standards. Key clusters in Hyderabad, Gujarat, and Maharashtra drive innovation and scale, boosting India's global competitiveness.

- **Skilled Workforce & R&D Strength**

  India's skilled workforce in pharmaceutical research and API development, combined with significant R&D investment in new formulations, process optimisation, and green chemistry, drives cost reduction, efficiency, and sustainable manufacturing, further solidifying India's global API market leadership.

- **Government Support & Policy Initiatives**

  The Indian government's policies, including the PLI scheme to boost local API production and reduce import dependence, along with reforms like single-window clearance and tax incentives, aim to enhance India's pharmaceutical self-reliance and global position.

- **Global Export Hub**

  India exports APIs to over 200 countries, including key markets like the US, Europe, and Japan. Its strength in generics fuels global demand, while strict compliance with international standards helps maintain a strong global presence.

- **Rising Self-Reliance & Reduced Import Dependency**

  Aligned with "Make in India" and Atmanirbhar Bharat, India is investing heavily in KSM and intermediate production to reduce API import dependence, strengthen its supply chain, ensure steady API production, and reinforce its global competitive advantage.

THE COMPANY AND ITS PERFORMANCE

THE COMPANY OVERVIEW

Concord Biotech Limited is an Indian research and development-driven biopharmaceutical company established in 2000. Headquartered in Ahmedabad, Gujarat, the company specialises in the manufacturing of active pharmaceutical ingredients (APIs) through fermentation and semi-synthetic processes, as well as finished formulations.

The company's product portfolio encompasses both biopharmaceutical APIs and formulations across various therapeutic areas, including immunosuppressants, oncology, anti-infectives, nephrology, and critical care.

Concord Biotech operates four manufacturing facilities near Ahmedabad: two dedicated to API production and two for finished formulations. The Dholka facility, established in 2000, is approved by the USFDA and other international regulatory bodies. The Valthera facility, commissioned in 2016, focuses on manufacturing oral solids and liquids

The company has a global presence, distributing its products in over 70 countries, including markets like USA, Europe, Japan, Latin America, Africa, and Asia. In India, Concord Biotech offers a range of nephrology and critical care products.

Concord Biotech continues to focus on research and development to expand its product offerings and maintain its competitive position in the global biopharmaceutical industry.

THE COMPETITIVE ADVANTAGES

FERMENTATION EXPERTISE

The Company has a strong presence in the fermentation value chain, enabling it to produce diverse biopharmaceutical products that meet global quality standards

GLOBAL LEADERSHIP

The Company excels in the production of fermentation-based APIs, showcasing its expertise in this critical area of biopharmaceuticals

EXTENSIVE PORTFOLIO

Concord Biotech Limited boasts an extensive portfolio of over 30 fermentation-based products, each meticulously developed to meet global quality standards. This diverse range includes APIs across therapeutic segments such as immunosuppressants, anti-bacterial, anti-fungal, and oncology. Our commitment to excellence is reflected in our state-of-the-art manufacturing facilities, which adhere to stringent international regulatory requirements. With a strong market presence in over 70 countries, Concord Biotech continues to leverage its expertise in fermentation to deliver innovative and high-quality biopharmaceutical solutions, driving growth and maintaining a competitive edge in the global market

ROBUST SUPPLY CHAIN

The Company created a supply chain system that guarantees efficiency and prompt delivery. Working with numerous suppliers across the globe and maintaining a distribution network in many countries improves market access and increases customer satisfaction.

GLOBAL CUSTOMER BASE

Concord Biotech Limited maintains a diversified global customer base, serving over 250 customers across more than 70 countries. In FY25, the company further expanded this reach by adding 118 new customers across various business segments, aiming to broaden its geographical footprint and customer base.

Source: *Investor presentation*

MANUFACTURING FACILITIES WITH REGULATORY COMPLIANCE

The company's large facilities, with flexible plant configurations, have successfully undergone inspections by global regulators, demonstrating a consistent track record of regulatory compliance.

BUSINESS OPERATIONS

Research & Development:

Concord's R&D capabilities form the core of its fermentation and product development expertise across APIs and formulations. The company has DSIR-approved R&D units in India, employing [] professionals as of March 31, 2025. Its API R&D emphasises fermentation technology, including strain improvement, media optimisation, process development, scale-up, and technology transfer, alongside chemical processes such as downstream processing and analytical advancements.

Concord's formulations R&D focuses on niche dosage forms and advanced analytical capabilities. It also offers contract research and manufacturing services, spanning strain improvement, process optimisation, scale-up, biotransformation, and formulation development for global markets. With an R&D investment of Rs 27 crore for FY 2024-25, Concord showcases its commitment to innovation and excellence in pharmaceutical development.

Highlights for FY25

- The Company received final Abbreviated New Drug Application (ANDA) approval from the USFDA for Teriflunomide Tablets (7 mg & 14 mg)
- Concord Biotech filed two new Drug Master Files (DMFs) for Nystatin and Voclosporin.
- A strategic investment was made in Palvella Therapeutics Inc., a U.S.-based biotechnology company focusing on rare genetic skin disease.

Source: *Investor presentation*

R&D INVESTMENTS

(₹ crore)

FY 2021-22	FY 2022-23	FY 2023-24	FY 2024-25
26	30	23	27

Source: *Source: Investor presentation*

MANUFACTURING

Concord operates four state-of-the-art manufacturing facilities in Gujarat, India, covering a vast area. The company's API facilities consist of multiple specialised blocks equipped for fermentation, chemical synthesis, downstream processing, and key handling techniques such as filtration and chromatography. On the formulations front, Concord has dedicated units for producing oral solids, liquid formulations, and injectable dosage forms.

Its facilities are globally recognised, holding approvals from regulatory authorities such as the USFDA, EMA, and PMDA, reflecting the company's commitment to stringent quality standards. With a robust, vertically integrated infrastructure that complies with international regulatory requirements, Concord Biotech is well-positioned to reliably deliver a diverse portfolio of high-quality APIs and formulations to customers worldwide.

Highlights for FY25

- Regulatory inspection by USFDA–the U.S. Food and Drug Administration (USA)
- Regulatory inspection by MFDS–Ministry of Food and Drug Safety (South Korea)
- Regulatory inspection by HPRA–Health Products Regulatory Authority (Ireland)
- Regulatory inspection by SFDA–Food and Drug Authority (Saudi Arabia)
- There are Inspections by other Emerging Markets Regulatory Authorities
- The injectable manufacturing facility (Unit IV) at Valthera was successfully commissioned and commenced commercial operations.
- The Valthera Facility Unit 2 was awarded an EU-GMP certificate by the Health Products Regulatory Authority of Ireland, reinforcing adherence to international quality standards.

Source: *Investor presentation*

FINANCIAL REVIEW

For the financial year 2024-25 (FY25), Concord Biotech Limited delivered a strong financial performance. The Company recorded revenue of Rs 1,200.1 crores, which represents an 18% growth on a year-on-year basis. Profit After Tax (PAT) increased by 21% to Rs 371.6 crores, while EBITDA grew by 17% to Rs 506.3 crores. This sustained growth highlights the company's operational discipline and execution excellence. Furthermore, Concord Biotech maintained a prudent financial position by remaining a zero-debt company. Overall, FY25 was characterised by focused execution and disciplined progress.

PARTICULARS	FY 25	FY 24	Change (%)	Reason for change
EBITDA/Turnover (%)	42.2%	42.8%		
Return on Capital Employed	26.8%	27.0%		
Return on equity (%)	20.50%	22.0%		
Book value per share (INR)	172.64	145.9		
Earnings per share (INR)	35.5	29.5		
Working Capital Days	289	259		
Current ratio (x)	6.17	6.3		
Net profit margin (%)	31.0%	30.3%		

Ratio Source: *Investor presentation and our own internal calculation. Word file is attached for that.*

RISK MANAGEMENT

Concord utilises a cohesive risk management strategy to achieve effective risk reduction. This all-encompassing method secures regulatory adherence, safeguards its reputation, minimises negative impacts, and enables the company to seize new opportunities. By adopting strategic actions and proactive initiatives, the Company adeptly manages financial challenges, operational hurdles, brand risk, and market fluctuations. This approach fosters ongoing growth and stability in its operations.

HUMAN RESOURCES

Concord values its personnel as its most valuable asset and is committed to fostering an inclusive and stimulating work environment. The organisation emphasises the attraction and retention of exceptional talent via innovative recruitment strategies, prioritising adept researchers, scientists, and technical professionals who are dedicated to innovation.

To facilitate their professional development, Concord offers comprehensive training programs and actively promotes diversity and inclusion, ensuring equitable opportunities for all. The well-being and satisfaction of employees are paramount concerns, with wellness initiatives, employee assistance programs, and open communication channels implemented. Regular feedback, coaching, and performance evaluations enable employees to fulfil and enhance the company's mission effectively.

As of March 31, 2025, Concord Biotech employed [] individuals. Its human resource practices are structured to nurture and retain premier scientific and technical talent, boost engagement, and drive organisational success through proficient workforce management.

INTERNAL CONTROL SYSTEMS AND ITS ADEQUACY

Concord is committed to upholding robust internal control systems that promote operational efficiency and integrity. The company adheres to principles of integrity, accountability, and ethical behaviour, with its leadership establishing a clear precedent. Regular risk assessments allow Concord to pinpoint and address potential threats, while customised control measures—such as separation of duties and IT controls—improve its healthcare operations.

Effective internal controls are strengthened through transparent communication, training initiatives, and ongoing monitoring. Concord nurtures a culture of compliance and accountability, empowering employees to maintain control measures and voice concerns. The company continually refines its internal control framework to meet shifting risks and industry best practices, ensuring the consistent provision of quality healthcare services.

CAUTIONARY STATEMENT

The statement in this section outlines the Company's objectives, projections, expectations, and estimates, which may be considered 'forward-looking' under applicable securities laws and regulations. These forward-looking statements are based on certain assumptions and anticipations regarding future events. However, it's important to note that the Company cannot guarantee the accuracy or realisation of these assumptions and expectations. Actual results may differ significantly from those expressed or implied in the statement due to various external factors beyond the Company's control. The Company assumes no responsibility to publicly amend, modify, or revise any forward-looking statements based on subsequent developments. Stakeholders should exercise caution and consider the inherent uncertainties associated with forward-looking statements when making decisions based on such information.

DIRECTORS' REPORT

TO THE MEMBERS:

The Directors have pleasure in presenting the **40th Annual Report** on the business and operations along with audited standalone and consolidated financial statement of accounts of the Company for the financial year ended on 31st March, 2025.

1. FINANCIAL RESULTS

The financial results of the company for the year under review are as under:

Particulars	2024-25 (₹in Lacs)		2023-24 (₹in Lacs)	
	Standalone	Consolidated	Standalone	Consolidated
Revenue from Operation	1,20,009	1,20,009	1,01,694	1,01,694
Other Income	4,445	4,445	3,378	3,378
Share of Profit in Joint venture with Japan	-	-132	-	337
Profit/loss before Depreciation, Finance Costs, Exceptional items and Tax Expense	55,078	54,946	46,534	46,871
Less: Depreciation/ Amortization/ Impairment	5,437	5,437	5,359	5,359
Profit /loss before Finance Costs, Exceptional items and Tax Expense	49,641	49,509	41,175	41,512
Less: Finance Costs	53	53	255	255
Profit /loss before Exceptional items and Tax Expense	49,588	49,456	40,920	41,257
Add/(less): Exceptional items	0	0	0	0
Profit /loss before Tax Expense	**49,588**	**49,456**	**40,920**	**41,257**
Less: Tax Expense:				
Current	11,896	11,896	9,983	9,983
Deferred	395	395	463	463
Short provision for tax of earlier years	-	-	-	-
Profit /loss for the year (1)	**37,297**	**37,165**	**30,474**	**30,811**
Total Comprehensive Income/loss (2)	597	597	(1)	(1)
Total (1+2)	**37,894**	**37,762**	**30,473**	**30,810**
Balance of profit /loss for earlier years	1,51,480	1,51,619	1,28,152	1,27,954
Add: Profit for the Year	37,297	37,165	30,474	30,811
Add: Other Comprehensive Income	597	597	(1)	(1)
Less: Dividend paid on Equity Shares	(9,154)	(9,154)	(7,145)	(7,145)
Less: Dividend paid on Preference Shares	0.00	0.00	0.00	0.00
Less: Dividend Distribution Tax	0.00	0.00	0.00	0.00
Balance carried forward	**1,80,220**	**1,80,227**	**1,51,480**	**1,51,619**

The standalone and consolidated financial statement of the Company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as notified under the Companies (Indian Accounting Standard) Rules, 2015 as amended.

REVIEW OF OPERATIONS AND THE STATE OF COMPANY'S AFFAIRS

In FY25, your Company achieved a robust revenue from operations of ₹1,20,009 lakhs, marking an impressive year-on-year growth of 18.01% compared to ₹1,01,694 lakhs in FY24. This growth was primarily driven by the continued strength of our **Active Pharmaceutical Ingredients (API)** segment, which contributed ₹94,009 lakhs, accounting for 78% of total revenue. The **Formulations** segment contributed ₹26,000 lakhs, representing the remaining 22%.

From a geographical perspective, **domestic sales** constituted ₹66,183 lakhs (55%), while **exports** contributed ₹53,826 lakhs (45%), reaffirming our strong global footprint and sustained international demand.

Other Income rose to ₹4,445 lakhs in FY25 from ₹3,378 lakhs in FY24, primarily driven by gains from strategic investments.

On a consolidated basis, the Company reported Net Profit of ₹37,165 Lakhs for the year ended 31 March 2025, as against ₹30,811 Lakhs in the previous financial year.

The consistent growth in both revenue and profitability underscores the Company's strategic focus, operational efficiency, and resilience in a dynamic business environment.

AWARDS AND RECOGNITIONS:

- Concord has been honored with the DET Hurun Award for Outstanding Contribution to India's Manufacturing Economy at the India Manufacturing Excellence Awards 2025. This prestigious event, held on February 25, 2025, in Mumbai, was organized by Hurun India in

collaboration with the Dubai Department of Economy and Tourism.

- Concord Biotech has been honored with the prestigious Sustainability Reporting Award for 2023–2024 by the Institute of Chartered Accountants of India (ICAI). This esteemed recognition underscores the company's commitment to excellence in Business Responsibility and Sustainability Reporting (BRSR), reflecting our dedication to transparency, ethical governance, and sustainable business practices.

2. DIVIDEND

Your directors have recommended final dividend of ₹ 10.70/- per equity share having face value of ₹ 1 each for the financial year ended on 31st March, 2025. The dividend, if approved at the ensuing Annual General Meeting ('AGM'), will be paid to those members whose names appear as on Record date fixed on close of Wednesday, 3rd September, 2025. The total dividend payout will be approximately 111.94 Crores.

Pursuant to Regulation 43A(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Board has formulated and adopted Dividend Distribution Policy which has been hosted on the website of the Company and the same can be accessed through below weblink.

https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Dividend-Distribution-Policy.pdf.

CHANGE IN THE NATURE OF BUSINESS, IF ANY:

There is no change in the nature of business during the financial year 2024-25.

SHARE CAPITAL

During the year there was no change in share capital of the Company. The Paid-up Equity Share Capital as at 31 March, 2025 stood at ₹10,46,16,204.

KEY DEVELOPMENTS AND STRATEGIC INITIATIVES

During the financial year ended **31 March 2025**, your Company achieved several significant milestones that reinforce its commitment to innovation, regulatory excellence, and sustainable growth:

- **Commissioning of Injectable Facility:** The Company successfully commissioned and commenced production of injectable formulations at its manufacturing facility located in Valthera, marking a key expansion in its product portfolio.
- **Strategic Investment in Palvella Therapeutics Inc. USA:** The Company made a strategic investment in M/s Palvella Therapeutics, a biotechnology company focused on developing and commercializing therapies for rare genetic skin diseases, thereby supporting innovation in rare disease therapeutics.
- **Investment in Renewable Energy:** In line with our long-term sustainability objectives, the Company has made a strategic investment in M/s Clean Max Everglades Private Limited through a rights issue. This investment is directed towards the installation of a hybrid renewable energy plant dedicated to powering our manufacturing operations at the Dholka facility. The initiative underscores our commitment to reducing carbon emissions and enhancing energy efficiency across our operations.

REGULATORY APPROVALS:

In 2024-25, different plants of your company were inspected by various regulatory bodies.

i. MFDS Inspection at Manufacturing Unit-I, Dholka

We successfully completed an inspection by the Ministry of Food and Drug Safety (MFDS), South Korea, at our Manufacturing Unit located in Dholka. This achievement reflects our adherence to stringent international regulatory standards and strengthens our position in the South Korean pharmaceutical market.

ii. EU-GMP Certification for Valthera Facility

Our Valthera facility received EU-GMP certification from the Health Products Regulatory Authority of Ireland. This certification is a testament to our robust quality systems and enables us to expand our reach in European markets with confidence and credibility.

iii. SFDA Inspection at our Formulation Unit at Valthera

The Company successfully completed an inspection by the Saudi Food and Drug Authority (SFDA) at our Formulation Unit at Valthera. This highlights our commitment to regulatory compliance and supports our strategic growth in the Middle East region.

Following are the updates on regulatory Approvals till signing of this report:-

i. USFDA Inspection of API Facility, Dholka

The Active Pharmaceutical Ingredient (API) facility at Dholka underwent a successful inspection by the USFDA, reaffirming our compliance with global quality and regulatory benchmarks. This milestone underscores our dedication in maintaining excellence in manufacturing practices and product integrity.

ii. USFDA Approval for Teriflunomide Tablets

The Company received final approval from the United States Food and Drug Administration (USFDA) for the marketing of Teriflunomide Tablets. This approval marks a significant step in expanding our footprint in the U.S. generics market and reinforces our commitment to delivering high-quality, affordable medications globally.

Russian GMP (Good Manufacturing Practice) inspection of API facility, Dholka

Successful completion of the Russian GMP (Good Manufacturing Practice) inspection at our Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat. This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance across all aspects of our operations.

3. RESERVES

The Board does not propose to carry any amount to the reserves for the financial year ending 31st March 2025.

4. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Pursuant to Regulation 34 of the SEBI Listing Regulations, the Management Discussion and Analysis Report for the year under review, is forms part of the Integrated Annual Report.

5. BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORTING

In Compliance with Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is required to prepare a Business Responsibility and Sustainability Report on the environmental, social and governance disclosures.

The Business Responsibility and Sustainability Report of the Company for the financial year ended 31 March, 2025, is presented in the separate section forming part of this Annual Report.

6. CORPORATE GOVERNANCE

The Company remains determined in its commitment to uphold the highest standards of corporate governance. We believe that sound governance practices are fundamental to build and sustain a resilient and responsible organization. Our approach is rooted in implementing robust policies, fostering a culture of ethical leadership, and ensuring compliance with applicable laws and regulations across all levels of the organization.

A separate section on Corporate Governance standards followed by your Company, as stipulated under Regulation 27 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed to this Report.

A Certificate from Mr. Ashish Shah, Practicing Company Secretary, conforming compliance to the conditions of Corporate Governance as stipulated under Regulation 27 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is annexed to this Report.

7. MATERIAL CHANGES AND COMMITMENTS

Pursuant to the provisions of the Companies Act, 2013, a material change and commitment has occurred between the end of the financial year and the date of this report that may have a bearing on the financial position of the Company.

- Concord Biotech Limited has made a strategic investment by acquiring a 75% equity interest in Stellon Biotech Inc., thereby designating it as a subsidiary entity incorporated in the United State. This initiative is aimed to enhance the Company's commercial presence in the U.S. market. Stellon Biotech Inc. will serve as a dedicated platform for the distribution and sale of Concord's products, thereby reinforcing its global footprint and supporting long-term growth objectives.
- Concord Lifegen Limited, a wholly Owned Subsidiary of Concord Biotech Limited, is Incorporated to manage the marketing, sales, and distribution of pharmaceutical products. It's primary objectives include executing targeted sales strategies, ensuring regulatory compliance across domestic and international markets, handling logistics and customer support, and maintaining transparent reporting to the holding company.

8. INTERNAL FINANCIAL CONTROL

The Company has established a comprehensive framework of internal financial controls designed to ensure the orderly and efficient conduct of its business operations. These controls encompass robust framework of internal financial controls that includes clearly defined policies, procedures, and systems—both manual and technology-enabled. These controls are designed to ensure adherence to internal guidelines, safeguard the Company's assets, prevent and detect fraud and errors, and support the accuracy, completeness, and reliability of financial reporting. Continuous technological enhancements further strengthen the effectiveness and efficiency of these controls, aligning with evolving business needs and regulatory expectations.

Periodic internal audits are conducted by the Company's Internal Auditors to provide reasonable assurance on the effectiveness of the control systems and to recommend improvements aligned with industry best practices. The Audit Committee, comprising Independent Directors, regularly reviews key findings from both internal and statutory audits, monitors the implementation of corrective actions, and ensures timely mitigation of identified risks.

9. DETAILS OF SUBSIDIARY/JOINT VENTURES/ ASSOCIATE COMPANIES

Concord Biotech Japan KK based in Japan is a Joint venture Company in which Company holds 50 % Stake.

During the financial year, the Company acquired a 26% equity interest in M/s Clean Max Everglades Private Limited to facilitate the establishment of a hybrid renewable energy facility. This strategic investment is in alignment with the Company's long-term sustainability goals and has led to the

classification of Clean Max Everglades Private Limited as an associate company.

Pursuant to provisions of Section 129(3) of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014, Concord Biotech Japan KK and M/s Clean Max Everglades Private limited are Joint Venture and Associate Company respectively, a statement containing salient features of the financial statements in **Form AOC-1** is attached to the financial statements of the Company as **Annexure I.**

10. ANNUAL RETURN

As per provisions of Section 92(3) Annual Return of the Company for the financial year ended on March 31, 2025 is placed on the website of the Company and the same can be accessed through https://www.concordbiotech.com/investors.

11. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 are given in the notes to the Financial Statement.

12. CHANGES IN DIRECTORS AND KEY MANAGERIAL PERSONNEL

Pursuant to the provisions of Section 152 (6) of the Companies Act, 2013 and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof for the time being in force) Mr. Rajiv Agrawal (Din: 00379990), Director of the Company is liable to retire by rotation, and being eligible, offer himself for re-appointment. The Board of Directors in its meeting held on August 08, 2025 recommends to the members of the Company, reappointment of Mr. Rajiv Agrawal (Din: 00379990) as Director. Necessary resolution for his appointment is therefore proposed in the ensuing Annual General Meeting.

After the closure of financial year, there was a change in the Key Managerial Personnel of the Company. Mr. Prakash Sajnani ceased to hold office as the Company Secretary and Compliance Officer with effect from close of working hours on 29th May 2025. Upon the recommendation of the Nomination and Remuneration Committee, the Board of Directors, at its meeting held on 29th May 2025, appointed Ms. Hina Patel (ACS: 56541) as the Company Secretary and Compliance Officer of the company with effect from 30th May, 2025.

13. DECLARATION BY INDEPENDENT DIRECTORS

Pursuant to Section 149(6) of the Companies Act, 2013, Independent Directors of the Company have made a declaration confirming the compliance of the conditions of the independence stipulated in the aforesaid section read with Schedule IV of the Companies Act, 2013.

14. NUMBER OF THE MEETINGS OF THE BOARD OF DIRECTORS

During the financial year 2024-25, the Board of Directors met Five (5) times i.e. 23rd May, 2024, 9th August, 2024, 11th November, 2024, 13th February, 2025 and 4th March, 2025. Detailed information on the Board Meetings is included in the Corporate Governance Report, which forms part of this Annual Report.

Committees of the Board of Directors

Your Company has diverse Committees which have been constituted as part of the best Corporate Governance practices and are in compliance with the requirements of the relevant provisions of applicable laws and statutes.

The Company has following Committees:

- Audit Committee
- Stakeholder's Grievances and Relationship Committee
- Nomination and Remuneration Committee
- Corporate Social Responsibility Committee
- Risk Management Committee
- Management Committee

The details with respect to the compositions, powers, terms of reference and other information of the relevant committees of the Board of Directors are given in details in the Corporate Governance Report which forms part of this Annual Report.

15. DEPOSITS

The Company has not accepted any deposits during the period under review and there are no outstanding deposits as on March 31, 2025. There have been no matured deposits remaining unpaid at the year-end.

16. PARTICULARS OF CONTRACTS OR ARRAGEMENTS WITH RELATED PARTIES

During the financial year, all related party transactions entered into by the Company were conducted in the ordinary course of business and on an arm's length basis, in accordance with applicable regulatory requirements. There were no materially significant transactions with Promoters, Directors, Key Managerial Personnel, or other related parties that could potentially conflict with the interests of the Company.

All related party transactions, were presented to the Audit Committee for prior approval. For transactions of a repetitive nature that occur in the ordinary course of business, the Company has obtained omnibus approval from the Audit Committee. In accordance with the approval, the requisite disclosures are submitted to the Committee on a quarterly basis, ensuring transparency and compliance with applicable regulatory requirements.

Details of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013 are provided in Form AOC-2, which forms part of this Board of Directors' Report as **Annexure II.**

17. INFORMATION PURSUANT TO SECTION 134 OF THE COMPANIES ACT, 2013

a. Conservation of energy and technology absorption.

Information pursuant to clause (m) sub-section (3) of section 134 of The Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 and forming part of this report are given in the **Annexure III.**

b. The details of foreign exchange earnings and outgo are annexed in **Annexure III.**

18. DIRECTOR'S RESPONSIBILITY STATEMENT:

Pursuant to Section 134(3)(c) of the Companies Act, 2013 the Directors confirm the following:

i. In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures.

ii. Your Directors had selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period.

iii. Your directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.

iv. Your directors had prepared the attached Annual Accounts for the year ended on March 31, 2025 on a going concern basis.

v. Your directors had laid down internal financial controls to be followed by the Company and such internal financial controls are adequate and were operating effectively.

vi Your Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

19. DETAILS OF COMMITTEE OF DIRECTORS:

Detailed note on Composition of Audit Committee of Directors, Nomination and Remuneration Committee, Risk Management Committee, CSR Committee, and Stake Holders Relationship Committee of Directors and management committee, number of meetings held of each Committee during the financial year 2024-25 and meetings attended by each member of the Committee as required under the Companies Act, 2013 are provided in Corporate Governance Report.

20. PARTICULARS OF EMPLOYEES:

Company does not have any employees who is drawing remuneration in excess of limit prescribed under Section 197(12) of the Companies Act, 2013 read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

The information required under section 197(12) of the Act read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, attached as **"Annexure- IV"**

The statement containing the names of top ten employees will be made available on request sent to the Company on complianceofficer@concordbiotech.com.

21. POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION AND OTHER DETAILS

The Company's Policy relating to appointment of Directors, payment of Managerial remuneration, Directors' qualifications, positive attributes, independence of Directors and other related matters as provided under Section 178(3) of the Companies Act, 2013 is furnished as attached to this report. **"Annexure – V".** The weblink for the same is https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Nomination-and-Remuneration-Policy.pdf

22. ANNUAL EVALUATION BY THE BOARD OF ITS OWN PERFORMANCE, ITS COMMITTEES AND INDIVIDUAL DIRECTORS:

Board Diversity

The Board remains committed to fostering a diverse and inclusive leadership structure that reflects a wide range of perspectives, experiences, and expertise. We believe that diversity at the board level enhances governance quality, promotes balanced decision-making, and strengthens stakeholder confidence. During the year, we continued to advance our diversity agenda by ensuring representation across gender, professional backgrounds, and industry experience. This approach not only aligns with our corporate values but also supports our long-term strategic objectives and sustainable growth.

Board Evaluation

Pursuant to the provisions of the Companies Act, 2013 and Regulation 17 and Regulation 25 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a structured questionnaire was prepared after taking into consideration of the various aspects of the Board's functioning, Composition of the Board and Committees, culture, execution and performance of specific duties, obligation and governance. The performance evaluation of the Independent Directors was completed.

During the financial year under review, the Independent Directors met on 13th February, 2025, inter alia, to discuss:

- Performance evaluation of Non-Independent Directors and Board of Directors as a whole;
- Performance evaluation of the Chairman of the Company;
- Evaluation of the quality of flow of information between the Management and Board for effective performance by the Board.

The Board of Directors expressed their satisfaction with the evaluation process.

23. CORPORATE SOCIAL RESPONSIBILITY:

In Compliance with Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules, 2014, the Company has established Corporate Social Responsibility (CSR) Committee and statutory disclosures with respect to CSR Committee and an Annual Report on CSR Activities forms part of this Board of Director's Report as **"Annexure-VI"** to this report.

The details of policy developed and implemented by the Company on Corporate Social Responsibility is available on website of Company at www.concordbiotech.com.

24. AUDITORS

Statutory Auditors

The Statutory Auditors, M/s. BSR & Co. LLP, Chartered Accountants (ICAI Registration No. 101248W/W-100022), has been appointed for a period of five years till the conclusion of 44th Annual General Meeting to be held in the Financial year 2028-29 on such remuneration as may be decided by the Board in consultation with the Statutory Auditors of the Company.

The Auditors' Report on the financial statements of the Company for the Financial Year ended March 31, 2025, is unmodified i.e. it does not contain any qualification, reservation or adverse remark or disclaimer. The Auditors' Report is enclosed with the financial statements forming part of the Integrated Annual Report.

Cost Auditors

The Cost Records as specified by the central government under sub-section(1) of the Section 148 of the Companies Act, 2013 are made and maintained by the company.

The Board, on recommendation of the Audit Committee, has appointed M/s. Dalwadi & Associate, Cost Accountants (Firm Registration Number 000338) as the Cost Auditors of the Company to conduct the audit of Company's cost records for the Financial Year 2025-26. The Cost Auditors have confirmed that their appointment is within the limits of Section 141(3) (g) of the Companies Act, 2013 and have also certified that they are free from any disqualifications specified under Section 141(3) and proviso to Section 148(3) read with Section 141(4) of the Companies Act, 2013. The Audit Committee has also received a certificate from the Cost Auditors certifying their independence and arm's length relationship with the Company. In accordance with the provisions of Section 148 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, since the remuneration payable to the Cost Auditor is required to be ratified by the members, the Board recommends the same for approval by members at the ensuing AGM.

Internal Auditor

M/s Manubhai & Shah LLP, Chartered Accountants, Ahmedabad, were appointed as Internal Auditors for FY 2024–25 and reappointed for FY 2025–26 by the Board on the Audit Committee's recommendation.

The Internal Auditor presents their report and findings on the internal audit of the Company to the Audit Committee on a quarterly basis. The scope and coverage of the internal audit are reviewed and approved by the Audit Committee to ensure alignment with the Company's risk management framework and operational priorities. The internal audit function continues to play a critical role in evaluating the effectiveness of internal controls, identifying areas for improvement, and supporting the Board in maintaining robust governance standards.

Secretarial Auditors

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and rules thereunder, M/s. Ashish Shah & Associates, Practicing Company Secretaries (Firm Registration Number S2001GJ041700), were appointed to conduct the secretarial audit of the Company for the Financial Year 2024-25. The Secretarial Audit Report for the Financial Year 2024-25 does not contain any qualification, reservation or adverse remark or disclaimer. It is annexed herewith as **"Annexure-VI"** to this Report.

Pursuant to the provisions of Regulation 24A of the SEBI Listing Regulations, the Annual Secretarial Compliance Report for the Financial Year 2024-25, issued by M/s. Ashish Shah & Associates, Practicing Company Secretaries has been submitted with the stock exchanges where shares of the Company are listed, within stipulated timeline.

M/s. Ashish Shah & Associates, Practicing Company Secretaries, proposed to be appointed on the basis of recommendation of Audit committee as the Secretarial Auditors of the Company from the conclusion of this 40th Annual General Meeting till the conclusion of 45th Annual General Meeting of the Company pursuant to the provisions of Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 204 of the Companies Act, 2013 and rules made thereunder, subject to approval of shareholder of the company in the ensuing

Annual General Meeting of the Company. Written consent of the Secretarial Auditors and confirmation to the effect that they are eligible and not disqualified to be appointed as the Secretarial Auditors of the Company in the terms of the provisions of the Listing Regulations, the Companies Act, 2013 and the rules made thereunder has been received.

25. EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESERVATIONS OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE AUDITORS AND SECRETARIAL AUDITOR

There are no qualifications or comments by the Statutory Auditors and Secretarial Auditors which require any explanation from the Directors.

26. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE.

There are no material orders passed by the Regulators, Courts, and tribunals impacting going concern status and the Company's operations in future.

27. VIGIL MECHANISM/ WHISTLE BLOWER MECHANISM:

The Company has established a vigil mechanism and accordingly framed a Whistle Blower Policy. The policy enables the employees to report to the management instances of unethical behavior, actual or suspected fraud or violation of Company's Code of Conduct. Further the mechanism adopted by the Company encourages the Whistle Blower to report genuine concerns or grievances and provide for adequate safe guards against victimization of Whistle Blower who avails of such mechanism and also provides for direct access to the Chairman of the Audit Committee, in exceptional cases. The functioning of vigil mechanism is reviewed by the Audit Committee from time to time.

The Whistle Blower Policy of the Company is available on the website of the Company https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Whistle-Blower-Policy.pdf

28. RISK MANAGEMENT POLICY OF THE COMPANY:

The Company has structured risk management policy. The Risk management process is designed to safeguard the organization from various risks through adequate and timely actions. It is designed to anticipate, evaluate and mitigate risks in order to minimize its impact on the business. The potential risks are inventoried and integrated with the management process such that they receive the necessary consideration during decision making.

The Risk Management Policy of the Company is available on the website of the Company https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Risk-Management-Policy.pdf

29. INCREASE AND SUB DIVISION IN AUTHORISED SHARE CAPITAL:

There were no changes in Authorized Share Capital of the Company during the year.

30. INCREASE IN ISSUED, SUBSCRIBED AND PAID-UP SHARE CAPITAL:

There were no changes in the Paid-Up Share Capital of the Company during the year.

31. CONSTITUTION OF INTERNAL COMPLAINTS COMMITTEE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

In accordance with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013 ("POSH Act") and the Rules made thereunder, the Company has in place a policy which mandates no tolerance against any conduct amounting to sexual harassment of women at workplace. The Company has inbuilt mechanism to redress and resolve any complaints arising under the POSH Act.

Training/awareness Programme were conducted during the financial year to create sensitivity towards ensuring respectable workplace.

32. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB-SECTION (12) OF SECTION 143 OTHAR THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL GOVERNMENT:

No frauds have been noticed or reported during the year under audit report which are reportable to the Central Government.

33. HUMAN RESOURCES

The employees have played a major role in the performance of the Company over the years. They will continue to be the Company's pillars of strength in the years to come as proper training and exposure to the new products will be forthcoming. Industrial relations in the Company were amicable throughout the year under review.

34. INSURANCE

The Company's assets are comprehensively insured to mitigate financial exposure arising from a broad spectrum of operational, environmental, and other insurable risks, in alignment with our risk management framework and commitment to safeguarding stakeholder interests.

35. COMPLIANCE WITH SECRETARIAL STANDARDS:

Your Directors confirm that, Company complies with applicable mandatory Secretarial Standards issued by the Institute of Company Secretaries of India.

36. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE FINANCIAL YEAR:

During the year under review, the Company has not made any application before the National Company Law Tribunal under Insolvency and Bankruptcy Code, 2016 for recovery of outstanding loans against customer and there is no pending proceeding against the Company under Insolvency and Bankruptcy Code, 2016.

37. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF DURING THE FINANCIAL YEAR:

It is not applicable to the Company, during the financial year.

38. ACKNOWLEDGEMENT

The Directors wish to place on record their appreciation for the unwavering trust and confidence reposed by the shareholders in the management and governance of the Company.

Further, the Board acknowledges the valuable contributions and support received from various regulatory agencies, customers, suppliers, and all other stakeholders who have played a vital role in the successful conduct of the Company's business.

Your continued support and collaboration remain the cornerstone of our progress, and we look forward to strengthening these relationships in the years to come.

FOR AND **ON BEHALF OF THE BOARD OF DIRECTORS**
CONCORD BIOTECH LIMITED

SUDHIR VAID
Chairman & Managing Director
DIN: 00055967

Place: Ahmedabad
Date: 8th August, 2025

Annexure-I

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)
Statement containing salient features of the financial statement of subsidiaries /associate companies/joint ventures

PART "B": ASSOCIATES AND JOINT VENTURES

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures

Joint Venture -1

Sr. No.	Block -1	Details
1	Name of Associate/Joint Venture	Concord Biotech Japan KK
2	Latest audited Balance Sheet Date	31-03-2025
3	Date on which the Associate or Joint Venture was associated or acquired	23rd October, 2019
4	Shares of Associate/Joint Ventures held by the company on the year end	50%
A	Number	200 equity shares
B	Amount of Investment in Joint Venture	₹ 66,52,000
C	Extent of Holding %	50%
5	Description of how there is significant influence	Concord Is holding 50% equity share capital in Join venture
6	Reason why the associate/joint venture is not consolidated	NA
7	Net worth attributable to Shareholding as per latest audited Balance Sheet	₹ 4,55,58,609 (exchange rate 0.5552) JPY 8,20,63,349
8	Loss for the year	₹ -21,17,454 (exchange rate 0.5552) JPY -38,14,107
A	Considered in Consolidation	Yes
B	Not Considered in Consolidation	NA

Number of associates or joint ventures which are yet to commence operations – N.A.

Sr. No.	CIN /any other registration number	Names of Associates and Joint Ventures which are yet to commence operations
		N.A.

Number of associates or joint ventures which have been liquidated or have ceased to be associate or joint venture during the year- N.A.

Sr. No.	CIN /any other registration number	Names of Associates and Joint Ventures
		N.A.

For and **on behalf of the Board of Directors of**
Concord Biotech Limited

SD/-
Mr. Sudhir Vaid
Chairman and Managing Director
(DIN: 00055967)

SD/-
Mr. Ankur Vaid
Joint Managing Director and CEO
(DIN: 01857225)

SD/-
Mr. Lalit Sethi
Chief Financial Officer

SD/-
Ms. Hina Patel
Company Secretary & Compliance Officer
(ACS: 56541)

Date : 8th August, 2025
Place : Ahmedabad

Annexure-I

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)
Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

PART "B": ASSOCIATES AND JOINT VENTURES

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures

Number of Associate :-1

Sr. No.	Block -1	Details
1	Name of Associate/Joint Venture	Clean Max Everglades Private Limited
2	Latest audited Balance Sheet Date	31-03-2025
3	Date on which the Associate or Joint Venture was associated or acquired	16-01-2025
4	Shares of Associate/Joint Ventures held by the company on the year end	26%
A	Number	75,856 equity shares
B	Amount of Investment in Associates/Joint Venture	₹ 6,09,83,836/-
C	Extent of Holding %	26%
5	Description of how there is significant influence	Company has invested in 26% equity share capital of associate company
6	Reason why the associate/joint venture is not consolidated	Associate entity's financials are not consolidated considering that *concord neither has the representation on the board of directors of the **Clean Max and nor has the ability to participate in the investee's policy-making processes.
7	Net worth attributable to Shareholding as per latest audited Balance Sheet	₹ 6,09,25,800/-
8	Profit / Loss for the year	₹ -2,30,000/-
A	Considered in Consolidation	NA
B	Not Considered in Consolidation	Yes

***Concord- Concord Biotech Limited**
****Clean Max- Clean Max Everglades Private Limited**

Number of associates or joint ventures which are yet to commence operations – N.A.

Sr. No.	CIN /any other registration number	Names of Associates and Joint Ventures which are yet to commence operations
		N.A.

Number of associates or joint ventures which have been liquidated or have ceased to be associate or joint venture during the year- N.A.

Sr. No.	CIN /any other registration number	Names of Associates and Joint Ventures
		N.A.

For and **on behalf of the Board of Directors of**
Concord Biotech Limited

SD/-
Mr. Sudhir Vaid
Chairman and Managing Director
(DIN: 00055967)

SD/-
Mr. Ankur Vaid
Joint Managing Director and CEO
(DIN: 01857225)

SD/-
Mr. Lalit Sethi
Chief Financial Officer

SD/-
Ms. Hina Patel
Company Secretary & Compliance Officer
(ACS: 56541)

Date : 8th August, 2025
Place : Ahmedabad

Annexure-I

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)
Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

PART "A": SUBSIDIARIES

Details of Subsidiaries

(Information in respect of each subsidiary to be presented with amounts in ₹)

Number of subsidiaries – 2

Sr. No.	Particulars	Block -1
1.	CIN/ any other registration number of subsidiary company	
2.	Name of the subsidiary	
3.	Date since when subsidiary was acquired	
4.	Provisions pursuant to which the company has become a subsidiary (Section 2(87)(i)/Section 2(87)(ii))	
5.	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	
6.	Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries:-	
7.	Share capital	
8.	Reserves & surplus	
9.	Total assets	
10.	Total Liabilities	
11.	Investments	
12.	Turnover	
13.	Profit before taxation	
14.	Provision for taxation	
15.	Profit after taxation	
16.	Proposed Dividend	
17.	% of shareholding	

Number of subsidiaries which are yet to commence operations – 2 (Two)

Sr. No.	CIN /any other registration number	Names of subsidiaries which are yet to commence operations
1	20244546292	Stellon Biotech Inc
2	U21002GJ2025PLC165303	Concord Lifegen Limited

Number of subsidiaries which have been liquidated or have ceased to be a subsidiary during the year- Nil

Sr. No.	CIN /any other registration number	Names of subsidiaries which are yet to commence operations
	NIL	

For and **on behalf of the Board of Directors of**
Concord Biotech Limited

SD/-
Mr. Sudhir Vaid
Chairman and Managing Director
(DIN: 00055967)

SD/-
Mr. Ankur Vaid
Joint Managing Director and CEO
(DIN: 01857225)

SD/-
Mr. Lalit Sethi
Chief Financial Officer

SD/-
Ms. Hina Patel
Company Secretary & Compliance Officer
(ACS: 56541)

Date : 8th August, 2025
Place : Ahmedabad

Annexure-II

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis:

Name of Related Party	Nature of Relationship	Nature of Contract / Arrangements / Transactions	Duration of Contracts / Arrangements / Transactions	Salient Terms of the Contracts / Arrangements / Transactions	Justification of entering	Date of Approval by Board	Amount paid in Advance	Date on which Special Resolution was passed in general meeting U/S 188
				NIL				

2. Details of material contracts or arrangement or transactions at arm's length basis:

Name of Related Party	Nature of Relationship	Nature of Contract / Arrangements / Transactions	Duration of Contracts / Arrangements / Transactions	Salient Terms of the Contracts / Arrangements / Transactions	Transactions Value	Date of Approval by Board	Amount paid in Advance
Mr. Sudhir Vaid	Chairman and Managing Director	Lease Agreement	3 Years	Lease Office at Mondeal Heights	Lease rent of ₹ 139.22 lakhs p.a.	01/07/2023	Nil
Mrs. Manju Vaid	Wife of Chairman & MD	Lease Agreement	3 Years	Lease Office at Mondeal Heights	Lease rent of ₹ 44.67 lakhs p.a.	01/07/2023	Nil
Col. S.K. Vaid	Brother of MD	Service Contract	N.A.	Providing of professional Services	Increase in service charges 4.05 Lakhs p.m. to 4.61 Lakhs p.m	08/11/2023	NIL
Mrs. Megha Vaid	Wife of Joint MD	Remuneration	N.A.	Periodical review by board	Increase in monthly Remuneration from ₹ 6.70 to ₹ 7.64 lakhs p.m.	11/11/2024	NIL
Mrs. Sonal Kumra	Daughter of MD	remuneration	N.A.	Periodical review by board	Increase in monthly Remuneration from ₹ 7.41 to ₹ 8.44 lakhs p.m.	11/11/2024	NIL
Concord Biotech Japan K.K.	Joint Venture	Sale of Goods	From 01/04/2024 to 31/03/2029	Sale of Goods at prevailing market rate	₹ 3,035.14 lacs p.a.	23/05/2024	Nil

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
CONCORD BIOTECH LIMITED

SUDHIR VAID
Chairman & Managing Director
DIN: 00055967

Place: Ahmedabad
Date: 8th August, 2025

ANNEXURE - III

PARTICULARS REQUIRED UNDER THE COMPANIES (ACCOUNTS) RULES, 2014

A. PARTICULARS WITH RESPECT TO CONSERVATION OF ENERGY

a. The Steps taken or impact on conservation of energy:-

During the year, the company implemented several measures aimed at conserving energy and improving overall energy efficiency across its operations. These included the installation of energy-efficient machinery, optimization of production processes to reduce power consumption, and the adoption of LED lighting systems in manufacturing and office facilities. Additionally, regular energy audits were conducted to identify areas for improvement, and employee awareness programs were organized to promote responsible energy usage

b. The steps taken by the Company for utilizing alternate sources of energy

During the year, the Company invested in an entity for the installation of a hybrid renewable energy plant dedicated to powering our Dholka manufacturing facility. This initiative reflects our commitment to sustainable operations by reducing reliance on conventional energy sources and enhancing energy efficiency through the use of solar and wind power.

c. The Capital investment on energy conservation equipments

No Capital investments are planned at this stage.

B. TECHNOLOGY ABSORPTION

i. Efforts made towards technology absorption:

During the financial year, the company undertook significant initiatives aimed at absorbing and adapting advanced technologies to enhance operational efficiency, product quality, and regulatory compliance. These efforts included the integration of automated systems in manufacturing processes, adoption of digital platforms for supply chain management, and implementation of data-driven tools for market analysis and customer engagement.

ii. The benefits derived like product improvement, cost reduction, product development or import substitution

At Concord, continuous efforts toward product enhancement have led to notable improvements in efficacy, stability, and alignment with global regulatory standards. Through the adoption of advanced manufacturing technologies, automation, and optimized resource utilization, the company achieved significant cost efficiencies. These initiatives also contributed to reducing reliance on imported materials, thereby promoting self-sufficiency in critical raw materials and strengthening the company's supply chain resilience.

iii. In case of imported technology (imported during the last three years reckoned from the beginning of the financial year) –

Year	Details of technology	Fully absorbed or not
2021-2022	Technology for Anti-Bacterial Drugs.	Fully Absorbed
2022-2023	N.A.	
2023-2024	Technology for Bacitracin ointment	Fully Absorbed

iv. The expenditure incurred on Research and Development

Company has incurred Revenue Expenditure of ₹ 2,713.87 lacs and Capital Expenditure of ₹ 113.97 lacs during the current year on Research and Development.

C. FOREIGN EXCHANGE EARNINGS AND OUTGO:

Total earnings in foreign exchange for the year ended 31st March, 2025 were ₹ 30,481 Lacs and the total outflow was ₹ 16,746 Lacs.

FOR AND **ON BEHALF OF THE BOARD OF DIRECTORS**
CONCORD BIOTECH LIMITED

SUDHIR VAID
Chairman & Managing Director
DIN: 00055967

Place: Ahmedabad
Date: 8th August, 2025

ANNEXURE – IV

PARTICULARS OF EMPLOYEES:-

The information required under section 197 of the Act read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are given below:

A. THE RATIO OF THE REMUNERATION OF EACH DIRECTOR TO THE MEDIAN REMUNERATION OF THE EMPLOYEES OF THE COMPANY FOR THE FINANCIAL YEAR.

Sr. No	Name of the Director	Designation	Ratio to median remuneration
1	Mr. Sudhir Vaid	Chairman and Managing Director	121.46
2.	Mr. Ankur Vaid	Jt. Managing Director & CEO	72.01

Remuneration drawn by the Managing Director includes perquisites. The Non-executive directors are not paid any remuneration except sitting fees for attending the meetings of the Board and / or Committees thereof which is within the limits prescribed by the Companies Act, 2013

B. THE PERCENTAGE INCREASE IN REMUNERATION OF EACH DIRECTOR, CHIEF EXECUTIVE OFFICER, CHIEF FINANCIAL OFFICER, COMPANY SECRETARY IN THE FINANCIAL YEAR.

Percentage Increase in Remuneration for FY 2024-205	
Chairman/MD	25%
JMD/CEO	25%
CFO	15%
CS	12%

C. THE PERCENTAGE INCREASE IN THE MEDIAN REMUNERATION OF EMPLOYEES IN THE FINANCIAL YEAR:- 0%.

D. THE NUMBER OF PERMANENT EMPLOYEES ON THE ROLLS OF THE COMPANY: 1571

E. AVERAGE PERCENTILE INCREASES ALREADY MADE IN THE SALARIES OF EMPLOYEES OTHER THAN THE MANAGERIAL PERSONNEL IN THE LAST FINANCIAL YEAR AND ITS COMPARISON WITH THE PERCENTILE INCREASE IN THE MANAGERIAL REMUNERATION AND JUSTIFICATION THEREOF AND POINT OUT IF THERE ARE ANY EXCEPTIONAL CIRCUMSTANCES FOR INCREASE IN THE MANAGERIAL REMUNERATION:

The Average percentile increase/decrease made in salaries of employees is 10.16% while that of KMP is 23.67%.

The Managerial Personnel are responsible for the consolidated performance of the Company, unlike non-managerial personnel. Thus, it is not meaningful to compare the increase in their remuneration with that of the other employees who do not have similar responsibilities.

F. AFFIRMATION THAT THE REMUNERATION IS AS PER THE REMUNERATION POLICY OF THE COMPANY

The Company affirms remuneration as per the remuneration policy of the Company.

Information as per Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

a) The company does not have any employee covered under the provisions of section 197(12) of the Companies Act, 2013 read with Rule 5(2) of the Companies (Appointment and remuneration of Managerial Personnel) Rules, 2014.

b) The statement containing the names of top ten employees will be made available on request sent to the Company on complianceofficer@concordbiotech.com

ANNEXURE – V

POLICY ON REMUNERATION OF DIRECTORS, KEY MANAGERIAL PERSONNEL ("KMP") AND OTHER EMPLOYEES

PREAMBLE

This Policy on Remuneration of Directors, Key Managerial Personnel ("KMP") and Other Employees (hereinafter referred as the "Policy") of Concord Biotech Limited ("the Company") is designed and formulated by the Nomination and Remuneration Committee ("the Committee") of the Company pursuant to the Companies Act, 2013 (the "Act") and rules made thereunder. In case of any inconsistency between the provisions of law and this remuneration policy, the provisions of the law shall prevail and the Company shall abide by the applicable law.

The Policy lays down the criteria with regard to remuneration of Directors, KMP and other employees.

A. Guiding Principles for remuneration: The Company shall remunerate all its personnel reasonably and sufficiently as per industry benchmarks and standards. The remuneration shall be commensurate with their contributions and shall be sufficient enough to retain and motivate the human resources of the Company. The compensation package will, inter alia, take into account the experience of the personnel, the knowledge and skill required including complexity of the job, work duration and risks associated with the work, and attitude of the worker like positive outlook, team work, loyalty, past remuneration, past performance etc.

The level and components of the remuneration shall be such so as to align with the long term interest of the company and its shareholders.

B. Components of Remuneration:

The following will be the various remuneration components which may be paid to the personnel of the Company based on the designation and class of the personnel.

a. Fixed compensation: The fixed salaries of the Company's personnel shall be competitive and based on the individual personnel's responsibilities and performance.

b. Variable compensation: The personnel of the Company may be paid remuneration by way of variable salaries based on their performance evaluation. Such variable salaries should be based on the performance of the individual against his short- and long-term performance objectives and the performance of the Company.

c. Share based payments: The Board of Directors may, on the recommendation of the Nomination and Remuneration Committee, issue to certain class of personnel a share and share price related incentive program.

d. Non-monetary benefits: Senior management personnel of the Company may, on a case-to-case basis, be awarded customary non-monetary benefits such as discounted salary advance /credit facility, rent free accommodation, company cars with or without chauffer's, share and share price related incentive, reimbursement of electricity and telephone bills etc.

e. Commission: The directors may be paid commission if approved by the shareholders. The shareholders may authorize the Board to declare commission to be paid to any director of the Board.

f. Retirement benefits: The Company shall provide retirement benefits applicable in accordance with law.

g. Sitting Fee and Commission: The Company may pay sitting fee for attending Board and Committee meeting and commission to the Directors of the Company in compliance with law.

h. Loan/ advances to the Employees: The Company may give loan or advances to the employees in accordance with the provisions of the Companies Act, 2013 and the terms and conditions of the Loan Policy of the Company, as approved by the Board or any Committees thereof, from time to time.

C. Entitlement: The authority to determine the entitlement to various components as aforesaid for each class and designation of personnel shall be as follows:

Designation / Class	To be determined by
Managing Director/ Joint Managing Director/ Whole Time Director	The remuneration for the Managing Director/ Joint Managing Director/ Whole-time Director is as per the agreement approved by the shareholders on recommendation of the Board of Directors. In case of any change, the same would require the approval of the shareholders on recommendation of the Board of Directors and other applicable compliances required by laws.
Independent Directors*	Board of Directors / Executive Committee
Other Directors	Board of Directors
Senior Management	Recommendation of the Nomination and Remuneration Committee and approval of Board of Directors
Recommendation of the Nomination and Remuneration Committee and approval of Board of Directors	Departmental Heads in consultation with Human Resources Head

*Sitting fee payable to the directors shall be as approved by the Board in accordance with the provisions of the law.

D. Amendment:

The Remuneration policy may be reviewed by the Board of the Company on the recommendation of the Nomination & Remuneration Committee of the Board.

Annexure-VI

ANNUAL REPORT ON CSR ACTIVITIES FOR THE YEAR ENDED 31ST MARCH 2025

1. BRIEF OUTLINE ON CSR POLICY OF THE COMPANY:

Concord Biotech Limited shall strive to reach out to the under-privileged, needy and weaker sections of the society and to address the social, educational, cultural, environmental and economic needs of such sections of the society. The company shall give preference to the local area of its operations.

Key Focus Areas of the CSR Policy are

a) Promoting education

b) Health Care

c) Sustainable Livelihood

d) Protection of the environment

e) Promotion of sports

f) Gender Equality & Empowerment of Women

g) Rural Development

h) Infrastructure development

2. COMPOSITION OF THE CSR COMMITTEE:

Sl. No.	Name of Director	Designation / Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Mr. Ankur Vaid	Chairman and Joint Managing Director & CEO	2	1
2	Mr. Arvind Agarwal	Member and Director	2	2
3	Mr. M Sriraman	Member and Director	2	2

3. PROVIDE THE WEB-LINK WHERE COMPOSITION OF CSR COMMITTEE, CSR POLICY AND CSR PROJECTS APPROVED BY THE BOARD ARE DISCLOSED ON THE WEBSITE OF THE COMPANY

Weblink for composition of CSR Committee is https://www.concordbiotech.com/social-responsibility-policy

Weblink for CSR Policy is https://www.concordbiotech.com/social-responsibility-policy

Weblink for CSR Projects as approved by the Board is https://www.concordbiotech.com/csr

4. PROVIDE THE DETAILS OF IMPACT ASSESSMENT OF CSR PROJECTS CARRIED OUT IN PURSUANCE OF SUB-RULE (3) OF RULE 8 OF THE COMPANIES (CORPORATE SOCIAL RESPONSIBILITY) RULES, 2014, IF APPLICABLE (ATTACH THE REPORT)

N.A.

5.

(a)	**Average net profit of the Company as per Section 135(5)**	:	₹ 31,579.39 lakhs
(b)	**Two percent of average net profit of the Company as per Section 135(5)**	:	₹ 631.59 lakhs
(c)	**Surplus arising out of the CSR projects or programmes or activities of the previous financial years**	:	Nil
(d)	**Amount required to be set off for the financial year, if any**	:	₹21.33 lakhs
(e)	**Total CSR obligation for the financial year (b + c - d)**	:	₹610.26 lakhs

6.

(a)	**Amount spent on CSR Projects (both Ongoing Project and other than Ongoing Project)**	:	₹ 588.91 lakhs
(b)	**Amount spent in Administrative Overheads:**	:	₹ 31.20 lakhs
(c)	**Amount spent on Impact Assessment, if applicable**	:	N.A.
(d)	**Total amount spent for the Financial Year (a+b+c)**	:	₹ 620.11 lakhs
(e)	**CSR Amount spent or unspent for the financial year:**	:	Nil

Total Amount Spent for the Financial Year (in ₹ Lakhs)	Amount Unspent (In ₹ Lakhs)				
	Total Amount transferred to Unspent CSR Account as per Section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to Section 135(5)		
	Amount (in ₹ Lakhs)	Date of Transfer	Name of the Fund	Amount (in ₹ Lakhs)	Date of Transfer
₹ 620.11	Nil	N.A.	N.A.	Nil	N.A.

(f) Excess amount for set off, if any:

Sl. No.	Particular	Amount (in ₹ Lakhs)
(i)	Two percent of average net profit of the company as per section 135(5)	631.59
(ii)	Total amount spent for the Financial Year	641.44*
(iii)	Excess amount spent for the financial year [(ii)-(i)]	9.85
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	Nil
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	9.85

*Excess ₹ 21.33 Lakhs spend on CSR activities upto immediately preceeding three financial years

7. DETAILS OF UNSPENT CSR AMOUNT FOR THE PRECEDING THREE FINANCIAL YEARS: N.A.

Sr. No.	Preceding Financial Year	Amount Transferred to Unspent CSR Account under Section 135(6) (₹ in Lakhs	Balance Amount in Unspent CSR Account under subsection (6) of section 135 (₹ In Lakhs)	Amount spent in the Reporting Financial Year (₹ in Lakhs)	Amount Spent to any Specified Fund mentioned in Schedule VII as per second proviso to subsection (5) of section 135, if any		Amount remaining to be spent in remaining Financial Years (₹ in Lakhs)	Deficiency if any,
					Amount (Rs) in lakhs	Date of Transfer		
1	2022-23	N.A.	N.A.	N. A.	Nil	N.A.	N.A.	
2	2021-22	N.A.	N.A.	N. A.	Nil	N.A.	N.A.	
3	2020-21	N.A.	N.A.	N. A.	Nil	N.A.	N.A.	
	TOTAL	**N.A.**	**N.A.**	**N. A.**	**Nil**	**N.A.**	**N.A.**	

8. WHETHER ANY CAPITAL ASSETS HAVE BEEN CREATED OR ACQUIRED THROUGH CORPORATE SOCIAL RESPONSIBILITY AMOUNT SPENT IN THE FINANCIAL YEAR (ASSET-WISE DETAILS): NO

9. SPECIFY THE REASON(S), IF THE COMPANY HAS FAILED TO SPEND TWO PER CENT OF THE AVERAGE NET PROFIT AS PER SECTION 135(5) : N.A.

Sudhir Vaid
Managing Director
DIN: 00055967

Ankur Vaid
Chairman of CSR Committee, JMD & CEO
DIN: 01857225

Date: 8th August, 2025
Place: Ahmedabad

CORPORATE GOVERNANCE REPORT

(Pursuant to Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Financial Year ended on 31.03.2025)

1. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE:

Your Company believes in simple, moral, accountable, responsive and transparent policies to attain the highest standards of Corporate Governance by ensuring transparency in all its actions, operations and to maximize values of its stakeholders. The Company recognizes its responsibility towards all its stakeholders and therefore constantly endeavors to create and enhance their wealth and value by implementing its business plans at appropriate times and thus taking maximum advantage of available opportunities to benefit the Company, its stakeholders and society at large.

2. BOARD OF DIRECTORS:

The Board of Directors comprises of Nine Directors out of which two Directors are Executive Directors and seven Directors are Non-Executive Directors. Out of seven Non-Executive Directors, five Directors are Independent Directors.

A. Board Meetings:

The Company places before the Board all the relevant and necessary information at their meetings for the information of the Board. During the year 5 (Five) Board Meetings were held on 23.05.2024, 09.08.2024, 11.11.2024, 13.02.2025 and 04.03.2025. The time gap between the two meetings did not exceed one hundred and twenty days.

B. Composition and attendance of each director at the meetings of the Board and the last Annual General Meeting:

Sr. No.	Name of Director	Category & Designation	No. of shares held	No. of board meetings attended out of 5	Last AGM attendance (Yes/No)	No. of other directorships	No. of committees in which chairman/ member in other public companies*		List of Directorship held in other listed Companies and category of Directorship
							Chairman	Member	
1	Mr. Sudhir Vaid	Promoter- Chairman & Managing Director	3,01,69,524	4	Yes	1	0	0	0
2	Mr. Ankur Vaid	Promoter-Jt. Managing Director and CEO	5,86,520	5	Yes	1	0	0	0
3	Mr. Ravi Kapoor	Non Executive-Director	2,10,000	5	Yes	7	0	8	Sanghi Industries Limited – Non-Executive Independent Director
4	Mr. Rajiv Agarwal	Non Executive-Director	1,30,482	5	Yes	6	0	1	Nazara Technologies Ltd- Non-Executive -Non Independent Director Aptech Limited- Non-Executive -Non Independent Director
5	Mr. Amitabh Thakore	Independent-Non Executive Director	111	5	Yes	1	0	0	0
6	Mrs. Bharti Khanna	Independent-Non Executive Woman Director	-	5	Yes	1	0	0	Nil
7	Mr. Arvind Agarwal	Independent –Non-Executive Director	1,103	5	Yes	2	0	0	Gujarat Small industries Corporation limited (Under Liquidation) - Nominee Director
8	Mr. Jayaram Easwaran	Independent –Non-Executive Director	500	5	Yes	1	2	1	Jindal Stainless Ltd-Independent Director
9	Mr. Mandayam Chakravarthy Sriraman	Independent –Non-Executive Director	-	5	Yes	0	0	0	Nil

* This relates to Committee referred under Regulation 18 & 20 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, viz. Audit Committee and Stakeholder Relationship Committee.

None of the Directors are related to the other Directors or to any other employee of the Company except Mr. Sudhir Vaid and Mr. Ankur Vaid. Mr. Ankur Vaid is son of Mr. Sudhir Vaid.

C. Directors' interest in the Company:

- None of the Non-Executive Directors of the Company have any pecuniary relationships or transactions with the Company except payment of Director Sitting Fees.
- The Non-Executive Directors of the Company are highly respected and accomplished professionals in the corporate and academic world.
- There is no compensation package for Non-Executive Directors.
- There is no Nominee Director on the board as on 31.03.2025.
- All the information required to be furnished to the Board was made available to them along with detailed agenda notes.
- The familiarization programs imparted to Independent Directors as required under the Listing Regulations are undertaken from time to time. Details of such programs are available on website of the Company at web link https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Policy-for-Familiarisation-Programme-for-Independent-Directors.pdf

List of Matrix / chart of special skills:

As required under the provisions of Schedule V(C) (2)(h) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015, the Board of Directors has identified the core skills / expertise / competencies as required in the context of its business(es) and sector(s) for it to function effectively and those actually available with the Board as follows:

Sr. No.	Name of Directors	Skills/Expertise identified by the Board	Specialization
1	Mr. Sudhir Vaid	Specialization in Biotechnology	Biotechnology
2	Mr. Ankur Vaid	Finance	Finance
3	Mr. Ravi Kapoor	Practicing company secretary	Legal Advisor
4	Mr. Rajiv Agarwal	Business	Business
5	Mr. Amitabh Thakore	Consulting	Consulting
6	Mrs. Bharti Khanna	Specialisation in Marketing Management	Marketing Management
7	Mr. Arvind Agarwal	Business	Business
8	Mr. Jayaram Easwaran	Business	Business
9	Mr. Mandayam Chakravarthy Sriraman	Doctor of Philosophy	Doctor of Philosophy

None of the Non-Executive Directors of the Company is holding any equity shares of the Company except Mr. Ravi Kapoor, Mr. Arvind Agarwal, Mr. Amitabh Thakore, Mr. Jayaram Easwaran and Mr. Rajiv Agarwal.

D. The Board of Directors be and is hereby confirm that, the Independent Directors fulfill the conditions specified in these regulations and are Independent of the Management.

E. No Independent Director has resigned before the expiry of their tenure during the year; therefore there is no requirement to make any disclosure in the said matter.

F. Board membership criteria:
The Company inducts eminent individual from diverse fields as Directors on its Board. The Nomination and Remuneration Committee works with the entire Board to determine the appropriate characteristics, skills and experience required for the Board as a whole and for individual members. Members are expected to possess the required qualifications, integrity, expertise and experience for the position. They should also possess deep expertise and insights in sectors/ areas relevant to the Company, and ability to contribute to the Company's growth.

3. AUDIT COMMITTEE:

The Audit Committee of the Company comprises of three Independent Directors of the Company. Mr. Amitabh Thakore, Chairman, Mr. Jayaram Easwaran, and Mr. Arvind Agarwal are members of Audit Committee. Mr. Amitabh Thakore, Chairman, of Audit Committee was present at last Annual General Meeting of the Company.

The terms of reference and powers of the Audit Committee are in compliance with the provisions of the Corporate Governance – Chapter III Regulation 18 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 177 of the Companies Act, 2013. Minutes of the Committee meetings are circulated and placed at the Board meetings.

(A) The role and responsibilities of the Audit Committee are as under:

(1) oversight of the listed entity's financial reporting process and the disclosure of its financial information to ensure that the Financial Statement is correct, sufficient and credible;

(2) recommendation for appointment, remuneration and terms of appointment of auditors of the listed entity;

(3) approval of payment to statutory auditors for any other services rendered by the statutory auditors;

(4) reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:

(a) matters required to be included in the Director's responsibility statement to be included in the board's report in terms of clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013;

(b) changes, if any, in accounting policies and practices and reasons for the same;

(c) major accounting entries involving estimates based on the exercise of judgment by management;

(d) significant adjustments made in the financial statements arising out of audit findings;

(e) compliance with listing and other legal requirements relating to financial statements;

(f) disclosure of any related party transactions;

(g) modified opinion(s) in the draft audit report;

(5) reviewing, with the management, the quarterly financial statements before submission to the board for approval;

(6) reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the board to take up steps in this matter;

(7) reviewing and monitoring the auditor's independence and performance, and effectiveness of audit process;

(8) approval or any subsequent modification of transactions of the listed entity with related parties;

(9) scrutiny of inter-corporate loans and investments;

(10) valuation of undertakings or assets of the listed entity, wherever it is necessary;

(11) evaluation of internal financial controls and risk management systems;

(12) reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;

(13) reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;

(14) discussion with internal auditors of any significant findings and follow up there on;

(15) reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;

(16) discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;

(17) to look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;

(18) to review the functioning of the whistle blower mechanism;

(19) approval of appointment of chief financial officer after assessing the qualifications, experience and background, etc. of the candidate;

(20) Carrying out any other function as is mentioned in the terms of reference of the audit committee;

(21) reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision;

(22) consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders.

(B) The audit committee shall mandatorily review the following information:

(1) management discussion and analysis of financial condition and results of operations;

(2) management letters / letters of internal control weaknesses issued by the statutory auditors;

(3) internal audit reports relating to internal control weaknesses; and

(4) the appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee.

(5) statement of deviations:

(a) quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1).

(b) annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7).

During the year 5 (five) meetings of the Audit Committee were held on 23/05/2024, 09/08/2024, 11/11/2024, 13/02/2024 and 04/03/2025 and attendance of each member of Audit Committee at Audit Committee Meetings are as mentioned below:

Name of Member	Category	Designation	No. of Audit Committee Meetings Attended
Mr. Amitabh Thakore	Independent Director	Chairman	5
Mr. Jayaram Easwaran	Independent Director	Member	5
Mr. Arvind Agarwal	Independent Director	Member	5

4. NOMINATION AND REMUNERATION COMMITTEE:

Brief description of terms of reference:

The terms of reference of the Nomination and Remuneration Committee are as per Section 178 of the Companies Act, 2013 and as per the requirements of Regulation 19 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The policy is framed by the Nomination and Remuneration Committee and approved by the Board. The terms and conditions for appointment are disclosed at the website of the Company at www.concordbiotech.com and weblink for the same is https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Nomination-and-Remuneration-Policy.pdf

Composition, Meetings & Attendance:

Nomination and Remuneration Committee of the Company comprises of 3 Directors, all of whom are Non-Executive Independent Directors. During the year under review, 2 (two) meeting of the Nomination & Remuneration Committee were held on 23.05.2024 and 11.11.2024.

The Composition and attendance is as under:

Name of Member	Category	Designation	No. of Nomination and Remuneration Committee Meetings Attended
Mr. Amitabh Thakore	Independent Director	Chairman	2
Mrs. Bharti Khanna	Independent Director	Member	2
Mr. Mandayam Chakravarthy Sriraman	Independent Director	Member	2

The performance of each Independent Director is evaluated by the committee and entire Board of Directors (in the absence of the director being evaluated) on the basis of engagement, leadership, analysis, decision making, communication, governance, interest of stakeholders, etc. The performance evaluation criteria for Independent Directors is mentioned and uploaded on website of the Company www.concordbiotech.com

Role of the Nomination and Remuneration Committee is as under:

(1) formulation of the criteria for determining qualifications, positive attributes and independence of a Director and recommend to the Board of Directors a policy relating to, the remuneration of the Directors, Key Managerial Personnel and other employees;

(2) For every appointment of an independent director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:

(a) use the services of an external agencies, if required;

(b) consider candidates from a wide range of backgrounds, having due regard to diversity; and

(c) consider the time commitments of the candidates.

(3) formulation of criteria for evaluation of performance of Independent Directors and the Board of Directors;

(4) devising a policy on diversity of Board of Directors;

(5) Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board of Directors their appointment and removal;

(6) whether to extend or continue the term of appointment of the Independent Director, on the basis of the report of performance evaluation of Independent Directors;

(7) recommend to the board, all remuneration, in whatever form, payable to senior management.

Senior Management:

Particulars of senior management including the changes therein since the close of the previous financial year.

There are no changes in senior management since the close of the previous financial year. The senior Management of the Company are as follows:

Sr.	Name of the Senior Management	Designation
1	Mr. Lalit Sethi	Chief Financial Officer
2	Mr. Prakash Sajnani	Asst. Vice President- Account & Finance & Company Secretary
3	Mr. Devang Bhatt	Vice-President of Sales and Marketing
4	Mr. Manoj Kumar	Vice-President of Formulation
5	Mr. Sundeep Bengani	General Manager, International Business Development

** Mr. Prakash Sajnani ceased to be Company secretary and Compliance officer of the company after working hours on 29.05.2025 and continue to act as Asst. Vice President- Accounts & Finance of the company.

Nomination and Remuneration Policy and details of remuneration paid / payable to the Directors for the year ended 31st March 2025:

The Board of Directors approved the Nomination and Remuneration Policy on the recommendation of Nomination and Remuneration Committee.

The salient aspects of the Policy are outlined below:

(i) Objectives:

1 To guide the Board in relation to appointment and removal of Directors, Key Managerial Personnel and Senior Management Personnel;

2) To evaluate the performance of the members of the Board and provide necessary report to the Board for further evaluation of the Board; and

3) To recommend to the Board on remuneration payable to the Directors, Key Managerial Personnel and Senior Management Personnel.

(ii) Remuneration to Non-Executive and Independent Director:

1) Non-Executive and Independent Directors may receive remuneration/ commission as per the slabs and conditions mentioned in the Articles of Association of the Company and the Companies Act, 2013 and the rules made thereunder.

2) Non-Executive and Independent Directors may receive sitting fees for each meeting of the Board or Committee of the Board attended by him, of such sum as may be approved by the Board of Directors within the overall limits prescribed under the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. The Independent Director shall be entitled to reimbursement of expenses for participation in the Board and other meeting.

3) Non-Executive and Independent Directors may receive commission within the monetary limit approved by shareholders, subject to permissible limit as per the applicable provisions of the Companies Act, 2013.

4) An Independent Director shall not be entitled to any stock option of the Company.

5) Company's remuneration policy is guided by a common reward framework and set of principles and objectives as particularly envisaged under section 178 of the Companies Act 2013, inter alia, principles pertaining to determining qualifications, positives attributes, integrity and independence etc.

6) Apart from the above, there are no materially significant related party transactions, pecuniary transactions or relationships between the Company and its Directors except those disclosed in the financial statements for the year ended on 31st March, 2025.

(iii) Remuneration to CEO & Managing Director:

Mr. Sudhir Vaid is Chairman & Managing Director of the Company and Mr. Ankur Vaid is Jt. Managing Director and CEO of the Company. On the recommendation of the Nomination and Remuneration Committee, the Board of Directors approved the remuneration payable to Mr. Sudhir Vaid and Mr. Ankur Vaid, fixed by shareholders as per the resolution passed at 38th Annual General Meeting of the Company. As per the recommendation of the Nomination and Remuneration Committee, Mr. Sudhir Vaid is Chairman & Managing Director and Mr. Ankur Vaid is Jt. Managing Director and CEO were paid remuneration during the financial year ended on 31st March 2025 as below:

(Rs. In Lakhs)

Particulars	Salary	Perquisites	Commission	Others	Total	Notice Period and Severance Fees
Mr. Sudhir Vaid	600.00	-	-	-	600.00	Nil
Mr. Ankur Vaid	333.50	-	-	-	333.50	Nil

Sitting Fees paid to Non- Executive and Independent Directors (in lacs)

Name of Directors	Sitting Fees						
	BM	AC	NRC	SRC	CSR	RMC	IDM
Mr. Ravi Kapoor	2.50	-	-	0.60	-	0.15	-
Mr. Rajiv Agrawal	2.50	-	-	0.60	-	-	-
Mr. Amitabh Thakore	2.50	0.75	0.30	-	-	0.15	0.15
Mr. Arvind Agarwal	2.50	0.75	-	-	0.30	-	0.15
Ms. Bharti Khanna	2.50	-	0.30	-	-	-	0.15
Mr. Jayaram Easwaran	2.50	0.75	-	0.60	-	-	0.15
Mr. Mandayam Chakravarthy Sriraman	2.50	-	0.30	-	0.30	-	0.15

BM-Board Meeting, AC- Audit Committee Meeting, NRC- Nomination and remuneration committee Meeting, SRC- Stakeholders' relationship Committee Meeting, RMC- Risk Management Committee, CSR- Corporate Social responsibility Committee, IDM- Independent Director Meeting

(iv) Remuneration to Senior Management Employees:

The Managing Director with the help of the Human Resources Department, carry out the individual performance review based on the standard appraisal matrix and after taking into account the appraisal score card and other factors like – Key Performance Area v/s initiatives, balance between fixed and variable pay, fixed components and perquisites and retirement benefits, criticality of roles and responsibilities, industry benchmarks and current compensation trends in the market. Further, any promotion at a senior level management is approved by the Management based on a predetermined process and after accessing the candidates' capability to shoulder higher responsibility.

(v) Service Contracts:- No

(vi) Notice Period:- 3 Months

(vii) Severance Fees:- Nil

(viii) Stock Option: The Company does not have any stock option scheme for its Directors or employees. Moreover, there is no separate provision for payment of severance fees to the Directors.

5. STAKEHOLDERS RELATIONSHIP COMMITTEE:

Terms of Reference:

The terms of reference of the Committee include the following:

a) To resolve the grievances of the security holders of the Company including complaints related to transfer/ transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/ duplicate certificates, general meetings etc. and assisting with quarterly reporting of such complaints;

b) To review measures taken for effective exercise of voting rights by shareholders;

c) To review adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent;

d) To review the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the Company; and

e) Carrying out such other functions as may be specified by the Board from time to time or specified/provided under the Companies Act, 2013 or the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, each as amended or by any other regulatory authority."

The Stakeholder Relationship Committee comprises of Two Non-Executive Directors and one Independent Director. The Committee oversees the share transfers as well as takes care of investor grievances.

During the year 4 (Four) meeting of Stakeholder Relationship Committee were held on 23/05/2024, 09/08/2024, 11/11/2024 and 13/02/2025.

The members of the Company's Stakeholders Relationship Committee are:

Name of Member	Category	Designation	No. of Stakeholder Relationship Committee Meetings Attended
Mr. Rajiv Ambrish Agarwal	Non- Executive Director	Chairman	4
Mr. Jayaram Easwaran	Independent Director	Member	4
Mr. Ravi Kapoor	Non- Executive Director	Member	4

- Name and Designation of Compliance Officer: Mr. Prakash Sajnani, Company Secretary
- Number of shareholders complaints received, not solved to the satisfaction of shareholders and pending complaints:

No. of Complaints received	No. of Complaints not solved to the satisfaction of shareholders	No. of Complaints pending
4	0	0

Risk management committee: -

The terms of reference of the Risk Management Committee shall include the following:

1. To formulate a detailed risk management policy which shall include:
   a) A framework for identification of internal and external risks specifically faced by the listed entity, in particular including financial, operational, sectoral, sustainability (particularly, ESG related risks), information, cyber security risks or any other risk as may be determined by the Risk Management Committee;
   b) Measures for risk mitigation including systems and processes for internal control of identified risks; and
   c) Business continuity plan.
2. To ensure that appropriate methodology, processes and systems are in place to monitor and evaluate risks associated with the business of the Company;
3. To monitor and oversee implementation of the risk management policy, including evaluating the adequacy of risk management systems;
4. To periodically review the risk management policy, at least once in two years, including by considering the changing industry dynamics and evolving complexity;
5. To keep the board of directors informed about the nature and content of its discussions, recommendations and actions to be taken; and
6. The appointment, removal and terms of remuneration of the chief risk officer (if any) shall be subject to review by the Risk Management Committee."
7. To carry out such other functions as may be specified by the Board from time to time or specified/provided under the Companies Act, 2013 or the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, each as amended or by any other regulatory authority."

During the year under review, two meetings of Risk management committee were held on 09/08/2024 and 13/02/2025.

The members of the Company's Risk management Committee are:

Name of Member	Category	Designation	No. of Risk Management Committee Meetings Attended
Mr. Ankur Vaid	Executive Director	Chairman	2
Mr. Ravi Kapoor	Non- Executive Director	Member	2
Mr. Amitabh Thakore	Independent Director	Member	2

Corporate Social Responsibility Committee: -

The terms of reference of the CSR shall include the following:

The Corporate Social Responsibility Committee is constituted to perform the following functions:

1. Formulate and recommend to the Board, a Corporate Social Responsibility policy which shall indicate the activities to be undertaken by the Company as specified in Schedule VII of the Companies Act, 2013.
2. Recommend the amount of expenditure to be incurred on the activities referred in CSR policy.
3. Monitor the Corporate Social Responsibility policy of the Company from time to time. The Company has framed a Corporate Social Responsibility policy and placed it on the website of the Company i.e. www.concordbiotech.com

The Corporate Social Responsibility Committee constituted under Board to oversee and give directions to Company's CSR activities under section 135 of Companies Act, 2013. During the financial year ended on 31 March, 2025, Two (2) Meeting of CSR Committee were held on 23rd May, 2024 and 13th February, 2025.

The members of the Company's Corporate Social Responsibility Committee are:

Name of Member	Category	Designation	No. of Corporate Social Responsibility Meetings Attended
Mr. Ankur Vaid	Executive Director	Chairman	1
Mr. Arvind Agarwal	Independent Director	Member	2
Mr. M Sriraman	Independent Director	Member	2

Other committees:

During the year under review, one meeting of Independent Directors was held on 13/02/2025.

During the year Board has constituted management committee w.e.f. 13th February, 2025. There was no meeting held up to 31st March,2025.

The Composition of Management Committee as on 31st March, 2025 is mentioned below:

Name of Member of Management Committee	Designation
Mr. Sudhir Vaid, Managing Director	Chairman
Mr. Ankur Vaid, Joint Managing director	Member
Mr. Ravi Kapoor, Non- Executive Director	Member
Mr. Lalit Sethi, Chief financial Officer	Member
Mr. Prakash Sajnani, Company Secretary	Member

6. GENERAL MEETING:

i) Annual General Meeting (AGM): -

The date and time of annual general meetings held during last three years and the special resolution(s) passed there at, are as follows:

Meeting No.	Financial year	Date and Time	Venue	Special Resolution passed
39th	2023-24	Saturday,29th June, 2024 at 4:00 .PM.	Through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM") The Deemed venue was the Registered office of the Company located at 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad - 382225	Nil
38th	2022-23	Monday, 13th September 2021 At 11:00 A.M.	Through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM") The Deemed venue was the Registered office of the Company located at Shivarth Ambit, Plot No 142/2, Ramdas Road Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat - 380054	• Re-appointment of Mr. Sudhir Vaid, (DIN: 00055967) Chairman & Managing Director with effect from 1st April 2024 to 31st March 2029 for a period of 5 years. • Re-appointment of Mr. Ankur Vaid (DIN 01857225) as a Jt. Managing Director and CEO of the Company w.e.f. 1st June 2024 to 31st May 2029 for a period of 5 years. • Adoption of amended set of Articles of Association to incorporate the observations issued by the Securities and Exchange Board of India on the draft red herring prospectus dated 12th August 2022.
37th	2021-22	Monday, 29th August 2022 At 11:00 A.M.	Registered office of the Company located at: 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225	• Revision of the remuneration of Mr. Sudhir Vaid (DIN 00055967), Chairman & Managing Director of the Company. • Revision of the remuneration of Mr. Ankur Vaid (DIN 01857225), Jt. Managing Director and CEO of the Company. • Continuing the term of appointment of Mr.SudhirVaid,(DIN:00055967)asChairman & Managing Director till 31st March 2024.

ii) Extra-Ordinary General Meeting (EGM)/Postal Ballot Resolution:

During the financial year 2024-25, the Company has not passed any Resolution through Postal Ballot. Further Company is also not proposing to pass any special resolution through postal ballot for the current financial year.

During the year under review, no Extra Ordinary General Meeting was convened.

Sr. No.	Particulars of Resolution	Type of Resolution
1	Nil	Nil
2	Nil	Nil

7. MEANS OF COMMUNICATION:

Tentative Financial Results for the Quarter ended:

30th June, 2025	45 days from end of Quarter 30th June, 2025
30th September, 2025	45 days from end of Quarter 30th June, 2025
31st December, 2025	45 days from end of Quarter 30th June, 2025
Audited Results for the year ended on 31st March, 2026	60 days from end of financial Years as per Reg.33 of SEBI(LODR),2015

Quarterly / Annual Results: The quarterly / half-yearly / annual financial results as required under Regulation 33 of the Listing Regulations have been intimated to the Stock Exchanges and published in the newspaper- 'The Financial Express' (English & Gujarati editions). Presentations made to institutional investors or to the analyst are also available at the website of the Company i.e. www.concordbiotech.com.

News releases, presentations and others: Official news releases and official media releases are sent to Stock Exchanges and are put on the Company's website.

Information on the website of the Company: The Company is in compliance of Regulation 46 of the Listing Regulations. On the website of the Company (www.concordbiotech.com), a separate section under 'Investors' tab has been created, where Company disseminates information and various announcements made by the Company are available.

Presentations to institutional investors / analysts: The transcript of the conference calls for Results, presentations made to institutional investors and financial analysts are intimated to the Stock Exchanges and are put on the Company's website i.e. www.concordbiotech.com.

8. DISCLOSURES:

i) Disclosures on materially significant related party transactions:

Transactions with related parties, as per the requirements of Ind AS 24, are disclosed in notes to accounts annexed to the financial statements.

The Company does not have any related party transaction, which may have potential conflict with the larger interest of the Company. The related party transactions entered during the year are disclosed in the notes to the accounts in this Annual Report.

The Policy on Related Party Transactions of the Company for determining the materiality of related party transactions and also on the dealings with related parties. This Policy has been placed on the Company's official website at the web-link https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Policy-on-Related-Party-Transactions.pdf

Policy for determination of "Material Subsidiaries" and Policy for dealing with "Related Party Transaction" has been posted on company's website: https://www.concordbiotech.com and weblink for the same is https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Policy-on-Material-Subsidiaries.pdf

ii) Code of Conduct:

The Code of Conduct for all Board Members and Senior Management of the Company has been prescribed by the Company.

iii) Certification under Regulation 17(8):

The Managing Director and Chief Financial Officer of the Company have furnished the requisite certificate to the Board of Directors under Regulation 17(8) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

iv) Cases of Non-compliance / Penalties:

No case of Non-compliance/ penalty is filed against the Company.

v) Details of compliances with the Code of Conduct/ Ethics: All the mandatory requirements of Regulations 17 to 27 and clauses (b) to (i) of sub-regulation (2) of Regulation 46 of the listing regulations have been complied with by the Company.

vi) The Company has authorized Registrar and Transfer agents viz. MUFG Intime India Private Limited to issue the securities in dematerialized form only while processing shareholder request such as issue of duplicate share certificate, claim from Unclaimed Suspense account, renewal /exchange of securities certificate, endorsement, subdivision/ splitting of shares, consolidation of share certificates/folios, transmission and transposition as per Securities and Exchange Board of India vide its circular dated January 25, 2022. The RTA shall credit the shares to the Suspense Escrow Demat Account of the Company if the

shareholder/claimant fails to submit the demat request within 120 days of issuance of Letter of Confirmation.

9. GENERAL SHAREHOLDER INFORMATION:

I. Annual General Meeting:

Date: 9th September, 2025
Time:. 4:00P.M.

II. Mode: Through Video Conferencing or other Audio-Visual Means

III. Current Financial Year: The current financial year covers the period from 01.04.2024 to 31.03.2025.

IV. Dividend Payment Date:-

Dividend declared by the shareholders in this 40th Annual General Meeting will be deposited in separate dividend account within 5 days of AGM and will be paid to the eligible shareholders within 30 days of declaration i.e. on or before 8th October, 2025

V. ISIN No. for equity shares of the Company- INE338H01029

VI. Listing on Stock Exchange(s):

Your Company's Shares are listed on

Sr. No.	Name of Stock Exchange	Address of Stock Exchange	Symbol
1.	National Stock Exchange of India	Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051	CONCORDBIO
2.	BSE Limited	Phiroze Jeejeebhoy Towers, dalal Street Mumbai-400001	543960

Notes:

a. Annual Listing fees for the year 2024-25 have been duly paid to the stock exchange.

VII. Plant Locations:

1. Unit I -1482 - 1486, Trasad Road, Dholka - 382225, Ahmedabad, Gujarat, India.
2. Unit II - 297 - 298/2p, At. Valthera., Tal. Dholka, Dist., Ahmedabad - 382225, Gujarat, India.
3. Unit III - Plot No.84 and 668, Ranasar and Malawada, Limbasi Sojitra Road, Near Limbasi, Taluka - Matar, Kheda, Gujarat 387520 India.
4. Unit IV - 1482 - 1486, Trasad Road, Dholka - 382225, Ahmedabad, Gujarat, India.

VIII. Address for Correspondence:

Shareholders may correspond with the Company at the Corporate Office the Company:

Compliance Department
16th Floor, B-Wing, Mondeal Heights,
Iscon Cross Road, S.G. Highway,
Ahmedabad - 380015, Gujarat, India.

IX. Registrars and Transfer Agents:

M/s. MUFG INTIME INDIA PRIVATE LIMITED (Formerly known as Link Intime India Private Limited) is the Share Transfer Agent for entire functions of share registry, both for physical transfers as well as dematerialization /rematerialisation of shares, issue of duplicate / split / consolidation of shares etc.

Shareholders are requested to send their share transfer related requests at the following address:

MUFG Intime India Private Limited

C 101, Embassy 247, L.B.S.Marg, Vikhroli (West), Mumbai - 400083.

Email – rnt.helpdesk@in.mpms.mufg.com

X. Share Transfer Systems:

Since the Company's shares are compulsorily traded in the demat segment on stock exchanges, bulk of the transfers take place in the electronic form.

XI. Categories of Shareholding Pattern as on 31st March, 2025:

Sr. No.	Category	No. of shares held	% of shareholding
1	Promoters	41364356	39.54
2	Trusts	25314468	24.19
3	Public	7488972	7.16
4	FPI (Corporate) - I	9371273	8.96
5	Overseas Corporate Bodies	2092325	2.00
6	Mutual Funds	5394790	5.16
7	Corporate Bodies (Promoter Company)	4752000	4.54
8	Insurance Companies	3504495	3.35
9	Non Resident (Non Repatriable)	2147361	2.05

Sr. No.	Category	No. of shares held	% of shareholding
10	Other Bodies Corporate	1639211	1.57
11	FPI (Corporate) – II	410666	0.39
12	Alternate Invst Funds - III	665595	0.64
13	Hindu Undivided Family	195881	0.19
14	Non Resident Indians	127279	0.12
15	Body Corporate - Ltd Liability Partnership	132273	0.13
16	NBFCs registered with RBI	15000	0.01
17	Clearing Members	259	0.00
	GRAND TOTAL	**10,46,16,204**	**100.00**

XII. Distribution of Shareholding as on 31st March, 2025:

No. of Equity Shares	No. of Folio	% to Total Folios	No. of Shares	% Share Holding
Less than 500	80278	97.89	2671150	2.55
501 to 1000	739	0.90	523865	0.50
1001 to 2000	491	0.60	695729	0.67
2001 to 3000	141	0.17	343490	0.33
3001 to 4000	67	0.08	235896	0.23
4001 to 5000	44	0.05	200225	0.19
5001 to 10000	78	0.10	549491	0.53
10001 & above	167	0.20	99396358	95.01
Total	**82005**	**100.00**	**104616204**	**100.00**

XIII. Dematerialization of Shares and Liquidity:

The Company's shares are available for dematerialization on both the Depositories viz. National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). Shares of the Company are compulsorily traded in the demat form on Stock Exchanges by all investors. As on 31st March 2025, total share capital has been dematerialized by investors and all of the transfer takes place in the demat form.

XIV. Outstanding GDRs/ADRs/Warrants or any convertible instruments and conversion date and likely impact on equity:

There is no outstanding GDRs/ADRs/Warrants or any convertible instruments.

XV. Unclaimed Shares lying in Demat Suspense Account:

There are no equity shares lying in the demat suspense accounts or unclaimed suspense account.

XVI. Shares lying under Investor Education and Protection Fund (IEPF) Account:

There are no equity shares of the Company lying under Investor Education and Protection Fund (IEPF) Account as on 31.03.2025.

XVII. Foreign Exchange Risk and Hedging activities:

In order to reduce the uncertainty arising on account of exchange rate movements and currency movements on forex exchange exposure, the Company has been placed the hedging policy to secure forex exposures either naturally or otherwise, so that the volatility does not impact the core business of the Company.

XVIII. Management Responsibility Statement:

The Management confirms that the financial statements are in full conformity with requirements of the Companies Act, 2013 and the same have been prepared in accordance with IND-AS, as prescribed under Section 133 of Companies Act, 2013 and rules made thereunder. The Management accepts responsibility for the integrity and objectivity of these financial statements as well as for estimates and judgments relating to matters not concluded by the period end. The management believes that the financial statements of operation reflect fairly the form and substance of transactions and reasonably present the Company's financial condition and the results of operations. The Company has a system of internal control, which is reviewed, evaluated and updated on an ongoing basis. The Internal Auditors have conducted periodic audits to provide reasonable assurance that the Company's established policy and procedures have been followed.

XIX. Details of Establishment of Whistle Blower Policy/ Vigil Mechanism:

The Company has established a vigil mechanism called 'Whistle Blower Policy', for Directors and employees to report to the management instances of unethical behavior, actual or suspected, fraud or violation of the Company's code of conduct or ethics policy.

Accordingly, the Company has established a mechanism for employees vide 'Whistle Blower Policy which seeks (i) to ensure greater transparency in all aspects of the Company's functioning by formulating a procedure to bring to the attention of Company incidents of improper-activities or violation of the company's Code of Conduct & Ethics for Board Members and Senior Management, and (ii) to provide for adequate safeguards against victimization of employees who avail of the mechanism.

All Employees of the Company are eligible to make Protected Disclosures under the Policy. The Protected Disclosures may be in relation to matters concerning the Company. Whistle Blower by virtue of his/her having reported a Protected Disclosure under the policy is fairly protected.

XX. Policy for dealing with Related Party Transactions:

The policy for dealing with related party transactions has been disclosed at www.concordbiotech.com. The weblink for the same is https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Policy-on-Related-Party-Transactions.pdf

XXI. Credit Rating:

The credit ratings assigned to the Company on 23th July 2025 for total bank facilities are as under:

Total Bank loan facilities rated	₹125.00 Crore
Long term rating	[ICRA]AA- (Stable); reaffirmed
Short Term Rating	[ICRA]A1+; reaffirmed

XXII. Subsidiary Companies:

There is no subsidiary of Concord Biotech Limited as on 31st March 2025

Pursuant to provisions of Regulation 27 of SEBI (LODR) Regulations, 2015, The policy on Material Subsidiaries as approved by the Board is uploaded on the Company's website and weblink for same is https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Policy-on-Material-Subsidiaries.pdf

XXIII. Weblink where dividend Distribution Policy Pursuant to regulation 43A of the SEBI regulations:

The Company has formulated the dividend distribution policy and the same been placed on the Company's website and weblink for same is

https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Dividend-Distribution-Policy.pdf

10. OTHER DISCLOSIRES:

(a) Disclosures on materially significant related party transactions that may have potential conflict with the interests of listed entity at large:

All transactions entered into with the Related Parties as defined under the Companies Act, 2013 and Regulation 23 of the Listing Regulations during the financial year were on arm's length basis and do not attract the provisions of Section 188 of the Companies Act, 2013. There were no materially significant transactions with Related Parties during the financial year. Related party transactions have been disclosed under significant accounting policies and notes forming part of the Financial Statements in accordance with "IND AS". A statement in summary form of transactions with Related Parties in ordinary course of business and arm's length basis is periodically placed before the Audit committee for review and recommendation to the Board for their approval.

Details of non-compliance by the listed entity, penalties, strictures imposed on the listed entity by stock exchange(s) or the board or any statutory authority, on any matter related to capital markets, during the last three years:

There are no non-compliance and no penalties, strictures imposed by the Stock Exchange or SEBI or Statutory Authority on any matter related to capital markets during the last three years.

(b) Vigil Mechanism/Whistle Blower Policy & Audit Committee:

Pursuant to Section 177(9) & (10) of the Companies Act, 2013, and Regulation 22 of the Listing Regulations, the Company has formulated Whistle Blower Policy for vigil mechanism of Directors and employees to report to the management about the unethical behavior, fraud or violation of Company's code of conduct. The mechanism provides for adequate safeguards against victimization of employees and Directors who use such mechanism and makes provision for direct access to the Chairman of the Audit Committee in exceptional cases. None of the personnel of the Company have been denied access to the Audit Committee. The Whistle Blower Policy is displayed on the Company's website viz. www.concordbiotech.com . Weblink for the same is https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Whistle-Blower-Policy.pdf

(c) The Company has complied with all mandatory requirements laid down by the Regulations 27 of the Listing Obligations and Disclosure Requirements Regulations, 2015. The non-mandatory requirements complied with wherever requires and same has been disclosed at the relevant places.

(d) Disclosure of Accounting Treatment:

In the preparation of the financial statements, the Company has followed the Accounting Standards referred to in Section 133 of the Companies Act, 2013. The significant accounting policies which are consistently applied are set out in the Notes to the Financial Statements.

(e) Commodity price risk and Commodity hedging activities:

The Company has adequate risk assessment and minimization system in place including for commodities. The Company does not have material exposure of any commodity and accordingly, no hedging activities for the same are carried out. Therefore, there is no disclosure to offer in terms of SEBI circular no. SEBI/HO/CFD/CMD1/ CIR/P/2018/0000000141 dated November 15, 2018.

(f) Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A): Not Applicable

(g) Company has obtained a certificate from a Company Secretary in practice that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as Directors of Company by the Board/Ministry of Corporate Affairs or any such statutory authority forms part of this report.

(h) Where the Board had not accepted any recommendation of any committee of the Board which is mandatorily required, in the relevant financial year:

Not applicable

(i) Total fees for all services paid by the listed entity and its subsidiaries, on a consolidated basis, to the statutory auditor and all entities in the network firm/network entity of which the statutory auditor is a part:

Details relating to fees paid to the Statutory Auditors are given in Note 33 to the Standalone Financial Statements.

(j) Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

During the year under review, there were no complaint i.e. incidences of sexual harassment reported.

(k) There is no non-compliance of any requirement of Corporate Governance Report of sub-para (2) to (10) of Schedule V read with Regulation 34(3) of SEBI LODR Regulations.

(l) The Company does not have any demat suspense account/unclaimed suspense account and therefore, the details pertaining the same are not given.

(m) The Company has fully complied with mandatory requirements of the SEBI (LODR) Regulations, 2015.

(n) Disclosure of Loans and advances to firms/ Companies in which directors are interested:

During the year under review the Company has advanced following loans and advances to the firms/companies in which Directors are interested:-

(Rs. in Lakhs)

Sr. No.	Name of Firm/Company	Relationship	Loans and advances given during the year	Balance outstanding as on 31st March, 2025
1.		NIL		

(o) Disclosure of certain types of agreements binding listed entities: Not Applicable

(p) Details of material subsidiaries of the listed entity; including the date and place of incorporation and the name and date of appointment of the statutory auditors of such subsidiaries:

Name of Material Subsidiary	Not Applicable
Date of Incorporation	Not Applicable
Place of Incorporation	Not Applicable
Name of Statutory Auditor	Not Applicable
Date of Appointment/Re appointment of Statutory Auditor	Not Applicable

(q) Non Mandatory Requirements:

Company has not adopted non mandatory requirements as specified in Part-E of Schedule-II of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

[Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To,
The Members of
CONCORD BIOTECH LIMITED
1482-86 Trasad Road, Dholka,
Ahmedabad, Gujarat,
India, 38225.

We have examined online the relevant registers, records, forms, returns and disclosures received from the Directors of **Concord Biotech Limited** having CIN L24230GJ1984PLC007440 and having registered office at 1482-86 Trasad Road, Dholka, Ahmedabad, Gujarat, India, 387810. (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2025 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority.

Sr. No.	Name of Director	DIN	Date of appointment in Company
1	Mr. Sudhir Vaid	00055967	14/02/2011
2	Mr. Ankur Vaid	01857225	01/09/2011
3	Mr. Ravi Kapoor	00003847	15/12/2003
4	Mr. Rajiv Agarwal	00379990	30/06/2008
5	Mr. Amitabh Thakore	00016715	31/01/2017
6	Mrs. Bharti Khanna	05147844	31/01/2017
7	Mr. Arvind Agarwal	00122921	24/05/2022
8	Mr. Jayaram Easwaran	02241192	14/06/2022
9	Mr. Mandayan Chakravarthy Sriraman	09631555	14/06/2022

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For, Ashish Shah and Associates

Ashish Shah
Proprietor
Mem. No. FCS: 5974
COP No.: 4178
UDIN: F005974G000962006

Date: 8th August, 2025
Place: Ahmedabad

CERTIFICATE ON **CORPORATE GOVERNANCE**

To,
The Members of
CONCORD BIOTECH LIMITED

We have examined the Compliance Conditions of Corporate Governance by **CONCORD BIOTECH LIMITED** for the year ended on 31st March, 2025 as per Para E of Schedule V read with Regulation 34(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') for the period 1st April, 2024 to 31st March, 2025. We have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purpose of certification.

The Compliance of Conditions of Corporate Governance is the responsibility of the management. Our examination was limited to review of the procedures and implementations thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, and the representation made by the Directors and the Management, we certify that the Company has materially complied with the conditions of Corporate Governance as stipulated in Listing Regulations.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For, Ashish Shah and Associates

Ashish Shah
Proprietor
Mem. No. FCS: 5974
COP No.: 4178
UDIN: F005974G000962061

Date: 8th August, 2025
Place: Ahmedabad

CERTIFICATE OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

We, Mr. Sudhir Vaid, Chairman & Managing Director and Mr. Lalit Sethi, Chief Financial Officer of CONCORD BIOTECH LIMITED certify that:

We have reviewed the financial statements and the cash flow statement of the Company for the year ended March 31, 2025 and to the best of our knowledge and belief:

i. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.

ii. These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

iii. To the best of our knowledge and belief, no transactions entered into by the Company during the year ended March 31, 2025 which are fraudulent, illegal or violative of the Company's Code of Conduct.

iv. We accept responsibility for establishing and maintaining internal control system and that we have evaluated the effectiveness of the internal control system of the Company and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal control system, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

v. We further certify that we have indicated to the auditors and the Audit Committee:

   a. There have been no significant changes in internal control over financial reporting system during the year;

   b. There have been no significant changes in accounting policies during the year except for the changes disclosed in the note 1 to 4 to the financial statements; and

   c. There have been no instances of significant fraud, of which we have become aware, involving management or any employee having a significant role in the Company's internal control system over financial reporting.

Date: May 29, 2025
Place: Ahmedabad

Sudhir Vaid
Chairman & Managing Director
(DIN: 00055967)

Mr. Lalit Sethi
Chief Financial Officer

DECLARATION

I, Sudhir Vaid, Chairman & Managing Director of Concord Biotech Limited hereby declare that as of March 31, 2025 all the Board Members and Senior Management Personnel have affirmed compliance with the Code of Conduct and Ethics for Directors and Senior Management Personnel1 laid down by the Company.

For and on behalf of the Board of Directors of
CONCORD BIOTECH LIMITED

Sudhir Vaid
Chairman & Managing Director
(DIN: 00055967)

Date: May 29, 2025
Place: Ahmedabad

Form No. MR- 3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2025

[Pursuant to section 204(1) of the Companies Act, 2013 and rule no. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members
Concord Biotech Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Concord Biotech Limited** (hereinafter called the "Company"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on our verification of the books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company, during the audit period covering the financial year ended on 31st March, 2025 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2025 and verified the provisions of the following acts and regulations and also their applicability as far as the Company is concerned during the period under audit:

i) The Companies Act, 2013 (the Act) and the rules made thereunder;

ii) The Securities Contracts (Regulation) Act, 1956 ("SCRA") and the rules made thereunder;

iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;

iv) The Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings to the extent of their applicability to the Company;

v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'): -

(a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

(b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015;

(c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;

(d) Securities And Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;

(e) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Debt Securities) Regulations, 2021;

(f) The Securities and Exchange Board of India (Registrar to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with clients;

(g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; and

(h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018;

We have also examined compliance with applicable clauses of the following

1. Secretarial Standards issued by the Institute of Company Secretaries of India.
2. Provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that:

i) The Board of Directors of the Company is duly constituted with proper balance of Executive Director, Non-Executive Directors and Independent Directors.

ii) Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

iii) All decisions at Board Meetings & Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or the Committees of the Board, as the case may be.

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period there are no specific events / actions having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc. referred to above.

For, Ashish Shah and Associates

Ashish Shah
Proprietor
Mem. No. FCS: 5974
COP No.: 4178
UDIN: F005974G000961940

Date: 8th August, 2025
Place: Ahmedabad

This report is to be read with our letter of even date which is annexed as **Annexure - A** and forms an integral part of this report.

Annexure A

To,
The Members
Concord Biotech Limited

Our report of even date is to be read along with this letter.

1. Maintenance of Secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. We believe that the process and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management representation about the Compliance of laws, rules and regulations and happening of events, etc.
5. The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedure on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For, Ashish Shah and Associates

Ashish Shah
Proprietor
Mem. No. FCS: 5974
COP No.: 4178
UDIN: F005974G000961940

Date: 8th August, 2025
Place: Ahmedabad

Business Responsibility and Sustainability Report

SECTION A: GENERAL DISCLOSURE

I. Details of the listed entity

1	Corporate Identity Number (CIN) of the Listed Entity	L24230GJ1984PLC007440	
2	Name of the Listed Entity	Concord Biotech Limited	
3	Year of Incorporation	1984	
4	Registered office address	1482-1486, Trasad Road, Dholka, Dist. Ahmedabad - 382 225, Gujarat	
5	Corporate address	B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad - 380 015, Gujarat	
6	E-mail	lalitsethi@concordbiotech.com	
7	Telephone	074860 23290	
8	Website	www.concordbiotech.com	
9	Financial year for which reporting is being done		
	Current Financial Year	1st April 2024	31st March 2025
	Previous Financial Year	1st April 2023	31st March 2024
	Prior to Previous Financial year	1st April 2022	31st March 2023
10	Name of the Stock Exchange(s) where shares are listed-		

Details of the Stock Exchanges

Sr. No.	Name of the Stock exchange	Description of other stock exchange	Name of the Country
1.	National Stock Exchange of India Ltd.	NA	India
2.	BSE Ltd.	NA	India

11	Paid-up Capital (In ₹)	₹10,46,16,204
12	Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report	
	Name	Mr. Lalit Sethi
	Contact	074860 23290
	E mail	E-mail: lalitsethi@concordbiotech.com
13	Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together).	Standalone basis
14	Whether the company has undertaken assessment or assurance of the BRSR Core?	No, the company has not undertaken assessment or assurance of the BRSR Core as it is currently not applicable.
15	Name of assessment or assurance provider	NA
16	Type of assessment or assurance obtained	NA

II. Products/ Services

17. Details of business activities (accounting for 90% of the turnover)

Sr. No.	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1.	Manufacturing of pharmaceuticals	Research, development, manufacturing and sale of active pharmaceutical ingredients	78%
2.	Manufacturing of pharmaceuticals	Research, development, manufacturing and sale of finished formulations	22%

18. Products/Services sold by the entity (accounting for 90% of the entity's Turnover)

Sr. No.	Product/Service	NIC Code	% of total Turnover contributed
1.	Manufacturing of Pharmaceuticals, medicinal chemical and botanical products.	210	78%
2.	Formulations	210	22%

III. Operations

19. Number of locations where plants and/or operations/offices of the entity are situated

Location	Number of plants	Number of offices	Total
National	4 manufacturing units (All are located in Gujarat)	1 corporate office	5
International	0	0	0

20. Markets served by the entity

A	Number of locations	
	Locations	Number
	National (No. of States)	Pan India
	International (No. of Countries)	70+
B	What is the contribution of exports as a percentage of the total turnover of the entity?	45%
C	A brief on types of customers	Concord is a research-driven biopharmaceutical company operating across three strategic verticals: Active Pharmaceutical Ingredients (API), Finished Formulations, and Contract Research & Manufacturing Services (CRAMS). In the API segment, Concord collaborates with global formulation companies to supply high-quality APIs used in therapies such as immunosuppressants, oncology, and anti-infectives, including anti-bacterial and anti-fungal agents. The Finished Formulations division serves international markets including the United States, Latin America, the Middle East, and Southeast Asia. Domestically, Concord operates through both B2B and B2C channels, partnering with government and corporate hospitals to deliver healthcare solutions directly to end patients. In the CRAMS vertical, Concord supports global biopharmaceutical companies in fermentation, semi-synthetic APIs, and finished formulations, undertaking advanced activities such as strain improvement, media and process optimization, and scale-up from R&D to pilot and commercial production. With a robust portfolio catering to over 250 customers across more than 70 countries, Concord has built a reputation for quality, safety, and reliability over the past twenty-five years. Our products continue to play a vital role in enhancing healthcare delivery in both developed and emerging markets.

IV. Employees

21. Details as at the end of Financial Year

A. Employees and workers (including differently abled)

Sr. No.	Particulars	Total (A)	Male		Female		Other	
			No. (B)	% (B / A)	No. (C)	% (C / A)	No. (H)	% (H / A)
EMPLOYEES								
1	Permanent (D)	1571	1466	93.32%	105	6.68%	-	NA
2	Other than permanent (E)	26	26	100.00%	0	0.00%	-	NA
3	**Total employees(D + E)**	**1597**	**1492**	**93.43%**	**105**	**6.57%**	**-**	**NA**
WORKERS								
4	Permanent (F)	-	-	-	-	-	-	NA
5	Other than permanent (G)	1185	-	98.40%	19	1.60%	-	NA
6	**Total workers (F + G)**	**1185**	**1166**	**98.40%**	**19**	**1.60%**	**-**	**NA**

B. Differently abled Employees and Workers:

Sr. No.	Particulars	Total (A)	Male		Female		Other	
			No. (B)	% (B / A)	No. (C)	% (C / A)	No. (H)	% (H / A)
DIFFERENTLY ABLED EMPLOYEES								
1	Permanent (D)	NA	-	NA	-	NA	-	NA
2	Other than Permanent (E)	NA	-	NA	-	NA	-	NA
3	Total differently abled employees (D + E)	NA	-	NA	-	NA	-	NA
DIFFERENTLY ABLED WORKERS								
4	Permanent (F)	NA	-	NA	-	NA	-	NA
5	Other than Permanent (G)	NA	-	NA	-	NA	-	NA
6	Total differently abled workers (F+G)	NA	-	NA	-	NA	-	NA

22. Participation/Inclusion/Representation of women

	Total (A)	No. and percentage of Females	
		No. (B)	% (B / A)
Board of Directors	9	1	11.11%
Key Management Personnel	4	0	0%

23. Turnover rate for permanent employees and workers (Disclose trends for the past 3 years)

	Turnover rate in current FY (2024-25)			
	Male	Female	Other	Total
Permanent Employees	28.97%	28.86%	-	28.99%
Permanent Workers	-	-	-	-

	Turnover rate in previous FY (2023-24)			
	Male	Female	Other	Total
Permanent Employees	14.32%	85.71%	-	16.70%
Permanent Workers	-	-	-	-

	Turnover rate in year prior to the previous FY (2022-23)			
	Male	Female	Other	Total
Permanent Employees	12.12%	18.18%	-	12.00%
Permanent Workers	-	-	-	-

V. Holding, Subsidiary and Associate Companies (including joint venturs)

24. (a) Names of holding / subsidiary / associate companies / joint ventures

Sr. No.	Name of the holding / subsidiary/associate companies/joint ventures (A)	Indicate whether holding/Subsidiary/ Associate/Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1.	Concord Japan KK	Joint Venture Company	50%	No
2.	Clean Max Everglades Private Limited	Associate	26%	No

VI. CSR Details

25. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013 (Yes/No): Yes

(ii) Turnover (in ₹): 1,200.09 crores

(iii) Net worth (in ₹): 1,812.71 crores

VII. Transparency and Disclosure Compliances

26. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/ No/NA)	(If Yes, then provide web-link for grievance redress policy)	FY (2024-25)			FY (2023-24)		
			Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	No		NA	NA	-	NA	NA	-
Investors (other than shareholders)	Yes	Concord Biotech Limited has implemented a unified grievance redressal mechanism to efficiently address concerns raised by both shareholders and investors. This system ensures that all queries, complaints, and service requests are captured and resolved in a timely and transparent manner. The Company is committed to maintaining high standards of investor relations and has established dedicated channels to facilitate seamless communication and resolution of issues.	0	0	-	0	0	-

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/ No/NA)	(If Yes, then provide web-link for grievance redress policy)	FY (2024-25)			FY (2023-24)		
			Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Shareholders	Yes	Yes, The Company has established a robust and transparent mechanism to address shareholder queries and grievances. To facilitate this, Concord has appointed MUFG Link Intime India Private Limited as its Registrar and Share Transfer Agent (RTA). Link Intime India Private Limited is responsible for handling all shareholder-related enquiries, requests, and complaints in a timely and efficient manner. The RTA ensures that shareholder communications are managed with diligence and professionalism, in accordance with the framework prescribed by SEBI. A dedicated email ID has been created to receive grievances from shareholders: complianceofficer@concordbiotech.com. This mail id is actively monitored to ensure prompt responses and resolution of concerns.	0	0	-	0	0	-
Employees and workers	Yes	All employees and workers are covered under the Company's Whistle Blower Policy, which provides a secure and confidential channel for registering complaints. The policy can be accessed at the following link: https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Whistle-Blower-Policy.pdf.	0	0	-	0	0	NA

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/ No/NA)	(If Yes, then provide web-link for grievance redress policy)	FY (2024-25)			FY (2023-24)		
			Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Customers	No. Since the majority of the business is B2B, Concord does not have a defined grievance redressal policy for customers.	0	0	0	-	0	0	-
Value Chain Partners	No	0	0	0	-	0	0	-
Others	NA	0	0	0	-	0	0	-

27. Overview of the entity's material responsible business conduct issues

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with its financial implications, as per the following format

Sr. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
1.	R&D and innovation	Opportunity	R&D investments drive green innovation, supporting environmental sustainability and strengthening ESG performance. Thoughtful R&D strategies, coupled with transparent disclosures, help stakeholders understand the organisation's approach and scale of commitment.	-	**Positive** Cutting-edge technological innovations position Concord at the forefront of industry breakthroughs, unlocking new opportunities for business growth.

Sr. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
2.	Quality management	Risk	Quality is of utmost importance in pharmaceutical manufacturing. Any compromise can have adverse effects, while consistently upholding high standards builds customer trust and reinforces reliability.	• A robust system is maintained to consistently ensure product quality and adherence to regulatory requirements • Pharmacovigilance practices are actively implemented to monitor and mitigate product-related risks, supporting ongoing product enhancement • A specialised team handles customer complaints through a dedicated web portal and toll-free number, enabling swift investigation and resolution • All employees undergo mandatory pharmacovigilance training, reinforcing the organisation's commitment to safety and quality	**Negative** Substandard product quality can lead to an increase in product recalls, resulting in both operational disruptions and reputational harm. This, in turn, negatively impacts customer satisfaction and trust.
3.	Supply chain disruption	Risk	Maintaining a stable supply chain is crucial for business continuity in the pharmaceutical industry. Hence, it is essential to implement proactive measures to anticipate, prevent, and mitigate potential disruptions.	• A well-integrated supply chain ensures uninterrupted global access to medicines • Focus on cost-efficient and sustainable logistics, spanning from raw material sourcing to final product distribution • Environmental compliance is upheld through mandatory audits for key vendors • Providing guidance to partners on legal, regulatory, and ethical standards through a well-defined Supplier Code of Conduct.	**Negative** Delays in raw material supply from vendors can cause late deliveries to customers, leading to reputational harm for the Company. Any disruption within Concord's value chain may negatively impact operations, potentially affecting product availability and increasing costs.

Sr. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
4.	Business conduct & ethics	Risk	Engaging in unethical behaviour and neglecting ethical standards can severely harm our reputation.	• Adhering to the core values of integrity, transparency, accountability, and ethical conduct • Forming professional management teams and independent boards to strengthen governance • Adopting global best practices in corporate governance and risk management • Consistently safeguarding and creating long-term value across the Group	**Negative** Reputational damage can adversely impact the Company's business growth and revenue.
5.	GHG emissions	Risk	GHG emissions present regulatory, market, physical, reputational, and financial risks. Key concerns include compliance expenses, declining demand, infrastructure damage, reputational harm, and potential investor pushback. Implementing mitigation strategies is essential to managing these risks and promoting long-term sustainability.	• Shifting to natural gas for steam generation • Offsetting emissions through tree plantation initiatives • Installing energy-efficient boilers and equipment, including LED lighting and solar-powered systems	**Negative** The impact of GHG emissions includes regulatory compliance costs, revenue loss due to declining demand for unsustainable products, expenses from climate-related infrastructure damage, costs associated with reputation management and marketing, and higher borrowing costs.
6.	Water management	Opportunity	Water is a critical yet limited resource, and our processes require significant usage. To ensure responsible consumption, we have adopted Effluent Treatment Plants equipped with Zero Liquid Discharge (ZLD) systems.	-	**Positive** The adoption of ZLD leads to decreased reliance on freshwater, thereby reducing the Company's water sourcing expenses for its operations.

Sr. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
7.	Inclusion and diversity	Opportunity	Concord is committed to cultivating a workplace culture that upholds diversity and inclusivity, reflected in its approach to recruitment, promotions, and leadership development at all levels of the organisation. The Company strongly values building a workforce that welcomes diverse perspectives and inclusive practices, spanning from entry-level positions to senior management.	-	**Positive** A diverse workforce comprising various genders, age groups, and ethnic backgrounds empowers Concord to drive growth, foster innovation, and effectively manage operational risks.
8.	Community engagement	Opportunity	We view it as our duty to support and care for the communities surrounding our operational areas.	-	**Positive** By empowering and uplifting the communities around us, we can prevent future grievances or concerns, thereby safeguarding our business from potential adverse outcomes.
9.	Data privacy & cybersecurity	Risk	Data breaches, along with unauthorised access to intellectual property and R&D data, can pose serious threats to Concord's operations.	Investing in the development of a strong digital infrastructure that enables data platforms across all functions.	**Negative** Unauthorised access to intellectual property or other confidential company information can lead to substantial financial losses for the organisation.

Sr. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
10.	Employee health & safety	Risk	Failure to maintain a safe working environment can lead to legal liabilities. Workplace accidents and health issues may result in decreased productivity, while unsafe conditions can negatively affect employee morale, job satisfaction, and engagement.	• Maintaining a safe and healthy workplace by implementing well-defined protocols focused on employee wellbeing and safety • Creating a work environment that attracts and retains talent by offering empowerment, growth opportunities, flexibility, competitive compensation, and a strong sense of purpose • Enforcing stringent safety procedures and driving continuous process improvements across all locations to cultivate a zero-incident safety culture • Providing employee training and strictly enforcing protocols to prevent, report, and address misconduct, including sexual harassment and discrimination	**Negative** The lack of a safe and empowering workplace can lead to negative financial outcomes, including fines and penalties. It may also cause operational disruptions and reputational harm.
11.	End-user health & safety	Risk	Products that fail to meet quality standards can pose health risks to consumers, potentially leading to product recalls, financial losses, and reputational damage for the organisation. Such incidents may also result in litigation risks and diminished consumer trust.	• Conducting regular inspections of raw materials and finished products to detect any impurities or variations in composition.	**Negative** Products that cause harm or fail to meet end-user standards can damage the Company's brand reputation and may lead to financial losses.

Sr. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
12.	Waste management	Risk	Improper handling and disposal of waste can lead to environmental pollution, legal liabilities, and risks to human health. Regulatory violations may trigger increased scrutiny and cleanup obligations, which can disrupt operations and result in financial losses and reputational harm.	• Complying with regulatory requirements for waste management • Ensuring responsible treatment of generated waste • Implementing proper methods for waste disposal	**Negative** Improper waste management can result in regulatory fines, environmental cleanup costs, legal expenses, and elevated insurance premiums. It may also cause reputational harm that affects business opportunities, increase operating costs, and ultimately impact profitability.

SECTION B: MANAGEMENT AND PROCESS DISCLOSURES

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements.

The National Guidelines for Responsible Business Conduct (NGRBC), as prescribed by the Ministry of Corporate

Affairs advocates nine Principles referred to as P1-P9 given below:

P1	Businesses should conduct and govern themselves with integrity in a manner that is ethical, transparent and accountable
P2	Businesses should provide goods and services in a manner that is sustainable and safe
P3	Businesses should respect and promote the well-being of all employees, including those in their value chains
P4	Businesses should respect the interests of and be responsive towards all its stakeholders
P5	Businesses should respect and promote human rights
P6	Businesses should respect and make efforts to protect and restore the environment
P7	Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent
P8	Businesses should promote inclusive growth and equitable development
P9	Businesses should engage with and provide value to their consumers in a responsible manner

Disclosure Questions			P1	P2	P3	P4	P5	P6	P7	P8	P9
Policy and management processes											
1.	a.	Whether your entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No/NA)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	b.	Has the policy been approved by the Board? (Yes/No/NA)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	c.	Web Link of the Policies, if available	1,2,3,4,5	-	6,8	2,6,7	6,8	7	-	7	-

		1. Insider Trading Policy: https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Insider-Trading-Policy.pdf 2. Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information: https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Code-of-Practises-Fair-Disclosure-of-UPSI.pdf 3. Code of Conduct for Board of Directors and Senior Management Personnel : https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Code-of-Conduct-for-BoD-and-SMPs.pdf 4. Policy for Familiarisation Programmes for Independent Directors : https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Policy-for-Familiarisation-Programme-for-Independent-Directors.pdf 5. Policy for Evaluation of the Performance of the Board of Directors : https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-POLICY-FOR-EVALUATION-OF-THE-PERFORMANCE-OF-THE-BOARD-OF-DIRECTORS.pdf 6. Whistle Blower Policy : https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Whistle-Blower-Policy.pdf 7. Social Responsibility Policy: https://www.concordbiotech.com/public/assets/pdf/CSR-Annual-Action-Plan.pdf 8. Nomination & Remuneration Policy : https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Nomination-and-Remuneration-Policy.pdf 9. Risk Management Policy : https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Risk-Management-Policy.pdf 10. Policy for Determination of Materiality: https://www.concordbiotech.com/public/assets/pdf/Policy-for-Determination-of-Materiality.pdf								
2.	Whether the entity has translated the policy into procedures. (Yes / No/ NA)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3.	Do the enlisted policies extend to your value chain partners? (Yes/No/NA)	Yes, Concord's Supplier Code of Conduct largely includes the above-mentioned principles, and the value chain partners are expected to adhere to the requirements outlined.								
4.	Name of the national and international codes/ certifications/labels/ standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustee) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.	-	-	ISO 45001	-	-	ISO 14001	-	-	USFDA EUGMP PMDA, Japan MDFS, Korea, ANVISA (Brazil) GMP certificate
5.	Specific commitments, goals and targets set by the entity with defined timelines, if any.	1. Increase in recycling of treated waste water 2. Supplier assessment on ESG parameters as per BRSR 3. Scope 1 & 2 emissions' measurement 4. Reach the target of zero LTA 5. 100% statutory compliance 6. External EHS audit with no major NC 7. 100% implementation of ISO 14001 and ISO 45001								
6.	Performance of the entity against the specific commitments, goals and targets along-with reasons in case the same are not met.	• 2 of our units are ISO14001 & ISO 45001 certified • Our facilities have Effluent Treatment Plants (ETPs) and ETP sludge dewatering systems. With these facilities, we have reduced 90% of the sludge volume in our dewatering system, thereby contributing towards Zero Liquid Discharge.								

Governance, leadership and oversight

7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements (listed entity has flexibility regarding the placement of this disclosure)

   Please refer to the Chairman's message from Concord's Annual Report for FY 2024-25.

8. Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies).

   The Chairman, the Chief Executive Officer and the KMPs broadly manage the Business Responsibility (BR) policies.

9. Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No/ NA).
Yes
If yes, provide details.
CSR Committee

10. Details of Review of NGRBCs by the Company*

Subject for Review	Indicate whether review was undertaken by Director/Committee of the Board/Any other Committee									Frequency (Annually / Half yearly /Quarterly/ Any other-please specify)								
	P1	P2	P3	P4	P5	P6	P7	P8	P9	P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action	Board									Annual basis								
	CSR committee									Half yearly Basis								
Description of other committee for performance against above policies and follow up action	-									-								
Compliance with statutory requirements of relevance to the principles and rectification of any non-compliances	The Company publishes its Business Responsibility report on a yearly basis as part of its annual report, fulfilling the requirements set by the SEBI Listing Regulations, which can be accessed at https://www.concordbiotech.com/investors																	
Description of other committee for compliance with statutory requirements of relevance to the principles and rectification	-									-								

**Concord actively engages in public policy advocacy through regular interactions with key external stakeholders, such as industry associations, government bodies, and regulatory authorities. While these engagements support informed policymaking and industry development, the Company does not currently have a formalised advocacy policy in place.*

11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If Yes, Provide name of the agency:

P1	P2	P3	P4	P5	P6	P7	P8	P9
No. Concord does not undergo independent assessments by external agencies. However, all policies are consistently monitored and reviewed by their respective policy owners.								

12. If answer to question (1) above is "No" i.e. not all Principles are covered by a policy, reasons to be stated:

Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
The entity does not consider the Principles material to its business (Yes/No)	** The Company considers all the principles material to the business. It does not currently conduct independent third-party assessments of its policies.								
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)					No				
The entity does not have the financial or/ human and technical resources available for the task (Yes/No)					No				
It is planned to be done in the next financial year (Yes/No)					No				
Any other reason (please specify)					-				

SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorized as "Essential" and "Leadership". While the essential indicators are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically responsible.

PRINCIPLE 1: Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.

Essential Indicators

1. Percentage coverage by training and awareness programmes on any of the Principles during the financial year:

Segment	Total number of training and awareness programmes held	Topics/principles covered under the training and its impact	%age of persons in respective category covered by the awareness programmes
Board of Directors	5	Overview of Business Units, Building Strategies, and Business Modelling.	100%
Key Managerial Personnel	7	Talent Development for Customised Development.	100%
Employees other than BoD and KMPs	90	Quality Management System, GMP GLP, Good Documents Practices, Data integrity	100%
Workers	60	Operations, cleaning and handling of Equipment, Dust collection and disposal, skills upgradation	100%

2. Details of fines/penalties/punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website):

Monetary

Penalty/ Fine	Nil
Settlement	Nil
Compounding fee	Nil

Non- Monetary

Imprisonment	Nil
Punishment	Nil

Note: During the financial year, there were no fines, penalties, punishments, compounding fees, or settlement amounts paid by the Company, its Directors, or Key Managerial Personnel to any regulatory, law enforcement, or judicial authorities. The Company remains committed to full legal compliance and has not been subject to any such proceedings requiring disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed

Sr. No.	Case Details	Name of the regulatory/ enforcement agencies/ judicial institutions
		NA

4. Does the entity have an anti-corruption or anti-bribery policy? (Y/N/NA)

If yes, provide details in brief. Provide a web link if the entity has an anti-corruption or anti-bribery policy. Provide a web-link if the entity has anti-corruption or anti-bribery policy

Yes, We have established Anti-Fraud, Anti-Corruption, and Anti-Money Laundering policies to prevent, detect, and address instances of fraud, corruption, and money laundering within the organisation. These policies require all team members to act with honesty and integrity, strictly prohibiting any participation in fraudulent activities. They also set out clear procedures for

reporting suspected incidents, detail the investigation process, and define disciplinary actions for policy violations. Adherence to these policies is mandatory for all employees and contractors, reinforcing our commitment to ethical conduct and responsible business practices.

Link is https://www.concordbiotech.com/public/assets/pdf/anti-fraud-and-anti-corruption-policy.pdf

5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:

	FY (2024-25)	FY (2023-24)
Directors	No disciplinary action has been taken by any law enforcement agency against any Director, Key Managerial Personnel (KMP), employee, or worker of the Company for charges related to bribery or corruption during the reporting period.	
KMPs		
Employees		
Workers		

6. Details of complaints with regard to conflict of interest:

	FY (2024-25)		FY (2023-24)	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	Nil			
Number of complaints received in relation to issues of Conflict of Interest of the KMPs				

7. Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.

Not Applicable. During the reporting period, there were no instances of corruption or conflicts of interest that resulted in fines, penalties, or actions by regulators, law enforcement agencies, or judicial institutions. Consequently, no corrective actions were required. The organisation remains committed to ethical conduct and compliance with all applicable laws and regulations.

8. Number of days of accounts payables

		FY (2024-25)	FY (2023-24)
i)	Accounts payable x 365 days (in lacs)	41,25,953	34,46,885
ii)	Cost of goods/services procured (in lacs)	30,551.31	22,919.81
iii)	Number of days of accounts payables	135 Days	150 Days

9. Open-ness of business - Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties, in the following format

Parameter	Metrics			FY (2024-25)	FY (2023-24)
Concentration of Purchases	a.	i)	Purchases from trading houses	160.83	156.02
		ii)	Total purchases	320.30	241.27
		iii)	Purchases from trading houses as % of total purchases	50.21%	64.67%
	b.		Number of trading houses where purchases are made	137	110
	c.	i)	Purchases from top 10 trading houses	105.48	84.40
		ii)	Total purchases from trading houses	160.83	156.02
		iii)	Purchases from top 10 trading houses as % of total purchases from trading houses	65.59%	42.25%
Parameter	**Metrics**			**FY (2024-25)**	**FY (2023-24)**
Concentration of Sales	a.	i)	Sales to dealer / distributors	167.59	167.85
		ii)	Total Sales	1,200.08	1,016.93
		iii)	Sales to dealer / distributors as % of total sales	13.96	16.51%
	b.		Number of dealers / distributors to whom sales are made	367	327
	c.	i)	Sales to top 10 dealers / distributors	80.73	96.56
		ii)	Total Sales to dealer / distributors	167.59	167.85
		iii)	Sales to top 10 dealers / distributors as % of total sales to dealer / distributors	48.17%	57.53%

Parameter	Metrics			FY (2024-25)	FY (2023-24)
Share of RPTs in	a.	i)	Purchases (Purchases with related parties)	0	0
		ii)	Total Purchases	0	0
		iii)	Purchases (Purchases with related parties as % of Total Purchases)	Nil	Nil
	b.	i)	Sales (Sales to related parties)	30.35 Cr	43.06 Cr
		ii)	Total Sales	1,200.09 Cr	1,016.94 Cr
		iii)	Sales (Sales to related parties as % of Total Sales)	2.53%	4.23%
	c.	i)	Loans & advances given to related parties	0	0
		ii)	Total loans & advances	0	0
		iii)	Loans & advances given to related parties as % of Total loans & advances	Nil	Nil
	d.	i)	Investments in related parties	0	0
		ii)	Total Investments made	₹ 6.09 Cr	0
		iii)	Investments in related parties as % of Total Investments made	Nil	Nil

Leadership Indicators

1. Awareness programmes conducted for value chain partners on any of the Principles during the financial year.

Sr. No.	Total number of awareness programmes held	Topics / principles covered under the training	Percentage of value chain partners covered (by value of business done with such partners) under the awareness programmes
1.	5	**Environmental:-** Waste Management, energy Efficiency, Water usage & conservation and sustainable sourcing **Social Responsibility:-** Occupational health & safety, Human rights & Labour practices, Community engagement **Value chain specific:-** ESG data collection & report, suppliers code of conduct, risk management and resilience, understanding BRSR core KPI	80%

2. Does the entity have processes in place to avoid/manage conflict of interests involving members of the Board? (Yes/No/NA)

If Yes, provide details of the same.

Yes. Concord acknowledges the significance of preventing and addressing conflicts of interest among Board members to ensure transparency, integrity, and ethical conduct throughout the organisation. To this end, the Company has put in place a dedicated policy to manage such situations. The policy requires both the Board of Directors and Senior Management Personnel to avoid any business, relationship, or activity that could conflict with the interests of Concord or negatively impact its reputation. Any scenario where personal interests may be at odds with those of the Company or its stakeholders is strictly forbidden. In instances where a potential conflict arises, necessary approvals are obtained from the Board, excluding members with a vested interest.

https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Code-of-Conduct-for-BoD-and-SMPs.pdf

PRINCIPLE 2 : Businesses should provide goods and services in a manner that is sustainable and safe

Essential Indicators

1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.

	FY (2024-25)	FY (2023-24)	Details of improvements in environmental and social impacts
R & D	Nil	Nil	NA
Capex	0.04%	0.49%	Expenditure in ETP

2. a. Does the entity have procedures in place for sustainable sourcing? (Yes/No)

Yes, Concord has established procedures to ensure sustainable sourcing. A significant portion of our raw materials comprises agro-based compounds. To align with our long-term sustainability goals, we have implemented a due diligence system

that requires suppliers to provide specific details about their operations through our internally developed preliminary information questionnaire, which addresses various ESG parameters. This allows us to assess and select suppliers and vendors based on well-defined criteria, including their capabilities to recycle, repurpose, reprocess, or recover materials; their internal environmental and social controls; compliance with regulatory requirements; safety standards; and overall business practices.

b. If yes, what percentage of inputs were sourced sustainably?

100%

3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for

(a) Plastics (including packaging) : Concord ensures responsible handling of plastic waste, particularly HDPE bags used in operations. These bags are reused in-house to fill ETP (Effluent Treatment Plant) sludge and MEE (Multiple Effect Evaporator) salt. Any surplus HDPE bags are sold to authorized plastic recyclers in compliance with statutory recycling norms. This dual approach supports both reuse and recycling, reducing plastic waste disposal.

(b) E-waste : All electronic waste generated is sent to registered e-waste recyclers authorized by the relevant pollution control boards. The process is fully compliant with the E-Waste Management Rules, ensuring safe and environmentally sound disposal or recycling of obsolete electronic equipment.

(c) Hazardous waste: Concord follows stringent procedures to manage hazardous waste. Depending on the nature of the waste, it is:

- Reused within operations where feasible,
- Recycled through registered recyclers,
- Co-processed in cement kilns, or
- Safely disposed of at authorized TSDFs (Treatment, Storage and Disposal Facilities).

ETP sludge, categorized as hazardous, is dried using paddle dryers to reduce moisture content by up to 90%, making it safer for disposal. Biomedical waste, where applicable, is sent to registered incineration facilities for environmentally sound treatment.

(d) other waste: In addition to the above, Concord manages non-hazardous operational waste in line with environmental regulations. Waste minimization and resource recovery are prioritized, and the company actively engages with stakeholders to promote a circular economy across its value chain. Efforts are ongoing to reduce waste generation and improve resource efficiency through continuous innovation and compliance-driven stewardship.

4. Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No).

If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards?

Yes, Extended Producer Responsibility (EPR) is applicable to our operations. Our waste collection and management practices are aligned with the EPR plan submitted to the respective Pollution Control Boards, ensuring compliance with regulatory requirements.

If not, provide steps taken to address the same.

NA

Leadership Indicators

1. Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)? (Yes/No/NA)

Yes.

If yes, provide details

The entity conducted Life Cycle Perspective/Assessments (LCA)							
Sr. No.	**NIC Code**	**Name of Product/ Service**	**% of total Turnover contributed**	**Boundary for which the Life Cycle Perspective/ Assessment was conducted**	**Whether conducted by independent external agency (Yes/No)**	**Results communicated in public domain (Yes/No)**	**If yes, provide the web-link.**
1.	21001	API	NA	Manufacturing facility	No	No	NA
2.	21002	Formulation	NA	Manufacturing facility	No	No	NA

We have adopted the Life Cycle Assessment approach for our key products, which involves evaluating the sequential and interconnected stages of a product (or service) system — from the extraction of raw materials or natural resource generation to its final disposal.

2. **If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same.**

Action taken to mitigate significant social or environmental concerns and/or risks arising from production or disposal of products / services		
Name of Product / Service	**Description of the risk / concern**	**Action Taken**
Nil	Nil	Nil

3. **Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry).**

In the pharmaceutical industry, the proportion of recycled or reused input materials in total production varies due to regulatory constraints. While 100% recycling is not always feasible owing to statutory requirements, Concord has established adequate facilities for solvent recovery to promote resource efficiency wherever possible.

Indicate input material	Recycled or re-used input material to total material	
	FY25 Current Financial Year	FY24 Previous Financial Year
	NA	NA

4. **Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely disposed, as per the following format:**

	FY25 Current Financial Year			FY24 Previous Financial Year		
	Re-Used	Recycled	Safely Disposed	Re-Used	Recycled	Safely Disposed
Plastics (including packaging)	7.091	4.81	0	346.43	0	9.66
E-waste	0	0.16	0	0	0	0.47
Hazardous waste	0	377.02	2668.21	0	0	6.88
Other waste-Spent solvent	0	0	602.23		NA	

5. **Reclaimed products and their packaging materials (as percentage of products sold) for each product category**

Indicate product category	Reclaimed products and their packaging materials as % of total products sold in respective category
NA	NA

Note: Currently, Concord does not reclaim products and their packaging materials; however, the Company is actively exploring sustainable practices and initiatives to enhance product stewardship and reduce environmental impact across its product categories.

PRINCIPLE 3: Businesses should respect and promote the well-being of all employees, including those in their value chains

Essential Indicators

1. a. **Details of measures for the well-being of employees:**

Category	Total (A)	% of employees covered by									
		Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A)
Permanent employees											
Male	1466	0	0	1466	100%	0	0	0	NA	0	NA
Female	105	0	0	105	100%	105	100%	0	NA	0	NA
Other	0	0	0	0	NA	0	NA	0	NA	0	NA
Total	**1571**	**0**	**0**	**1571**	**100%**	**105**	**100%**	**0**	**NA**	**0**	**NA**

Category	Total (A)	% of employees covered by									
		Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A)
Other than permanent employees											
Male	26	0	NA	0	NA	0	NA	0	NA	0	NA
Female	0	0	NA	0	NA	0	NA	0	NA	0	NA
Other	0	0	NA	0	NA	0	NA	0	NA	0	NA
Total	**26**	**0**	**NA**	**0**	**NA**	**0**	**NA**	**0**	**NA**	**0**	**NA**

b. Details of measures for the well-being of workers:

Category	Total (A)	% of workers covered by									
		Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A)
Permanent workers											
Male	NA	-	NA	-	NA	-	NA	-	NA	-	NA
Female	NA	-	NA	-	NA	-	NA	-	NA	-	NA
Other	NA	-	NA	-	NA	-	NA	-	NA	-	NA
Total	**NA**	**-**	**NA**	**-**	**NA**	**-**	**NA**	**-**	**NA**	**-**	**NA**
Other than permanent workers											
Male	1,166	0	NA	1,166	100%	0	NA	0	NA	0	NA
Female	19	0	NA	19	100%	0	NA	0	NA	0	NA
Other	0	0	NA	0	NA	0	NA	0	NA	0	NA
Total	**1,185**	**0**	**NA**	**1,185**	**100%**	**0**	**NA**	**0**	**NA**	**0**	**NA**

Note: Laborers employed through contractors and their subcontractors have been classified as workers. These workers are not on the direct payroll of the Company.

c. Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format:

		FY 2024-25	FY 2023-24
i)	Cost incurred on wellbeing measures (well-being measures means well-being of employees and workers (including male, female, permanent and other than permanent employees and workers)	₹ 2,00,66,000	₹ 1,93,21,845.69
ii)	Total revenue of the company	₹ 1200,08,68,947	₹ 1016,93,92,470
iii)	Cost incurred on wellbeing measures as a % of total revenue of the company	0.17%	0.19%

2. Details of retirement benefits

Benefits	FY 2024-25			FY 2023-24		
	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/NA)	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/NA)
PF	100%	100%	Yes	99.86%	0.00%	Yes
Gratuity	99%	100%	Yes	99.06%	0.00%	Yes
ESI	0	0	Yes	0.01%	0.00%	Yes
Others – Please specify	-					

3. Accessibility of workplaces

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

If not, whether any steps are being taken by the entity in this regard.

Concord consistently strives to enhance the accessibility of its workplace for all employees. This involves providing ramps, elevators, and other essential infrastructure across its manufacturing units, administrative offices, and corporate headquarters to ensure convenient access for individuals with disabilities.

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy.

Concord is an equal opportunity employer and is committed to providing equal access to education, employment, leadership positions, and other opportunities to individuals of all genders. The Company follows a non-discriminatory approach, irrespective of gender, caste, or nationality, in line with the principles of the Rights of Persons with Disabilities Act, 2016.

5. Return to work and Retention rates of permanent employees and workers that took parental leave.

Gender	Permanent employees		Permanent workers	
	Return to work rate	Retention rate	Return to work rate	Retention rate
Male	0	0	0	0
Female	0	0	0	0
Other	0	0	0	0
Total	**0**	**0**	**0**	**0**

6. Is there a mechanism available to receive and redress grievances for the following categories of employees and worker?(Yes/No) If yes, give details of the mechanism in brief.

Yes

If yes, give details of the mechanism in brief.	Yes/No	(If Yes, then give details of the mechanism in brief)
Permanent Workers	NA	
Other than Permanent Workers	Yes	The Company has an Employees' Grievance Redressal Policy that enables any aggrieved employee to report concerns to their Department Head for resolution. If the issue remains unresolved, the matter can be escalated to the HR Head, followed by the Grievance Committee, and ultimately to the CEO for final resolution.
Permanent Employees	Yes	
Other than Permanent Employees	NA	

7. Membership of employees and worker in association(s) or Unions recognised by the listed entity:

Category	FY 2025			FY 2024		
	Total employees/ workers in respective category (A)	No.of employees / workers in respective category, who are part of association(s) or Union (B)	% (B / A)	Total employees / workers in respective category (C)	No.of employees / workers in respective category, who are part of association(s) or Union (D)	% (D / C)
Total Permanent Employees						
Male						
Female						
Other						
Total Permanent Workers						
Male						
Female						
Other						

NA

Note: Currently, no employees or workers are members of any association or union recognized by the Company. However, Concord fosters a transparent and inclusive workplace culture that emphasizes direct engagement, open communication, and mutual respect. We maintain robust internal grievance redressal mechanisms and regularly engage with employees through formal and informal channels to address their concerns, ensuring that their voices are heard and valued without the need for third-party representation.

8. Details of training given to employees and workers:

Category	FY 2025					FY 2024				
	Total (A)	On Health and safety measures		On Skill upgradation		Total (D)	On Health and safety measures		On Skill upgradation	
		No. (B)	% (B/A)	No. (C)	% (C/A)		No. (E)	% (E / D)	No. (F)	% (F / D)
Employees										
Male	1466	1466	100%	1466	100%	1,288	1,288	100%	1,288	100%
Female	105	105	100%	105	100%	89	89	100%	89	100%
Other	-	-	-	-	-	-	-	-	-	-
Total	**1571**	**1571**	**100%**	**1571**	**100%**	**1,377**	**1,377**	**100%**	**1,377**	**100%**
Workers										
Male	1166	1166	100%	0	0	1,011	1,011	100%	0	0%
Female	19	19	100%	0	0	13	13	100%	0	0%
Other	-	-	-	-	-	-	-	-	-	-
Total	**1185**	**1185**	**100%**	**0**	**0**	**1,024**	**1,024**	**100%**	**0**	**0%**

9. Details of performance and career development reviews of employees and worker:

Category	FY 2025			FY 2024		
	Total (A)	No. (B)	% (B/A)	Total (D)	No. (E)	% (E / D)
Employees						
Male	1466	1466	100%	1,288	1,288	100%
Female	105	105	100%	89	89	100%
Other	-	-	-	-	-	-
Total	**1571**	**1571**	**100%**	**1,377**	**1,377**	**100%**
Workers						
Male	1166	0	0	1,011	0	0
Female	19	0	0	13	0	0
Other	-	-	-	-	-	-
Total	**1185**	**0**	**0**	**1,024**	**0**	**0**

10. Health and safety management system:

a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No/ NA).

Concord's EHS department leads multiple initiatives aimed at cultivating a safety-first culture across the organization. Its core objective is to eliminate any adverse impact on individuals, operations, or the environment. This is achieved through the implementation of a comprehensive, 360-degree EHS management system that spans all business activities. The EHS team ensures full compliance with relevant legal and regulatory standards related to pollution control, workplace and plant safety, and the health of employees and contractors. By proactively identifying and mitigating risks, and by delivering thorough training to both management and staff, Concord significantly minimizes incidents and occupational health risks. Regular training programs not only support operational efficiency and productivity but also help maintain the highest standards of compliance related to quality and safety. The Company's API manufacturing units in Dholka and Limbasi, Gujarat, are certified under ISO 14001 and ISO 45001. The system offers 100% coverage, encompassing all internal and external stakeholders at the manufacturing sites, including employees, suppliers, and contractors, under its health and safety framework.

b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

The Company has implemented a robust risk management policy designed to proactively identify and address potential threats. Our risk management framework is structured to safeguard the organisation from a wide range of risks through

timely and appropriate actions. It is built to anticipate, evaluate, and mitigate risks effectively, thereby reducing their potential impact on business operations. Concord systematically identifies and documents all risks that could affect its operations and embeds them into its broader management systems to ensure informed decision-making. Routine process safety risk assessments are conducted to address workplace hazards, supported by the necessary permits for both routine and non-routine activities. The Company employs integrated process safety management systems to evaluate existing operations and new developments for associated risks. Various process safety studies—such as process hazard analysis, equipment safety evaluations using HAZOP, HIRA, EAI, PSSR, scenario analysis, and risk assessment matrices—are conducted by cross-functional teams. In addition, regular risk-based assessments and thorough audits are carried out to continuously monitor and enhance Concord's health and safety performance at the site level.

https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Risk-Management-Policy.pdf

c. Whether you have processes for workers to report the work related hazards and to remove themselves from such risks? Yes. At Concord's facilities, established protocols are in place for reporting near-misses, unsafe acts, hazardous conditions, and for tracking their resolution. These processes are periodically reviewed during management review meetings. To strengthen work-related risk management, several key initiatives have been implemented:

- Employees are actively encouraged to report safety concerns through multiple channels, including regular departmental safety meetings. Concerns raised are promptly addressed through well-defined action plans with clear timelines and assigned responsibilities.
- In line with our standard operating procedure for 'Incident Reporting and Investigation,' all incidents are reported immediately to the appropriate supervisors. A multidisciplinary team then conducts a detailed analysis to determine root causes and recommend corrective actions.
- Our manufacturing plants use a structured Hazard Identification and Risk Assessment (HIRA) system to continuously monitor and evaluate workplace risks. Additionally, regular safety committee meetings—conducted in compliance with factory regulations—provide a forum for collaboration between management, employees, and contractors to jointly address health and safety matters.

d. Do the employees/ worker of the entity have access to non-occupational medical and healthcare services?

Yes. We provide our employees and workers with access to non-occupational medical and healthcare services, including complimentary health check-ups.

11. Details of safety related incidents, in the following format:

Safety Incident/Number	Category*	FY 2025	FY 2024
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)	Employees	Nil	Nil
	Workers	Nil	Nil
Total recordable work-related injuries	Employees	Nil	Nil
	Workers	Nil	Nil
No. of fatalities	Employees	Nil	Nil
	Workers	Nil	Nil
High consequence work related injury or ill-health (excluding fatalities)	Employees	Nil	Nil
	Workers	Nil	Nil

**including in the contract workforce*

12. Describe the measures taken by the entity to ensure a safe and healthy work place.

As part of Concord's continued commitment to ensuring a safe and healthy workplace, we have undertaken a comprehensive range of initiatives, including:

- Complying with all applicable legal and regulatory requirements related to pollution control, workplace safety, and the health of employees and contractors
- Carrying out regular risk assessments to proactively identify and mitigate potential hazards
- Implementing well-defined safety policies and procedures, delivering ongoing training on safety protocols and emergency preparedness, and providing employees with appropriate safety equipment and infrastructure
- Operating robust fire protection and prevention systems across all manufacturing sites
- Maintaining ISO 14001 and ISO 45001 certifications at our production facilities in Dholka and Limbasi

- Welcoming regular inspections by Indian regulatory bodies and international agencies such as the USFDA, EU-GMP, PMDA (Japan), ANVISA (Brazil),SFDA (Middle east region) and MFDS (Korea).

These initiatives reflect Concord's ongoing efforts to create a secure, compliant, and supportive work environment for all its employees.

13. Number of Complaints on the following made by employees and workers:

	FY 2025			FY 2024		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Working Conditions	Nil	Nil	-	Nil	Nil	-
Health & Safety	Nil	Nil	-	Nil	Nil	-

14. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Health and safety practices	100%
Working Conditions	100%

All our manufacturing plants are audited by the following third parties:

1. BVQI for ISO for API facilities
2. Factory inspector and medical officer from District Industrial Safety and Health Department

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions. NA. During the reporting period, there were no safety-related incidents or significant risks identified from assessments of health and safety practices or working conditions that required corrective action. The Company continues to maintain a strong focus on proactive safety measures and a safe working environment across all its operations.

Leadership Indicators

1. Does the entity extend any life insurance or any compensatory package in the event of death of

(A) Employees (Y/N)	Yes
(B) Workers (Y/N).	Yes

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners.

Concord ensures that all statutory dues arising from its transactions with value chain partners are properly deducted and deposited in compliance with applicable laws and regulations. These processes are regularly monitored and verified through routine audits. The Company also systematically obtains relevant certificates and documentation from contractors, including proof of statutory payments such as Provident Fund (PF) contributions for contractual employees and workers. Additionally, Concord expects its value chain partners to maintain high ethical standards and conduct all business activities with integrity.

3. Provide the number of employees / workers having suffered high consequence work related injury / ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:

	Total no. of affected employees/ workers		No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY 2025	FY 2024	FY 2025	FY 2024
Employees	Nil	Nil	Nil	Nil
Workers	Nil	Nil	Nil	Nil

4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/ No/ NA)

No. Concord provides regular skill enhancement programmes to its employees throughout their tenure. These training initiatives are designed to address the specific requirements of various job roles and functional areas, enabling employees to leverage the skills gained for career opportunities even after retirement.

5. Details on assessment of value chain partners:

	% of value chain partners (by value of business done with such partners) that were assessed
Health and safety practices	NA
Working Conditions	NA

Note: As part of the vendor development process, the Company reviews all aspects of the vendor's health, safety, and working condition practices.

6. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners.

NA. Vendor qualification processes, including both physical and virtual audits, form an essential part of the Quality Assurance department's oversight for our key raw material suppliers.

PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders

Essential Indicators

1. Describe the processes for identifying key stakeholder groups of the entity.

A structured approach was adopted for stakeholder consultation across the organisation, involving the use of questionnaires and interviews. Internal stakeholders, particularly senior management and functional heads, identified Concord's key sustainability priorities. Consultations with external stakeholders were also carried out to assess the impact and effectiveness of our sustainability efforts. Subsequently, sustainability reports of industry peers were reviewed, and relevant government regulations were examined to incorporate the perspectives of customers and regulators. The gathered data was consolidated, considering the relative significance of each stakeholder. Stakeholders were then prioritised based on the extent to which they could influence the Company's performance and the impact the Company's performance could have on them.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.

Sr. No.	Stakeholder Group	Whether identified as Vulnerable & Marginalized Group	Channels of communication	Details of Other Channels of communication	Frequency of engagement	Details of Other Frequency of engagement	Purpose and scope of engagement including key topics and concerns raised during such engagement
1.	Healthcare Professionals	No	Individual meetings focused on recent developments and best practices in scientific research related to emerging therapies.	-	Half yearly and need-based	-	Concord engages with healthcare professionals to keep them informed about its products and innovations, with key areas of focus being product quality and availability.

Sr. No.	Stakeholder Group	Whether identified as Vulnerable & Marginalized Group	Channels of communication	Details of Other Channels of communication	Frequency of engagement	Details of Other Frequency of engagement	Purpose and scope of engagement including key topics and concerns raised during such engagement
2.	Customers	No	customer surveys, review meetings, phone calls, emails, as well as physical and virtual meetings	-	Half yearly and need-based	-	Ensuring timely delivery of products and services, responding to customer queries and grievances, gathering feedback, understanding customer needs, and keeping customers informed about its offerings. Key topics of concern include access, affordability, availability, product quality, and resolution of consumer grievances.
3.	Suppliers	No	Scheduled meetings, weekly e-mail briefings, regular phone calls, and e-mails.	-	Half yearly and need-based	-	Ensuring smooth business operations through timely availability of materials and services, maintaining quality and quantity of supplies, and identifying potential supply chain issues. Key topics of concern include material pricing and sustaining long-term contracts.
4.	Regulators	No	One-on-one meetings, periodical regulatory filings, periodic audits, e-mails, letters.	-	Periodic and need-based	-	Engagement focuses on compliance, adherence to guidelines, and seeking technical guidance. Key topics of concern include changes in laws and regulations, regulatory compliance, and timely disclosures.
5.	NGO's/ communities	Yes	Direct engagement at facility and project sites, dedicated CSR-team-led engagement, visits and camps.	-	Continuous and need-based	-	Engagement involves CSR initiatives, advancing environmental sustainability, and promoting science education among students. Key topics of concern include CSR efforts focused on livelihood development and improving access to education and healthcare.

Sr. No.	Stakeholder Group	Whether identified as Vulnerable & Marginalized Group	Channels of communication	Details of Other Channels of communication	Frequency of engagement	Details of Other Frequency of engagement	Purpose and scope of engagement including key topics and concerns raised during such engagement
6.	Investors and leadership	No	Annual reports and quarterly results, email, Stock Exchange intimations, analysts meet/ conference calls, Annual General Meeting, media releases, performance and business update calls, investor meetings, and newspaper advertisements.	-	Quarterly, annual and need-based	-	Engagement focuses on maintaining business performance, formulating future growth strategies, addressing shareholder queries and suggestions, and understanding their expectations. Key topics of concern include business profitability and growth, the Company's reputation, and corporate governance.
7.	Employees	No	Review meets, festive events, welfare events, out bound training programmes, e-mails, website, notice boards, meetings, one-on-one discussions, and townhalls	-	Ongoing and need-based	-	Engagement centres on employee well-being, gathering feedback, and providing training and career development opportunities. Key topics of concern include employee welfare, career advancement, and capacity building.

Leadership Indicators

1. **Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.**

   The Relevant business and functional heads engage in consultations with their respective stakeholders. Any feedback obtained through these interactions is subsequently shared with senior management and/or the Board, as appropriate.

2. **Whether stakeholder consultation is used to support the identification and management of environmental, and social topics. (Yes/No)**

   If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into policies and activities of the entity.

   Yes, Concord has carried out a comprehensive materiality assessment based on data and insights gathered from relevant stakeholders. This assessment thoroughly examined environmental, social, governance, and economic factors essential to the organisation's long-term sustainability and viability. As a result, key issues critical to our business sustainability were identified and prioritised, and corresponding goals were set to achieve our sustainability targets, thereby driving long-term value creation.

3. Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized stakeholder groups.

We place strong emphasis on the welfare of communities surrounding our manufacturing facilities, recognising them as a vulnerable or marginalised stakeholder group. To support their needs, we have implemented several initiatives, such as offering healthcare services, funding education and scholarships, promoting sports, and contributing to Army welfare programs.

PRINCIPLE 5 Businesses should respect and promote human rights

Essential Indicators

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:

Category	FY (2024-25)			FY (2023-24)		
	Total (A)	No. of employees/ workers covered (B)	% (B / A)	Total (C)	No. of employees/ workers covered (D)	% (D / C)
Employees						
Permanent	1,571	1,571	100%	1,377	1,377	100%
Other than permanent	26	26	100%	Nil	Nil	Nil
Total Employees	**1,597**	**1,597**	**100%**	**1,377**	**1,377**	**100%**
Workers						
Permanent	Nil	Nil	Nil	Nil	Nil	Nil
Other than permanent	1,185	Nil	Nil	1,024	Nil	Nil
Total Workers	**1,185**	**Nil**	**Nil**	**1,024**	**Nil**	**Nil**

2. Details of minimum wages paid to employees and workers, in the following format:

Category	FY (2024-25)					FY (2023-24)				
	Total (A)	Equal to Minimum Wage		More than Minimum Wage		Total (D)	Equal to Minimum Wage		More than Minimum Wage	
		No. (B)	% (B /A)	No. (C)	% (C /A)		No. (E)	% (E /D)	No. (F)	% (F /D)
Employees										
Permanent										
Male	1,466	Nil	Nil	1,466	100%	1,288	Nil	Nil	1,288	100%
Female	105	Nil	Nil	105	100%	89	Nil	Nil	89	100%
Other	-	-	-	-	-	-	-	-	-	-
Other than Permanent										
Male	26	Nil	Nil	26	100%	Nil	Nil	Nil	Nil	Nil
Female	0	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Other	-	-	-	-	-	-	-	-	-	-
Workers										
Permanent										
Male	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Female	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Other	-	-	-	-	-	-	-	-	-	-
Other than Permanent										
Male	1,166	Nil	Nil	1,166	100%	1,011	Nil	Nil	1,011	100%
Female	19	Nil	Nil	19	100%	13	Nil	Nil	13	100%
Other	-	-	-	-	-	-	-	-	-	-

3. Details of remuneration/salary/wages, in the following format:

a. Median remuneration / wages:

	Male		Female		Other	
	Number	Median remuneration/ salary/ wages of respective category	Number	Median remuneration/ salary/ wages of respective category	Number	Median remuneration/ salary/ wages of respective category
Board of Directors (BoD)- Executive Directors	2	4,87,85,500	0	0	-	-
Key Managerial Personnel	2	56,97,747	-	-	-	-
Employees other than BoD and KMP	1462	5,49,744	105	3,40,116	-	-
Workers	1185	1,84,952	19	1,87,966	-	-

b. Gross wages paid to females:

	FY (2024-25)	FY (2023-24)
Gross wages paid to females	35,71,359	-
Total wages	22,27,40,000	-
Gross wages paid to females (Gross wages paid to females as % of total wages)	1.60%	0

Note: Laborers employed through contractors and their subcontractors have been classified as workers. These workers are not on the direct payroll of the Company.

Note: Employees don't include other than Permanent Employees

4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business?(Y/N)

Yes, Concord is committed to preventing human rights violations and ensuring a safe, inclusive work environment. To support this, we have implemented a POSH (Prevention of Sexual Harassment) Policy, a grievance redressal mechanism, and a Whistle Blower Policy. Employees and contractors are encouraged to voice human rights-related concerns during Safety & Health Committee meetings. These concerns are addressed by the Site HR and EHS teams, operating under the supervision of the site head, and escalated to the corporate level when required. Relevant governance committees then review and deliberate on the matters in detail.

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

Our POSH and Whistle Blower policies enable employees to report any grievances. Additionally, concerns can be directly communicated to the Human Resources team via email.

6. Number of Complaints on the following made by employees and workers:

	FY (2024-25)			FY (2023-24)		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Sexual Harassment	Nil	Nil	-	Nil	Nil	-
Discrimination at workplace	Nil	Nil	-	Nil	Nil	-
Child Labour	Nil	Nil	-	Nil	Nil	-
Forced Labour/Involuntary Labour	Nil	Nil	-	Nil	Nil	-
Wages	Nil	Nil	-	Nil	Nil	-
Other human rights related issues	Nil	Nil	-	Nil	Nil	-

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

		FY (2024-25)	FY (2023-24)
i)	Total Complaints reported under Sexual Harassment on of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	Nil	Nil
ii)	Average number of female employees/workers at the beginning of the year and as at end of the year	113	96
iii)	Complaints on POSH as a % of female employees / workers	Nil	Nil
iv)	Complaints on POSH upheld	Nil	Nil

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

Our Whistle Blower Policy ensures protection for individuals raising concerns in good faith, particularly in cases of discrimination and harassment. It strictly prohibits any form of harassment or retaliation against whistle blowers and prescribes disciplinary action, including termination, for supervisors or managers found engaging in such behaviour. The Policy emphasizes confidentiality, allowing whistle blowers to make anonymous disclosures, and guarantees fair treatment and comprehensive investigation of all complaints.

Link to the policy: https://www.concordbiotech.com/public/assets/pdf/Concord-Biotech-Limited-Whistle-Blower-Policy.pdf

9. Do human rights requirements form part of your business agreements and contracts? (Yes/No/NA)

Yes. Human rights requirements form an integral part of our business agreements and contractual obligations. We ensure that all our partners, suppliers, and contractors adhere to relevant human rights principles, including the prohibition of forced labour, child labour, discrimination, and unsafe working conditions. These requirements are embedded in our contractual terms to promote ethical practices, accountability, and compliance with applicable laws and international standards on human rights.

10. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labour	100%
Forced/involuntary labour	
Sexual harassment	
Discrimination at workplace	
Wages	
Others – please specify	-

The sites were assessed through internal reviews and third-party audits including TFS, ISO, and EcoVadis, covering key areas like child labour, forced labour, discrimination, wages, and workplace safety.

11. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 10 above.

NA

Leadership Indicators

1. Details of a business process being modified / introduced as a result of addressing human rights grievances/complaints.

NA

2. Details of the scope and coverage of any Human rights due-diligence conducted

None

3. Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

Concord actively takes necessary measures to ensure a more inclusive and accessible workplace for its people. Our manufacturing units, administrative offices, and corporate headquarters are equipped with ramps, elevators, and other infrastructure to facilitate ease of access for individuals with disabilities.

4. Details on assessment of value chain partners:

	% of value chain partners (by value of business done with such partners) that were assessed
Sexual harassment	NA
Discrimination at workplace	
Child Labour	
Forced Labour/Involuntary Labour	
Wages	
Others – please specify	

Note: During the vendor development process, the Company thoroughly evaluates all aspects of the vendor's human rights practices.

5. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 4 above.

NA

PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment

Essential Indicators

1. Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:

Whether total energy consumption and energy intensity is applicable to the company?

Yes. Total energy consumption and energy intensity are applicable to the Company.

Revenue from operations (in ₹)		FY (2024-25)	FY (2023-24)
		12,00,08,68,947	10,16,93,92,470
Parameter	**Units**	**FY (2024-25)**	**FY (2023-24)**
From renewable sources			
Total electricity consumption (A)	Gigajoule (GJ)	0	0
Total fuel consumption (B)	Gigajoule (GJ)	0	0
Energy consumption through other sources (C)	Gigajoule (GJ)	0	0
Total energy consumed from renewable sources (A+B+C)	Gigajoule (GJ)	0	0
From non-renewable sources			
Total electricity consumption (D)	Gigajoule (GJ)	3,00,866.84	2,12,048.38
Total fuel consumption (E)	Gigajoule (GJ)	6,76,971.61	2,80,971.46
Energy consumption through other sources (F)	Gigajoule (GJ)	-	0
Total energy consumed from non-renewable sources (D+E+F)	Gigajoule (GJ)	9,77,578.90	4,93,019.84
Total energy consumed (A+B+C+D+E+F)	Gigajoule (GJ)	9,77,578.90	4,93,019.84
Energy intensity per rupee of turnover (Total energy consumed / Revenue from operations)	Gigajoule (GJ) / ₹	0.000081	0.00048
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total energy consumed / Revenue from operations adjusted for PPP)	Gigajoule (GJ) / ₹	0.0016	0.00013
Energy intensity in terms of physical Output	Gigajoule (GJ) / ₹	2,734.33	205.34
Energy intensity (optional) – the relevant metric may be selected by the entity	-	Nil	Nil

Energy consumption through other sources (C)

Details of Energy consumed from renewable				
Sr. No.	**Name of other parameter**	**Unit**	**FY (2024-25)**	**FY (2023-24)**
1.	NA	NA	NA	NA

Energy consumption through other sources (F)

Details of Energy consumed from non-renewable				
Sr. No.	**Name of other parameter**	**Unit**	**FY (2024-25)**	**FY (2023-24)**
1.	NA	NA	NA	NA

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

No

If yes, name of the external agency.

NA

2. Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N)

No, the PAT Scheme is not applicable to Concord, as it does not fall under energy-intensive industries.

If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any.

NA

3. Provide details of the following disclosures related to water, in the following format:

Parameter	**FY (2024-25)**	**FY (2023-24)**
Water withdrawal by source (in kilolitres)		
(i) Surface water	0	0
(ii) Groundwater	3,85,410	3,57,436.5
(iii) Third party water	0	0
(iv) Seawater / desalinated water	0	0
(v) Others	0	0
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)	3,85,410	3,57,436.5
Total volume of water consumption (in kilolitres)	3,85,410	3,57,436.5
Water intensity per rupee of turnover (Total water consumption / Revenue from operations)	0.0000321	0.000035
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total water consumption / Revenue from operations adjusted for PPP)	0.000663	0.00001
Water intensity in terms of physical output	0.001915	148.87
Water intensity (optional) – the relevant metric may be selected by the entity	-	-

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

If yes, name of the external agency.

Yes, according to Notification S.O. 3289 (E), the Ministry of Jal Shakti has issued guidelines to regulate groundwater extraction in India. Moreover, our Industry Unit 1 and Unit 3 undergo audits.

4. Provide the following details related to water discharged:

Parameter		FY (2024-25)	FY (2023-24)
Water discharge by destination and level of treatment (in kilolitres)			
(i)	To Surface water	0	0
	No treatment	0	0
	With treatment – please specify level of treatment	0	0
(ii)	To Groundwater	3,85,410	0
	No treatment	23,397	0
	With treatment – please specify level of treatment	96,938	0
(iii)	To Seawater	0	0
	No treatment	0	0
	With treatment – please specify level of treatment	0	0
(iv)	Sent to third-parties	0	0
	No treatment	0	0
	With treatment – please specify level of treatment	0	0
(v)	Others	2,29,770	0
	No treatment	0	0
	With treatment – please specify level of treatment	1,32,832	1,81,193
Total water discharged (in kilolitres)		**2,53,167**	**1,81,193**

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)
No
If yes, name of the external agency.
N/A

5. Has the entity implemented a mechanism for Zero Liquid Discharge?(Y/N/NA) If yes, provide details of its coverage and implementation.

Yes. Every Concord facility is equipped with Effluent Treatment Plants (ETPs) designed to achieve Zero Liquid Discharge. These facilities treat wastewater generated from various sources including washing operations, utility blowdowns, restroom facilities, and cafeterias using cutting-edge technology.

The comprehensive treatment process involves multiple stages - ETP, reverse osmosis (RO), multiple effect evaporators (MEE), and agitated thin film dryers (ATFD). Once treated to meet regulatory standards, the processed water is recycled for irrigation, utility operations, and chemical preparation within the ETP system.

Our innovative Zero Liquid Discharge approach has achieved a remarkable 90% reduction in sludge volume through our dewatering systems. This commitment to environmental stewardship positions us as a key contributor to creating a sustainable future with minimized ecological impact for upcoming generations.

Beyond waste reduction, Concord's advanced treatment technologies enhance overall water quality while significantly lowering chemical oxygen demand (COD) levels. This dual benefit reduces our dependence on freshwater resources, ultimately increasing the availability of clean water for broader community use.

6. Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:

Whether air emissions (other than GHG emissions) by the entity is applicable to the company?

Yes

Parameter	Please specify unit	FY (2024-25)	FY (2023-24)
NOx	Kg/year	2,068.87	4,804.04
SOx	Kg/year	1,077.36	7,617.50
Particulate matter (PM)	Kg/year	1,675.60	6,302.76
Persistent organic pollutants (POP)	Kg/year	0	0
Volatile organic compounds (VOC)	Kg/year	0	0
Hazardous air pollutants (HAP)	Kg/year	0	0
Others – please specify	NA	-	-

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

Yes, an independent assessment has been carried out by a NABL-approved external agency, Excel Envirotech

7. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:

Whether greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity is applicable to the company? (Y/N)

Yes

Parameter	Unit	FY (2024-25)	FY (2023-24)
Total Scope 1 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	Metric tonnes of CO2 equivalent	12.5108	14,340.18
Total Scope 2 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	Metric tonnes of CO2 equivalent	0.0229	42,409.68
Total Scope 1 and Scope 2 emission intensity per rupee of turnover (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations)	Metric tonnes of CO2 equivalent/ ₹	0.00000000104	0.000006
Total Scope 1 and Scope 2 emission intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations adjusted for PPP)	Metric tonnes of CO2 equivalent / ₹	0.0000000215	0.000002
Total Scope 1 and Scope 2 emission intensity in terms of physical output	Metric tonnes of CO2 equivalent	0.0000000622	23.64
Total Scope 1 and Scope 2 emission intensity (optional) – the relevant metric may be selected by the entity	-	-	-

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

Yes

If yes, name of the external agency.

The data related to Scope 1 and Scope 2 greenhouse gas emissions and its intensity has been independently assessed by DQS, a recognized certifying agency. DQS has reviewed the submitted information and issued a letter of conformance, validating the accuracy and reliability of the reported data.

8. Does the entity have any project related to reducing Green House Gas emission? (Y/N/NA)

If Yes, then provide details.

Yes, we have several initiatives in place to reduce our GHG emissions

- Switching to natural gas to produce steam, in place of using furnace oil
- Implementing energy efficient boilers to reduce fuel consumption
- Implementing measures to improve transportation efficiency can reduce emissions from vehicles and logistics operations. This may involve optimising delivery routes, promoting carpooling or use of public transportation for employees
- Implementing sustainable manufacturing practices such as waste reduction, recycling, and using agricultural materials and petrochemicals can help lower GHG emissions associated with production processes
- Conducting tree plantation drives on a regular basis to offset GHG emissions generated through the Company's facilities Some examples for energy efficient measures adopted by Concord include:
- Installation of energy efficient centrifugal air compressors and water chillers
- Implementation of LED lighting to replace fluorescent lamps
- Installation of a waste steam recovery system
- Installation of requirement-based insulation and smart thermostats
- Upgrading HVAC systems, implementing energy management systems, upgrading windows, and incorporating energy efficient design principles all contribute to lowering energy consumption and emissions in buildings

9. Provide details related to waste management by the entity, in the following format:

Parameter	FY (2024-25)	FY (2023-24)
Total Waste generated (in metric tonnes)		
Plastic waste (A)	4.64	408.21
E-waste (B)	4.16	0.35
Bio-medical waste (C)	11.61	10.21
Construction and demolition waste (D)	0	0
Battery waste (E)	0	0
Radioactive waste (F)	0	0
Other Hazardous waste. Please specify, if any. (G)	2,857.16	3,352.68
ETP sludge & MEE salt/35.3 IN MT	-	2,283.71
Spent solvent/28.6 IN MT	-	686.32
Distillation residue/20.3 IN MT	-	233.86
Spent carbon/28.2 IN MT	-	148.79
Other Non-hazardous waste generated (H). Please specify, if any. (Break-up by composition i.e. by materials relevant to the sector) Used oil in metric tonne	0	4.53
Total (A+B + C + D + E + F + G + H)	2,877.57	3,775.98
Waste intensity per rupee of turnover (Total waste generated / Revenue from operations)	0.00000024	0.00000037
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total waste generated / Revenue from operations adjusted for PPP)	0.0000495	0.0000001
Waste intensity in terms of physical output	0.000014	1.57
Waste intensity (optional) – the relevant metric may be selected by the entity	-	-

For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)

Category of waste		
(i) Recycled	602.577	36.06
(ii) Re-used	4,058.928	373.25
(iii) Other recovery operations	0	-
Total	**4,661.505**	**409.31**

For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)

Category of waste		
(i) Incineration	11.605	10.21
(ii) Landfilling	1,149.765	2,283.71
(iii) Other disposal operations	2,081.197	920.18
Total	**3,242.567**	**3,214.10**

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

If yes, name of the external agency.

Yes.

The facilities undergo an annual audit in compliance with the Hon'ble High Court order dated 20th December 1996, for the Environmental Audit Scheme. The scheme was subsequently modified with significant changes outlined in Officer Order No. GPCB/EAS-C-28/301928 dated 23rd January 2015.

10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

Concord has implemented a comprehensive waste management strategy focused on reducing hazardous and toxic waste, ensuring regulatory compliance, and promoting environmental sustainability across its operations.

To minimise hazardous waste generation, Concord uses fermentation-based API production processes instead of conventional chemical synthesis, significantly reducing reliance on toxic chemicals and raw materials. The company strictly adheres to Indian environmental laws and regulations, including the Environment Protection Act, 1986, Bio-Medical Waste Management Rules, 2016, and Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016.

Our waste management approach is guided by the principles of reduce, reuse, and recycle, with an emphasis on fostering circular resource use within the communities we serve. Concord's Environment, Health, and Safety (EHS) policy governs our environmentally responsible waste practices.

Standard operating procedures are in place for categorising, segregating, minimising, handling, transporting, and disposing of various waste types. These procedures ensure safe disposal through authorised channels, including TSDFs (Treatment, Storage, and Disposal Facilities), CHWIFs (Common Hazardous Waste Incineration Facilities), and certified recyclers.

Waste generation and disposal activities are tracked through monthly reports, ensuring proper segregation, secure storage, and environmentally sound disposal via authorised waste handlers.

Concord has also invested in a robust effluent treatment plant featuring physio-chemical, biological, and advanced treatment systems to ensure safe treatment of liquid waste. Treated effluent is reused for gardening and is discharged safely within the factory premises.

11. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required, please specify details in the following format:

Sr. No.	Location of operations/offices	Type of operations	Whether the conditions of environmental approval / clearance are being complied with?	If no, the reasons thereof and corrective action taken, if any.
			NA	

Note : No. Concord's operations and offices are not located in or near ecologically sensitive zones such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, or coastal regulation areas. As confirmed by the environmental impact assessment study report, these locations do not require specific environmental approvals or clearances.

12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

Sr. No.	Name and brief details of project	EIA Notification No.	Date	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
NA. No environmental impact assessments were undertaken during the financial year, as there were no new projects requiring such assessments under applicable environmental regulations.						

13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N/NA).

Yes. Concord adheres to all relevant environmental laws, regulations, and guidelines in India.

If not, provide details of all such non-compliances, in the following format:

Sr. No.	Specify the law/regulation/ guidelines which was not complied with	Provide details of the non-compliance	Any fines / penalties / action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any
			NA	

Leadership Indicators

1. Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):

For each facility / plant located in areas of water stress, provide the following information:

Details For each facility / plant located in areas of water stress

Sr. No.	Particulars		
1	Name of the area	NA	
2	Nature of operations	NA	
3	Water withdrawal, consumption and discharge in the following format:		
	Parameter	FY (2024-25)	FY (2023-24)
	Water withdrawal by source (in kilolitres)		
	(i) Surface water	NA	NA
	(ii) Groundwater	NA	NA
	(iii) Third party water	NA	NA
	(iv) Seawater / desalinated water	NA	NA
	(v) Others	NA	NA
	Total volume of water withdrawal (in kilolitres)	NA	NA
	Total volume of water consumption (in kilolitres)	NA	NA
	Water intensity per rupee of turnover (Water consumed / turnover)	NA	NA
	Water intensity (optional) – the relevant metric may be selected by the entity	NA	NA
	Water discharge by destination and level of treatment (in kilolitres)		
	(i) Into Surface water	NA	NA
	No treatment	NA	NA
	With treatment – please specify level of treatment	NA	NA
	(ii) Into Groundwater	NA	NA
	No treatment	NA	NA
	With treatment – please specify level of treatment	NA	NA
	(iii) Into Seawater	NA	NA
	No treatment	NA	NA
	With treatment – please specify level of treatment	NA	NA
	(iv) Sent to third-parties	NA	NA
	No treatment	NA	NA
	With treatment – please specify level of treatment	NA	NA
	(v) Others	NA	NA
	No treatment	NA	NA
	With treatment – please specify level of treatment	NA	NA
	Total water discharged (in kilolitres)	**NA**	**NA**

Not applicable, as Concord's sites are not located in water-stressed areas.

2. Please provide details of total Scope 3 emissions & its intensity, in the following format:

Whether total Scope 3 emissions & its intensity is applicable to the company?(Y/N)

During the reporting period, we have not calculated Scope 3 emissions.

Parameter	Unit	FY (2024-2025)	PY (2023-2024)
Total Scope 3 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	NA	NA	NA
Total Scope 3 emissions per rupee of turnover	NA	NA	NA
Total Scope 3 emission intensity (optional) – the relevant metric may be selected by the entity	NA	NA	NA

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N)

If yes, name of the external agency.

NA

3. With respect to the ecologically sensitive areas reported at Question 10 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities.

NA

4. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:

Sr. No.	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative	Corrective action taken, if any
1.	Use of energy efficient appliances	The Company's facilities are equipped with energy-efficient LED lighting, centrifugal air, compressors, water chillers, and motors.	Reduction in electricity consumption, leading to lower electricity bills and a corresponding decrease in GHG emissions.	-
2	Zero liquid discharge	Concord's manufacturing facilities have ZLD where the treated effluents are recycled.	• Reduction in water footprints • Judicious use of the available water resources	-

5. Does the entity have a business continuity and disaster management plan? (Y/N/NA)

Yes

Details of entity at which business continuity and disaster management plan is placed or weblink.

Concord's disaster management plan covers both natural disasters (like earthquakes and floods) and man-made threats (such as bomb threats), with mitigation strategies in place. Responsibilities are assigned to key personnel including the site controller and incident controller. In case of a bomb threat, measures from the onsite emergency plan are activated. The IT team has implemented a disaster recovery system to restore critical infrastructure swiftly. Routine inspections and regular employee training are conducted to ensure preparedness. Additionally, Concord has adopted an ERP system to enhance efficiency in material management, sales, and distribution.

6. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard.

No significant adverse environmental impact incidents were reported within the supply chain during the reporting period.

7. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.

Concord places strong emphasis on ensuring that all vendors operate in alignment with socially responsible standards. These include compliance with norms related to contract labour, non-discrimination, equal opportunity, fair working hours, and environmental stewardship. The Company actively evaluates and selects vendors based on their adherence to ethical manufacturing practices, sustainable production techniques, and environmentally sound processes.

Furthermore, Concord prioritizes the Environmental and Social (E&S) dimensions of its supply chain, supporting suppliers in enhancing their performance across these critical areas. This approach reflects the Company's commitment to fostering a responsible and resilient supply ecosystem.

8. How many Green Credits have been generated or procured:

a.	By the listed entity	Nil
b.	By the top ten (in terms of value of purchases and sales, respectively) value chain partners	Nil

PRINCIPLE 7 Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

Essential Indicators

1. a. Number of affiliations with trade and industry chambers/ associations.

5

b. List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to

Sr. No.	Name of the trade and industry chambers/ associations	Reach of trade and industry chambers/ associations (State/National/International)
1	Indian Drug Manufacturers Association	National
2	Confederation of Indian Industries	National
3	Gujarat Chamber of Commerce	State
4	Pharmaceuticals Export Promotion council of India	National
5	Federation of Indian Export Organisation	National

2. Provide details of corrective action taken or underway on any issues related to anti- competitive conduct by the entity, based on adverse orders from regulatory authorities.

Sr. No.	Name of authority	Brief of the case	Corrective action taken
		NA	

Note: NA. During the reporting period, there were no instances of anti-competitive conduct involving the Company, and no adverse orders were issued by any regulatory authorities. The Company remains committed to fair competition and operates in full compliance with applicable antitrust and competition laws.

Leadership Indicators

1. Details of public policy positions advocated by the entity:

Sr. No.	Public policy advocated	Method resorted for such advocacy	Whether information available in public domain? (Yes/No)	Frequency of Review by Board	Web Link,if available
The Company has not undertaken any advocacy or taken a public position on government policies during the financial year.					

PRINCIPLE 8 Businesses should promote inclusive growth and equitable development

Essential Indicators

1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.

A third-party Social Impact Assessment was successfully conducted at Unit 1 through the TFS (Together for Sustainability) audit, in line with applicable regulatory requirements. The assessment evaluated the project's social and community impact, ensuring alignment with sustainability and ethical standards.

Sr. No.	Name and brief details of project	SIA Notification No.	Date of notification	Whether conducted by independent external agency	Results communicated in public domain	Relevant Web link
				NA		

2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:

NA. During the reporting period, Concord Biotech did not undertake any projects requiring Rehabilitation and Resettlement (R&R) as defined under applicable laws. The Company has not been involved in any land acquisition or infrastructure development activities that would trigger statutory R&R obligations.

Sr. No.	Name of Project for which R&R is ongoing	State	District	No. of Project Affected Families (PAFs)	% of PAFs covered by R&R	Amounts paid to PAFs in the FY (In INR)
NA						

3. Describe the mechanisms to receive and redress grievances of the community.

Concord's Code of Conduct includes clear mechanisms for raising concerns related to misconduct. It is accessible on the Company's website and outlines structured procedures for addressing and resolving grievances.

4. Percentage of input material (inputs to total inputs by value) sourced from suppliers:

	FY (2024-25)	FY (2023-24)
Directly sourced from MSMEs/ small producers	26.76%	32.16%
Sourced directly from within the district and neighbouring districts	74.15%	60.26%

5. Job creation in smaller towns - Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost:

		FY (2024-25)	FY (2023-24)
1.	**Rural**		
i)	Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis)	22,27,40,244	-
ii)	Total Wage Cost	1,38,93,36,254	-
iii)	% of Job creation in Rural areas	16%	-
2.	**Semi-urban**		
i)	Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis)	-	-
ii)	Total Wage Cost	-	-
iii)	% of Job creation in Semi-Urban areas	Nil	Nil
3.	**Urban**		
i)	Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis)	1,16,65,96,010	-
ii)	Total Wage Cost	1,38,93,36,254	-
iii)	% of Job creation in Urban areas	84%	-
4.	**Metropolitan**		
i)	Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis)	-	-
ii)	Total Wage Cost	-	-
iii)	% of Job creation in Metropolitan area	Nil	Nil

Leadership Indicators

1. Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments (Reference: Question 1 of Essential Indicators above):

NA.

During the reporting period, Concord Biotech did not undertake any projects requiring a Social Impact Assessment (SIA) under applicable laws. Consequently, no adverse social impacts were identified, and no mitigation actions were necessary.

Sr. No.	Details of negative social impact identified	Corrective action taken
NA		

2. Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies:

No CSR projects were undertaken in government-notified aspirational districts during the reporting period.

Sr.No.	State	Aspirational District	Amount spent (In INR)
		NA	

3. (a) Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized /vulnerable groups? (Yes/No/NA)

No

(b) From which marginalized /vulnerable groups do you procure?

NA

(c) What percentage of total procurement (by value) does it constitute?

The Company is dedicated to providing equal opportunities to all vendors and suppliers, with a fair and transparent selection process aligned with our Supplier Code of Conduct. We actively encourage and prioritise local sourcing for a significant portion of our raw material requirements. Although our supplier selection criteria do not specifically target vulnerable or marginalised groups, we are pleased to note that procurement from MSME suppliers was undertaken during the year.

4. Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge:

Sr. No.	Intellectual Property based on traditional knowledge	Owned/ Acquired (Yes/ No)	Benefit shared (Yes / No)	Basis of calculating benefit share
		NIL		

5. Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes wherein usage of traditional knowledge is involved.

Sr. No.	Name of authority	Brief of the Case	Corrective action taken
		NIL	

6. Details of beneficiaries of CSR Projects:

Sr.No.	CSR Project	No. of persons benefitted from CSR Projects	% of beneficiaries from vulnerable and marginalized groups
1.	EDUCATIONAL: GYANJYOT – Smart Classes in Rural Schools, Stem on Wheels, Science Safari, Spreading awareness sessions and seminars	4,000+ students, 100 teachers	100%
2.	HEALTHCARE: Mobile Medical Units, Vision Centres (Blind Peoples Association), Patient Care Program, Morning Nutrition Program	Approx. 45,000–50,000 beneficiaries annually	100%
3.	RURAL DEVELOPMENT: Promotion of Sports as development, Primary Health Centre Upgradation and others	Approx. 10,000–12,000 beneficiaries	100%
4.	SPORTS: Scholarship for aspiring sports personnel, Project Udaan	Approx. 300–500 direct beneficiaries	100%
5.	ENVIRONMENTAL: Say No to Plastic-Jute Bag distribution, Environmental Green Project, Doctors' Day- Plant	Approx. 15,000–18,000 beneficiaries	100%
6.	CULTURAL: Protection of national heritage	Approx. 5,000–7,000 beneficiaries	100%
7.	SUPPORTING VETERANS: ECHS-Supporting with medical van, Air Force Association	Approx. 1,500–2,000 beneficiaries	100%

PRINCIPLE 9 Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators

1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback.

Concord has established a robust Product Quality Management System to ensure prompt and effective handling of consumer complaints related to product quality. Consumers can register complaints through multiple channels, including written, electronic, or oral communication via our landline number, email at sales@concordbiotech.com, or by post. These complaints may relate to the quality, identity, reliability, safety, or efficacy of a product after distribution.

Our complaint resolution process is aligned with health authority guidelines and regulatory compliance requirements to ensure timely responses and optimal customer satisfaction. Furthermore, Concord's global pharmacovigilance policy, overseen by a dedicated Product Safety Committee, reinforces our ongoing commitment to patient safety.

2. Turnover of products and/ services as a percentage of turnover from all products/service that carry information about

	As a percentage to total turnover
Environmental and social parameters relevant to the product	NA
Safe and responsible usage	100%
Recycling and/or safe disposal	NA

3. Number of consumer complaints in respect of the following

	FY (2024-25)			FY (2023-24)		
	Received during the year	Pending resolution at end of year	Remark	Received during the year	Pending resolution at end of year	Remark
Data privacy	Nil	Nil	-	Nil	Nil	-
Advertising	Nil	Nil	-	Nil	Nil	-
Cyber-security	Nil	Nil	-	Nil	Nil	-
Delivery of essential services	Nil	Nil	-	Nil	Nil	-
Restrictive Trade Practices	Nil	Nil	-	Nil	Nil	-
Unfair Trade Practices	Nil	Nil	-	Nil	Nil	-
Other	Nil	Nil	-	Nil	Nil	-

4. Details of instances of product recalls on account of safety issues

	Number	Reasons for recall
Voluntary recalls	Nil	Nil
Forced recalls	Nil	Nil

5. Does the entity have a framework/ policy on cyber security and risks related to data privacy?(Y/N/NA)

If available, provide a web-link of the policy

Yes, We have implemented a comprehensive IT policy that defines clear guidelines and protocols for the use of information technology across all departments. To ensure data security, the Company has also established protective measures, including robust access controls to prevent unauthorised access to sensitive information.

6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services.

No IT-related issues have been reported to date.

7. Provide the following information relating to data breaches:

a. Number of instances of data breaches along-with impact: None

b. Percentage of data breaches involving personally identifiable information of customers : None

c. Impact, if any, of the data breaches: NA, The Company's proactive approach to cybersecurity has ensured zero data breaches to date.

Leadership Indicators

1. **Channels / platforms where information on products and services of the entity can be accessed (provide web link, if available).**

   https://www.concordbiotech.com/product-overview

2. **Steps taken to inform and educate consumers about safe and responsible usage of products and/or services**

   Each of our products carries a label that informs consumers about its composition, ingredients, recommended storage conditions, manufacturing and expiry dates, as well as safe usage guidelines.

3. **Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.**

   Concord manufactures Active Pharmaceutical Ingredients (APIs) and API intermediates, which are supplied to customers for further processing into finished drug products. Although we do not directly serve end consumers, we prioritise transparent and timely communication with our customers, including prompt notification of any potential supply disruptions or product discontinuations in line with our contractual obligations.

4. **Does the entity display product information on the product over and above what is mandated as per local laws? (Y/N/NA)**

   If yes, provide details in brief.

   Did your entity carry out any survey with regard to consumer satisfaction relating to the major products / services of the entity, significant locations of operation of the entity or the entity as a whole? (Y/N/NA)

   Yes, product labels provide comprehensive information, including the product name, grade (USP/EP/BP/IP), batch number, manufacturing date, retest date, quantity, manufacturing site address, license details, and storage or handling instructions. Each label is reviewed, signed, and approved by the Quality Department to ensure accuracy and compliance.

   The Company also conducts regular customer satisfaction surveys to evaluate feedback on its products and services, helping to drive continuous improvement.

Independent Auditor's Report

To the Members of **Concord Biotech Limited**

REPORT ON THE AUDIT OF THE STANDALONE FINANCIAL STATEMENTS

We have audited the standalone financial statements of Concord Biotech Limited (the "Company") which comprise the standalone balance sheet as at 31 March 2025, and the standalone statement of profit and loss (including other comprehensive income), standalone statement of changes in equity and standalone statement of cash flows for the year then ended, and notes to the standalone financial statements, including material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2025, and its profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue Recognition

See Note 3.11 and 24 to standalone financial statements

The key audit matter	How the matter was addressed in our audit
Revenue from the sale of products is recognized when control over goods is transferred to a customer. The actual point in time when revenue is recognized varies depending on the specific terms and conditions of the sales contracts entered with customers. The Company has many customers and sales contracts with customers have distinct terms relating to the timing of revenue recognition. We have identified the recognition of revenue from sale of products as a key audit matter considering revenue is a key performance indicator for the Company. Accordingly, there could be pressure to meet the expectations of investor/other stakeholders and/or to meet revenue targets for a reporting year. We have considered that there is risk of fraud related to revenue being overstated by recognition in the wrong period or before control has passed during the year and at the year end.	Our procedures included the following: - Evaluated appropriateness of the Company's accounting policy for revenue recognition by comparing with applicable accounting standards; - Evaluated the design, implementation and operating effectiveness of Company's controls in respect of revenue recognition; - Tested revenue recognized during the year by selecting samples, through statistical sampling, and verifying the underlying customer contracts and proof of dispatch/ delivery in accordance with the contractual terms agreed with the customers; - Tested revenue recognized near the year-end, using statistical sampling, to verify only revenue pertaining to current year is recognized based on underlying documents along with terms and conditions set out in customer contracts; and - Assessed journal entries posted to revenue to identify unusual items.

Other Information

The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and auditor's reports thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take necessary actions, as applicable under the relevant laws and regulations.

Management's and Board of Directors' Responsibilities for the Standalone Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/ loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of standalone financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements

regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matter

The standalone financial statements of the Company for the year ended 31 March 2024 were audited by the predecessor auditor who had expressed an unmodified opinion dated 23 May 2024.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2 A. As required by Section 143(3) of the Act, we report that:

   a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

   b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   c. The standalone balance sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone statement of cash flows dealt with by this Report are in agreement with the books of account.

   d. In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.

   e. On the basis of the written representations received from the directors as on 31 March 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2025 from being appointed as a director in terms of Section 164(2) of the Act.

   f. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

   a. The Company has disclosed the impact of pending litigations as at 31 March 2025 on its financial position in its standalone financial statements - Refer Note 34(b) to the standalone financial statements.

   b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

   c. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

   d (i) The management has represented that, to the best of their knowledge and belief, as disclosed in the Note 42 (iv) to the standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

   (ii) The management has represented that, to the best of their knowledge and belief, as disclosed in the Note 42 (v) to the standalone financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.

e. The final dividend paid by the Company during the year, in respect of the same declared for the previous year, is in accordance with Section 123 of the Act to the extent it applies to payment of dividend.

As stated in Note 46 to the standalone financial statements, the Board of Directors of the Company has proposed final dividend for the year which is subject to the approval of the members at the ensuing Annual General Meeting. The dividend declared is in accordance with Section 123 of the Act to the extent it applies to declaration of dividend.

f. Based on our examination which included test checks, the Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit, we did not come across any instance of audit trail feature being tampered with. Additionally, other than the period where audit trail was not enabled in the previous year, the audit trail has been preserved by the Company as per the statutory requirements for record retention.

C. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Rupen Shah
Partner
Membership No.: 116240
ICAI UDIN:25116240BMMLLR2701

Place: Ahmedabad
Date: 29 May 2025

ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT ON THE STANDALONE FINANCIAL STATEMENTS OF CONCORD BIOTECH LIMITED FOR THE YEAR ENDED 31 MARCH 2025

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

(i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(i) (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all property, plant and equipment are verified in a phased manner over a period of three years. In accordance with this programme, certain property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No discrepancies were noticed on such verification.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) disclosed in the standalone financial statements are held in the name of the Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a) The inventory, except stocks lying with third parties, has been physically verified by the management during the year.For stocks lying with third parties at the year-end, written confirmations have been obtained and for goods-in-transit subsequent evidence of receipts/ delivery has been linked with inventory records. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. However the company is not required to file quarterly returns or statements. Accordingly clause 3 (ii) (b) of the order is not applicable to the Company.

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnership or any other parties during the year. The Company has made investments in mutual funds and in companies, in respect of which the requisite information is provided in clause (a) to clause (f) as below to the extent applicable. The Company has not made any investments in firms or limited liability partnership.

(a) The Company has not provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnership or any other parties during the year. Accordingly, clause (iii) (a) of the Order is not applicable.

(b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion the investments made, during the year are not prejudicial to the interest of the Company.

(c) The Company has not provided any loans or advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnership or any other parties during the year. Accordingly, clause (iii) (c) of the Order is not applicable.

(d) The Company has not provided any loans or advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnership or any other parties during the year. Accordingly, clause (iii) (d) of the Order is not applicable.

(e) The Company has not provided any loans or advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnership or any other parties during the year. Accordingly, clause (iii) (e) of the Order is not applicable.

(f) The Company has not provided any loans or advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnership or any other parties during the year. Accordingly, clause (iii) (f) of the Order is not applicable.

(iv) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not given any loans, or provided any guarantee or security as specified under Section 185 and 186 of the Companies Act, 2013 ("the Act"). In respect of the investments made by the Company, in our opinion the provisions of Section 186 of the Act have been complied with.

(v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

(vi) We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Act in respect of its manufactured goods and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not carried out a detailed examination of the records with a view to determine whether these are accurate or complete.

(vii) (a) The Company does not have liability in respect of Service tax, Duty of excise, Sales tax and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion, the undisputed statutory dues including Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues have been regularly deposited by the Company with the appropriate authorities.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues were in arrears as at 31 March 2025 for a period of more than six months from the date they became payable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, statutory dues relating to Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues which have not been deposited on account of any dispute are as follows:

Name of the statute	Nature of the dues	Amount involved (Rs.) (INR in Lakhs)	Amount unpaid (INR in lakhs)	Period to which the amount relates	Forum where dispute is pending
The Income tax Act, 1961	Income tax	14.61	-	A.Y. 2016-17	The Commissioner of Income tax (Appeals)
The Central Excise Act, 1944	Excise Duty	376.37	348.15	January, 2015 to June, 2017	The Commissioner of Central Excise (Appeals)

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to any lender.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.

(c) In our opinion and according to the information and explanations given to us by the management, the Company has not obtained any term loans. Accordingly, clause 3(ix)(c) of the Order is not applicable.

(d) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.

(e) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its joint venture as defined under the Act.

(f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its joint venture (as defined under the Act).

(x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

(xi) (a) During the course of our examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the year.

(b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.

(xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Act, where applicable, and the details of the related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

(xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.

(b) We have considered the internal audit reports of the Company issued till date for the period under audit.

(xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Act are not applicable to the Company.

(xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) The Company is not part of any group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016 as amended). Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

(xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

Also refer to the Other Information paragraph of our main audit report which explains that the other information comprising the information included in annual report is expected to be made available to us after the date of this auditor's report.

(xx) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Act pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Rupen Shah
Partner
Membership No.: 116240
ICAI UDIN:25116240BMMLLR2701

Place: Ahmedabad
Date: 29 May 2025

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT ON THE STANDALONE FINANCIAL STATEMENTS OF CONCORD BIOTECH LIMITED FOR THE YEAR ENDED 31 MARCH 2025

REPORT ON THE INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE AFORESAID STANDALONE FINANCIAL STATEMENTS UNDER CLAUSE (I) OF SUB-SECTION 3 OF SECTION 143 OF THE ACT

(Referred to in paragraph 2(A)(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

OPINION

We have audited the internal financial controls with reference to financial statements of Concord Biotech Limited ("the Company") as of 31 March 2025 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2025, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

MANAGEMENT'S AND BOARD OF DIRECTORS' RESPONSIBILITIES FOR INTERNAL FINANCIAL CONTROLS

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

AUDITOR'S RESPONSIBILITY

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

MEANING OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

INHERENT LIMITATIONS OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Rupen Shah
Partner
Membership No.: 116240
ICAI UDIN:25116240BMMLLR2701

Place: Ahmedabad
Date: 29 May 2025

Standalone Balance Sheet as at 31 March 2025

(₹ in Lakhs, except per share data)

Particulars	Note No.	As at 31 March 2025	As at 31 March 2024
Assets			
I. Non-current assets			
(a) Property, plant and equipment	5 (A)	79,180.50	57,173.27
(b) Capital work-in-progress	5 (B)	5,013.10	21,148.24
(c) Intangible assets	6	59.61	31.97
(d) Right-of use assets	7	228.43	326.34
(e) Intangible assets under development	5 (B)	52.60	-
(f) Financial assets			
(i) Investments	8 (a)	1,865.42	66.52
(ii) Other Financial Assets	9	2,056.41	496.95
(g) Other non-current assets	10	1,260.07	797.99
(h) Income tax assets (Net)	20 (d)	177.66	267.12
Total non-current assets (A)		**89,893.80**	**80,308.40**
II. Current assets			
(a) Inventories	11	23,966.72	20,795.38
(b) Financial assets			
(i) Investments	8 (b)	31,654.48	24,370.19
(ii) Trade receivables	12	52,165.15	34,960.89
(iii) Cash and cash equivalents	13 (a)	90.45	1,514.21
(iv) Bank balances other than (iii) above	13 (b)	27.86	3,188.23
(v) Other Financial Assets	14	4,083.19	1,944.88
(c) Other Current assets	15	1,536.37	2,849.33
Total current assets (B)		**1,13,524.22**	**89,623.11**
TOTAL ASSETS (A) + (B)		**2,03,418.02**	**1,69,931.51**
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	16	1,046.16	1,046.16
(b) Other equity	17	1,80,218.46	1,51,479.05
Total equity (A)		**1,81,264.62**	**1,52,525.21**
LIABILITIES			
I. Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	18	-	-
(ii) Lease liabilities	7	62.98	188.70
(b) Provisions	19	281.99	195.61
(c) Deferred tax liabilities (net)	20 (b)	3,402.17	2,806.45
Total non-current liabilities (B)		**3,747.14**	**3,190.76**
II. Current liabilities			
(a) Financial liabilities			
(i) Borrowings	18	38.11	622.98
(ii) Lease liabilities	7	195.84	162.08
(iii) Trade payables	21		
Total outstanding dues of micro enterprises and small enterprises		595.24	961.54
Total outstanding dues of creditors other than micro enterprises and small enterprises		10,708.74	8,481.99
(iv) Other Financial Liabilities	22	4,169.79	2,420.63
(b) Provisions	19	554.00	390.19
(c) Other current liabilities	23	1,131.86	626.75
(d) Current tax liabilities (net)	20 (d)	1,012.68	549.38
Total current liabilities (C)		**18,406.26**	**14,215.54**
Total Liabilities (D)		**22,153.40**	**17,406.30**
TOTAL EQUITY AND LIABILITIES (A) + (D)		**2,03,418.02**	**1,69,931.51**
Summary of material accounting policies	1 to 46		

See accompanying notes forming part of the Standalone Financial Statements

As per our attached report of even date

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No : 101248W/W-100022

Rupen Shah
Partner
Membership No. : 116240

Place: Ahmedabad
Date: 29 May 2025

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Lalit Sethi
Chief Financial Officer

Ankur Vaid
Joint Managing Director & CEO
DIN: 01857225

Prakash Sajnani
Asst. Vice President - Finance & Company Secretary

Place: Ahmedabad
Date: 29 May 2025

Standalone Statement of Profit and Loss for the year ended 31 March 2025

(₹ in Lakhs, except per share data)

Particulars	Note No.	Year ended 31 March 2025	Year ended 31 March 2024
Income			
Revenue from operations	24	1,20,008.69	1,01,693.92
Other income	25	4,444.67	3,378.00
TOTAL INCOME		**1,24,453.36**	**1,05,071.92**
Expenses			
Cost of materials consumed	26	26,431.26	18,453.71
Purchases of stock-in-trade		5,598.72	5,673.89
Changes in inventories of finished goods, work-in-progress and stock-in-trade	27	(1,478.67)	(1,207.79)
Employee benefits expense	28	13,893.36	12,304.67
Finance costs	29	52.93	255.19
Depreciation and amortization expense	30	5,437.35	5,359.15
Other expenses			
Power and fuel	31 (a)	11,223.02	10,496.87
Others	31 (b)	13,707.85	12,816.86
TOTAL EXPENSES		**74,865.82**	**64,152.54**
PROFIT BEFORE TAX		**49,587.54**	**40,919.37**
Tax expenses	20		
Current tax		11,896.14	9,983.39
Deferred tax		394.96	462.79
Total tax expenses		12,291.10	10,446.18
PROFIT FOR THE YEAR		**37,296.44**	**30,473.19**
Other Comprehensive Income / (loss)			
Items that will not be reclassified to the statement of Profit or Loss			
Re-measurement gain/ (loss) on defined benefit plans		(56.98)	(0.97)
Income tax relating to re-measurement gain/ (loss) on defined benefit plans		14.34	0.24
Re-measurement gain/ (loss) on Equity Instruments		854.62	-
Income tax relating to re-measurement gain/ (loss) on Equity Instruments		(215.09)	-
		596.89	**(0.73)**
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		**37,893.33**	**30,472.46**
Earnings per share (Nominal value per equity share of ₹ 1 each)			
Basic and diluted (Refer note 32)		35.65	29.13
Summary of material accounting policies	1 to 46		

See accompanying notes forming part of the Standalone Financial Statements

As per our attached report of even date

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No : 101248W/W-100022

Rupen Shah
Partner
Membership No. : 116240

Place: Ahmedabad
Date: 29 May 2025

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Lalit Sethi
Chief Financial Officer

Place: Ahmedabad
Date: 29 May 2025

Ankur Vaid
Joint Managing Director & CEO
DIN: 01857225

Prakash Sajnani
Asst. Vice President - Finance & Company Secretary

Standalone Statement of Changes in Equity for the year ended 31 March 2025

A. EQUITY SHARE CAPITAL

(₹ in Lakhs)

Particulars	Year ended 31 March 2025	Year ended 31 March 2024
Opening balance	1,046.16	1,046.16
Changes during the year	-	-
Closing Balance	**1,046.16**	**1,046.16**

B. OTHER EQUITY

Particulars	Reserves and Surplus			Total Other Equity
	Retained Earnings	General Reserve	Securities Premium	
Balance as at 01 April 2023	**1,17,032.99**	**2,921.79**	**8,197.10**	**1,28,151.88**
Profit for the year	30,473.19	-	-	30,473.19
Other comprehensive Income / (loss) (Net of tax)	(0.73)	-	-	(0.73)
Total Other Comprehensive Income	**30,472.46**	**-**	**-**	**30,472.46**
Transactions with owners of the group				
Contribution and distribution				
Dividend*	(7,145.29)	-	-	(7,145.29)
Balance as at 31 March 2024	**1,40,360.16**	**2,921.79**	**8,197.10**	**1,51,479.05**
Profit for the year	37,296.44	-	-	37,296.44
Other comprehensive Income (Net of tax)	596.89	-	-	596.89
Total Other Comprehensive Income	**37,893.33**	**-**	**-**	**37,893.33**
Transactions with owners of the group				-
Contribution and distribution				
Dividend**	(9,153.92)	-	-	(9,153.92)
Balance as at 31 March 2025	**1,69,099.57**	**2,921.79**	**8,197.10**	**1,80,218.46**

*Final Dividend of ₹ 6.83 per equity share for the FY 2022-23.

**Final Dividend of ₹ 8.75 per equity share for the FY 2023-24.

Summary of material accounting policies 1 to 46

See accompanying notes forming part of the Standalone Financial Statements

In terms of our report attached

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No : 101248W/W-100022

Rupen Shah
Partner
Membership No. : 116240

Place: Ahmedabad
Date: 29 May 2025

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Lalit Sethi
Chief Financial Officer

Place: Ahmedabad
Date: 29 May 2025

Ankur Vaid
Joint Managing Director & CEO
DIN: 01857225

Prakash Sajnani
Asst. Vice President - Finance & Company Secretary

Standalone Cash Flow Statement for the year ended 31 March 2025

(₹ in Lakhs)

Particulars		For the Year ended 31 March 2025	For the Year ended 31 March 2024
A	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Profit before tax as per Statement of Profit and Loss	49,587.54	40,919.37
	Adjustment for:		
	Depreciation and amortization expenses	5,437.35	5,359.15
	Interest Income	(171.01)	(304.11)
	Finance Cost	52.93	255.19
	Interest Subsidy Income	(7.25)	(107.96)
	Net gain/loss on termination of lease	(2.30)	-
	(Reversal) /Provision for loss allowance	178.44	66.94
	Excess provision no longer required written back	(273.24)	(3.81)
	(Profit)/loss on sale/discard of Property, plant & equipment	22.47	(1.19)
	Net gain on sale of investments	(1,360.57)	(345.14)
	Net gain on financial assets measured at fair value through profit or loss	(865.80)	(1,061.33)
	Net unrealised foreign exchange (gain) / loss	(129.24)	222.54
	Operating Profit before Working Capital Changes	**52,469.32**	**44,999.65**
	Working Capital Changes:		
	(Increase)/Decrease in Inventories	(3,171.34)	436.09
	(Increase) in trade receivables	(17,078.77)	(7,865.96)
	(Increase)/Decrease in other financial assets	(2,193.43)	489.52
	(Increase)/Decrease in other assets	799.39	(456.23)
	Increase/(Decrease) in provisions	193.21	(205.83)
	Increase/(Decrease) in trade payables	2,208.91	(1,128.66)
	Increase in other financial liabilities	1,661.16	363.01
	Increase in other liabilities	505.11	250.08
		(17,075.76)	**(8,117.98)**
	Cash generated from operations	**35,393.56**	**36,881.67**
	Direct Taxes paid (Net of Income Tax refund)	(10,941.87)	(10,334.96)
Net cash generated from operating activities		**24,451.69**	**26,546.71**
B	**CASH FLOW FROM INVESTING ACTIVITIES**		
	Purchase of Property, plant & equipment and Intangible Assets (including CWIP and capital advance)	(11,117.22)	(8,568.85)
	Proceeds from disposal of Property, plant & equipment	19.90	17.51
	Purchase of Current Investments	(86,993.89)	(83,810.00)
	Proceeds from sale of Current Investment	80,137.07	74,551.74
	Interest received	299.46	277.28
	Proceeds from Bank Deposits (Net) (including margin money deposits)	2,387.74	2,071.39
	Investment in non current deposits with banks (including margin money deposits)	(1,511.71)	-
	Proceeds from Non current deposits with Bank (including margin money deposits)	780.00	-
Net cash used in investing activities		**(15,998.65)**	**(15,460.92)**
C	**CASH FLOW FROM FINANCING ACTIVITIES**		
	Repayment of Long Term borrowings	(584.87)	(2,500.58)
	Dividend Paid	(9,153.92)	(7,145.29)
	Interest Paid	(25.07)	(220.88)
	Interest Subsidy Received	14.96	139.12
	Principal Payment of Lease Liabilities	(89.66)	(149.78)
	Interest paid on Lease Liabilities	(38.25)	(44.08)
	Net cash used in financing activities	(9,876.80)	(9,921.49)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A)+(B)+(C)		**(1,423.76)**	**1,164.30**
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR		**1,514.21**	**349.92**
CASH AND CASH EQUIVALENTS AT END OF THE YEAR		**90.45**	**1,514.21**

Standalone Cash Flow Statement for the year ended 31 March 2025

Reconciliation of Cash and cash equivalents

Particulars	As at 31 March 2025	As at 31 March 2024
Cash and Cash Equivalents:		
Cash on hand	1.89	2.73
Balance with Banks	88.56	1,511.48
Cash and cash equivalents as per Balance Sheet [Refer Note 13(a)]	**90.45**	**1,514.21**

Notes to the standalone cashflow statement

Note 1: The cash flow statement has been prepared under the indirect method as set out in Ind AS 7 statement of cash flows.

Note 2 : The above statement of cash flows for the year ended 31st March,2024, excludes the proceeds received in the share escrow account amounting to ₹ 1,55,052.08 Lakhs on account of offer for sale made by the selling shareholders. Book running lead manager disbursed ₹ 1,48,814.66 Lakhs to its selling shareholders and ₹ 5,669.89 Lakhs to various parties for initial public offer expenses. The remaining funds amounting to ₹ 567.53 Lakhs which are yet to be paid to the selling shareholders after payments of initial public offer expenses is held in share escrow account. The mentioned amount has been completely paid off to the selling shareholders in FY 2024-25.

RECONCILIATION OF MOVEMENTS OF LIABILITIES TO CASH FLOWS ARISING FROM FINANCING ACTIVITIES

Particulars	As at 1 April 2024	Cash flows- Inflows/ (Outflows)	Non-cash Movement	As at 31 March 2025
Borrowings (including current maturities) (Note - 18)	622.98	(584.87)	-	38.11
Lease Liability (Note - 7)	350.78	(127.91)	127.44	258.82
Interest accrued but not paid (Note - 22)	10.39	(25.07)	14.68	-
Total liabilities from financing activities	**984.15**	**(737.84)**	**142.12**	**296.93**

RECONCILIATION OF MOVEMENTS OF LIABILITIES TO CASH FLOWS ARISING FROM FINANCING ACTIVITIES

Particulars	As at 1 April 2023	Cash flows- Inflows/ (Outflows)	Non-cash Movement	As at 31 March 2024
Borrowings (including current maturities) (Note - 18)	3,123.56	(2,500.58)	-	622.98
Lease Liability (Note - 7)	31.07	(193.86)	513.57	350.78
Interest accrued but not paid (Note - 22)	25.97	(220.88)	205.30	10.39
Total liabilities from financing activities	**3,180.60**	**(2,915.32)**	**718.87**	**984.15**

Summary of material accounting policies 1 to 46

See accompanying notes forming part of the Standalone Financial Statements

In terms of our report attached

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No : 101248W/W-100022

Rupen Shah
Partner
Membership No. : 116240

Place: Ahmedabad
Date: 29 May 2025

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Lalit Sethi
Chief Financial Officer

Ankur Vaid
Joint Managing Director & CEO
DIN: 01857225

Prakash Sajnani
Asst. Vice President - Finance & Company Secretary

Place: Ahmedabad
Date: 29 May 2025

Notes to the Standalone Financial Statements for the year ended 31 March 2025

1. CORPORATE INFORMATION

Concord Biotech Limited (the Company) is a public limited company incorporated and domiciled in India, having registered office at 1482-86 Trasad Road, Dholka, Ahmedabad – 382225 and corporate office is located at B-1601 & B-1602, Mondeal Heights, S G highway, Ahmedabad-380051. The Company is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. The Company's API manufacturing facilities are located at Dholka and Limbasi, and its formulations facility at Valthera in the state of Gujarat, India.

The Company's equity shares have been listed on National Stock Exchange ("NSE") and on BSE Limited ("BSE") on August 18, 2023, by completing Initial Public Offering ("IPO") through offer for sale ("OFS") of 2,09,25,652 equity shares of face value of ₹ 1 each at an issue price of ₹ 741 per equity share by Helix Investment Holdings Pte Limited, Singapore ("selling shareholder").

2. BASIS OF PREPARATION AND PRESENTATION OF STANDALONE FINANCIAL STATEMENTS

2.1. Statement of compliance

The standalone financial statements comply in all material aspects with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 (the Act) read with Companies (Indian Accounting Standards) Rules, 2015 as amended and other relevant provisions of the Act and presentation requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS compliant Schedule III) (as amended from time to time).

These standalone financial statements have been prepared for the Company as a going concern on the basis of relevant Ind AS that are effective at the Company's annual reporting date, March 31, 2025. These standalone financial statements were authorized for issuance by the Company's Board of Directors on May 29, 2025.

The Company adopted Disclosures of Accounting policies (Amendments to Ind As 1) from 1st April, 2023, although the amendments did not result in any changes in the accounting policies themselves, they impacted the accounting policy information disclosed in the financial statements.

The amendments require the disclosure of 'material' rather than 'significant' accounting policies. The amendments also provide guidance on the application of materiality to disclosure of accounting policies, assisting the entities to provide useful, entity-specific accounting policy information that users need to understand other information in the financial statement.

2.2. Functional and Presentation Currency

The standalone financial statements are presented in Indian Rupees (₹), the currency of the primary economic environment in which the Company operates. All the amounts are rounded to the nearest rupee lakhs, unless otherwise indicated. Transaction and balances with values below ₹ 50,000 have been reflected as "0.00" in standalone financial statements. Transaction in foreign currencies are translated into respective function currencies of company at the exchange rates at the date of transaction.

2.3. Basis of Measurement

Historical cost convention

The standalone financial statements have been prepared on the historical cost basis (i.e. on accrual basis), except for the following items:

- Investments in mutual funds, equity instruments for investment in Palvella Therapeutics Inc. and derivative instruments are measured at fair value and
- Net defined benefit assets/(liability) are measured at fair value of plan assets, less present value of defined benefit obligations.

2.4. Measurement of Fair Value

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if the market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value measurement and/or disclosure purposes in the financial statements is determined on such a basis except for leasing transactions that are within the scope of Ind AS 116 Leases, and measurements that have some similarities to fair value but are not fair value, such as net realizable value in Ind AS 2 Inventories

In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly; and
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company has an established control framework with respect to the measurement of fair values. This includes a finance team that has overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values.

The Company regularly reviews significant unobservable inputs and valuation adjustments. If third party information is used to measure fair values, then the finance team assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of Ind AS, including the level in the fair value hierarchy in which the valuations should be classified.

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

2.5. Use of estimates and judgements

The preparation of the standalone financial statements in conformity with Ind AS requires Management to make estimates, judgements and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the standalone financial statements.

Judgement – Note 8 a(i), whether Company has significant influence over an investee.

2.6. Assumptions and estimation uncertainties:

Key source of estimation of uncertainty at the date of standalone financial statements, which may cause material adjustment to the carrying amount of assets and liabilities within the next financial year, is in respect of:

- Useful lives of property, plant and equipment (Refer note no. 3.1)
- Leases-Company as a lessee (Refer note no. 3.5)
- Valuation of Inventories (Refer note no. 3.6)
- Employee benefits (refer note no.3.8)
- Provisions & Contingent Liabilities (Refer note no. 3.9)
- Recognition of deferred tax assets (Refer note no. 3.12)
- Impairment of financial assets (Refer note no. 3.7)
- Estimate of expected return (Refer note no. 3.11)
- Measurement of ECL allowance for trade and finance receivables. (Refer note no. 3.7.3)

2.7. Current versus non-current classification:

Based on the time involved between the acquisition of assets for processing and their realization in cash and cash equivalents, the company has identified 12 months as its operating cycle for determining current and non-current classification of assets and liabilities in the balance sheet.

3. MATERIAL ACCOUNTING POLICIES

3.1. Property, Plant and Equipment

i. Recognition and measurement

Property, plant and equipment are stated at cost of acquisition or construction less accumulated depreciation and any accumulated impairment losses. The cost of Plant, Property & Equipment comprises of its purchase price, non-refundable taxes & levies, freight and other incidental expenses related to the acquisition and installation of the respective assets. Borrowing cost attributable to financing of acquisition or construction of the qualifying Property, Plant and Equipment is capitalized to respective assets when the time taken to put the assets to use is substantial.

When major items of property, plant and equipment have different useful lives, they are accounted for as separate items of property, plant

Notes to the Standalone Financial Statements for the year ended 31 March 2025

and equipment. The cost of replacement of any property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefit associated with the item will flow to the Company and its cost can be measured reliably.

Capital work-in-progress comprises cost of Property, Plant and Equipment those are not yet installed and ready for their intended use at the Balance sheet date.

Pre-operative expenditure comprising of revenue expenses incurred in connection with project implementation during the period up to commencement of commercial production are treated as part of the project costs and are capitalized. Such expenses are capitalized only if the project to which they relate, involve substantial expansion of capacity or upgradation.

An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from its use. Difference between the sales proceeds and the carrying amount of the asset is recognized in profit and loss.

The cost of property, plant and equipment as at 1 April, 2016, the company's date of transition to Ind AS, was determined with reference to its carrying value recognised as per the previous GAAP (deemed cost), as at the date of transition to Ind AS.

ii. Subsequent expenditure

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company and the cost of the item can be measured reliably.

iii. Depreciation

Freehold land is carried at historical cost and not depreciated. Depreciation on Property, Plant and Equipment is provided using straight line method based as per the useful life prescribed in Schedule II to the Companies Act, 2013. Depreciation on assets added / disposed off during the year is provided on pro-rata basis with reference to month of addition / disposal. The estimated useful lives, residual values and depreciation method are reviewed at each financial year-end and changes in estimates, if any are accounted for on a prospective basis. The residual values are not more than 5% of the original cost of asset.

Class of Asset	Useful Life
Building	5 Years - 60 Years
Plant & Equipment	10 Years - 20 Years
Office Equipments	5 Years
Laboratory Equipments	10 Years
Computers	3 Years
Furniture & Fixtures	10 Years
Vehicles	3-5 Years

3.2. Intangible Assets

i. Recognition and measurement

Intangible assets acquired separately are measured at cost of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortisation and impairment losses if any.

Intangible assets (software & technical know-how) are amortised over the estimated useful life of three years which reflects the manner in which the economic benefit is expected to be generated. The estimated useful life of amortizable intangibles is reviewed at the end of each reporting period and change in estimates if any are accounted for on a prospective basis.

ii. Subsequent Expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred.

iii. Amortisation

Intangible assets are amortised on a straight line basis over the estimated useful life.

Amortisation method, useful lives and residual values are reviewed at the end of each financial year and adjusted if appropriate.

The cost of intangibles as at 1 April, 2016, the Group's date of transition to Ind AS, was determined with reference to its carrying value recognised as per the previous GAAP (deemed cost), as at the date of transition to Ind AS.

3.3. Foreign currency Transaction and Translation

Foreign currency transactions are recorded at exchange rates prevailing on the date of the transaction. The net gain or loss on account of exchange differences arising on settlement of foreign currency transactions are recognized as income or expense of the period in which they arise. Monetary assets and liabilities denominated in foreign currency as at the balance

sheet date are translated at the closing rate. The resultant exchange rate differences are recognized in the statement of profit and loss. Non-monetary assets and liabilities are carried at the rates prevailing on the date of transaction.

3.4. Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets and financial liabilities are recognized when an entity becomes a party to the contractual provisions of the instruments.

3.4.1. Financial assets

(a) Classification of financial assets:

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. On initial recognition, the company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financials Assets are not reclassified subsequent to their initial recognition unless the company changes its business model for managing financial assets, in which case all affected financial assets are reclassified on the first day of the first reporting period following the change in the business model.

(b) Recognition and initial measurement:

Financial assets are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets (other than financial assets at fair value through profit or loss) are added to or deducted from the fair value of the financial assets, as appropriate, on initial recognition. Transaction costs that are directly attributable to the acquisition or issue of financial assets at fair value through profit or loss are recognised immediately in profit or loss.

(c) Subsequent measurement:

- **Amortised Cost**

  Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. A gain or loss on a debt investment that is subsequently measured at amortised cost and is not part of a hedging relationship is recognised in profit or loss when the asset is derecognised or impaired. Interest income from these financial assets is included in finance income using the effective interest rate method.

- Fair value through other comprehensive income (FVOCI):

  Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at fair value through other comprehensive income (FVOCI). Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses which are recognised in profit and loss. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to profit or loss and recognised in other gains / (losses). Interest income from these financial assets is included in other income using the effective interest rate method. Foreign exchange gains and losses are presented in other gains and losses and impairment expenses in other expenses.

- **Fair value through profit or loss (FVTPL)**

  Assets that do not meet the criteria for amortised cost or FVOCI are measured at fair value through profit or loss. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss and is not part of a hedging relationship is recognised in profit or loss and presented net in the statement of profit and loss within other gains / (losses) in the period in which it arises. Interest income from

Notes to the Standalone Financial Statements for the year ended 31 March 2025

these financial assets is included in other income.

(d) Derecognition of financial assets:

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset

When the Company has transferred an asset, the Company evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. In such cases, the financial asset is derecognised. Where the Company has not transferred substantially all risks and rewards of ownership of the financial asset, the financial asset is not derecognised.

Where the Company has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of financial asset, the financial asset is derecognised if the Company has not retained control over the financial asset. Where the Company retains control of the financial asset, the asset is continued to be recognised to the extent of continuing involvement in the financial asset.

(e) Income recognition:

Dividend is accounted when the right to receive payment is established.

(f) Cash and cash equivalents:

Cash and cash equivalents consists of cash on hand, bank balances, short demand deposits and highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of change in value. Short term means investments with original maturities / holding period of three months or less from the date of investments. Bank overdrafts that are repayable on demand and form an integral part of the Company's cash management are included as a component of cash and cash equivalent for the purpose of statement of cash flow.

(g) Investments:

Investments in mutual funds are primarily held for the Company's temporary cash requirements and can be readily convertible in cash. These investments are initially recorded at fair value and classified as fair value through profit or loss.

(h) Trade receivables:

Trade receivables are amounts due from customers for sale of goods or services performed in the ordinary course of business. Trade receivables are initially recognized at its transaction price which is considered to be its fair value and are classified as current assets as it is expected to be received within the normal operating cycle of the business.

3.4.2. Financial liabilities

The Company's financial liabilities include trade payables, loans, borrowing and derivative financial instruments.

(a) Classification:

All the Company's financial liabilities, except for financial liabilities at fair value through profit or loss, are measured at amortised cost.

(b) Initial measurement:

Financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial liabilities (other than financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial liabilities, as appropriate, on initial recognition. Transaction costs that are directly attributable to the acquisition or issue of financial liabilities at fair value through profit or loss are recognised immediately in profit or loss.

(c) Subsequent measurement:

Financial liabilities are subsequently measured at amortised cost using the Effective Interest Rate Method. The Effective Interest Rate Method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including transaction costs and other premiums or

discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the net carrying amount on initial recognition.

(d) Derecognition of financial liabilities:

The Company derecognises financial liabilities when, and only when, the Company's obligations are discharged, cancelled or waived off or have expired. An exchange between the Company and the lender of debt instruments with substantially different terms is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in profit or loss.

(e) Borrowings:

Borrowings are initially recorded at fair value and subsequently measured at amortised costs using effective interest rate method. Transaction costs are charged to statement of profit and loss as financial expenses over the term of borrowing.

(f) Trade payables:

Trade payables are amounts due to vendors for purchase of goods or services acquired in the ordinary course of business and are classified as current liabilities to the extent it is expected to be paid within the normal operating cycle of the business

3.4.3. Derivative Financial Instruments:

The Company enters into derivative financial instruments to manage its foreign exchange rate risk. Derivatives are initially recognized at fair value at the date a derivative contract is entered into and are subsequently re-measured to their fair value at the end of each reporting period. The resulting gain or loss is recognized in profit or loss immediately.

3.5 Leases – Company as lessee

At inception of a contract, the Company assesses whether a contract is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified assets for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset the Company assesses whether contract involves the use of an identified asset, the Company has a right to obtain substantially all of the economic benefits from the use of the asset throughout the period of use and the Company has the right to direct the use of the asset.

At the inception date, right-of-use asset ("ROU") is recognised at cost which includes present value of lease payments adjusted for any payments made on or before the commencement of lease and initial direct cost, if any. It is subsequently measured at cost less accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the lease liability. Right-of-use asset ("ROU") is depreciated using the straight-line method from the commencement date over the earlier of useful life of the asset or the lease term. When the Company has purchase option available under lease and cost of right-of-use assets ("ROU") reflects that purchase option will be exercised, right-of-use asset is depreciated over the useful life of underlying asset. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit and loss.

At the inception date, lease liability is recognised at present value of lease payments that are not made at the commencement of lease. Lease liability is subsequently measured by adjusting carrying amount to reflect interest, lease payments and remeasurement, if any.

Lease payments are discounted using the incremental borrowing rate or interest rate implicit in the lease, if the rate can be determined.

The Company has elected not to apply requirements of Ind AS 116 to leases that has a term of 12 months or less and leases for which the underlying asset is of low value. Lease payments of such lease are recognised as an expense on straight line basis over the lease term.

3.6 Inventories

Inventories are Valued at the lower of cost and net realizable value.

The cost incurred in bringing the inventory to their existing location and conditions are determined as follows:

(a) Raw Material and Packing Material - Purchase cost of materials on FIFO basis.

(b) Finished Goods (Manufactured) and work in progress - Cost of purchase, conversion cost, and other costs attributable to inventories.

(c) Trading goods - Purchase cost on FIFO basis.

The cost of purchase of inventories comprises the purchase price, import duties and other taxes (other

than those subsequently recovered by the Company from taxing authorities), and transport, handling and other costs directly attributable to the bringing the inventory to their existing location and conditions. Trade discounts, rebates and other similar items are deducted in determining the costs of purchase.

Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sales. The net realisable value of work-in-progress is determined with reference to the selling prices of related finished products.

The comparison of cost and net realisable value is made on an item-by-item basis.

The Company considers various factors like ageing of inventory, product discontinuation, obsolete items and any other factor which impact the Company's business in determining the allowance for inventories. The Company considers the above factors and adjusts the inventory provision to reflect its actual experience on a periodic basis.

3.7 Impairment of Assets

3.7.1 Financial Assets

At each balance sheet date, the Company assesses whether a financial asset is to be impaired. Ind AS 109 requires expected credit losses to be measured through loss allowance. The Company measures the loss allowance for financial assets at an amount equal to lifetime expected credit losses if the credit risk on that financial asset has increased significantly since initial recognition. If the credit risk on a financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for financial assets at an amount equal to 12-month expected credit losses. Loss allowance for financial assets measured at amortised cost are deducted from gross carrying amount of the assets. The amount of ECL (or reversal) that is required to adjust the loss allowance at the reporting date is recognised as an impairment gain or loss in the Statement of Profit and Loss.

3.7.2 Non-financial Assets

Property, plant and equipment and intangible assets with finite life are evaluated for recoverability whenever there is any indication that their carrying amounts may not be recoverable. If any such indication exists, the recoverable amount (i.e. higher of the fair value less cost to sell or the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the cash generating unit (CGU) to which the asset belongs.

If the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU) is reduced to its recoverable amount. An impairment loss is recognized in the profit or loss to such extent. When an impairment loss subsequently reverses, the carrying amount of the asset (or a cash-generating unit) is increased to the revised estimate of its recoverable amount, such that the increase in the carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss.

3.7.3 Presentation of allowance for ECL in the balance sheet

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets. For debt securities at FVOCI, the loss allowance is charged to profit or loss and is recognised in OCI.

3.7.4 Credit-impaired financial assets

At each reporting date, the Company assesses whether financial assets carried at amortised cost and debt securities at FVOCI are credit-impaired. A financial asset is 'credit-impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit-impaired includes the following observable data:

- significant financial difficulty of the debtor;
- a breach of contract such as a default or being more than 90 days past due;
- the restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;
- it is probable that the debtor will enter bankruptcy or other financial reorganisation; or
- the disappearance of an active market for a security because of financial difficulties.

3.7.5 Write Off

The gross carrying amount of a financial asset is written off when the Company has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof. For individual customers, the Company has a policy of writing off the gross carrying amount when the financial asset is 3 years past due based on historical experience of recoveries of similar assets. For corporate customers, the Company individually makes an assessment with respect to the timing and amount of write-off based on whether there is a reasonable expectation of recovery. The Company expects no significant recovery from the amount written off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

3.8 Employee Benefits

3.8.1 Short term employee benefits

Short term benefits payable before twelve months after the end of the reporting period in which the employees have rendered service are accounted as expense in profit and loss account.

3.8.2 Long term employment benefits

Defined Contribution Plans

Contributions to defined contribution plans (provident fund and other social security schemes) are recognized as expense when employees have rendered services entitling them to such benefits.

Defined Benefit Plans

The Company's net obligation in respect of an approved gratuity plan, which is defined benefit plan, is calculated using the projected unit credit method and the same is carried out by qualified actuary. The current service cost and net interest on the net defined benefit liability (asset) is recognized in the statement of profit and loss. Past service cost are immediately recognized in the statement of profit and loss. Actuarial gains and losses net of deferred taxes arising from experience adjustment and changes in actuarial assumptions are recognized in other comprehensive income in the period in which they arise.

Compensated absences and earned leaves

The Company's current policy permit eligible employees to accumulate compensated absences up to a prescribed limit and receive cash in lieu thereof in accordance with the terms of the policy. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company expects to pay as a result of unused entitlement that has accumulated as at the reporting date. The expected cost of these benefits is calculated using the projected unit credit method by qualified actuary every year. Expense on non-accumulating compensated absences is recognized is the period in which the absences occur.

The liability in respect of all defined benefit plans and other long-term benefits is accrued in the books of account on the basis of actuarial valuation carried out by an independent actuary using the Projected Unit Credit Method. The obligation is measured at the present value of estimated future cash flows. The discount rates used for determining the present value of obligation under defined benefit plans, is based on the market yields on Government securities as at the Balance Sheet date, having maturity periods approximating to the terms of related obligations.

Remeasurement gains and losses in respect of all defined benefit plans arising from experience adjustments and changes in actuarial assumptions are recognised in the period in which they occur, directly in other comprehensive income. They are included in other equity in the Statement of Changes in Equity and in the Balance Sheet. Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognised immediately in profit or loss as past service cost. Gains or losses on the curtailment or settlement of any defined benefit plan are recognised when the curtailment or settlement occurs. Any differential between the plan assets (for a funded defined benefit plan) and the defined benefit obligation as per actuarial valuation is recognised as a liability if it is a deficit or as an asset if it is a surplus (to the extent of the lower of present value of any economic benefits available in the form of refunds from the plan or reduction in future contribution to the plan).

Past service cost is recognised as an expense in the Statement of Profit and Loss on a straight-line basis over the average period until the benefits become vested. To the extent that the benefits are already vested immediately following

the introduction of, or changes to, a defined benefit plan, the past service cost is recognised immediately in the Statement of Profit and Loss. Past service cost may be either positive (where benefits are introduced or improved) or negative (where existing benefits are reduced).

3.9 Contingent liabilities, contingent assets and provisions

(a) Contingent liabilities:

A possible obligation that arises from past events and the existence of which will be confirmed only by the occurrence or nonoccurrence of one or more uncertain future events not wholly within the control of the enterprise are disclosed as Contingent liability and not provided for. Such liability is not disclosed if the possibility of outflow of resources is remote.

(b) Contingent assets:

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity. Contingent assets are not recognised and disclosed only when an inflow of economic benefits is probable.

(c) Provisions (other than employee benefits):

A provision is recognized when as a result of a past event, the Company has a present obligation whether legal or constructive that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the obligation is expected to be settled more than 12 months after the end of reporting date or has no definite settlement date, the provision is recorded as non-current liabilities after giving effect for time value of money, if material. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

Provisions, contingent liabilities and contingent assets are reviewed at each Balance Sheet date.

3.10 Government Grant

The Company recognizes government grants at their fair value only when there is reasonable assurance that the conditions attached to them will be complied with, and the grants will be received.

Government grants received in relation to assets are recognised directly to respective assets for which it is received. Government grants, which are revenue in nature are either recognised as income or deducted in reporting the related expense based on the terms of the grant, as applicable.

3.11 Revenue recognition

Revenue is measured based on the transaction price adjusted for discounts and rebates, which is specified in a contract with customer. Revenue are net of estimated returns and taxes collected from customer.

Revenue from sale of goods is recognized at point in time when control is transferred to the customer and it is probable that consideration will be collected. Control is usually transferred upon the shipment, at the time of dispatch, delivery to or upon receipt of goods by the customer, in accordance with the delivery and acceptance terms agreed with the customer.

The transaction price is documented on the sales invoice and payment is generally due as per agreed credit terms with customer.

The consideration can be fixed or variable. Variable consideration is only recognised when it is highly probable that a significant reversal will not occur.

Revenue from services are recognised as the related services are performed, the contractual performance obligations are satisfied and there is no uncertainty related to the collection of the said revenue.

The Company has concluded that it is the principal in all of its revenue arrangements since it is the primary obligor in all the revenue arrangements as it has pricing latitude and is also exposed to inventory and credit risks.

Export entitlements

Export entitlements are recognised as income when right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

Interest Income

Interest income is recognized using effective interest rate method.

The 'effective interest rate' is the rate that exactly discounts estimated future cash payments or receipts through the expected life of financial instrument to:

- The gross carrying amount of the financial assets; or
- The amortised cost of the financial liabilities

In calculating interest income and expense, the effective interest rate is applied to the gross carrying amount of the asset (when the asset is not credit-impaired) or to the amortised cost of the liability.

However, for financial assets that have become credit-impaired subsequent to initial recognition, interest income is calculated by applying the effective interest rate to the amortised cost of the financial asset. If the asset is no longer credit-impaired, then the calculation of interest income reverts to the gross basis.

Estimate of Expected Return

Sales return is variable consideration that is recognised and recorded based on historical experience, market conditions and provided for in the year of sale as reduction from revenue. The methodology and assumptions used to estimate returns are monitored and adjusted regularly in line with trade practices, historical trends, past experience and projected market conditions.

3.12 Income Taxes

Income tax expense comprises current and deferred tax expense. Income tax expenses are recognized in statement of profit or loss, except when they relate to items recognized in other comprehensive income or directly in equity.

Current Tax

Current tax is the tax payable on the taxable profit for the year, using tax rates enacted or substantively enacted by the end of reporting period by the governing taxation laws, and any adjustment to tax payable in respect of previous periods. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred Tax

Deferred taxes arising from deductible and taxable temporary differences between the tax base of assets and liabilities and their carrying amount in the standalone financial statements are recognized using substantively enacted tax rates and laws expected to apply to taxable income in the years in which the temporary differences are expected to be received or settled.

Deferred tax asset are recognized only to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax assets to be utilized.

Deferred tax assets and liabilities are offset when the Company has a legally enforceable right to do the same.

3.13 Earnings per share

Basic earnings per share is computed by dividing profit or loss attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares.

3.14 Research and development

Expenditure on research activities is recognised in profit and loss as incurred.

Development expenditure is capitalized as part cost of the resulting intangible asset only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the company intends to and has sufficient resources to complete development and to use or sell the asset. Otherwise, it is recognised in profit and loss as incurred.

Subsequent to initial recognition, development expenditure is measured at cost less accumulated amortisation and any accumulated impairment loss.

3.15 Operating Segments

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker (CODM). The CODM of the Company is responsible for allocating resources and assessing performance of the operating segments and accordingly is identified as the Chief Operating Decision Maker (CODM). All operating segments' operating results are reviewed regularly by the CODM to make decisions about resources to be allocated to the segments and assess their performance.

3.16 Share Capital

The paid-up equity capital of the company as on 31st March, 2025 was Rs. 1046.16 Lakhs. The said shares are listed on the BSE Limited and the National Stock Exchange of India Limited. There was no change in the paid-up capital of the company, during the year under audit.

4. Recent Pronouncements

Ministry of Corporate Affairs ('MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year March 31, 2025, MCA has not notified any new standards or amendments to the existing standards applicable to the Company.

5. (A) Property, Plant and Equipment

As at 31 March 2025

(₹ in Lakhs)

Particulars	Freehold Land	Building	Plant & Equipments	Laboratory Equipments	Office Equipments	Furniture & Fixtures	Computers	Vehicles	Total
Gross carrying amount as at 1 April 2024	5,471.11	25,756.78	40,598.20	5,199.45	641.61	2,035.09	763.20	553.66	81,019.10
Additions during the year	828.18	9,776.02	14,092.31	1,479.92	200.03	576.23	244.37	83.19	27,280.25
Disposals during the year	-	-	99.19	-	-	-	-	152.36	251.55
Gross carrying amount as at 31 March 2025	**6,299.29**	**35,532.80**	**54,591.32**	**6,679.37**	**841.64**	**2,611.32**	**1,007.57**	**484.49**	**1,08,047.80**
Accumulated depreciation as at 1 April 2024	-	3,798.87	15,047.88	2,588.42	449.59	967.47	679.55	314.05	23,845.83
Depreciation charge for the year	-	952.68	3,443.87	447.34	67.95	175.71	49.59	93.51	5,230.65
Disposals	-	-	66.93	-	-	-	-	142.25	209.18
Accumulated depreciation as at 31 March 2025	**-**	**4,751.55**	**18,424.82**	**3,035.76**	**517.54**	**1,143.18**	**729.14**	**265.31**	**28,867.30**
Carrying value as at 31 March 2025	**6,299.29**	**30,781.25**	**36,166.50**	**3,643.61**	**324.10**	**1,468.14**	**278.43**	**219.18**	**79,180.50**
Capital work-in-progress									**5,013.10**

As at 31 March 2024

(₹ in Lakhs)

Particulars	Freehold Land	Building	Plant & Equipments	Laboratory Equipments	Office Equipments	Furniture & Fixtures	Computers	Vehicles	Total
Gross carrying amount as at 1 April 2023	5,471.11	24,628.54	39,187.34	4,937.99	633.77	1,971.92	729.02	423.19	77,982.88
Additions during the year	-	1,128.24	1,428.42	289.48	7.84	63.17	34.18	144.05	3,095.38
Disposals during the year	-	-	17.56	28.02	-	-	-	13.58	59.16
Gross carrying amount as at 31 March 2024	**5,471.11**	**25,756.78**	**40,598.20**	**5,199.45**	**641.61**	**2,035.09**	**763.20**	**553.66**	**81,019.10**
Accumulated depreciation as at 1 April 2023	-	2,865.93	11,702.95	2,169.80	369.28	788.06	583.89	250.71	18,730.62
Depreciation charge for the year	-	932.94	3,357.53	434.06	80.31	179.41	95.66	76.22	5,156.13
Disposals	-	-	12.60	15.44	-	-	-	12.88	40.92
Accumulated depreciation as at 31 March 2024	**-**	**3,798.87**	**15,047.88**	**2,588.42**	**449.59**	**967.47**	**679.55**	**314.05**	**23,845.83**
Carrying value as at 31 March 2024	**5,471.11**	**21,957.91**	**25,550.32**	**2,611.03**	**192.02**	**1,067.62**	**83.65**	**239.61**	**57,173.27**
Capital work-in-progress									**21,148.24**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

Notes:

(i) Depreciation for the year includes ₹ 163.04 Lakhs (as at 31 March 2024 ₹ 162.96 Lakhs) for depreciation on Research & Development assets. (Refer Note 41)

(ii) Additions to Property, Plant & Equipment during the year include capital expenditure on Research & Development related activities amounting to ₹ 113.97 Lakhs (as at 31 March 2024 ₹ 241.61 Lakhs). The details of the same are as under:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Factory Building	0.33	-
Plant & Equipments	10.86	22.56
Laboratory Equipment	102.78	216.54
Office Equipment	-	1.26
Furniture & Fixtures	-	1.25
Total	**113.97**	**241.61**

(iii) The immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the Company) are held in the name of the Company.

(iv) Details of property, plant and equipments which are hypothecated/mortgaged as security for borrowings are disclosed under note 18 (i).

(v) The amount of capital commitments is disclosed in Note 34 (a).

(B) Capital work in progress:

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Capital Work-In-Progress	5,013.10	21,148.24
Total	**5,013.10**	**21,148.24**

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Balance at the beginning of the year	21,148.24	17,269.71
Additions during the year	8,892.68	3,878.53
Capitalised during the year	25,027.82	-
Balance at the end of the year	**5,013.10**	**21,148.24**

(i) Capital work in progress ageing schedule as on 31st March,2025

(₹ in Lakhs)

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Projects in Progress	4,578.57	434.53	-	-	5,013.10
As at 31 March 2025	**4,578.57**	**434.53**	**-**	**-**	**5,013.10**

Capital work in progress ageing schedule as on 31st March,2024

(₹ in Lakhs)

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Projects in Progress	3,878.53	13,549.87	3,325.38	394.46	21,148.24
As at 31 March 2024	**3,878.53**	**13,549.87**	**3,325.38**	**394.46**	**21,148.24**

As on date of balance sheet, there are no capital work in progress whose completion is overdue or has exceeded the cost compared to its original plan.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

There is no project which is temporarily suspended.

CWIP as at 31st March,2025 and 31st March, 2024 mainly includes Plant & Machinery, tools, equipments, buildings for new projects.

(ii) Intangible assets under development ageing schedule as on 31st March,2025

(₹ in Lakhs)

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Projects in Progress	52.60	-	-	-	52.60
Total	**52.60**	**-**	**-**	**-**	**52.60**

Intangible assets under development ageing schedule as on 31st March,2024

(₹ in Lakhs)

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Projects in Progress	-	-	-	-	-
Total	**-**	**-**	**-**	**-**	**-**

As on date of balance sheet, there are no intangible under development whose completion is overdue or has exceeded the cost compared to its original plan.

There is no project which is temporarily suspended.

6 INTANGIBLE ASSETS

As at 31 March 2025

(₹ in Lakhs)

Particulars	Software	Technical Know-How	Total
Gross carrying amount as at 1 April 2024	117.59	1,088.28	1,205.87
Additions during the year	-	59.00	59.00
Disposals during the year	-	-	-
Gross carrying amount as at 31 March 2025	**117.59**	**1,147.28**	**1,264.87**
Accumulated Amortisation as at 1 April 2024	116.33	1,057.57	1,173.90
Amortisation for the year	1.26	30.10	31.36
Disposals during the year	-	-	-
Accumulated depreciation as at 31 March 2025	**117.59**	**1,087.67**	**1,205.26**
Carrying value as at 31 March 2025	**-**	**59.61**	**59.61**

As at 31 March 2024

(₹ in Lakhs)

Particulars	Software	Technical Know-How	Total
Gross carrying amount as at 1 April 2023	117.59	1,042.20	1,159.79
Additions during the year	-	46.08	46.08
Disposals during the year	-	-	-
Gross carrying amount as at 31 March 2024	**117.59**	**1,088.28**	**1,205.87**
Accumulated Amortisation as at 1 April 2023	111.44	1,028.58	1,140.02
Amortisation for the year	4.89	28.99	33.88
Disposals during the year	-	-	-
Accumulated depreciation as at 31 March 2024	**116.33**	**1,057.57**	**1,173.90**
Carrying value as at 31 March 2024	**1.26**	**30.71**	**31.97**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

7 RIGHT-OF USE ASSETS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Right-of use Assets (RoU)	228.43	326.34
Total	**228.43**	**326.34**

LEASE LIABILITIES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Lease Liabilities-Current	195.84	162.08
Lease Liabilities- Non Current	62.98	188.70
Total	**258.82**	**350.78**

A. The Company has taken Office building and warehouse on lease. Disclosures as per Ind AS 116 - Leases are as follows:

The changes in the carrying value of ROU assets for the year ended on 31 March 2025 are as follows :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Opening Balance	313.00	13.34	326.34
Additions during the year	-	89.19	89.19
Deletions/cancellation/modification during the year	-	(11.76)	(11.76)
Amortisation	(156.50)	(18.84)	(175.34)
Balance at the end of the year	**156.50**	**71.93**	**228.43**

The changes in the carrying value of ROU assets for the year ended on 31 March 2024 are as follows :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Opening Balance	-	25.99	25.99
Additions during the year	469.49	-	469.49
Deletions/cancellation/modification during the year	-	-	-
Amortisation	(156.49)	(12.65)	(169.14)
Balance at the end of the year	**313.00**	**13.34**	**326.34**

The aggregate amortisation expense on ROU assets is included under amortisation expense in the Statement of Profit and Loss.

During the previous year the Company had renewed lease agreement for its Head Office on 06 July 2023 for three years. The monthly rent is ₹ 15.32 Lakhs (as at 31 March 2024 ₹ 14.32 Lakhs) with escalation of 7% after completion of each Financial Year.

Extension and termination options are included in some of the lease contracts. These are used to maximise operational flexibility in terms of managing assets used in companies operations.

B. The movement in lease liabilities for the year ended on 31 March 2025 are as follows :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Opening Balance	335.00	15.78	350.78
Additions during the year	-	89.19	89.19
Deletions/cancellation/modification during the year	-	(14.06)	(14.06)
Finance cost accrued during the year	29.65	8.60	38.25
Payment of lease labilities	(183.89)	(21.45)	(205.34)
Balance at the end of the year	**180.76**	**78.06**	**258.82**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

7 RIGHT-OF USE ASSETS (CONTINUED...):

The break-up of current and non-current lease liabilities as on 31 March 2025 is as under :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Current	180.76	15.08	195.84
Non Current	-	62.98	62.98
Total	**180.76**	**78.06**	**258.82**

The movement in lease liabilities for the year ended on 31 March 2024 are as follows :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Opening Balance	-	31.07	31.07
Additions during the year	469.49	-	469.49
Finance cost accrued during the year	41.55	2.53	44.08
Payment of lease labilities	(176.04)	(17.82)	(193.86)
Balance at the end of the year	**335.00**	**15.78**	**350.78**

The break-up of current and non-current lease liabilities as on 31 March 2024 is as under :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Current	154.24	7.84	162.08
Non Current	180.76	7.94	188.70
Total	**335.00**	**15.78**	**350.78**

C. The details of contractual maturities of lease liabilities as on 31 March 2025 on undiscounted basis are as follows:

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Less than one year	196.76	22.48	219.24
One to five years	-	75.64	75.64
Total	**196.76**	**98.12**	**294.88**

The details of contractual maturities of lease liabilities as on 31 March 2024 on undiscounted basis are as follows:

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Less than one year	183.88	9.08	192.96
One to five years	196.76	9.26	206.02
Total	**380.64**	**18.34**	**398.98**

D. The Company does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.

E. The amount recognised in the statement of profit or loss for the year ended 31 March 2025 are as follows:

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Amortisation expense of RoU (Refer Note 30)	156.50	18.84	175.34
Interest expense on lease liabilities (Refer Note 29)	29.65	8.60	38.25
Rent expense*	2.46	-	2.46
Total	**188.61**	**27.44**	**216.05**

*Rent expenses for short-term leases and leases of low value assets (Refer Note 31)

Notes to the Standalone Financial Statements for the year ended 31 March 2025

The amount recognised in the statement of profit or loss for the year ended 31 March 2024 are as follows:

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Amortisation expense of RoU (Refer Note 30)	156.49	12.65	169.14
Interest expense on lease liabilities (Refer Note 29)	41.55	2.53	44.08
Rent expense*	2.00	-	2.00
Total	**200.04**	**15.18**	**215.22**

*Rent expenses for short-term leases and leases of low value assets (Refer Note 31)

8 INVESTMENTS

(₹ in Lakhs)

Particulars	No. of share / units as at 31 March 2025	No. of share / units as at 31 March 2024	As at 31 March 2025	As at 31 March 2024
(a) Non Current				
(i) Unquoted equity instruments				
Concord Biotech Japan K.K. - In Joint Venture Company at cost:	200	200	66.52	66.52
Investment in Clean Max Everglades Pvt Ltd (26% of Partners Capital) *	75,956		73.68	-
* The purpose of the agreement is to purchase renewable energy and not for the purpose of investment / business.				
Entity has accounted for the investment in Clean-max everglades Private Limited (inspite of holding 26% of its equity share capital) as investment as per IND AS 109 and not as an associate considering that entity neither has the representation on the board of directors of the investee and nor has the ability to participate in the investee's policy-making processes.				
(ii) Quoted Investments in equity security designated as at Fair value through Other Comprehensive Income				
Investment in Palvella Therapeutics Inc (0.31% holding)	71,472		1,725.22	-
Total Non-current Investments			**1,865.42**	**66.52**
Aggregate carrying value of unquoted investments			140.20	66.52
Aggregate carrying value of quoted investments			1,725.22	-
Aggregate market value of quoted investments			1,725.22	-
(b) Current				
(i) Quoted Investments in Mutual Funds measured at Fair value through profit & loss				
Edelweiss Arbitrage Fund - Direct Plan - Growth	62,70,431	48,67,121	1,281.92	920.59
Aditya Birla Sun Life Banking & PSU Debt Fund - Direct Plan - Growth	1,56,941	1,56,941	584.08	538.13
HDFC Banking & PSU Debt Fund - Direct Growth Option	24,97,216	24,97,216	584.84	538.95

Notes to the **Standalone Financial Statements** for the year ended 31 March 2025

Particulars	No. of share / units as at 31 March 2025	No. of share / units as at 31 March 2024	As at 31 March 2025	As at 31 March 2024
Kotak Banking and PSU Debt Fund - Direct Growth	8,79,152	8,79,152	585.45	539.43
SBI Banking & PSU Fund - Direct Growth	18,018	18,018	583.18	537.85
Aditya Birla Sun Life Corporate Bond Fund - Growth - Direct Plan	1,79,537	-	201.89	-
Nippon India Overnight Fund - Growth Plan	-	5,00,899	-	640.77
Axis Strategic Bond Fund - Regular Growth	11,61,353	11,61,353	317.81	292.33
Franklin India Short Term Income Plan - Retail Plan - Growth	36	36	1.84	1.84
ICICI Prudential Saving Fund - Direct Plan - Growth	1,16,856	2,96,506	622.27	1,474.15
Kotak Low Duration Fund Standard Growth - Regular Plan	-	18,324	-	559.30
Nippon India Corporate Bond Fund - Growth Plan - Growth Option	5,36,413	5,36,413	314.49	289.61
Nippon India Floating Rate Fund - Direct Growth Plan	17,71,457	17,71,457	821.92	756.74
Aditya Birla Sun Life Money Manager Fund-Growth- Direct Plan	55,397	-	203.68	-
ICICI Prudential Corporate Bond Fund-Direct Plan- Growth	9,88,699	-	302.06	-
Nippon India Money Market Fund - Growth Plan - Growth Option	12,354	-	509.20	-
SBI Liquid Fund - Regular Growth	3,494	-	140.30	-
HDFC Low Duration Fund - Direct Plan - Growth Option	-	15,90,086	-	-
HDFC Ultra Short Term Fund - Direct Growth	-	42,31,052	-	901.32
Trust MF Banking & PSU Debt Fund - Direct Plan - Growth	-	50,000	-	596.10
SBI Overnight Fund - Regular Growth	-	7,071	-	584.48
Aditya Birla Sun Life Short Term Fund - Direct Plan - Growth	15,03,685	7,01,471	756.06	272.15
Axis Short Term Fund - Direct Growth	27,53,388	21,41,030	905.94	324.09
ICICI Prudential Short Term Fund - Direct Plan - Growth	14,17,850	11,03,584	908.29	647.18
Kotak Bond Fund (Short Term) - Direct Plan - Growth	12,57,245	12,57,245	704.64	650.37
Nippon India Short Term Fund - Direct Growth Plan - Growth Option	16,20,879	12,60,923	907.07	647.77
SBI Short Term Debt Fund - Direct Plan - Growth	21,04,886	21,04,886	701.16	648.16
Aditya Birla Sun Life Arbitrage Fund - Direct Plan - Growth	42,00,578	23,36,300	1,181.06	645.77
HDFC Arbitrage Fund - Direct Plan - Wholesale Plan - Growth	58,54,765	50,78,119	1,160.88	608.16
ICICI Prudential Equity Arbitrage Fund - Direct Plan - Growth	50,00,101	42,84,289	1,807.46	932.65
Invesco India Arbitrage Fund - Direct Plan - Growth	50,89,249	35,63,612	1,725.86	1,434.56
Kotak Equity Arbitrage fund - Direct Plan - Growth	1,06,89,446	85,62,387	4,206.59	1,117.94

Notes to the Standalone Financial Statements for the year ended 31 March 2025

Particulars	No. of share / units as at 31 March 2025	No. of share / units as at 31 March 2024	As at 31 March 2025	As at 31 March 2024
Nippon India Arbitrage Fund - Direct Growth Plan - Growth Option	49,78,419	54,51,493	1,403.74	3,115.53
SBI Arbitrage Opportunities Fund - Direct Plan - Growth	58,96,072	64,80,485	2,082.08	1,424.81
Tata Arbitrage Fund - Direct Plan - Growth	79,61,074	44,28,525	1,181.47	2,121.31
ICICI PrudentiaL Money Market fund - Direct Plan - Growth	95,359	-	359.18	608.15
Nippon India Liquid Fund- Growth Plan- Growth Option	19,168	-	1,201.59	-
HDFC Corporate Bond Fund - Direct Plan - Growth Option	6,20,867	-	202.04	-
HDFC Liquid Fund- Growth	19,945	-	1,005.21	-
HDFC Money Market Fund - Direct Plan - Growth Option	6,284	-	359.23	-
HDFC Short Term Debt Fund- Direct Growth	18,73,315	-	604.81	-
Axis Money Market Fund Direct Growth	21,955	-	310.87	-
Kotak Money Market Fund- Direct Growth	6,922	-	307.71	-
TATA Money Market Fund - Direct Plan - Growth	13,074	-	616.61	-
Total Investments at FVTPL- Current			**31,654.48**	**24,370.19**
Aggregate carrying value of quoted investments			31,654.48	24,370.19
Aggregate market value of quoted investments			31,654.48	24,370.19

9 OTHER FINANCIAL ASSETS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Unsecured, considered good unless otherwise stated		
Non Current		
Security deposits	277.27	215.82
Production Linked Incentive Receivable [Refer Note (iii) below]	110.17	110.17
Bank deposits with maturity more than 12 months [Refer Note (i) below]	1,603.60	99.25
Interest accrued but not due on deposits	-	5.74
Other receivables		
Considered Good	65.37	65.97
Considered Doubtful	226.95	226.95
Less: Loss allowance on other receivables [Refer note (ii) below]	(226.95)	(226.95)
Net Other receivables	65.37	65.97
Total	**2,056.41**	**496.95**

Notes:

(i) Out of total Bank deposits of ₹ 1603.60 lakhs, term deposits amounting to ₹ 1198.09 lakhs (as at 31 March 2024 ₹ 98.16 lakhs) are lodged as margin money against Bank Guarantees and other Commitments.

(ii) Loss allowance of ₹ 226.95 lakhs is made for incentive receivable under Market Access Initiative Scheme(MAI scheme).

(iii) The Company had a short receipt of ₹ 110.17 Lakhs for claim of FY 22-23. The management has written to the respective authority for clarification. The management believes that the said amount is fully recoverable.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

10 OTHER NON CURRENT ASSETS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Unsecured, considered good unless otherwise stated		
Prepaid expenses	513.57	-
Capital advances	746.50	797.99
Total	**1,260.07**	**797.99**

11 INVENTORIES*

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
(At lower of Cost and Net Realizable Value)		
(a) Raw materials	7,997.87	6,330.47
(b) Work-in-progress	13,383.01	12,348.02
(c) Finished goods - Including Goods in transit (C.Y. 46.32 Lakhs , P.Y. 162.47 Lakhs)	894.24	402.95
(d) Fuel	78.84	69.75
(e) Stores & Spares	403.54	387.36
(f) Stock in Trade Including Goods in transit (C.Y. 2.49 Lakhs , P.Y. Nil)	1,209.22	1,256.83
Total	**23,966.72**	**20,795.38**

(i)* Inventories are given as security for borrowings as disclosed under note 18(ii).

(il) Finished goods -Inventory write down are accounted, considering the nature of inventory, ageing and net realisable value for ₹ 610.60 Lakhs (as at 31 March 2024 ₹ 678.20 Lakhs). The changes in write downs are recognised as an expense in the statement of Profit and loss.

12 TRADE RECEIVABLES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Trade receivables considered good- Unsecured	52,368.47	34,960.89
Trade receivables -credit impaired	114.19	139.07
Less:- Loss Allowance	(317.51)	(139.07)
Total	**52,165.15**	**34,960.89**

(i) The Company's exposure to credit and currency risk, and loss allowances are disclosed in Note 38.

(ii) Includes receivables from related parties [refer note 39 (c)].

(iii) Movements in the expected credit loss allowance:

(₹ in Lakhs)

Particulars	Year ended 31 March 2025	Year ended 31 March 2024
Opening balance	139.07	87.30
Add / (less) : Loss allowance measured at expected credit losses	178.44	51.77
Less: Provision used during the year	-	-
Closing balance	**317.51**	**139.07**

(iv) Trade receivables are given as security for borrowings as disclosed under note 18(ii).

(v) Trade receivables Ageing Schedule:

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(₹ in Lakhs)

Particulars	Outstanding for following periods from due date of payment						Total
	Not Due	Less than 6 months	6 months to 1 year	1 to 2 years	2 to 3 years	More than 3 years	
(i) Undisputed Trade Receivables - considered good	34,700.47	14,362.65	1,685.18	736.87	868.62	14.68	52,368.47
(ii) Undisputed Trade Receivables - credit impaired	-	-	-	0.01	3.23	110.95	114.19
Less Loss Allowance	(72.62)	(45.66)	(31.15)	(23.76)	(18.98)	(125.34)	(317.51)
As at 31 March 2025	**34,627.85**	**14,316.98**	**1,654.04**	**713.11**	**852.87**	**0.30**	**52,165.15**
Weighted average loss rate	**0.21%**	**0.32%**	**1.85%**	**3.23%**	**2.18%**	**99.76%**	**0.60%**

(₹ in Lakhs)

Particulars	Outstanding for following periods from due date of payment						Total
	Not Due	Less than 6 months	6 months to 1 year	1 to 2 years	2 to 3 years	More than 3 years	
(i) Undisputed Trade Receivables - considered good	25,727.18	7,084.88	1,649.35	459.59	11.43	28.46	34,960.89
(ii) Undisputed Trade Receivables - credit impaired	-	-	-	57.19	13.36	68.52	139.07
Less Loss Allowance	-	-	-	(57.19)	(13.36)	(68.52)	(139.07)
As at 31 March 2024	**25,727.18**	**7,084.88**	**1,649.35**	**459.59**	**11.43**	**28.46**	**34,960.89**
Weighted average loss rate	**0.00%**	**0.00%**	**0.00%**	**11.07%**	**53.87%**	**70.66%**	**0.40%**

The average credit period on sales of goods is 60-90 days. No interest is charged on outstanding trade receivables.

13 CASH AND BANK BALANCES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
(a) Cash and cash equivalents		
Cash on hand	1.89	2.73
Balance with Banks		
In Current accounts	88.56	1,511.48
Total	**90.45**	**1,514.21**
(b) Bank Balances other than cash and cash equivalents		
Bank Deposits with Maturity more than 3 months but less than 12 months [Refer note below]	27.86	2,620.70
Share Escrow Account (Refer note 44)	-	567.53
Total	**27.86**	**3,188.23**

(i) Out of total Bank deposits of ₹ 27.86 Lakhs, Term deposits amounting to ₹ 13.49 Lakhs (as at 31 March 2024 ₹ 338.55 Lakhs) are lodged as margin money against Bank Guarantees and other Commitments.

14 OTHER FINANCIAL ASSETS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Unsecured, considered good unless otherwise stated		
Current		
Subsidy receivable [Refer Note (i) below]	95.93	99.14
Interest Accrued but not due on deposits	-	122.71
Derivative financial instruments	35.78	12.12

Notes to the Standalone Financial Statements for the year ended 31 March 2025

Deposits with original maturity over 12 months -Current	1,784.54	-
Insurance claims	10.03	48.18
Security Deposit	309.73	307.42
Export Taxable Under Rebate Claim	670.22	-
Production Linked Incentive Receivable [Refer Note (ii) below]	1,000.00	1,000.00
Export Incentive Receivable	125.84	-
Other Receivables [Refer Note (iii) below]	51.12	355.31
Total	**4,083.19**	**1,944.88**

(i) Company is eligible to get various incentives namely – Capital subsidy, interest subsidy, incentive on power tariff, employment generation incentive subsidy etc. from GSBTM (Gujarat State Biotechnology Mission) under Biotechnology Policy of Gujarat for establishing new API Plant at Limbasi. Company has received claims of subsidies on timely manner from GSBTM. As at 31 March 2025, the Company has outstanding receivable on account of various subsidies as follows - Power Tariff Subsidy ₹ 79.48 Lakhs, Employment Generation Incentive ₹ 16.45 Lakhs (as at 31 March 2024 Interest Subsidy ₹ 14.96 lakhs for interest paid on term loan, Power Tariff Subsidy ₹ 68.59 lakhs , Employment Generation Incentive ₹ 15.59 lakhs).

(ii) The Company is eligible for claiming benefits under the Production Linked Incentive (PLI) Scheme of the Government of India and recognised the PLI income in accordance with the conditions prescribed in the PLI scheme.

(iii) Other receivable includes Nil (as at 31 March 2024 ₹ 336.72 lakhs) of amount recoverable from customer towards bank guarantees invoked.

15 OTHER CURRENT ASSETS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Unsecured, considered good unless otherwise stated		
Advance to Supplier	157.71	765.72
Balances with government authorities	480.65	1,032.98
Prepaid expenses	739.12	733.12
Export Incentive Receivable	151.44	311.23
Advances to Employees	7.45	6.28
Total	**1,536.37**	**2,849.33**

16 EQUITY SHARE CAPITAL

(₹ in Lakhs, except per share data)

Particulars	As at 31 March 2025	As at 31 March 2024
Authorised		
11,00,00,000 (Previous Year - 11,00,00,000) equity shares of ₹ 1/- each and 31 March, 2024 ₹ 1/-) [Refer note below]	1,100.00	1,100.00
	1,100.00	1,100.00
Issued, Subscribed and fully paid-up		
10,46,16,204 (as at 31 March 2024 - 10,46,16,204) equity shares of ₹ 1/- (as at 31 March 2024 ₹ 1/-) each fully paid up [Refer Note (v) below]	1,046.16	1,046.16
	1,046.16	1,046.16

(i) Reconciliation of equity shares outstanding at the beginning and at the end of the reporting year:

(₹ in Lakhs, except per share data)

	As at 31 March 2025		As at 31 March 2024	
Particulars	Number of Shares	in Lakhs	Number of Shares	in Lakhs
As at the beginning of the year	10,46,16,204	1,046.16	10,46,16,204	1,046.16
Outstanding at the end of the year	**10,46,16,204**	**1,046.16**	**10,46,16,204**	**1,046.16**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(ii) Terms/rights attached to equity shares with voting rights:

The Company has only one class of equity shares having a par value of ₹ 1 per share. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of the equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts, if any. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

(iii) Details of shareholders holding more than 5% shares in the Company:

(₹ in Lakhs, except per share data)

	As at 31 March 2025		As at 31 March 2024	
Particulars	**No. of shares**	**% of total Shares**	**No. of shares**	**% of total Shares**
Equity Shares of 1 each fully paid				
Mr. Sudhir Jairam Vaid	3,01,69,524	28.84%	3,01,69,524	28.84%
Mrs. Manju Sudhir Vaid	99,87,636	9.55%	99,87,384	9.55%
Nishtha Jhunjhunwala Disc Trust	83,99,732	8.03%	83,99,732	8.03%
Aryavir Jhunjhunwala Disc Trust	83,99,754	8.03%	83,99,754	8.03%
Aryaman Jhunjhunwala Disc Trust	83,99,754	8.03%	83,99,754	8.03%
M/s. Ontario Inc.	20,92,325	2.00%	56,40,536	5.39%

(iv) Shares held by Promoters & Promoters group at the end of the Year:

(₹ in Lakhs, except per share data)

Particulars	**As at 31 March 2025**		**As at 31 March 2024**		**% of change during the year**
	No. of Shares	**% of total Shares**	**No. of Shares**	**% of total Shares**	
Promoters					
Mr. Sudhir Vaid	3,01,69,524	28.84%	3,01,69,524	28.84%	-
Mr. Ankur Vaid	5,86,520	0.56%	5,86,520	0.56%	-
Promoters Group					
Mrs. Manju Sudhir Vaid	99,87,636	9.55%	99,87,384	9.55%	-
Mrs. Megha Vaid	5,47,008	0.52%	5,47,008	0.52%	-
Mrs. Sonal Kumra	73,920	0.07%	73,920	0.07%	-
Sudman Consultants LLP	47,52,000	4.54%	47,52,000	4.54%	-

(v) Pursuant to the approval of the shareholders at the Extra Ordinary General Meeting of the Company held on 8 July 2022, each equity share of face value of ₹ 10/- per share was sub-divided into 10 equity shares of face value of ₹ 1/- per share and approved the issuance of 1 bonus shares of face value ₹ 1 each for every 10 existing fully paid-up equity share of face value ₹ 1 each and accordingly 95,10,564 bonus shares were issued and allotted on 20 July 2022 out of securities premium.

(vi) No equity shares are issued for consideration other than cash or have been bought back in previous five financial years

17 OTHER EQUITY

(₹ in Lakhs, except per share data)

Particulars	**As at 31 March 2025**	**As at 31 March 2024**
Reserve and Surplus		
Retained Earnings	1,69,099.57	1,40,360.16
General Reserve	2,921.79	2,921.79
Securities premium	8,197.10	8,197.10
Total	1,80,218.46	1,51,479.05

Notes to the Standalone Financial Statements for the year ended 31 March 2025

Nature and purpose of reserves:

(i) General reserve:

The general reserve is used from time to time to transfer profits from retained earnings for appropriation purposes. There is no policy of regular transfer. Items included under General Reserve shall not be reclassified back into the Statement of Profit & Loss.

(ii) Retained Earnings:

Retained Earnings are the profits that the Company has earned till date less any transfer to general reserve, dividends , other distributions to shareholder and remeasurements of definied benefit obligations comprising acturial gains or losses and return on plan assets considering interest income.

(iii) Securities Premium:

This reserve represents Security Premium received at the time of issuance of Equity Shares.

18 BORROWINGS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Non-current		
Secured - at amortised cost		
Term Loan [Refer Note (i) below]	-	622.98
Less: Current maturities of term Loan	-	(622.98)
Total	**-**	**-**
Current borrowing		
Secured - at amortised cost		
Cash Credit Facility [Refer Note (ii) and (iii) below]	38.11	-
Current maturities of long term liabilities	-	622.98
Total	**38.11**	**622.98**

(i) The Company had availed Term Loan from State Bank of India. Term Loan of ₹ 10,000 lakhs (outstanding amounting as at 31 March 2025 ₹ Nil lakhs, 31 March 2024 ₹ 622.98 lakhs) secured by first charge on Factory Land & Building and Plant & Machinery of Unit-III at Limbasi, Dist. Kheda, (Survey No. 666,667,668 and 84 at Village Malavada and Survey No. 94A,94B,119,120,126,135 and 136 at Ranasar) and charge on the same has been created. Interest rate is 3 months MCLR + 0.20% p.a and loan is repayable in 16 quarterly instalments of ₹ 625 lakhs each starting from October, 2020.

(ii) Short term Borrowings from banks are in nature of working capital facilities which are secured by first pari passu charge on entire current assets of the Company. Interest rate is MCLR + 0.05% and this borrowing is repayable on demand.

(iii) The Company has Fund-based and Non-fund-based limits of Working Capital from Banks. For the said facility,the company is not required to submit quarterly returns with the bank as per sanction letter provided.

19 PROVISIONS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Non-current		
Employee Benefits		
Provisions for compensated absences (Refer note 36)	281.99	195.61
Total	**281.99**	**195.61**
Current		
Employee Benefits		
Provision for Compensated Absences (Refer note 36)	258.39	184.68
Provision for Gratuity (Refer Note 36)	58.03	42.70
Others		
Provision for Sales Return [Refer note (i) below]	237.58	162.81
Total	**554.00**	**390.19**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

Note:

(i) Provision for Sales Returns:

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Opening Balance	162.81	2,542.05
Add: Provision made during the period	215.05	2,853.11
Less: Provision utilised during the period	(140.28)	(5,232.35)
Closing Balance	**237.58**	**162.81**

20 INCOME TAXES

The major component of income tax expense for the years ended 31 March 2025 and 31 March 2024 are as follows:

(₹ in Lakhs)

Particulars	Year ended 31 March 2025	Year ended 31 March 2024
Statement of Profit and Loss		
Current tax	11,896.14	9,983.39
Deferred tax	394.96	462.79
Income tax expense in the Statement of Profit and Loss	**12,291.10**	**10,446.18**
Statement to Other comprehensive income (OCI)		
Income tax relating to fair valuation of investments measured at FVOCI	215.09	-
Income tax relating to re-measurement gain/ (loss) on defined benefit plans	(14.34)	(0.24)
Income tax charge/(credit) recognised in OCI	**200.75**	**(0.24)**

(a) Reconciliation of tax expense and the accounting profit multiplied by tax rate for the year ended 31 March 2025 and 31 March 2024.

(₹ in Lakhs)

Particulars	Year ended 31 March 2025	Year ended 31 March 2024
Accounting profit before tax	**49,587.54**	**40,919.37**
Tax Rate	25.168%	25.168%
Deferred tax	12,480.19	10,298.59
Adjustment		
Tax impact on income charged under capital gain	(324.75)	(8.94)
Tax impact on expenditure not deductible under tax	156.15	148.75
Changes in temporary differences of earlier years	-	3.32
Others	(20.50)	4.46
Total	**12,291.10**	**10,446.18**
Effective tax rate	**24.79%**	**25.53%**

(b) Deferred tax:

The major components of Deferred tax liabilities /(assets) arising on account of timing differences are as follows:

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Deferred tax liabilities		
Property, plant and equipment and intangible assets	3,125.17	2,609.32
Fair Valuation of Investments measured at FVTPL	417.69	442.29
Fair valuation of investments measured at FVOCI	215.09	-
Right of use assets	57.47	-
Total	**3,815.42**	**3,051.61**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

Particulars	As at 31 March 2025	As at 31 March 2024
Deferred tax assets		
Employee benefit obligations	178.29	120.69
Loss Allowance for trade receivables & other financial assets	140.87	95.97
Provision for expenses allowed for tax purpose on payment basis	28.97	22.35
Lease liabilities	65.12	6.15
Total	**413.25**	**245.16**
Deferred Tax liabilities (Net)	3,402.17	2,806.45
Total	**3,402.17**	**2,806.45**

Movement of deferred tax liabilities / (assets) during the year:

(₹ in Lakhs)

Particulars	For the Year ended 31 March 2025	For the Year ended 31 March 2024
Deferred tax liabilities / (assets) in relation to:		
Property, plant and equipment and intangible assets	514.38	222.26
Fair Valuation of Investments measured at FVTPL	(24.60)	267.12
Fair valuation of investments measured at FVOCI	215.09	-
Lease liabilities	58.97	-
Right of use assets	(58.97)	(4.87)
Employee benefit obligations	(57.61)	(4.24)
Loss Allowance for trade receivables & other financial assets	(44.91)	(16.88)
Provision for expenses allowed for tax purpose on payment basis	(6.63)	(0.84)
Total	**595.72**	**462.55**

(I) There are certain income-tax related legal proceedings which are pending against the Company. Potential liabilities, if any have been adequately provided for, and the Company does not currently estimate any probable material incremental tax liabilities in respect of these matters. Refer note 34 (b).

(ii) The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

(iii) The Tax rate used for Financial Year 2024-25 and 2023-24, in reconciliation above is the corporate tax rate of 25.168% payable by corporate entity in India on taxable profits under the Indian Tax Law.

(C) Non-Current tax asset / (Current tax Liabilities)

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Provision for Income Tax	(11,957.55)	(29,344.46)
Advance payment of Tax	11,122.53	29,062.20
Total	**(835.02)**	**(282.26)**

(D) Income Tax Balances (Net)

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Income tax assets (Net)	177.66	267.12
Current tax liabilities (net)	1,012.68	549.38
Total	**(835.02)**	**(282.26)**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

21 TRADE PAYABLES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Total outstanding dues of micro enterprises and small enterprises	595.24	961.54
Total outstanding dues of creditors other than micro enterprises and small enterprises	10,708.74	8,481.99
Total	**11,303.98**	**9,443.53**

(a) Trade Payables Ageing Schedule:

(₹ in Lakhs)

Particulars		Not Due	Outstanding for following periods from due date of payment				Total
			Less than 1 Year	1 to 2 years	2 to 3 years	More than 3 years	
(i)	MSME	463.83	17.56	48.34	34.25	31.26	595.24
(ii)	Others	7,137.95	3,109.77	275.33	157.45	28.24	10,708.74
(iii)	Disputed Dues MSME	-	-	-	-	-	-
(iv)	Disputed Dues -Other	-	-	-	-	-	-
As at 31 March 2025		**7,601.77**	**3,127.33**	**323.67**	**191.70**	**59.50**	**11,303.98**

(₹ in Lakhs)

Particulars		Not Due	Outstanding for following periods from due date of payment				Total
			Less than 1 Year	1 to 2 years	2 to 3 years	More than 3 years	
(i)	MSME	926.96	34.58	-	-	-	961.54
(ii)	Others	7,218.80	1,159.85	13.83	13.16	76.35	8,481.99
(iii)	Disputed Dues MSME	-	-	-	-	-	-
(iv)	Disputed Dues -Other	-	-	-	-	-	-
As at 31 March 2024		**8,145.76**	**1,194.43**	**13.83**	**13.16**	**76.35**	**9,443.53**

(b) Disclosure under the Micro, Small and Medium Enterprises Development Act (MSMED), 2006

(₹ in Lakhs)

Particulars		Year Ended 31 March 2025	Year Ended 31 March 2024
(i)	Principal amount and the interest due thereon remaining unpaid to each supplier at the end of each accounting year (but within due date as per the MSMED Act)		
	- Principal amount due to micro and small enterprise	597.20	848.82
	- Interest due on above	1.86	3.08
(ii)	Interest paid by the Company in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along-with the amount of the payment made to the supplier beyond the appointed day during the period.	-	-
(iii)	Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the period) but without adding interest specified under the Micro, Small and Medium Enterprises Act, 2006.	112.72	109.64
(iv)	The amount of interest accrued and remaining unpaid at the end of each accounting year.	114.58	112.72
(v)	Interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises.	114.58	112.72

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Company. This has been relied upon by the auditors.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

22 OTHER FINANCIAL LIABILITIES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Interest accrued but not due on borrowings	-	10.39
Payables for employee benefits	1,312.84	1,183.71
Security Deposits	10.00	10.00
Payable to customers	2,251.35	-
Unpaid Dividend	5.26	-
Payable to selling shareholders and others (Refer note 44)	-	714.19
Payable on purchase of Property, Plant and Equipment *	590.34	502.34
Total	**4,169.79**	**2,420.63**

Payable on purchase of Property, Plant and Equipment includes total outstanding dues of Micro enterprise and samll enterprises of ₹ 116.54 lakhs(as at 31 March 2024 Nil)

23 OTHER CURRENT LIABILITIES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Payable to Statutory and other authorities	291.39	260.59
Contract liabilities	840.47	366.16
Total	**1,131.86**	**626.75**

24 REVENUE FROM OPERATIONS

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Revenue From contracts with customers		
Sale of Goods (at point in time)	1,17,840.33	99,532.52
Sale of Services (at point in time)	141.45	273.21
	1,17,981.78	**99,805.73**
Other Operating Revenue		
Export benefits	1,026.91	888.19
Production Linked Incentive Income [Refer note 14 (ii)]	1,000.00	1,000.00
	2,026.91	**1,888.19**
Total	**1,20,008.69**	**1,01,693.92**

(a) Disaggregate revenues from contracts with customers :

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Domestic	66,183.16	53,420.94
Exports	53,825.53	48,272.98
Total	**1,20,008.69**	**1,01,693.92**

(b) Disaggregate revenues from contracts with customers based on products:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Active Pharmaceutical Ingredient (API)	94,009.07	82,802.78
Formulations	25,999.62	18,891.14
Total	**1,20,008.69**	**1,01,693.92**

There are no transactions with a single customer which amounts to 10% or more of the Company's revenue.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(c) Reconciliation of Revenue from operations with contract price:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Contract Price	**1,20,399.39**	**1,04,568.26**
Less : Adjustment made to contract price on account of:		
Provision for Sales Return	(215.05)	(2,853.11)
Others - rate difference	(175.65)	(21.23)
Total	**1,20,008.69**	**1,01,693.92**

(d) Contract Balances

The following table provides information about receivables,contract assets and contract liabilities from contracts with customers

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Receivables, which are included in 'trade receivables'	**52,165.15**	**34,960.89**
Contract assets	-	-
Contract liabilities	840.47	366.16

The amount of 366.16 lakhs as at 31 March 2024 has been recognised as revenue during the year ended 31 March 2025. (31 March 2024 ₹ 155.51 lakhs)

(e) Unsatisfied or partially satisfied performance obligation

Revenue to be recognised in future related to the performance obligations that are unsatisfied or partially satisfied as at 31 March, 2025 and expected to be recognised within one year is of ₹ 840.47 lakhs and for more than one year is Nil.

25 OTHER INCOME

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Interest income		
From Bank (under the effective interest method)	164.33	304.11
On income tax refund	6.19	-
On investment	0.49	-
Other Gain and Losses		
Net gain on sale of investments	1,360.57	345.14
Net gain on Investments in Mutual Funds measured at FVTPL	865.80	1,061.33
Net foreign exchange gain	819.84	648.05
Other Non Operating Income		
Subsidy income	791.94	764.69
Insurance claim Received	0.09	14.14
Net profit on sale of Property, plant & equipment	-	1.19
Testing Fees Income	-	111.43
Excess provision no longer required written back	273.24	3.81
Miscellaneous income	162.18	124.11
Total	**4,444.67**	**3,378.00**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

26 COST OF MATERIALS CONSUMED

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Raw materials including packing materials at the beginning of the year	6,330.47	8,042.87
Add: Purchases	28,098.66	16,741.31
	34,429.13	**24,784.18**
Less: Raw materials including packing materials at the end of the year	7,997.87	6,330.47
Total	**26,431.26**	**18,453.71**

27 CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Opening stock		
Finished goods	402.95	548.49
Stock-in-trade	1,256.83	931.70
Work-in-progress	12,348.02	11,319.82
	14,007.80	**12,800.01**
Less : Closing stock		
Finished goods	894.24	402.95
Stock-in-trade	1,209.22	1,256.83
Work-in-progress	13,383.01	12,348.02
	15,486.47	**14,007.80**
Total changes in inventories of finished goods, work-in-progress and stock-in-trade		
Finished goods	(491.29)	145.54
Stock-in-trade	47.61	(325.13)
Work-in-progress	(1,034.99)	(1,028.20)
Total changes in inventories of finished goods, work-in-progress and stock-in-trade	**(1,478.67)**	**(1,207.79)**

28 EMPLOYEE BENEFITS EXPENSE:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Salaries, wages and bonus	13,007.78	11,479.16
Contribution to provident and other funds	684.92	632.39
Staff welfare expenses	200.66	193.12
Total	**13,893.36**	**12,304.67**

29 FINANCE COSTS

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
(a) Interest expense on borrowings		
- Term Loan	9.30	183.90
- Cash Credit/Over Draft	5.38	21.41
(b) Interest on lease liabilities (Refer Note 7)	38.25	44.08
Total interest expense for financial liabilities carried at amortized cost	**52.93**	**249.39**
Interest on Income tax	-	5.80
Total	**52.93**	**255.19**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

30 DEPRECIATION AND AMORTIZATION

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Depreciation of property, plant and equipment (Refer Note 5)	5,230.65	5,156.13
Amortisation of intangible assets (Refer Note 6)	31.36	33.88
Depreciation of right of use assets (Refer Note 7)	175.34	169.14
Total	**5,437.35**	**5,359.15**

31 OTHER EXPENSES

(₹ in Lakhs)

Particulars		Year Ended 31 March 2025	Year Ended 31 March 2024
(a)	**Power & Fuel**		
	Power & Fuel Consumed	11,223.02	10,496.87
	Total	**11,223.02**	**10,496.87**
(b)	**Others**		
	Consumption of stores and spare parts	1,219.25	1,241.19
	Laboratory Charges & Testing Expenses	2,117.04	1,881.88
	Repairs & Maintenance	1,398.26	1,558.56
	Rent, Rates & Taxes	1,102.98	855.81
	Insurance Expense	253.62	312.94
	Bank Charges	51.24	63.21
	Travelling and conveyance	1,105.65	994.04
	Communication, IT and Stationery Expenses	259.60	223.28
	Payment to Auditors (Refer Note-33)	30.55	46.19
	Legal & Professional Fees	744.84	530.46
	Directors Sitting Fee	24.10	30.50
	Selling, Distribution and Advertisement Expenses	3,455.18	3,310.96
	Net loss on sale of Property, plant & equipment	22.47	-
	Loss allowance	178.44	51.77
	Corporate Social Responsibilities Expense (Refer Note 35)	620.11	590.33
	Membership & Subscription	69.60	64.76
	Security Service Charges	212.64	217.45
	Effluent Treatment Plant Charges	537.39	616.30
	Safety & Environment Charges	17.38	23.13
	Miscellaneous Expense	287.51	204.10
Total		**13,707.85**	**12,816.86**

32 EARNINGS PER SHARE (EPS)

(₹ in Lakhs)

Particulars		Year Ended 31 March 2025	Year Ended 31 March 2024
Basic and Diluted EPS			
(A)	Net profit after tax before other comprehensive income as per standalone statement of profit and loss (₹ in lakhs) (A)	37,296.44	30,473.19
(B)	Weighted average number of equity shares considered for calculation of EPS	10,46,16,204	10,46,16,204
(C)	Basic and Diluted Earning Per Share (₹) (A/B)	35.65	29.13
(D)	Nominal Value of equity share (₹)	1.00	1.00

Notes to the Standalone Financial Statements for the year ended 31 March 2025

33 PAYMENT TO AUDITORS

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
For Audit Fees	24.25	37.55
For Certification fees	5.00	7.71
For Other fees	0.85	-
For Reimbursement of expense	0.45	0.93
Total	**30.55**	**46.19**

Company has paid fees of ₹ Nil (as at 31 March 2024 ₹ 77.25 Lakhs) for issuing various reports and certificates in connection with the completed initial public offering (IPO) during the previous year. This expenses have been recovered from the selling shareholders and are not included in the above information.

34 COMMITMENTS AND CONTINGENCIES

(a) Commitments

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Estimated amount of contracts remaining to be executed on capital account and not provided for in respect of the Property, Plant & Equipment (Net of Advances)	2,276.01	1,244.29
Total	**2,276.01**	**1,244.29**

(b) Contingent liabilities

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Claims against the Company / disputed liabilities not acknowledged as debts:		
Disputed demand of Excise duty for which an appeal has been preferred	**376.37**	**376.37**
- The Company has preferred Appeal to Income Tax Appellate Tribunal (ITAT) against order received from Assessing officer in respect of short payment of Excise duty, non reversal of input credit		
Disputed demand of Income Tax in which company has preferred Appeal or filed rectification with Department :	**14.61**	**1,054.56**
- The Company has preferred Appeal to CIT(A) against order received from Assessing officer in respect of disallowance of additional depreciation in A.Y. 2013-14. Appeal order was received but effect order is pending		
- The Company has preferred Appeal to CIT(A) against order received from Assessing officer in respect of Penalty imposed u/s 271(1)(C) in A.Y. 2015-16 & 2016-17. Appeal order was received but effect order is pending		
- The Company has preferred Appeal to CIT(A) against order received from Assessing officer in respect of disallowance of Purchase of Raw Material in A.Y. 2016-17		
- The Company has preferred Appeal to CIT(A) against order received from Assessing officer in respect of disallowance of u/s 35(2)(AB) and Rule 8D r.w.s 14A in A.Y. 2018-19. Appeal order was received but effect order is pending		
- The Company has filed rectification with Assessing officer against intimation received from CPC regarding payment of Dividend Distribution Tax for A.Y. 2020-21. The Company has also filed Appeal to CIT(A) against order received from Assessing officer in respect of disallowance u/s Rule 8D r.w.s 14A in A.Y. 2020-21 and regarding not granting credit of payment of Dividend Distribution Tax. Appeal order was received but effect order is pending.		
Total	**390.98**	**1,430.93**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(i) It is not practicable for the Company to estimate the timing of cash outflows, if any, in respect of the above pending litigations of the respective proceedings.

(ii) The Company does not expect any reimbursements in respect of the above contingent liabilities.

(iii) The Company believes that the ultimate outcome of these proceedings will not have a material adverse effect on the Company's financial position and results of operations. These demands are with respect to income tax and service tax matters for which appeals have been filed.

(iv) The Company has ongoing disputes with various tax authorities (income tax,and excise) in India. The Company have disclosed contingent liability as above, respectively, in respect of various tax demands, which are being contested by the Company based on the management evaluation and advice of tax consultants.

(v) The amounts assessed as contingent liability do not include interest and penalty that could be claimed by counter parties.

35 CORPORATE SOCIAL RESPONSIBILITIES

Amount spent towards CSR activities during the year are as follows:

(₹ in Lakhs)

Particulars		Year Ended 31 March 2025	Year Ended 31 March 2024
(i)	Gross Amount required to be spent by the Company during the year	631.59	572.30
(ii)	Amount approved by the board to be spent during the year	631.59	572.30
(iii)	Amount spent during the year on	620.11	590.33
	(a) Construction or acquisation of any asset	-	-
	(b) On purpose other than (a) above	620.11	590.33
(iv)	Excess spent on CSR activities up to immediately preceeding three financial years	21.33	
(v)	Excess / (Shortfall) at the end of the year	9.85	18.03
(vi)	Total of previous years shortfall	-	-
(vii)	Reason for shortfall	Not Applicable	Not Applicable
(viii)	Nature of CSR activities	Medical, Educational, Environmental sustainability, Promoting sports, Social, Rural Development	Medical, Educational, Environmental sustainability, Promoting sports, Social, Rural Development
(ix)	details of related party transactions, e.g., contribution to a trust controlled by the Company in relation to CSR expenditure as per relevant Accounting Standard	Not Applicable	Not Applicable
(x)	where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year shall be shown separately.	Not Applicable	Not Applicable

36 EMPLOYEE BENEFITS PLANS:

(a) Defined contribution plans:

The Company makes contributions towards provident fund, a defined contribution retirement benefit plan for qualifying employees. The provident fund is operated by the Regional Provident Fund Commissioner. The Company recognized ₹ 549.45 Lakhs (Previous Year ₹ 500.34 Lakhs) for provident fund contributions in the Statement of Profit and Loss. The contributions payable to these plans by the company are at rates specified in the rules of the scheme.

(b) Defined benefit plans:

The Company makes annual contributions to the Employee's Group Gratuity cash accumulation scheme of the LIC, a funded defined benefit plan for qualifying employees. The Scheme provides for payment to vested employees at retirement/death while in employment or on termination of employment as per the provisions of the Payment of Gratuity Act, 1972. Vesting occurs on completion of 5 years of service. The present value of the defined benefit obligation and the related current service cost are measured using the Projected Unit Credit Method as per actuarial valuation carried out at the balance sheet date.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

Characteristics of Defined Benefit Plans and risk associated with them:

Valuation of defined benefit plan are performed on certain basic set of pre-determined assumptions and other regulatory framework, which may vary over time. Thus, Company is exposed to various risks in providing the above benefit plans which are as follows:

(i) Interest rate risk:

The plan exposes the Company to the risk of fall in interest rates. A fall in interest rates will result in an increase in the ultimate cost of providing the above benefit and will thus result in an increase in the value of the liability (i.e. value of defined benefit obligation).

(ii) Salary escalation risk:

The present value of the defined benefit plan is calculated with the assumption of salary increase rate of plan particulars in future. Deviation in the rate of increase of salary in future for plan participants from the rate of increase in salary used to determine the present value of obligation will have a bearing on the plan's liability.

(iii) Demographic risk:

The Company has used certain mortality and attrition assumptions in valuation of the liability. The Company is exposed to the risk of actual experience turning out to be worse compared to the assumptions.

(iv) Investment risk:

The Company has funded with LIC fund, there is no significant investment risk. Further the present value of the defined benefit plan liability is calculated using a discount rate which is determined by reference to market yields at the end of the reporting period on government bonds. If the return on plan asset is below this rate, it will create a plan deficit. Currently, for the plan in India, it has a relatively balanced mix of investments in government securities, and other debt instruments.

The following table sets out the status of the gratuity plan as required under Ind AS-19 and the amounts recognized in the Company's financial statements as at 31 March 2025:

(₹ in Lakhs)

Particulars		As at 31 March 2025	As at 31 March 2024
i.	**Reconciliation of Opening and Closing Balances of defined benefit obligation:**		
	Liability at the beginning of the Year	877.91	760.15
	Current Service Cost	124.13	119.88
	Interest Cost	62.95	55.87
	Benefits paid	(82.83)	(52.77)
	Actuarial (Gains)/Losses on Obligations - Due to Change in Demographic Assumptions	(33.53)	(26.97)
	Actuarial (Gains)/Losses on Obligations - Due to Change in Financial Assumptions	20.22	6.20
	Actuarial (Gains)/Losses on Obligations - Due to Experience	66.94	15.56
	Liability at the end of the Year	**1,035.79**	**877.91**
ii.	**Reconciliation of Opening and Closing Balances of the Fair value of Plan assets:**		
	Plan assets at the beginning of the Year, at Fair value	835.21	702.48
	Expected return on plan assets	59.88	51.63
	Contributions	168.84	140.06
	Benefit paid	(82.83)	(52.77)
	Actuarial gain/(loss) on plan assets	(3.34)	(6.19)
	Plan assets at the end of the Year, at Fair Value	**977.76**	**835.21**
iii.	**Present value of defined benefit obligation and Fair value of plan assets:**		-
	Obligations at the end of the Year	1,035.79	877.91
	Plan assets at the end of the Year, at Fair value	(977.76)	(835.21)
	Liability recognized in balance sheet at the end of the Year	**58.03**	**42.70**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

36 EMPLOYEE BENEFITS PLANS: (CONTINUED...)

(₹ in Lakhs)

Particulars		Year Ended 31 March 2025	Year Ended 31 March 2024
iv.	**Expense recognised in the statement of profit and loss for the year**		
	Current Service Cost	124.13	119.88
	Interest Cost	62.95	55.87
	Expected returns on plan assets	(59.88)	(51.63)
	Total	**127.19**	**124.12**
v.	**Expense recognised in the other comprehensive income for the year**		
	Actuarial (gain)/loss on obligation for the period	53.63	(5.22)
	Return on planned asset, excluding Interest Income	3.34	6.19
	Total	**56.98**	**0.97**
vi.	**Actuarial Assumptions**		-
	Discount Rate (per annum)*	6.54%	7.17%
	Expected rate of return on plan assets**	6.54%	7.17%
	Salary Escalation***	9.00%	9.00%
	Attrition Rate	22.00%	16.70%
	Weighted average duration of defined benefit obligation	5 Years	5 Years
	Retirement Age	58 Years	58 Years
	Mortality Rate	Indian Assured Lives Mortality (2012-14) Urban	Indian Assured Lives Mortality (2012-14) Urban

* The discount rate is based on the prevailing market yields of government of India securities as at the balance sheet date for the estimated term of the obligations.

**Expected rate of return on plan assets is determined based on the nature of assets and prevailing economic scenario.

*** The estimate of future salary increases considered, takes into account inflation, seniority, promotion, increments and other relevant factors.

vii. Sensitivity Analysis for each significant actuarial assumption:

The significant actuarial assumptions for the determination of the defined benefit obligations are discount rate and expected salary increase. The sensitivity analysis below have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Projected Benefit Obligation on Current Assumptions	**1,035.79**	**877.91**
Impact of increase in discount rate by 1 %	(31.66)	(33.22)
Impact of decrease in discount rate by 1 %	34.12	36.30
Impact of increase in salary escalation rate by 1 %	30.75	32.99
Impact of decrease in salary escalation rate by 1 %	(29.21)	(30.91)
Impact of increase in employee turnover rate by 1 %	(6.61)	(5.33)
Impact of decrease in employee turnover rate by 1 %	6.91	5.60

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligations as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the defined benefit obligations has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

36 EMPLOYEE BENEFITS PLANS: (CONTINUED...)

viii. Investment details of plan assets:

The plan assets are managed by Insurance Company viz Life Insurance Corporation of India who has invested the funds substantially as under:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Insurance Fund - investment in LIC policy	977.76	835.21

ix. Balance Sheet Reconciliation

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Opening Net Liability	**42.70**	**57.67**
Expense Recognized in Statement in profit or Loss	127.19	124.12
Expenses Recognized in OCI	56.98	0.97
Employer Contribution	(168.84)	(140.06)
Net Liability/(Asset) recognised in the balance sheet	**58.03**	**42.70**

x. Maturity Profile

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
1st Following Year	218.48	158.30
2nd Following Year	171.91	126.81
3rd Following Year	161.53	122.08
4th Following Year	156.93	109.16
5th Following Year	121.98	116.08
Sum of Years 6 to 10	332.37	344.01
Sum of Years 11 and above	155.81	261.58

xi. Expected contribution during the next annual reporting period

The Company's best expected contribution during the next year is ₹ 186.47 Lakhs.

(c) Compensated absences:

Actuarial Valuation for Compensated Absences is done as at the year end and the provision is made based on leave balances derived as per Company's Rules with corresponding charge to the Statement of Profit and Loss amounting to ₹ 260.99 Lakhs (as at 31 March 2024 ₹ 55.25 Lakhs) and it covers all regular employees. Major drivers in actuarial assumptions, typically, are years of service and employee compensation.

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Actuarial Assumptions		
Discount Rate (per annum)*	6.54%	7.17%
Salary Escalation***	9.00%	9.00%
Attrition Rate	22.00%	16.70%

37 The Company has taken various derivatives to hedge its risk associated with foreign exchange fluctuations. These transactions have been undertaken to act as economic hedges for the Company's exposures to various risks in foreign exchange markets. Forward exchange contracts (being derivative instruments), which are not intended for trading or speculative purposes but for hedge purposes are entered, which are available at the settlement date of certain payables and receivables.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(₹ in Lakhs)

Particulars	As at 31 March 2025		As at 31 March 2024	
	Amount (in Lakhs)	Amount (in Lakhs)	Amount (in Lakhs)	Amount (in Lakhs)
Hedging of Trade Receivables	-	-	-	-
Forward Contracts	USD 41.08	3,510.29	USD 72.46	6,041.35

The details of foreign currency exposures not hedged by derivative instruments are as under:

(₹ in Lakhs)

Particulars	As at 31 March 2025		As at 31 March 2024	
	Amount (in Lakhs)	Amount (in Lakhs)	Amount (in Lakhs)	Amount (in Lakhs)
Trade Receivables	USD 170.06	14,531.60	USD 81.07	6,759.21
	EURO 11.37	1,049.66	EURO 11.04	992.00
	JPY 2411.64	1,374.15	JPY 1231.99	678.16
	RUB 12.60	12.97	RUB 114.13	100.16
	CAD 0.01	0.74	CAD 0.01	0.75
	AED 8.90	207.12	-	-
Trade Payables	USD 53.40	4,563.01	USD 15.27	1,273.14

38 FINANCIAL INSTRUMENTS: FAIR VALUE AND RISK MANAGEMENT

(i) Categories of Financial instruments: Financial assets and liabilities

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Financial Assets :		
Amortised cost		
Trade receivables	52,165.15	34,960.89
Cash and Cash equivalents	90.45	1,514.21
Bank Balances other than cash and cash equivalents	27.86	3,188.23
Other Financial Assets	6,103.82	2,429.71
Fair value through profit or loss		
Non-current Investment - Investments in Clean Max Everglades Pvt Ltd	73.68	-
Current Investment - Investments in Mutual Funds	31,654.48	24,370.19
Derivative instruments	35.78	12.12
Fair value through other comprehensive income		
Non-current Investment - Investments in Palvella Therapeutics Inc	1,725.22	-
Total	**91,876.44**	**66,475.35**
Financial Liabilities :		
Amortised cost		
Borrowings (including current maturities)	38.11	622.98
Lease Liability	258.82	350.78
Trade payables	11,303.98	9,443.53
Other Financial Liabilities	4,169.79	2,420.63
Total	**15,770.70**	**12,837.92**

(ii) Fair value hierarchy :

The fair values of the financial assets and liabilities are determined based on the price that would be received to sell an asset or paid to transfer a liability at the reporting date considering the fair value hierarchy as under:

Level 1: It includes financial instruments measured using quoted prices. This includes listed equity instruments that have quoted price. The fair value of all equity instruments which are traded in the stock exchanges is valued using the closing price as at the reporting period.

Level 2: The fair value of financial instruments that are not traded in an active market (for example, traded bonds, over-the counter derivatives) is determined using valuation techniques which maximize the use of observable market data and rely

Notes to the Standalone Financial Statements for the year ended 31 March 2025

38 FINANCIAL INSTRUMENTS: FAIR VALUE AND RISK MANAGEMENT: (CONTINUED..)

as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities, contingent consideration and indemnification asset included in level 3.

Fair value hierarchy

The following tables categorise the financial assets and liabilities held at fair value by the valuation methodology applied in determining their fair value.

(₹ in Lakhs)

As at 31 March 2025	Level 1	Level 2	Level 3	Total
Financial Assets :				
Investment in Mutual Funds	31,654.48	-	-	31,654.48
Investment - Investments in Palvella Therapeutics Inc	1,725.22	-	-	1,725.22
Investment - Investments in Clean Max Everglades Pvt Ltd	-	-	73.68	73.68
Derivative financial assets	-	35.78	-	35.78

(₹ in Lakhs)

As at 31 March 2024	Level 1	Level 2	Level 3	Total
Financial Assets :				
Investment in Mutual Funds	24,370.19	-	-	24,370.19
Derivative financial assets	-	12.12	-	12.12

Determination of fair values:

Basis of assumptions used to estimated the fair value of financial assets and liabilities that are measured at fair value on recurring basis :

Investment in Mutual Funds: The fair values represent net asset value as stated by the issuers of these mutual fund units in the published statements. Net asset values represent the price at which the issuer will issue further units in the mutual fund and the price at which issuers will redeem such units from the investors.

Derivative instruments: For forward contracts, future cash flows are estimated based on forward exchange rates and forward interest rates (from observable forward exchange rates / yield curves at the end of the reporting period) and contract forward exchange rates and forward interest rates, discounted at a rate that reflects the credit risk of various counterparties.

Derivative instruments are financial contracts that derive their value from an underlying asset. Their main purpose is to mitigate financial risk and protect against price volatility. Given the uncertainties associated with export revenue from the sale of goods, company has engaged into derivative instruments, to hedge their risk against price fluctuations and safeguard their financial stability.

(iii) Financial Risk Management

The Company's activities are exposed to variety of financial risks. These risks include market risk (including foreign currency risk, interest rate risks and price risk), credit risks and liquidity risk. The Company's overall risk management program seeks to minimize potential adverse effects on the financial performance of the Company through established policies and processes which are laid down to ascertain the extent of risks, setting appropriate limits, controls, continuous monitoring and its compliance.

A Market Risk :

Market risk refers to the possibility that changes in the market rates may have impact on the Company's profits or the value of its holding of financial instruments. The Company is exposed to market risks on account of foreign currency rates, interest rates and underlying equity prices.

A1 Foreign currency risk :

The Company's foreign currency risk arises from its foreign currency transactions and foreign currency borrowings.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

38 FINANCIAL INSTRUMENTS: FAIR VALUE AND RISK MANAGEMENT: (CONTINUED..)

The fluctuation in foreign currency exchange rates may have potential impact on the income statement and equity, where any transaction references more than one currency or where assets/liabilities are denominated in a currency other than the functional currency of the company.

The overall objective of the foreign currency risk management is to minimize the short term currency impact on its revenue and cash-flow in order to improve the predictability of the financial performance.

The major foreign currency exposures for the Company are denominated in USD. Additionally, there are transactions which are entered into in other currencies and are not significant in relation to the total volume of the foreign currency exposures. The Company hedges some trade receivables and future cash flows upto a maximum of 6 months forward based on historical trends, budgets and monthly sales estimates.

The following table sets forth information relating to foreign currency exposure:

(₹ in Lakhs)

As at 31 March 2025	US Dollars	Others*	Total
Assets :			
Trade and other receivables	18,041.89	2,644.64	20,686.52
Total	**18,041.89**	**2,644.64**	**20,686.52**
Liabilities :			
Trade and other payables	4,563.01	-	4,563.01
Total	**4,563.01**	**-**	**4,563.01**
Net Balance (Assets - Liabilities)	**13,478.87**	**2,644.64**	**16,123.51**

(₹ in Lakhs)

As at 31 March 2024	US Dollars	Others*	Total
Assets :			
Trade and other receivables	12,800.56	1,771.07	14,571.63
Total	**12,800.56**	**1,771.07**	**14,571.63**
Liabilities :			
Trade and other payables	1,273.14	-	1,273.14
Total	**1,273.14**	**-**	**1,273.14**
Net Balance (Assets - Liabilities)	**11,527.42**	**1,771.07**	**13,298.49**

*Others mainly includes currencies namely Ruble, Euro and Japanese Yen.

Foreign currency sensitivity

The following tables demonstrate the sensitivity to a reasonably possible change in USD rates to the functional currency of entity, with all other variables held constant. The Company's exposure to foreign currency changes for all other currencies is not material. The impact on the Company's profit after tax is due to changes in the fair value of monetary assets and liabilities.

(₹ in Lakhs)

Particulars	Effect on profit before tax	Changes in USD rate	Equity effect net of tax
As at 31 March 2025	199.37	+2%	149.19
	(199.37)	-2%	(149.19)
As at 31 March 2024	109.72	+2%	82.11
	(109.72)	-2%	(82.11)

A2 Interest rate risk :

Interest rate risk refers to the possibility that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rate. The Company is exposed to fluctuations in interest rates in respect of term loan carrying a floating rate of interest. In respect of term loan, the Company has outstanding borrowing of ₹ 38.11 lakhs as at 31 March, 2025 (As at 31 March 2024: ₹ 622.98 lakhs) The following table demonstrates

Notes to the Standalone Financial Statements for the year ended 31 March 2025

the sensitivity to a reasonable possible change on interest rates on that position of borrowing affected. with all other variables held constant, the Company's profit before tax is affected through the impact on floating rate of borrowing as follows:

(₹ in Lakhs)

Particulars	Effect on profit before tax	Equity effect net of tax
As at 31 March 2025		
Increase by 50 basis points	-	-
Decrease by 50 basis points	-	-
As at 31 March 2024		
Increase by 50 basis points	(3.11)	(2.33)
Decrease by 50 basis points	3.11	2.33

A3 Price Risk :

Price risk is the risk that the value of the financial instrument will fluctuate as a result of changes in market prices which arises on account of movement in interest rates, liquidity and credit quality of underlying securities. The primary goal of the Company's investment in mutual funds is to hold investments for short term for strategic purpose. Management monitors their performance and they are managed on fair value basis. Further there is no price risk for investment in Clean Max Everglades Pvt Ltd.

(₹ in Lakhs)

Particulars	Effect on profit before tax	Equity effect net of tax
As at 31 March 2025		
Increase by 2% in prices of investment	667.59	499.57
Decrease by 2% in prices of investment	(667.59)	(499.57)
As at 31 March 2024		
Increase by 2% in prices of investment	487.40	364.73
Decrease by 2% in prices of investment	(487.40)	(364.73)

B Credit Risk :

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its operating activities (primarily trade receivables) and from its financing activities, including deposits with banks and financial institutions and other financial instruments.

The Company establishes a loss allowance that represents its estimate of expected losses in respect of trade receivables. The maximum exposure to credit risk as at reporting date is from trade receivables amounting to ₹ 317.51 Lakhs (March 31, 2024: ₹ 139.07 Lakhs). The movement in loss allowance in respect of trade receivables during the year was as follows:

(₹ in Lakhs)

Movement in expected credit loss allowance on trade receivable	Year Ended 31 March 2025	Year Ended 31 March 2024
Opening Balance	139.07	87.30
Add:- Loss Allowance	178.44	51.77
Closing Balance	**317.51**	**139.07**

There are no trade receivables accounting for more than 10% of the Company's total trade receivables as at 31 March 2025 and 31 March 2024. Refer note 12 for ageing of trade receivables.

(₹ in Lakhs)

Movement in expected credit loss allowance on trade receivable	Year Ended 31 March 2025	Year Ended 31 March 2024
Opening Balance	226.95	226.95
Add:- Loss Allowance	-	-
Closing Balance	**226.95**	**226.95**

Notes to the Standalone Financial Statements for the year ended 31 March 2025

38 FINANCIAL INSTRUMENTS: FAIR VALUE AND RISK MANAGEMENT: (CONTINUED..)

(₹ in Lakhs)

Movement in expected credit loss allowance on trade receivable	As on 31 March 2025	As on 31 March 2024
Not due	34,627.85	25,727.18
0-6 months	14,316.98	7,084.88
6 months-1 year	1,654.04	1,649.35
1-2 year	713.11	459.59
2-3 years	852.87	11.43
Greater than 3 years	0.30	28.46
Expected credit Losses rate	**0.60%**	**0.40%**
Amount of expected credit loss provided for	**317.51**	**139.07**

C Liquidity Risk :

Liquidity risk refers to the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company generates cash flows from operations to meet its financial obligations, maintains adequate liquid assets in the form of cash & cash equivalents and has undrawn short term line of credits from banks to ensure necessary liquidity.

Contractual maturities of significant financial liabilities are as below:

(₹ in Lakhs)

As at 31 March 2025	Less than 1 year	Between 1-2 years	Between 2 - 5 years	More than 5 years	Total
Borrowings	38.11	-	-	-	38.11
Lease Liabilities	195.84	62.98	-	-	258.82
Trade payables	11,303.98	-	-	-	11,303.98
Other financial Liabilities	4,169.79	-	-	-	4,169.79
Total	**15,707.72**	**62.98**	**-**	**-**	**15,770.70**

(in Lakhs)

As at 31 March 2024	Less than 1 year	Between 1-2 years	Between 2 - 5 years	More than 5 years	Total
Borrowings	622.98	-	-	-	622.98
Lease Liabilities	162.08	187.55	1.15	-	350.78
Trade payables	9,443.53	-	-	-	9,443.53
Other financial Liabilities	2,420.63	-	-	-	2,420.63
Total	**12,649.22**	**187.55**	**1.15**	**-**	**12,837.92**

(iv) Capital Management

The capital structure of the Company consists of equity and debt. The Company's objective for capital management is to maintain the capital structure which will support the Company's strategy to maximize shareholder's value, safeguarding the business continuity and help in supporting the growth of the Company.

The Company monitors capital using gearing ratio, which is net debt (total debt less Cash and cash equivalents) divided by total equity.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

Gearing Ratio

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Total borrowings (Refer Note 18)	38.11	622.98
Less: Cash and cash equivalents [Refer Note 13(a)]	90.45	1,514.21
Net Debt (A)	**(52.34)**	**(891.23)**
Total Equity (B)	**1,81,264.62**	**1,52,525.21**
Gearing Ratio (C=A/B)	**-0.03%**	**-0.58%**

39 RELATED PARTY TRANSACTIONS

(a) List of related parties and relationship

(₹ in Lakhs)

Key Management Personnel (KMP):	Mr. Sudhir Vaid, Chairman & Managing Director	Mr. Amitabh Thakore, Independent Director
	Mr. Ankur Vaid, Joint Managing Director & CEO	Mrs. Bharti Khanna, Independent Director
	Mr. Utpal Sheth, Non-executive Director (upto 30 Sept, 2023)	Mr. Anil Katyal, Independent Director (Upto 25 August, 2023)
	Mr. Amit Varma, Non-executive Director (Upto 19 August, 2023)	Mr. Arvind Agarwal, Independent Director
	Mr. Rajiv Ambrish Agarwal, Non-executive Director	Mr. Jayaram Easwaran, Independent Director
	Mr. Ravi Kapoor, Non-executive Director	Mr. Mandayam Chakravarthy Sriraman, Independent Director
	Mr. Lalit Sethi, Chief Financial Officer	
	Mr. Prakash Sajnani, AVP - Finance & Company Secretary	
Relative of Key Management Personnel:	Mrs. Manju Vaid	Mrs. Megha Vaid
	Col. S. K. Vaid	Mrs. Sonal Kumra
Enterprises controlled by / under significantly influenced by Directors and/or their relatives:	Sudman Consultants LLP	Ravi Kapoor & Associates
Joint Venture:	Concord Biotech Japan K.K.	

(b) Transaction with related parties:

(₹ in Lakhs)

Types of Transactions	Key Management Personnel		Relatives of Key Management Personnel		Joint Venture		Enterprises controlled by / under significantly influenced by Directors and/or their relatives:		Total	
	Year Ended 31 March 2025	Year Ended 31 March 2024	Year Ended 31 March 2025	Year Ended 31 March 2024	Year Ended 31 March 2025	Year Ended 31 March 2024	Year Ended 31 March 2025	Year Ended 31 March 2024	Year Ended 31 March 2025	Year Ended 31 March 2024
Remuneration Paid:										
Mr. Sudhir Vaid	627.00	501.60	-	-	-	-	-	-	627.00	501.60
Mr. Ankur Vaid	348.71	288.60	-	-	-	-	-	-	348.71	288.60
Mrs. Megha Vaid	-	-	87.50	76.76	-	-	-	-	87.50	76.76
Mrs. Sonal Kumra	-	-	96.66	84.79	-	-	-	-	96.66	84.79
Mr. Lalit Sethi	69.00	57.54	-	-	-	-	-	-	69.00	57.54
Mr. Prakash Sajnani	44.95	42.25	-	-	-	-	-	-	44.95	42.25
Total	**-**	**-**	**184.16**	**161.55**	**-**	**-**	**-**	**-**	**184.16**	**161.55**
Compensation to Key Managerial Person:										
Short term benefits	1,113.76	920.49							1,113.76	920.49
Post employment benefits	106.93	-							106.93	-
Total	**1,220.69**	**920.49**	**-**	**-**	**-**	**-**	**-**	**-**	**1,220.69**	**920.49**
Professional Fees:										
Ravi Kapoor & Associates	-	-	-	-	-	-	27.50	27.95	27.50	27.95
Col. S. K. Vaid	-	-	55.42	55.42	-	-	-	-	55.42	55.42
Total	**-**	**-**	**55.42**	**55.42**	**-**	**-**	**27.50**	**27.95**	**82.92**	**83.37**
Rent paid:										
Mr. Sudhir Vaid	139.22	130.11	-	-	-	-	-	-	139.22	130.11
Mrs. Manju Vaid	-	-	44.67	41.74	-	-	-	-	44.67	41.74
Total	**139.22**	**130.11**	**44.67**	**41.74**	**-**	**-**	**-**	**-**	**183.89**	**171.85**
Sale of Products:										
Concord Biotech Japan K.K.	-	-	-	-	3,035.14	4,305.98	-	-	3,035.14	4,305.98
Total	**-**	**-**	**-**	**-**	**3,035.14**	**4,305.98**			**3,035.14**	**4,305.98**
Dividend Paid:										
Mr. Sudhir Vaid	2,639.83	2,060.58	-	-	-	-	-	-	2,639.83	2,060.58
Mrs. Manju Vaid	-	-	873.90	682.14	-	-	-	-	873.90	682.14
Mr. Ankur Vaid	51.32	40.06	-	-	-	-	-	-	51.32	40.06
Mrs. Megha Vaid	-	-	47.86	37.36	-	-	-	-	47.86	37.36
Mrs. Sonal Kumra		-	6.47	5.05	-	-	-	-	6.47	5.05
Mr. Ravi Kapoor	18.38	15.03	-	-	-	-	-	-	18.38	15.03
Mr. Rajiv Ambrish Agarwal	11.42	8.91	-	-	-	-	-	-	11.42	8.91
Mr. Prakash Sajnani	1.93	1.50	-	-	-	-	-	-	1.93	1.50
Sudman Consultants LLP	-	-	-	-	-	-	415.80	324.56	415.80	324.56
Mr. Arvind Agarwal	0.10	-	-	-	-	-	-	-	0.10	-
Total	**2,722.97**	**2,126.08**	**928.23**	**724.55**	**-**	**-**	**415.80**	**324.56**	**4,067.00**	**3,175.19**

(c) Outstanding Balances with related parties

(₹ in Lakhs)

Types of Transactions	Key Management Personnel		Relatives of Key Management Personnel		Joint Venture		Enterprises controlled by / under significantly influenced by Directors and/or their relatives:		Total	
	As at 31 March 2025	As at 31 March 2024	As at 31 March 2025	As at 31 March 2024	As at 31 March 2025	As at 31 March 2024	As at 31 March 2025	As at 31 March 2024	As at 31 March 2025	As at 31 March 2024
Payables for employee benefits:										
Mrs. Megha Vaid	-	-	3.71	3.45	-	-	-	-	3.71	3.45
Mrs. Sonal Kumra	-	-	3.94	3.39	-	-	-	-	3.94	3.39
Total	**-**	**-**	**7.65**	**6.84**	**-**	**-**	**-**	**-**	**7.65**	**6.84**
Amount Payables (in respect to Compensation to Key Managerial Person)										
Short term benefits	49.71	40.65	-	-	-	-	-	-	49.71	40.65
Post employment benefits	106.93	-	-	-	-	-	-	-	106.93	-
Total	**156.64**	**40.65**	**-**	**-**	**-**	**-**	**-**	**-**	**156.64**	**40.65**
Trade Payables:										
Ravi Kapoor & Associates	-	-	-	-	-	-	-	2.06	-	2.06
Col. S. K. Vaid	-	-	4.99	4.99	-	-	-	-	4.99	4.99
Total	**-**	**-**	**4.99**	**4.99**	**-**	**-**	**-**	**2.06**	**4.99**	**7.05**
Trade receivables:										
Concord Biotech Japan K.K.	-	-	-	-	1,374.15	678.15	-	-	1,374.15	678.15
Total	**-**	**-**	**-**	**-**	**1,374.15**	**678.15**	**-**	**-**	**1,374.15**	**678.15**

1. Outstanding balance at the year end are unsecured and interest free and settlement occurs through bank.
2. Company has not provided any commitment to the related party as at 31 March 2025 (P.Y -Nil)
3. The Company has neither made any provision nor written off / written back any balances pertaining to related parties.
4. All above transactions are in the normal course of business and are made on terms equivalent to those that prevail arm's length transactions.

Notes to the Standalone Financial Statements for the year ended 31 March 2025

40 OPERATING SEGMENT

The chief operational decision maker monitors the operating results of its Business segment separately for the purpose of making decision about resource allocation and performance assessment. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the financial statements. Operating segment have been identified on the basis of nature of products and other quantitative criteria specified in the Ind AS 108.

The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment for the purpose of making decision on allocation of resources and assessing its performance.

Geographical segment

Geographical segment is considered based on sales within India and outside India. In outside India, company separately disclosed sales to America and Others.

(₹ in Lakhs)

Particulars			Year Ended 31 March 2025	Year Ended 31 March 2024
i)	**Segment Revenue**			
	Revenue from Operations [*]			
	(a)	Within India	66,183.16	53,420.94
	(b)	Outside India		
		(i) United States of America	13,797.36	10,798.23
		(ii) Others	40,028.17	37,474.75
	Total Revenue from Operations		**1,20,008.69**	**1,01,693.92**
ii)	**Non Current operating assets [**]:**			
	(a)	Within India	87,593.21	79,477.81
	(b)	Outside India	-	-
		(i) United States of America	-	-
		(ii) Others	-	-
	(c)	Unallocable [***]	66.52	66.52
	Total Non Current operating assets		**87,659.73**	**79,544.33**

[*] The revenue information above is based on the locations of the customers.

[**] Non Current Operating Assets for this purpose consist of property, plant and equipment, capital work-in-progress, intangible assets, right-of use assets and investment in joint venture, Investment in Palvella Therapeutics Inc and Clean Max Everglades Pvt Ltd.

[***] Non Current Investment in Concord Biotech Japan K.K. is considered as unallocable.

Information about major customers:

There are no customers accounting for more than 10% of the Revenue in the year ended 31 March 2025 and Previous year 31 March 2024.

41 RESEARCH & DEVELOPMENT

The Company's facility is approved for Research & Development by Department of Science & Industrial Research (DSIR). The Company has incurred expenditure of revenue nature on Research & Development, details of which are as under:

Notes to the Standalone Financial Statements for the year ended 31 March 2025

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Cost of Materials Consumed	493.25	391.21
Salaries & Wages	1,171.27	1,088.43
Power & Fuel	198.25	90.57
Depreciation	163.04	162.96
Other Expenses	688.07	528.20
Total	**2,713.87**	**2,261.37**

42 DISCLOSURE REQUIREMENT AS PER SCHEDULE III

(i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

(ii) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

(iii) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

(iv) The Company has not advanced or loaned or invested funds to any other person(s) or entity(is), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

(v) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(vi) The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

(vii) The Company is not declared as wilful defaulter by any bank or financial institution (as defined under the Companies Act, 2013) or consortium thereof or other lender in accordance with the guidelines on wilful defaulters issued by the Reserve Bank of India.

(viii) The Company has not revalued any of its Property, Plant and Equipment (including Right-of-Use Assets) during the year.

(ix) The Company doesn't have any co-owned properties or the properties (including properties for which the lease agreement executed and disclosed as 'Right-of-Use Assets' in restated consolidated financial information) title deed of which are held by the others.

(x) The Company has not granted any Loans or Advances in the nature of loans to promoters, Directors, KMPs and the related parties (as defined under Companies Act, 2013), either severally or jointly with any other person.

(xi) The Company has used the borrowings from the banks for its intended purpose during the financial year.

(xii) The Company did not have any transaction with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the current and previous financial year.

(xiii) The Company has complied with number of layers prescribed under the Companies Act,2013.

(xiv) The Company has not entered in to any scheme of arrangement which has an accounting impact on current or previous financial year.

(xv) Ratio Analysis

(₹ in Lakhs)

Name		Numerator	Denominator	Year Ended 31 March 2025	Year Ended 31 March 2024	% Variance	Reason
(a)	Current Ratio (in times)	Total current assets	Total current liabilities	6.17	6.30	-2.09%	-
(c)	Debt Service Coverage Ratio (DSCR) (in times)	Earning for Debt Service = Net Profit after taxes + Depreciation and Amortisation expenses + Interest	"Debt service = Interest and lease payments + Principal repayments"	60.03	13.39	348.29%	DSCR has increased due to increase in profitability for the year and repayment of entire borrowings in current year.
(d)	Return on Equity / Return on Net worth Ratio (in %)	Profit for the year	Average total equity	22.00%	22.00%	0.00%	-
(e)	Inventory turnover ratio (in times)	Cost of goods sold	Average inventory	1.37	1.09	26.33%	Due to increase in cost of goods sold and corresponding increase in sales let to increase in inventory turnover ratio.
(f)	Trade Receivables turnover ratio (in times)	Revenue from contract with customers	Average trade receivables	2.71	3.20	(15.20%)	-
(g)	Trade payables turnover ratio (in times)	Purchases of materials and & purchase of stock-in-trade	Average trade payables	3.25	2.38	36.55%	Due to improvement in payment cycle in current year.
(h)	Net capital turnover ratio (in times)	Revenue from operations	"Average working capital (i.e. Total current assets less Total current liabilities)"	1.26	1.35	(6.67%)	-
(i)	Net profit ratio (in %)	Profit for the year	Revenue from operations	31.00%	30.00%	3.33%	-
(j)	Return on Capital employed (in %)	Profit before tax and finance costs (excl. Interest expense on lease liabilities)	Capital employed = Tangible Net worth + Total Borrowings + Deferred tax liabilities	27.00%	26.00%	3.85%	-
(k)	Return on investment (in %)	Income generated from invested funds	Average invested funds in treasury investments	8.00%	8.00%	0.00%	

Notes to the Standalone Financial Statements for the year ended 31 March 2025

43 The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment had released draft rules for the Code on Social Security, 2020 on November 13, 2020, and invited suggestions from stakeholders which are under consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified. The Company will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.

44 During the previous year ended March 31, 2024, the Company's equity shares had been listed on National Stock Exchange ("NSE") and on BSE Limited ("BSE") on August 18, 2023, by completing Initial Public Offering ("IPO") through offer for sale ("OFS") of 2,09,25,652 equity shares of face value of ₹ 1 each at an issue price of ₹ 741 per equity share by Helix Investment Holdings Pte Limited, Singapore ("selling shareholder").

The Company had received proceeds in the share escrow account amounting to ₹ 1,55,052.08 Lakhs out of which ₹ 1,48,814.66 Lakhs paid to selling shareholders and ₹ 5,669.89 Lakhs to various parties for initial public offer expenses. The company has paid all dues to the parties for initial public offer expenses.

The Company has receivable balance of share issue expenses in connection with the public offer of equity shares amounting to ₹ NIL (as at March 2024 : ₹ NIL). As per the Offer Agreement entered between the Company and the selling shareholders, the selling shareholders shall reimburse the share issue expenses except for the listing fees which has been solely borne by the Company. Accordingly, the Company has recovered the expenses incurred in connection with the Issue on completion of IPO during the current year.

The Company's payable balance to selling shareholders and various parties for initial public offer expenses has been disclosed under the Note 22 Other financial liabilities as "Payable to selling shareholders and others".

Being 100% offer for sale, the Company has not presented the utilization of the proceeds of IPO. There is no unutilised amount as on March 31, 2025.

45 DISCLOSURE FOR MAINTENANCE OF BOOKS OF ACCOUNTS WITH AUDIT TRAIL

The Ministry of Corporate Affairs (MCA) has issued a notification dated 24 March 2021 (Companies(Accounts) Amendments Rules, 2021) which is effective from 1 April 2023, states that every Company which uses accounting software for maintaining its books of account shall use only such accounting software which has a feature of recording audit trail of each and every transaction, and further creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled.

In respect of accounting software, the Company has advanced version of the accounting software having feature of recording audit trail of each and every transaction, and creating an edit log of each change made along with the date when such changes were made and also audit trail cannot be disabled. Further, other than the period where audit trail was not enabled in the previous year, the audit trail has been preserved by the Company as per the statutory requirements for record retention.

46 EVENTS AFTER THE REPORTING PERIOD:

The board of directors have recommended final dividend of ₹ 10.70/- per fully paid up equity share of ₹ 1/- each for financial year ended March 31, 2025 on outstanding paid up share capital of the company as on date, in its board meeting held on May 29, 2025, subject to approval of shareholders at ensuing annual general meeting of the Company.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No : 101248W/W-100022

Rupen Shah
Partner
Membership No. : 116240

Place: Ahmedabad
Date: 29 May 2025

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Ankur Vaid
Joint Managing Director & CEO
DIN: 01857225

Lalit Sethi
Chief Financial Officer

Prakash Sajnani
Asst. Vice President - Finance & Company Secretary

Place: Ahmedabad
Date: 29 May 2025

Independent Auditor's Report

To the Members of **Concord Biotech Limited**

REPORT ON THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Opinion

We have audited the consolidated financial statements of Concord Biotech Limited (hereinafter referred to as the "Company") and its joint venture, which comprise the consolidated balance sheet as at 31 March 2025, and the consolidated statement of profit and loss (including other comprehensive income), consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Company, its joint venture as at 31 March 2025, of its consolidated profit and other comprehensive income, consolidated changes in equity and consolidated cash flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Company, its joint venture in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in terms of the Code of Ethics issued by the Institute of Chartered Accountants of India and the relevant provisions of the Act, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the consolidated financial statements.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue Recognition

See Note 3.11 and 24 to standalone financial statements

The key audit matter	How the matter was addressed in our audit
Revenue from the sale of products is recognized when control over goods is transferred to a customer. The actual point in time when revenue is recognized varies depending on the specific terms and conditions of the sales contracts entered with customers. The Company has many customers and sales contracts with customers have distinct terms relating to the timing of revenue recognition. We have identified the recognition of revenue from sale of products as a key audit matter considering revenue is a key performance indicator for the Company. Accordingly, there could be pressure to meet the expectations of investor/other stakeholders and/or to meet revenue targets for a reporting year. We have considered that there is risk of fraud related to revenue being overstated by recognition in the wrong period or before control has passed during the year and at the year end.	Our procedures included the following: - Evaluated appropriateness of the Company's accounting policy for revenue recognition by comparing with applicable accounting standards; - Evaluated the design, implementation and operating effectiveness of Company's controls in respect of revenue recognition; - Tested revenue recognized during the year by selecting samples, through statistical sampling, and verifying the underlying customer contracts and proof of dispatch/ delivery in accordance with the contractual terms agreed with the customers; - Tested revenue recognized near the year-end, using statistical sampling, to verify only revenue pertaining to current year is recognized based on underlying documents along with terms and conditions set out in customer contracts; and - Assessed journal entries posted to revenue to identify unusual items.

Other Information

The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and auditor's reports thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take necessary actions, as applicable under the relevant laws and regulations.

Management's and Board of Directors Responsibilities for the Consolidated Financial Statements

The Company's Management and Board of Directors are responsible for the preparation and presentation of these consolidated financial statements in term of the requirements of the Act that give a true and fair view of the consolidated state of affairs, consolidated profit and other comprehensive income, consolidated statement of changes in equity and consolidated cash flows of the Company including its joint venture in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. The respective Management and Board of Directors of the Company and the respective Management and Board of Directors of its joint venture are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of each company and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Management and Board of Directors of the Company, as aforesaid.

In preparing the consolidated financial statements, the respective Management and Board of Directors of the Company and the respective Management and Board of Directors of its joint venture are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Company and the respective Board of Directors of its joint venture are responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of consolidated financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may

cause the Company and its joint venture to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

a. The consolidated financial statements of the Company and its joint venture for the year ended 31 March 2024 were audited by the predecessor auditor who had expressed an unmodified opinion dated 23 May 2024.

b. The consolidated financial statements include the Company's share of net loss (and other comprehensive income, before consolidation adjustments) of Rs. 10.59 lakhs for the year ended 31 March 2025, as considered in the consolidated financial statements, in respect of one joint venture, whose financial information has not been audited by us or by other auditor. This unaudited financial information has been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of this joint venture, and our report in terms of sub-section (3) of Section 143 of the Act in so far as it relates to the aforesaid joint venture, is based solely on such financial information. In our opinion and according to the information and explanations given to us by the Management, this financial information is not material to the Company.

Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of this matter with respect to the financial information certified by the Management.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "**Annexure A**" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. **A. As required by Section 143(3) of the Act, we report, to the extent applicable, that:**

   a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.

   b. In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books.

   c. The consolidated balance sheet, the consolidated statement of profit and loss (including other comprehensive income), the consolidated statement of changes in equity and the consolidated statement of cash flows dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.

   d. In our opinion, the aforesaid consolidated financial statements comply with the Ind AS specified under Section 133 of the Act.

   e. On the basis of the written representations received from the directors of the Company as on 31 March 2025 taken on record by the Board of Directors of the Company, incorporated in India, none of the directors of the Company are disqualified as on 31 March 2025 from being appointed as a director in terms of Section 164(2) of the Act.

f. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company being the only Company incorporated in India and the operating effectiveness of such controls, refer to our separate Report in "**Annexure B**".

B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

a. The consolidated financial statements disclose the impact of pending litigations as at 31 March 2025 on the consolidated financial position of the Group. Refer Note 34(b) to the consolidated financial statements.

b. The Group did not have any material foreseeable losses on long-term contracts including derivative contracts during the year ended 31 March 2025.

c. There are no amounts which are required to be transferred to the Investor Education and Protection Fund by Holding Company during the year ended 31 March 2025.

d. (i) The management of the Holding Company whose financial statements have been audited under the Act has represented that, to the best of its knowledge and belief, other than as disclosed in the Note 42 (iv) to the consolidated financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(ii) The management of the Holding Company whose financial statements have been audited under the Act has represented that, to the best of its knowledge and belief, other than as disclosed in the Note 42 (v) to the consolidated financial statements, no funds have been received by the Holding Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Holding Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.

e. The final dividend paid by the Company during the year, in respect of the same declared for the previous year, is in accordance with Section 123 of the Act to the extent it applies to payment of dividend.

As stated in Note 48 to the consolidated financial statements, the Board of Directors of the Company has proposed final dividend for the year which is subject to the approval of the members at the ensuing Annual General Meeting. The dividend declared is in accordance with Section 123 of the Act to the extent it applies to declaration of dividend.

f. Based on our examination which included test checks, the Company have used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated

throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit, we did not come across any instance of audit trail feature being tampered with. Additionally, other than the period where audit trail was not enabled in the previous year, the audit trail has been preserved by the Company as per the statutory requirements for record retention.

C. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the remuneration paid during the current year by the Company being the only company to which such requirements of the Act are applicable to its directors is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director by the Company being the only company to which such requirements of the Act are applicable is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Rupen Shah
Partner
Membership No.: 116240
ICAI UDIN:25116240BMMLLS7851

Place: Ahmedabad
Date: 29 May 2025

ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT ON THE CONSOLIDATED FINANCIAL STATEMENTS OF CONCORD BIOTECH LIMITED FOR THE YEAR ENDED 31 MARCH 2025

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

(xxi) According to the information and explanations given to us and based on our examination, there are no companies included in the consolidated financial statements of the Company which are companies incorporated in India except the Company. The Companies (Auditor's Report) Order, 2020 of the Company did not include any unfavourable answers or qualifications or adverse remarks.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Rupen Shah
Partner
Membership No.: 116240
ICAI UDIN:25116240BMMLLS7851

Place: Ahmedabad
Date: 29 May 2025

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT ON THE CONSOLIDATED FINANCIAL STATEMENTS OF CONCORD BIOTECH LIMITED FOR THE YEAR ENDED 31 MARCH 2025

REPORT ON THE INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE AFORESAID CONSOLIDATED FINANCIAL STATEMENTS UNDER CLAUSE (I) OF SUB-SECTION 3 OF SECTION 143 OF THE ACT

(Referred to in paragraph 2(A)(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

OPINION

In conjunction with our audit of the consolidated financial statements of Concord Biotech Limited (hereinafter referred to as "the Company") as of and for the year ended 31 March 2025, we have audited the internal financial controls with reference to financial statements of the Company, as of that date.

In our opinion, the Company, has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2025, based on the internal financial controls with reference to financial statements criteria established by Company considering the essential components of such internal controls stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

MANAGEMENT'S AND BOARD OF DIRECTORS' RESPONSIBILITIES FOR INTERNAL FINANCIAL CONTROLS

The respective Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the respective Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

AUDITOR'S RESPONSIBILITY

Our responsibility is to express an opinion on the internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to financial statements.

MEANING OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

INHERENT LIMITATIONS OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Rupen Shah
Partner
Membership No.: 116240
ICAI UDIN:25116240BMMLLS7851

Place: Ahmedabad
Date: 29 May 2025

Consolidated Balance Sheet as at 31 March 2025

(₹ in Lakhs)

Particulars	Note No.	As at 31 March 2025	As at 31 March 2024
Assets			
I. Non-current assets			
(a) Property, plant and equipment	5 (A)	79,180.50	57,173.27
(b) Capital work-in-progress	5 (B)	5,013.10	21,148.24
(c) Intangible assets	6	59.61	31.97
(d) Right-of use assets	7	228.43	326.34
(e) Intangible assets under development	5 (B)	52.60	-
(f) Investment accounted for using the equity method	8 (a)	73.65	205.86
(g) Financial assets			
(i) Investments	8 (a)	1,798.90	-
(ii) Other Financial Assets	9	2,056.41	496.95
(h) Other non-current assets	10	1,260.07	797.99
(i) Income tax assets (Net)	20 (d)	177.66	267.12
Total non-current assets (A)		**89,900.93**	**80,447.74**
II. Current assets			
(a) Inventories	11	23,966.72	20,795.38
(b) Financial assets			
(i) Investments	8 (b)	31,654.48	24,370.19
(ii) Trade receivables	12	52,165.15	34,960.89
(iii) Cash and cash equivalents	13 (a)	90.45	1,514.21
(iv) Bank balances other than (iii) above	13 (b)	27.86	3,188.23
(v) Other Financial Assets	14	4,083.19	1,944.88
(c) Other Current assets	15	1,536.37	2,849.33
Total current assets (B)		**1,13,524.22**	**89,623.11**
TOTAL ASSETS (A) + (B)		**2,03,425.15**	**1,70,070.85**
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	16	1,046.16	1,046.16
(b) Other equity	17	1,80,225.59	1,51,618.39
Total equity (A)		**1,81,271.75**	**1,52,664.55**
LIABILITIES			
I. Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	18	-	-
(ii) Lease liabilities	7	62.98	188.70
(b) Provisions	19	281.99	195.61
(c) Deferred tax liabilities (net)	20 (b)	3,402.17	2,806.45
Total non-current liabilities (B)		**3,747.14**	**3,190.76**
II. Current liabilities			
(a) Financial liabilities			
(i) Borrowings	18	38.11	622.98
(ii) Lease liabilities	7	195.84	162.08
(iii) Trade payables	21		
Total outstanding dues of micro enterprises and small enterprises		595.24	961.54
Total outstanding dues of creditors other than micro enterprises and small enterprises		10,708.74	8,481.99
(iv) Other Financial Liabilities	22	4,169.79	2,420.63
(b) Provisions	19	554.00	390.19
(c) Other current liabilities	23	1,131.86	626.75
(d) Current tax liabilities (net)	20 (d)	1,012.68	549.38
Total current liabilities (C)		**18,406.26**	**14,215.54**
Total Liabilities (D)		**22,153.40**	**17,406.30**
TOTAL EQUITY AND LIABILITIES (A) + (D)		**2,03,425.15**	**1,70,070.85**
Summary of material accounting policies	1 to 48		

See accompanying notes forming part of the Consolidated Financial Statements

As per our attached report of even date

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No : 101248W/W-100022

Rupen Shah
Partner
Membership No. : 116240

Place: Ahmedabad
Date: 29 May 2025

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Ankur Vaid
Joint Managing Director & CEO
DIN: 01857225

Lalit Sethi
Chief Financial Officer

Prakash Sajnani
Asst. Vice President - Finance & Company Secretary

Place: Ahmedabad
Date: 29 May 2025

Consolidated Statement of Profit and Loss for the year ended 31 March 2025

(₹ in Lakhs, except per share data)

Particulars	Note No.	Year ended 31 March 2025	Year ended 31 March 2024
Income			
Revenue from operations	24	1,20,008.69	1,01,693.92
Other income	25	4,444.67	3,378.00
TOTAL INCOME		**1,24,453.36**	**1,05,071.92**
Expenses			
Cost of materials consumed	26	26,431.26	18,453.71
Purchases of stock-in-trade		5,598.72	5,673.89
Changes in inventories of finished goods, work-in-progress and stock-in-trade	27	(1,478.67)	(1,207.79)
Employee benefits expense	28	13,893.36	12,304.67
Finance costs	29	52.93	255.19
Depreciation and amortization expense	30	5,437.35	5,359.15
Other expenses			
Power and fuel	31 (a)	11,223.02	10,496.87
Others	31 (b)	13,707.85	12,816.86
TOTAL EXPENSES		**74,865.82**	**64,152.54**
Profit before share of profit of joint venture and income tax		**49,587.54**	**40,919.37**
Share of Profit / (loss) of Joint venture accounted using Equity method (Refer note 8 (a) (i))		(132.21)	337.13
Profit before tax		**49,455.33**	**41,256.50**
Tax expenses	20		
Current tax		11,896.14	9,983.39
Deferred tax		394.96	462.79
Total tax expenses		**12,291.10**	**10,446.18**
PROFIT FOR THE YEAR		**37,164.23**	**30,810.32**
Other Comprehensive Income / (loss)			
Items that will not be reclassified to the statement of Profit or Loss			
Re-measurement gain/ (loss) on defined benefit plans		(56.98)	(0.97)
Income tax relating to re-measurement gain/ (loss) on defined benefit plans		14.34	0.24
Re-measurement gain/ (loss) on Equity Instruments		854.62	-
Income tax relating to re-measurement gain/ (loss) on Equity Instruments		(215.09)	-
		596.89	**(0.73)**
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		**37,761.12**	**30,809.59**
Profit for the year attributable to:			
Owners of the Company		37,164.23	30,810.32
		37,164.23	**30,810.32**
Total Other Comprehensive Income / (loss) for the year attributable to:			
Owners of the Company		596.89	(0.73)
		596.89	**(0.73)**
Total Comprehensive Income for the year attributable to:			
Owners of the Company		37,761.12	30,809.59
		37,761.12	**30,809.59**
Earnings per share (Nominal value per equity share of ₹ 1 each)			
Basic and diluted (Refer note 32)		35.52	29.45
Summary of material accounting policies	1 to 48		

See accompanying notes forming part of the Consolidated Financial Statements

As per our attached report of even date

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No : 101248W/W-100022

Rupen Shah
Partner
Membership No. : 116240

Place: Ahmedabad
Date: 29 May 2025

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Lalit Sethi
Chief Financial Officer

Ankur Vaid
Joint Managing Director & CEO
DIN: 01857225

Prakash Sajnani
Asst. Vice President - Finance & Company Secretary

Place: Ahmedabad
Date: 29 May 2025

Consolidated Statement of Changes in Equity for the year ended 31 March 2025

A. EQUITY SHARE CAPITAL

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Opening balance	1,046.16	1,046.16
Changes during the year	-	-
Closing Balance	**1,046.16**	**1,046.16**

B. OTHER EQUITY

Particulars	Reserves and Surplus			Total Other Equity
	Retained Earnings	General Reserve	Securities Premium	
Balance as at 01 April 2023	**1,16,835.20**	**2,921.79**	**8,197.10**	**1,27,954.09**
Profit for the year	30,810.32	-	-	30,810.32
Other comprehensive Income / (loss) (Net of tax)	(0.73)	-	-	(0.73)
Total Other Comprehensive Income	**30,809.59**	**-**	**-**	**30,809.60**
Transactions with owners of the group				
Contribution and distribution				
Dividend*	(7,145.29)	-	-	(7,145.29)
Balance as at 31 March 2024	**1,40,499.50**	**2,921.79**	**8,197.10**	**1,51,618.39**
Profit for the year	37,164.23	-	-	37,164.23
Other comprehensive Income (Net of tax)	596.89	-	-	596.89
Total Other Comprehensive Income	**37,761.12**	**-**	**-**	**37,761.12**
Transactions with owners of the group				-
Contribution and distribution				
Dividend**	(9,153.92)	-	-	(9,153.92)
Balance as at 31 March 2025	**1,69,106.70**	**2,921.79**	**8,197.10**	**1,80,225.59**

*Final Dividend of ₹ 6.83 per equity share for the FY 2022-23.

**Final Dividend of ₹ 8.75 per equity share for the FY 2023-24.

Summary of material accounting policies 1 to 48

See accompanying notes forming part of the Consolidated Financial Statements

In terms of our report attached

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No : 101248W/W-100022

Rupen Shah
Partner
Membership No. : 116240

Place: Ahmedabad
Date: 29 May 2025

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Lalit Sethi
Chief Financial Officer

Place: Ahmedabad
Date: 29 May 2025

Ankur Vaid
Joint Managing Director & CEO
DIN: 01857225

Prakash Sajnani
Asst. Vice President - Finance & Company Secretary

Consolidated Cash Flow Statement for the year ended 31 March 2025

(₹ in Lakhs)

Particulars	For the Year ended 31 March 2025	For the Year ended 31 March 2024
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax as per Statement of Profit and Loss	49,455.33	41,256.50
Adjustment for:		
Share of Loss/(profit) from Joint Venture	132.21	(337.13)
Depreciation and amortization expenses	5,437.35	5,359.15
Interest Income	(171.01)	(304.11)
Finance Cost	52.93	255.19
Interest Subsidy Income	(7.25)	(107.96)
Net gain/loss on termination of lease	(2.30)	-
(Reversal) /Provision for loss allowance	178.44	66.94
Excess provision no longer required written back	(273.24)	(3.81)
(Profit)/loss on sale/discard of Property, plant & equipment	22.47	(1.19)
Net gain on sale of investments	(1,360.57)	(345.14)
Net gain on financial assets measured at fair value through profit or loss	(865.80)	(1,061.33)
Net unrealised foreign exchange (gain) / loss	(129.24)	222.54
Operating Profit before Working Capital Changes	**52,469.32**	**44,999.65**
Working Capital Changes:		
(Increase)/Decrease in Inventories	(3,171.34)	436.09
(Increase) in trade receivables	(17,078.77)	(7,865.96)
(Increase)/Decrease in other financial assets	(2,193.43)	489.52
(Increase)/Decrease in other assets	799.39	(456.23)
Increase/(Decrease) in provisions	193.21	(205.83)
Increase/(Decrease) in trade payables	2,208.91	(1,128.66)
Increase in other financial liabilities	1,661.16	363.01
Increase in other liabilities	505.11	250.08
	(17,075.76)	**(8,117.98)**
Cash generated from operations	**35,393.56**	**36,881.67**
Direct Taxes paid (Net of Income Tax refund)	(10,941.87)	(10,334.96)
Net cash generated from operating activities	**24,451.69**	**26,546.71**
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, plant & equipment and Intangible Assets (including CWIP and capital advance)	(11,117.22)	(8,568.85)
Proceeds from disposal of Property, plant & equipment	19.90	17.51
Purchase of Current Investments	(86,993.89)	(83,810.00)
Proceeds from sale of Current Investment	80,137.07	74,551.74
Interest received	299.46	277.28
Proceeds from Bank Deposits (Net) (including margin money deposits)	2,387.74	2,071.39
Investment in non current deposits with banks (including margin money deposits)	(1,511.71)	-
Proceeds from Non current deposits with Bank (including margin money deposits)	780.00	-
Net cash used in investing activities	**(15,998.65)**	**(15,460.92)**
C CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long Term borrowings	(584.87)	(2,500.58)
Dividend Paid	(9,153.92)	(7,145.29)
Interest Paid	(25.07)	(220.88)
Interest Subsidy Received	14.96	139.12
Principal Payment of Lease Liabilities	(89.66)	(149.78)
Interest paid on Lease Liabilities	(38.25)	(44.08)
Net cash used in financing activities	**(9,876.80)**	**(9,921.49)**
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A)+(B)+(C)	**(1,423.76)**	**1,164.29**
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	**1,514.21**	**349.92**
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	**90.45**	**1,514.21**

Consolidated Cash Flow Statement for the year ended 31 March 2025

Reconciliation of Cash and cash equivalents

Particulars	As at 31 March 2025	As at 31 March 2024
Cash and Cash Equivalents:		
Cash on hand	1.89	2.73
Balance with Banks	88.56	1,511.48
Cash and cash equivalents as per Balance Sheet [Refer Note 13(a)]	**90.45**	**1,514.21**

Notes to the consolidated cashflow statement

Note 1 : The cash flow statement has been prepared under the indirect method as set out in Ind AS 7 statement of cash flows.

Note 2 : The above statement of cash flows for the year ended 31st March,2024, excludes the proceeds received in the share escrow account amounting to ₹ 1,55,052.08 Lakhs on account of offer for sale made by the selling shareholders. Book running lead manager disbursed ₹ 1,48,814.66 Lakhs to its selling shareholders and ₹ 5,669.89 Lakhs to various parties for initial public offer expenses. The remaining funds amounting to ₹ 567.53 Lakhs which are yet to be paid to the selling shareholders after payments of initial public offer expenses is held in share escrow account. The mentioned amount has been completely paid off to the selling shareholders in FY 2024-25.

RECONCILIATION OF MOVEMENTS OF LIABILITIES TO CASH FLOWS ARISING FROM FINANCING ACTIVITIES

Particulars	As at 1 April 2024	Cash flows- Inflows/ (Outflows)	Non-cash Movement	As at 31 March 2025
Borrowings (including current maturities) (Note - 18)	622.98	(584.87)	-	38.11
Lease Liability (Note - 7)	350.78	(127.91)	127.44	258.82
Interest accrued but not paid (Note - 22)	10.39	(25.07)	14.68	-
Total liabilities from financing activities	**984.15**	**(737.84)**	**142.12**	**296.93**

RECONCILIATION OF MOVEMENTS OF LIABILITIES TO CASH FLOWS ARISING FROM FINANCING ACTIVITIES

Particulars	As at 1 April 2023	Cash flows- Inflows/ (Outflows)	Non-cash Movement	As at 31 March 2024
Borrowings (including current maturities) (Note - 18)	3,123.56	(2,500.58)	-	622.98
Lease Liability (Note - 7)	31.07	(193.86)	513.57	350.78
Interest accrued but not paid (Note - 22)	25.97	(220.88)	205.30	10.39
Total liabilities from financing activities	**3,180.60**	**(2,915.32)**	**718.87**	**984.15**

Summary of material accounting policies 1 to 48

See accompanying notes forming part of the Consolidated Financial Statements

In terms of our report attached

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No : 101248W/W-100022

Rupen Shah
Partner
Membership No. : 116240

Place: Ahmedabad
Date: 29 May 2025

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Lalit Sethi
Chief Financial Officer

Ankur Vaid
Joint Managing Director & CEO
DIN: 01857225

Prakash Sajnani
Asst. Vice President - Finance & Company Secretary

Place: Ahmedabad
Date: 29 May 2025

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

1. CORPORATE INFORMATION

Concord Biotech Limited (the Company) is a public limited company incorporated and domiciled in India, having registered office at 1482-86 Trasad Road, Dholka, Ahmedabad – 382225 and corporate office is located at B-1601 & B-1602, Mondeal Heights, S G highway, Ahmedabad-380051. The Company is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. The Company's API manufacturing facilities are located at Dholka and Limbasi, and its formulations facility at Valthera in the state of Gujarat, India.

The Company's equity shares have been listed on National Stock Exchange ("NSE") and on BSE Limited ("BSE") on August 18, 2023, by completing Initial Public Offering ("IPO") through offer for sale ("OFS") of 2,09,25,652 equity shares of face value of ₹ 1 each at an issue price of ₹ 741 per equity share by Helix Investment Holdings Pte Limited, Singapore ("selling shareholder").

2. BASIS OF PREPARATION AND PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS

2.1. Statement of compliance

The consolidated financial statements comply in all material aspects with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 (the Act) read with Companies (Indian Accounting Standards) Rules, 2015 as amended and other relevant provisions of the Act and presentation requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS compliant Schedule III) (as amended from time to time).

These consolidated financial statements have been prepared for the Company as a going concern on the basis of relevant Ind AS that are effective at the Company's annual reporting date, March 31, 2025. These consolidated financial statements were authorized for issuance by the Company's Board of Directors on May 29, 2025.

The Company adopted Disclosures of Accounting policies (Amendments to Ind As 1) from 1st April, 2023, although the amendments did not result in any changes in the accounting policies themselves, they impacted the accounting policy information disclosed in the financial statements.

The amendments require the disclosure of 'material' rather than 'significant' accounting policies. The amendments also provide guidance on the application of materiality to disclosure of accounting policies, assisting the entities to provide useful, entity-specific accounting policy information that users need to understand other information in the financial statement.

2.2. Functional and Presentation Currency

The consolidated financial statements are presented in Indian Rupees (₹), the currency of the primary economic environment in which the Company operates. All the amounts are rounded to the nearest rupee lakhs, unless otherwise indicated. Transaction and balances with values below ₹ 50,000 have been reflected as "0.00" in consolidated financial statements. Transaction in foreign currencies are translated into respective function currencies of group companies at the exchange rates at the date of transaction.

2.3. Basis of Measurement

Historical cost convention

The consolidated financial statements have been prepared on the historical cost basis (i.e. on accrual basis), except for the following items:

- Investments in mutual funds, equity instruments for investment in Palvella Therapeutics Inc. and derivative instruments are measured at fair value and
- Net defined benefit assets/(liability) are measured at fair value of plan assets, less present value of defined benefit obligations.

2.4. Measurement of Fair Value

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if the market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value measurement and/or disclosure purposes in the financial statements is determined on such a basis except for leasing transactions that are within the scope of Ind AS 116 Leases, and measurements that have some similarities to fair value but are not fair value, such as net realizable value in Ind AS 2 Inventories.

In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly; and
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company has an established control framework with respect to the measurement of fair values. This includes a finance team that has overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values.

The Company regularly reviews significant unobservable inputs and valuation adjustments. If third party information is used to measure fair values, then the finance team assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of Ind AS, including the level in the fair value hierarchy in which the valuations should be classified.

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

2.5. Basis of consolidation

The company's interests in equity accounted investees comprise interest in joint venture.

A joint venture is an arrangement in which the company has joint control, whereby the company has rights to the net assets of the arrangement, rather than rights to its assets and obligations for its liabilities.

Interests in a joint venture are accounted for using the equity method. It is initially recognised at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the company's share of the profit or loss and other comprehensive income of equity-accounted investees, until the date on which significant influence or joint control ceases.

The carrying amount of such the investment is tested for impairment at each reporting date.

2.6. Use of estimates and judgements

The preparation of the consolidated financial statements in conformity with Ind AS requires Management to make estimates, judgements and assumptions. These estimates, judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the period. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the consolidated financial statements.

Judgement – Note 8 a(i), whether Company has significant influence over an investee.

2.7. Assumptions and estimation uncertainties:

Key source of estimation of uncertainty at the date of consolidated financial statements, which may cause material adjustment to the carrying amount of assets and liabilities within the next financial year, is in respect of:

- Useful lives of property, plant and equipment (Refer note no. 3.1)
- Leases-Company as a lessee (Refer note no. 3.5)
- Valuation of Inventories (Refer note no. 3.6)
- Employee benefits (refer note no.3.8)
- Provisions & Contingent Liabilities (Refer note no. 3.9)
- Recognition of deferred tax assets (Refer note no. 3.12)
- Impairment of financial assets (Refer note no. 3.7)
- Estimate of expected return (Refer note no. 3.11)
- Measurement of ECL allowance for trade and finance receivables. (Refer note no. 3.7.3)

2.8. Current versus non-current classification:

Based on the time involved between the acquisition of assets for processing and their realization in cash and cash equivalents, the Group has identified 12 months as its operating cycle for determining current and non-current classification of assets and liabilities in the balance sheet.

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

3. MATERIAL ACCOUNTING POLICIES

3.1. Property, Plant and Equipment

i. Recognition and measurement

Property, plant and equipment are stated at cost of acquisition or construction less accumulated depreciation and any accumulated impairment losses. The cost of Plant, Property & Equipment comprises of its purchase price, non-refundable taxes & levies, freight and other incidental expenses related to the acquisition and installation of the respective assets. Borrowing cost attributable to financing of acquisition or construction of the qualifying Property, Plant and Equipment is capitalized to respective assets when the time taken to put the assets to use is substantial.

When major items of property, plant and equipment have different useful lives, they are accounted for as separate items of property, plant and equipment. The cost of replacement of any property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefit associated with the item will flow to the Company and its cost can be measured reliably.

Capital work-in-progress comprises cost of Property, Plant and Equipment those are not yet installed and ready for their intended use at the Balance sheet date.

Pre-operative expenditure comprising of revenue expenses incurred in connection with project implementation during the period up to commencement of commercial production are treated as part of the project costs and are capitalized. Such expenses are capitalized only if the project to which they relate, involve substantial expansion of capacity or upgradation.

An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from its use. Difference between the sales proceeds and the carrying amount of the asset is recognized in profit and loss.

The cost of property, plant and equipment as at 1 April, 2016, the Group's date of transition to Ind AS, was determined with reference to its carrying value recognised as per the previous GAAP (deemed cost), as at the date of transition to Ind AS.

ii. Subsequent expenditure

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company and the cost of the item can be measured reliably.

iii. Depreciation

Freehold land is carried at historical cost and not depreciated. Depreciation on Property, Plant and Equipment is provided using straight line method based as per the useful life prescribed in Schedule II to the Companies Act, 2013. Depreciation on assets added / disposed off during the year is provided on pro-rata basis with reference to month of addition / disposal. The estimated useful lives, residual values and depreciation method are reviewed at each financial year-end and changes in estimates, if any are accounted for on a prospective basis. The residual values are not more than 5% of the original cost of asset.

Class of Asset	Useful Life
Building	5 Years - 60 Years
Plant & Equipment	10 Years - 20 Years
Office Equipments	5 Years
Laboratory Equipments	10 Years
Computers	3 Years
Furniture & Fixtures	10 Years
Vehicles	**3-5 Years**

3.2. Intangible Assets

i. Recognition and measurement

Intangible assets acquired separately are measured at cost of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortisation and impairment losses if any.

Intangible assets (software & technical know-how) are amortised over the estimated useful life of three years which reflects the manner in which the economic benefit is expected to be generated. The estimated useful life of amortizable intangibles is reviewed at the end of each reporting period and change in estimates if any are accounted for on a prospective basis.

ii. Subsequent Expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred.

iii. Amortisation

Intangible assets are amortised on a straight line basis over the estimated useful life.

Amortisation method, useful lives and residual values are reviewed at the end of each financial year and adjusted if appropriate.

The cost of intangibles as at 1 April, 2016, the Group's date of transition to Ind AS, was determined with reference to its carrying value recognised as per the previous GAAP (deemed cost), as at the date of transition to Ind AS.

3.3. Foreign currency Transaction and Translation

Foreign currency transactions are recorded at exchange rates prevailing on the date of the transaction. The net gain or loss on account of exchange differences arising on settlement of foreign currency transactions are recognized as income or expense of the period in which they arise. Monetary assets and liabilities denominated in foreign currency as at the balance sheet date are translated at the closing rate. The resultant exchange rate differences are recognized in the statement of profit and loss. Non-monetary assets and liabilities are carried at the rates prevailing on the date of transaction.

3.4. Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets and financial liabilities are recognized when an entity becomes a party to the contractual provisions of the instruments.

3.4.1. Financial assets

(a) Classification of financial assets:

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. On initial recognition, the Group may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financials Assets are not reclassified subsequent to their initial recognition unless the company changes its business model for managing financial assets, in which case all affected financial assets are reclassified on the first day of the first reporting period following the change in the business model.

(b) Recognition and initial measurement:

Financial assets are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets (other than financial assets at fair value through profit or loss) are added to or deducted from the fair value of the financial assets, as appropriate, on initial recognition. Transaction costs that are directly attributable to the acquisition or issue of financial assets at fair value through profit or loss are recognised immediately in profit or loss.

(c) Subsequent measurement:

- **Amortised Cost**

  Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. A gain or loss on a debt investment that is subsequently measured at amortised cost and is not part of a hedging relationship is recognised in profit or loss when the asset is derecognised or impaired. Interest income from these financial assets is included in finance income using the effective interest rate method.

- **Fair value through other comprehensive income (FVOCI):**

  Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at fair value through other comprehensive income (FVOCI). Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses which are recognised in profit and loss. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to profit or loss and recognised in other gains / (losses). Interest

income from these financial assets is included in other income using the effective interest rate method. Foreign exchange gains and losses are presented in other gains and losses and impairment expenses in other expenses.

- **Fair value through profit or loss (FVTPL)**

  Assets that do not meet the criteria for amortised cost or FVOCI are measured at fair value through profit or loss. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss and is not part of a hedging relationship is recognised in profit or loss and presented net in the statement of profit and loss within other gains / (losses) in the period in which it arises. Interest income from these financial assets is included in other income.

(d) Derecognition of financial assets:

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset

When the Company has transferred an asset, the Company evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. In such cases, the financial asset is derecognised. Where the Company has not transferred substantially all risks and rewards of ownership of the financial asset, the financial asset is not derecognised.

Where the Company has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of financial asset, the financial asset is derecognised if the Company has not retained control over the financial asset. Where the Company retains control of the financial asset, the asset is continued to be recognised to the extent of continuing involvement in the financial asset.

(e) Income recognition:

Dividend is accounted when the right to receive payment is established.

(f) Cash and cash equivalents:

Cash and cash equivalents consists of cash on hand, bank balances, short demand deposits and highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of change in value. Short term means investments with original maturities / holding period of three months or less from the date of investments. Bank overdrafts that are repayable on demand and form an integral part of the Company's cash management are included as a component of cash and cash equivalent for the purpose of statement of cash flow.

(g) Investments:

Investments in mutual funds are primarily held for the Company's temporary cash requirements and can be readily convertible in cash. These investments are initially recorded at fair value and classified as fair value through profit or loss.

(h) Trade receivables:

Trade receivables are amounts due from customers for sale of goods or services performed in the ordinary course of business. Trade receivables are initially recognized at its transaction price which is considered to be its fair value and are classified as current assets as it is expected to be received within the normal operating cycle of the business.

3.4.2. Financial liabilities

The Company's financial liabilities include trade payables, loans, borrowing and derivative financial instruments.

(a) Classification:

All the Company's financial liabilities, except for financial liabilities at fair value through profit or loss, are measured at amortised cost.

(b) Initial measurement:

Financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial liabilities (other than financial

liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial liabilities, as appropriate, on initial recognition. Transaction costs that are directly attributable to the acquisition or issue of financial liabilities at fair value through profit or loss are recognised immediately in profit or loss.

(c) Subsequent measurement:

Financial liabilities are subsequently measured at amortised cost using the Effective Interest Rate Method. The Effective Interest Rate Method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the net carrying amount on initial recognition.

(d) Derecognition of financial liabilities:

The Company derecognises financial liabilities when, and only when, the Company's obligations are discharged, cancelled or waived off or have expired. An exchange between the Company and the lender of debt instruments with substantially different terms is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in profit or loss.

(e) Borrowings:

Borrowings are initially recorded at fair value and subsequently measured at amortised costs using effective interest rate method. Transaction costs are charged to statement of profit and loss as financial expenses over the term of borrowing.

(f) Trade payables:

Trade payables are amounts due to vendors for purchase of goods or services acquired in the ordinary course of business and are classified as current liabilities to the extent it is expected to be paid within the normal operating cycle of the business

3.4.3. Derivative Financial Instruments:

The Company enters into derivative financial instruments to manage its foreign exchange rate risk. Derivatives are initially recognized at fair value at the date a derivative contract is entered into and are subsequently re-measured to their fair value at the end of each reporting period. The resulting gain or loss is recognized in profit or loss immediately.

3.5 Leases – Company as lessee

At inception of a contract, the Company assesses whether a contract is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified assets for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset the Company assesses whether contract involves the use of an identified asset, the Company has a right to obtain substantially all of the economic benefits from the use of the asset throughout the period of use and the Company has the right to direct the use of the asset.

At the inception date, right-of-use asset ("ROU") is recognised at cost which includes present value of lease payments adjusted for any payments made on or before the commencement of lease and initial direct cost, if any. It is subsequently measured at cost less accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the lease liability. Right-of-use asset ("ROU") is depreciated using the straight-line method from the commencement date over the earlier of useful life of the asset or the lease term. When the Company has purchase option available under lease and cost of right-of-use assets ("ROU") reflects that purchase option will be exercised, right-of-use asset is depreciated over the useful life of underlying asset. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit and loss.

At the inception date, lease liability is recognised at present value of lease payments that are not made at the commencement of lease. Lease liability is subsequently measured by adjusting carrying amount to reflect interest, lease payments and re-measurement, if any.

Lease payments are discounted using the incremental borrowing rate or interest rate implicit in the lease, if the rate can be determined.

The Company has elected not to apply requirements of Ind AS 116 to leases that has a term of 12 months or less and leases for which the underlying asset is of low value. Lease payments of such lease are recognised as an expense on straight line basis over the lease term.

3.6 Inventories

Inventories are Valued at the lower of cost and net realizable value.

The cost incurred in bringing the inventory to their existing location and conditions are determined as follows:

(a) Raw Material and Packing Material - Purchase cost of materials on FIFO basis.

(b) Finished Goods (Manufactured) and work in progress - Cost of purchase, conversion cost, and other costs attributable to inventories.

(c) Trading goods - Purchase cost on FIFO basis.

The cost of purchase of inventories comprises the purchase price, import duties and other taxes (other than those subsequently recovered by the Company from taxing authorities), and transport, handling and other costs directly attributable to the bringing the inventory to their existing location and conditions. Trade discounts, rebates and other similar items are deducted in determining the costs of purchase.

Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sales. The net realisable value of work-in-progress is determined with reference to the selling prices of related finished products.

The comparison of cost and net realisable value is made on an item-by-item basis.

The Company considers various factors like ageing of inventory, product discontinuation, obsolete items and any other factor which impact the Company's business in determining the allowance for inventories. The Company considers the above factors and adjusts the inventory provision to reflect its actual experience on a periodic basis.

3.7 Impairment of Assets

2.7.1 Financial Assets

At each balance sheet date, the Company assesses whether a financial asset is to be impaired. Ind AS 109 requires expected credit losses to be measured through loss allowance. The Company measures the loss allowance for financial assets at an amount equal to lifetime expected credit losses if the credit risk on that financial asset has increased significantly since initial recognition. If the credit risk on a financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for financial assets at an amount equal to 12-month expected credit losses. Loss allowance for financial assets measured at amortised cost are deducted from gross carrying amount of the assets. The amount of ECL (or reversal) that is required to adjust the loss allowance at the reporting date is recognised as an impairment gain or loss in the Statement of Profit and Loss.

3.7.2 Non-financial Assets

Property, plant and equipment and intangible assets with finite life are evaluated for recoverability whenever there is any indication that their carrying amounts may not be recoverable. If any such indication exists, the recoverable amount (i.e. higher of the fair value less cost to sell or the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the cash generating unit (CGU) to which the asset belongs.

If the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU) is reduced to its recoverable amount. An impairment loss is recognized in the profit or loss to such extent. When an impairment loss subsequently reverses, the carrying amount of the asset (or a cash-generating unit) is increased to the revised estimate of its recoverable amount, such that the increase in the carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss.

2.7.3 Presentation of allowance for ECL in the balance sheet

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets. For debt securities at FVOCI, the loss allowance is charged to profit or loss and is recognised in OCI.

2.7.4 Credit-impaired financial assets

At each reporting date, the Company assesses whether financial assets carried at amortised cost and debt securities at FVOCI are credit-impaired. A financial asset is 'credit-impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit-impaired includes the following observable data:

- significant financial difficulty of the debtor;
- a breach of contract such as a default or being more than 90 days past due;
- the restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;
- it is probable that the debtor will enter bankruptcy or other financial reorganisation; or
- the disappearance of an active market for a security because of financial difficulties.

3.7.5 Write Off

The gross carrying amount of a financial asset is written off when the Company has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof. For individual customers, the Company has a policy of writing off the gross carrying amount when the financial asset is 3 years past due based on historical experience of recoveries of similar assets. For corporate customers, the Company individually makes an assessment with respect to the timing and amount of write-off based on whether there is a reasonable expectation of recovery. The Company expects no significant recovery from the amount written off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

3.8 Employee Benefits

3.8.1 Short term employee benefits

Short term benefits payable before twelve months after the end of the reporting period in which the employees have rendered service are accounted as expense in profit and loss account.

3.8.2 Long term employment benefits

Defined Contribution Plans

Contributions to defined contribution plans (provident fund and other social security schemes) are recognized as expense when employees have rendered services entitling them to such benefits.

Defined Benefit Plans

The Company's net obligation in respect of an approved gratuity plan, which is defined benefit plan, is calculated using the projected unit credit method and the same is carried out by qualified actuary. The current service cost and net interest on the net defined benefit liability (asset) is recognized in the statement of profit and loss. Past service cost are immediately recognized in the statement of profit and loss. Actuarial gains and losses net of deferred taxes arising from experience adjustment and changes in actuarial assumptions are recognized in other comprehensive income in the period in which they arise.

Compensated absences and earned leaves

The Company's current policy permit eligible employees to accumulate compensated absences up to a prescribed limit and receive cash in lieu thereof in accordance with the terms of the policy. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company expects to pay as a result of unused entitlement that has accumulated as at the reporting date. The expected cost of these benefits is calculated using the projected unit credit method by qualified actuary every year. Expense on non-accumulating compensated absences is recognized is the period in which the absences occur.

The liability in respect of all defined benefit plans and other long-term benefits is accrued in the books of account on the basis of actuarial valuation carried out by an independent actuary using the Projected Unit Credit Method. The obligation is measured at the present value of estimated future cash flows. The discount rates used for determining the present value of obligation under defined benefit plans, is based on the market yields on Government securities as at the Balance Sheet date, having maturity periods approximating to the terms of related obligations.

Remeasurement gains and losses in respect of all defined benefit plans arising from experience adjustments and changes in actuarial assumptions are recognised in the period in which they occur, directly in other comprehensive

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

income. They are included in other equity in the Statement of Changes in Equity and in the Balance Sheet. Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognised immediately in profit or loss as past service cost. Gains or losses on the curtailment or settlement of any defined benefit plan are recognised when the curtailment or settlement occurs. Any differential between the plan assets (for a funded defined benefit plan) and the defined benefit obligation as per actuarial valuation is recognised as a liability if it is a deficit or as an asset if it is a surplus (to the extent of the lower of present value of any economic benefits available in the form of refunds from the plan or reduction in future contribution to the plan).

Past service cost is recognised as an expense in the Statement of Profit and Loss on a straight-line basis over the average period until the benefits become vested. To the extent that the benefits are already vested immediately following the introduction of, or changes to, a defined benefit plan, the past service cost is recognised immediately in the Statement of Profit and Loss. Past service cost may be either positive (where benefits are introduced or improved) or negative (where existing benefits are reduced).

3.9 Contingent liabilities, contingent assets and provisions

(a) Contingent liabilities:

A possible obligation that arises from past events and the existence of which will be confirmed only by the occurrence or nonoccurrence of one or more uncertain future events not wholly within the control of the enterprise are disclosed as Contingent liability and not provided for. Such liability is not disclosed if the possibility of outflow of resources is remote.

(b) Contingent assets:

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity. Contingent assets are not recognised and disclosed only when an inflow of economic benefits is probable.

(c) Provisions (other than employee benefits):

A provision is recognized when as a result of a past event, the Company has a present obligation whether legal or constructive that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the obligation is expected to be settled more than 12 months after the end of reporting date or has no definite settlement date, the provision is recorded as non-current liabilities after giving effect for time value of money, if material. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

Provisions, contingent liabilities and contingent assets are reviewed at each Balance Sheet date.

3.10 Government Grant

The Company recognizes government grants at their fair value only when there is reasonable assurance that the conditions attached to them will be complied with, and the grants will be received.

Government grants received in relation to assets are recognised directly to respective assets for which it is received. Government grants, which are revenue in nature are either recognised as income or deducted in reporting the related expense based on the terms of the grant, as applicable.

3.11 Revenue recognition

Revenue is measured based on the transaction price adjusted for discounts and rebates, which is specified in a contract with customer. Revenue are net of estimated returns and taxes collected from customer.

Revenue from sale of goods is recognized at point in time when control is transferred to the customer and it is probable that consideration will be collected. Control is usually transferred upon the shipment, at the time of dispatch, delivery to or upon receipt of goods by the customer, in accordance with the delivery and acceptance terms agreed with the customer.

The transaction price is documented on the sales invoice and payment is generally due as per agreed credit terms with customer.

The consideration can be fixed or variable. Variable consideration is only recognised when it

is highly probable that a significant reversal will not occur.

Revenue from services are recognised as the related services are performed, the contractual performance obligations are satisfied and there is no uncertainty related to the collection of the said revenue.

The Company has concluded that it is the principal in all of its revenue arrangements since it is the primary obligor in all the revenue arrangements as it has pricing latitude and is also exposed to inventory and credit risks.

Export entitlements

Export entitlements are recognised as income when right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

Interest Income

Interest income is recognized using effective interest rate method.

The 'effective interest rate' is the rate that exactly discounts estimated future cash payments or receipts through the expected life of financial instrument to:

- The gross carrying amount of the financial assets; or
- The amortised cost of the financial liabilities

In calculating interest income and expense, the effective interest rate is applied to the gross carrying amount of the asset (when the asset is not credit-impaired) or to the amortised cost of the liability. However, for financial assets that have become credit-impaired subsequent to initial recognition, interest income is calculated by applying the effective interest rate to the amortised cost of the financial asset. If the asset is no longer credit-impaired, then the calculation of interest income reverts to the gross basis.

Estimate of Expected Return

Sales return is variable consideration that is recognised and recorded based on historical experience, market conditions and provided for in the year of sale as reduction from revenue. The methodology and assumptions used to estimate returns are monitored and adjusted regularly in line with trade practices, historical trends, past experience and projected market conditions.

3.12 Income Taxes

Income tax expense comprises current and deferred tax expense. Income tax expenses are recognized in statement of profit or loss, except when they relate to items recognized in other comprehensive income or directly in equity.

Current Tax

Current tax is the tax payable on the taxable profit for the year, using tax rates enacted or substantively enacted by the end of reporting period by the governing taxation laws, and any adjustment to tax payable in respect of previous periods. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred Tax

Deferred taxes arising from deductible and taxable temporary differences between the tax base of assets and liabilities and their carrying amount in the consolidated financial statements are recognized using substantively enacted tax rates and laws expected to apply to taxable income in the years in which the temporary differences are expected to be received or settled.

Deferred tax asset are recognized only to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax assets to be utilized.

Deferred tax assets and liabilities are offset when the Company has a legally enforceable right to do the same.

3.13 Earnings per share

Basic earnings per share is computed by dividing profit or loss attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares.

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

3.14 Research and development

Expenditure on research activities is recognised in profit and loss as incurred. Development expenditure is capitalized as part cost of the resulting intangible asset only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable and the Group intends to and has sufficient resources to complete development and to use or sell the asset. Otherwise, it is recognised in profit and loss as incurred. Subsequent to initial recognition, development expenditure is measured at cost less accumulated amortisation and any accumulated impairment loss.

3.15 Operating Segments

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker (CODM). The CODM of the Company is responsible for allocating resources and assessing performance of the operating segments and accordingly is identified as the Chief Operating Decision Maker (CODM). All operating segments' operating results are reviewed regularly by the CODM to make decisions about resources to be allocated to the segments and assess their performance.

3.16 Share Capital

The paid-up equity capital of the company as on 31st March, 2025 was Rs. 1046.16 Lakhs. The said shares are listed on the BSE Limited and the National Stock Exchange of India Limited. There was no change in the paid-up capital of the company, during the year under audit.

4. Recent Pronouncements

Ministry of Corporate Affairs ('MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year March 31, 2025, MCA has not notified any new standards or amendments to the existing standards applicable to the Company.

5. (A) Property, Plant and Equipment

As at 31 March 2025

(₹ in Lakhs)

Particulars	Freehold Land	Building	Plant & Equipments	Laboratory Equipments	Office Equipments	Furniture & Fixtures	Computers	Vehicles	Total
Gross carrying amount as at 1 April 2024	5,471.11	25,756.78	40,598.20	5,199.45	641.61	2,035.09	763.20	553.66	81,019.10
Additions during the year	828.18	9,776.02	14,092.31	1,479.92	200.03	576.23	244.37	83.19	27,280.25
Disposals during the year	-	-	99.19	-	-	-	-	152.36	251.55
Gross carrying amount as at 31 March 2025	**6,299.29**	**35,532.80**	**54,591.32**	**6,679.37**	**841.64**	**2,611.32**	**1,007.57**	**484.49**	**1,08,047.80**
Accumulated depreciation as at 1 April 2024	-	3,798.87	15,047.88	2,588.42	449.59	967.47	679.55	314.05	23,845.83
Depreciation charge for the year	-	952.68	3,443.87	447.34	67.95	175.71	49.59	93.51	5,230.65
Disposals	-	-	66.93	-	-	-	-	142.25	209.18
Accumulated depreciation as at 31 March 2025	**-**	**4,751.55**	**18,424.82**	**3,035.76**	**517.54**	**1,143.18**	**729.14**	**265.31**	**28,867.30**
Carrying value as at 31 March 2025	**6,299.29**	**30,781.25**	**36,166.50**	**3,643.61**	**324.10**	**1,468.14**	**278.43**	**219.18**	**79,180.50**
Capital work-in-progress									**5,013.10**

As at 31 March 2024

(₹ in Lakhs)

Particulars	Freehold Land	Building	Plant & Equipments	Laboratory Equipments	Office Equipments	Furniture & Fixtures	Computers	Vehicles	Total
Gross carrying amount as at 1 April 2023	5,471.11	24,628.54	39,187.34	4,937.99	633.77	1,971.92	729.02	423.19	77,982.88
Additions during the year	-	1,128.24	1,428.42	289.48	7.84	63.17	34.18	144.05	3,095.38
Disposals during the year	-	-	17.56	28.02	-	-	-	13.58	59.16
Gross carrying amount as at 31 March 2024	**5,471.11**	**25,756.78**	**40,598.20**	**5,199.45**	**641.61**	**2,035.09**	**763.20**	**553.66**	**81,019.10**
Accumulated depreciation as at 1 April 2023	-	2,865.93	11,702.95	2,169.80	369.28	788.06	583.89	250.71	18,730.62
Depreciation charge for the year	-	932.94	3,357.53	434.06	80.31	179.41	95.66	76.22	5,156.13
Disposals	-	-	12.60	15.44	-	-	-	12.88	40.92
Accumulated depreciation as at 31 March 2024	**-**	**3,798.87**	**15,047.88**	**2,588.42**	**449.59**	**967.47**	**679.55**	**314.05**	**23,845.83**
Carrying value as at 31 March 2024	**5,471.11**	**21,957.91**	**25,550.32**	**2,611.03**	**192.02**	**1,067.62**	**83.65**	**239.61**	**57,173.27**
Capital work-in-progress									**21,148.24**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

Notes:

(i) Depreciation for the year includes ₹ 163.04 Lakhs (as at 31 March 2024 ₹ 162.96 Lakhs) for depreciation on Research & Development assets. (Refer Note 41)

(ii) Additions to Property, Plant & Equipment during the year include capital expenditure on Research & Development related activities amounting to ₹ 113.97 Lakhs (as at 31 March 2024 ₹ 241.61 Lakhs). The details of the same are as under:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Factory Building	0.33	-
Plant & Equipments	10.86	22.56
Laboratory Equipment	102.78	216.54
Office Equipment	-	1.26
Furniture & Fixtures	-	1.25
Total	**113.97**	**241.61**

(iii) The immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the Company) are held in the name of the Company.

(iv) Details of property, plant and equipments which are hypothecated/mortgaged as security for borrowings are disclosed under note 18 (i).

(v) The amount of capital commitments is disclosed in Note 34 (a).

(B) Capital work in progress:

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Capital Work-In-Progress	5,013.10	21,148.24
Total	**5,013.10**	**21,148.24**

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Balance at the beginning of the year	21,148.24	17,269.71
Additions during the year	8,892.68	3,878.53
Capitalised during the year	25,027.82	-
Balance at the end of the year	**5,013.10**	**21,148.24**

(i) Capital work in progress ageing schedule as on 31st March,2025

(₹ in Lakhs)

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Projects in Progress	4,578.57	434.53	-	-	5,013.10
As at 31 March 2025	**4,578.57**	**434.53**	**-**	**-**	**5,013.10**

Capital work in progress ageing schedule as on 31st March,2024

(₹ in Lakhs)

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Projects in Progress	3,878.53	13,549.87	3,325.38	394.46	21,148.24
As at 31 March 2024	**3,878.53**	**13,549.87**	**3,325.38**	**394.46**	**21,148.24**

As on date of balance sheet, there are no capital work in progress whose completion is overdue or has exceeded the cost compared to its original plan.

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

There is no project which is temporarily suspended.

CWIP as at 31st March,2025 and 31st March, 2024 mainly includes Plant & Machinery, tools, equipments, buildings for new projects.

(ii) Intangible assets under development ageing schedule as on 31st March,2025

(₹ in Lakhs)

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Projects in Progress	52.60	-	-	-	52.60
Total	**52.60**	**-**	**-**	**-**	**52.60**

Intangible assets under development ageing schedule as on 31st March,2024

(₹ in Lakhs)

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Projects in Progress	-	-	-	-	-
Total	**-**	**-**	**-**	**-**	**-**

As on date of balance sheet, there are no intangible under development whose completion is overdue or has exceeded the cost compared to its original plan.

There is no project which is temporarily suspended.

6 INTANGIBLE ASSETS

As at 31 March 2025

(₹ in Lakhs)

Particulars	Software	Technical Know-How	Total
Gross carrying amount as at 1 April 2024	117.59	1,088.28	1,205.87
Additions during the year	-	59.00	59.00
Disposals during the year	-	-	-
Gross carrying amount as at 31 March 2025	**117.59**	**1,147.28**	**1,264.87**
Accumulated Amortisation as at 1 April 2024	116.33	1,057.57	1,173.90
Amortisation for the year	1.26	30.10	31.36
Disposals during the year	-	-	-
Accumulated depreciation as at 31 March 2025	**117.59**	**1,087.67**	**1,205.26**
Carrying value as at 31 March 2025	**-**	**59.61**	**59.61**

As at 31 March 2024

(₹ in Lakhs)

Particulars	Software	Technical Know-How	Total
Gross carrying amount as at 1 April 2023	117.59	1,042.20	1,159.79
Additions during the year	-	46.08	46.08
Disposals during the year	-	-	-
Gross carrying amount as at 31 March 2024	**117.59**	**1,088.28**	**1,205.87**
Accumulated Amortisation as at 1 April 2023	111.44	1,028.58	1,140.02
Amortisation for the year	4.89	28.99	33.88
Disposals during the year	-	-	-
Accumulated depreciation as at 31 March 2024	**116.33**	**1,057.57**	**1,173.90**
Carrying value as at 31 March 2024	**1.26**	**30.71**	**31.97**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

7 RIGHT-OF USE ASSETS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Right-of use Assets (RoU)	228.43	326.34
Total	**228.43**	**326.34**

LEASE LIABILITIES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Lease Liabilities-Current	195.84	162.08
Lease Liabilities- Non Current	62.98	188.70
Total	**258.82**	**350.78**

A. The Company has taken Office building and warehouse on lease. Disclosures as per Ind AS 116 - Leases are as follows:

The changes in the carrying value of ROU assets for the year ended on 31 March 2025 are as follows :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Opening Balance	313.00	13.34	326.34
Additions during the year	-	89.19	89.19
Deletions/cancellation/modification during the year	-	(11.76)	(11.76)
Amortisation	(156.50)	(18.84)	(175.34)
Balance at the end of the year	**156.50**	**71.93**	**228.43**

The changes in the carrying value of ROU assets for the year ended on 31 March 2024 are as follows :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Opening Balance	-	25.99	25.99
Additions during the year	469.49	-	469.49
Deletions/cancellation/modification during the year	-	-	-
Amortisation	(156.49)	(12.65)	(169.14)
Balance at the end of the year	**313.00**	**13.34**	**326.34**

The aggregate amortisation expense on ROU assets is included under amortisation expense in the Statement of Profit and Loss.

During the previous year the Company had renewed lease agreement for its Head Office on 06 July 2023 for three years. The monthly rent is ₹ 15.32 Lakhs (as at 31 March 2024 ₹ 14.32 Lakhs) with escalation of 7% after completion of each Financial Year.

Extension and termination options are included in some of the lease contracts. These are used to maximise operational flexibility in terms of managing assets used in companies operations.

B. The movement in lease liabilities for the year ended on 31 March 2025 are as follows :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Opening Balance	335.00	15.78	350.78
Additions during the year	-	89.19	89.19
Deletions/cancellation/modification during the year	-	(14.06)	(14.06)
Finance cost accrued during the year	29.65	8.60	38.25
Payment of lease labilities	(183.89)	(21.45)	(205.34)
Balance at the end of the year	**180.76**	**78.06**	**258.82**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

7 RIGHT-OF USE ASSETS (CONTINUED...):

The break-up of current and non-current lease liabilities as on 31 March 2025 is as under :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Current	180.76	15.08	195.84
Non Current	-	62.98	62.98
Total	**180.76**	**78.06**	**258.82**

The movement in lease liabilities for the year ended on 31 March 2024 are as follows :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Opening Balance	-	31.07	31.07
Additions during the year	469.49	-	469.49
Finance cost accrued during the year	41.55	2.53	44.08
Payment of lease labilities	(176.04)	(17.82)	(193.86)
Balance at the end of the year	**335.00**	**15.78**	**350.78**

The break-up of current and non-current lease liabilities as on 31 March 2024 is as under :

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Current	154.24	7.84	162.08
Non Current	180.76	7.94	188.70
Total	**335.00**	**15.78**	**350.78**

C. The details of contractual maturities of lease liabilities as on 31 March 2025 on undiscounted basis are as follows:

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Less than one year	196.76	22.48	219.24
One to five years	-	75.64	75.64
Total	**196.76**	**98.12**	**294.88**

The details of contractual maturities of lease liabilities as on 31 March 2024 on undiscounted basis are as follows:

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Less than one year	183.88	9.08	192.96
One to five years	196.76	9.26	206.02
Total	**380.64**	**18.34**	**398.98**

D. The Company does not face a significant liquidity risk with regard to its lease liabilities as the current assets are sufficient to meet the obligations related to lease liabilities as and when they fall due.

E. The amount recognised in the statement of profit or loss for the year ended 31 March 2025 are as follows:

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Amortisation expense of RoU (Refer Note 30)	156.50	18.84	175.34
Interest expense on lease liabilities (Refer Note 29)	29.65	8.60	38.25
Rent expense*	2.46	-	2.46
Total	**188.61**	**27.44**	**216.05**

*Rent expenses for short-term leases and leases of low value assets (Refer Note 31)

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

The amount recognised in the statement of profit or loss for the year ended 31 March 2024 are as follows:

(₹ in Lakhs)

Particulars	Office Building	Warehouse	Total
Amortisation expense of RoU (Refer Note 30)	156.49	12.65	169.14
Interest expense on lease liabilities (Refer Note 29)	41.55	2.53	44.08
Rent expense*	2.00	-	2.00
Total	**200.04**	**15.18**	**215.22**

*Rent expenses for short-term leases and leases of low value assets (Refer Note 31)

8 INVESTMENTS

(₹ in Lakhs)

Particulars	No. of share / units as at 31 March 2025	No. of share / units as at 31 March 2024	As at 31 March 2025	As at 31 March 2024
(a) Non Current				
(i) Unquoted equity instruments				
Concord Biotech Japan K.K. - In Joint Venture Company at cost:	200	200	66.52	66.52
Add: Share of (Loss) from Joint Venture			7.13	139.34
Net Investment / (Deferred Income)			73.65	205.86
Less: Deferred Income transferred to other current liability (Refer note 23)			-	-
Net Investment accounted using equity method			**73.65**	**205.86**
Note: The net loss related to previous year is mainly on account of unrealised profit of inventory lying with Concord Biotech Japan K.K.				
Reconciliation of closing balance of cumulative share of profit in Joint venture with Concord Biotech Japan K.K.:				
Opening balance (a)			139.34	(197.79)
Share of Profit of current year (b)			(10.59)	81.29
Add/Less: Unrealised profit on closing stock and reversal of Unrealised profit on opening stock (net) (C)			(121.63)	255.84
Share of Profit/ (loss) of Joint venture as per equity method for the year end (d = b + c)			(132.21)	337.13
Closing balance (e = a + d)			**7.13**	**139.34**
Investment in Clean Max Everglades Pvt Ltd (26% of Partners Capital) *	75,956		73.68	-
* The purpose of the agreement is to purchase renewable energy and not for the purpose of investment / business.				
Entity has accounted for the investment in Clean-max everglades Private Limited (inspite of holding 26% of its equity share capital) as investment as per IND AS 109 and not as an associate considering that entity neither has the representation on the board of directors of the investee and nor has the ability to participate in the investee's policy-making processes.				-

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

Particulars		No. of share / units as at 31 March 2025	No. of share / units as at 31 March 2024	As at 31 March 2025	As at 31 March 2024
(ii)	**Quoted Investments in equity security designated as at Fair value through Other Comprehensive Income**				
	Investment in Palvella Therapeutics Inc (0.31% holding)	71,472		1,725.22	-
	Total Non-current Investments			**1,872.55**	**205.86**
	Aggregate carrying value of unquoted investments			147.33	-
	Aggregate carrying value of quoted investments			1,725.22	-
	Aggregate market value of quoted investments			1,725.22	-
(b)	**Current**				
(i)	**Quoted Investments in Mutual Funds measured at Fair value through profit & loss**				
	Edelweiss Arbitrage Fund - Direct Plan - Growth	62,70,431	48,67,121	1,281.92	920.59
	Aditya Birla Sun Life Banking & PSU Debt Fund - Direct Plan - Growth	1,56,941	1,56,941	584.08	538.13
	HDFC Banking & PSU Debt Fund - Direct Growth Option	24,97,216	24,97,216	584.84	538.95
	Kotak Banking and PSU Debt Fund - Direct Growth	8,79,152	8,79,152	585.45	539.43
	SBI Banking & PSU Fund - Direct Growth	18,018	18,018	583.18	537.85
	Aditya Birla Sun Life Corporate Bond Fund - Growth - Direct Plan	1,79,537	-	201.89	-
	Nippon India Overnight Fund - Growth Plan	-	5,00,899	-	640.77
	Axis Strategic Bond Fund - Regular Growth	11,61,353	11,61,353	317.81	292.33
	Franklin India Short Term Income Plan - Retail Plan - Growth	36	36	1.84	1.84
	ICICI Prudential Saving Fund - Direct Plan - Growth	1,16,856	2,96,506	622.27	1,474.15
	Kotak Low Duration Fund Standard Growth - Regular Plan	-	18,324	-	559.30
	Nippon India Corporate Bond Fund - Growth Plan - Growth Option	5,36,413	5,36,413	314.49	289.61
	Nippon India Floating Rate Fund - Direct Growth Plan	17,71,457	17,71,457	821.92	756.74
	Aditya Birla Sun Life Money Manager Fund-Growth- Direct Plan	55,397	-	203.68	-
	ICICI Prudential Corporate Bond Fund-Direct Plan- Growth	9,88,699	-	302.06	-
	Nippon India Money Market Fund - Growth Plan - Growth Option	12,354	-	509.20	-
	SBI Liquid Fund - Regular Growth	3,494	-	140.30	-
	HDFC Low Duration Fund - Direct Plan - Growth Option	-	15,90,086	-	-
	HDFC Ultra Short Term Fund - Direct Growth	-	42,31,052	-	901.32
	Trust MF Banking & PSU Debt Fund - Direct Plan - Growth	-	50,000	-	596.10
	SBI Overnight Fund - Regular Growth	-	7,071	-	584.48

Notes to the **Consolidated Financial Statements** for the year ended 31 March 2025

Particulars	No. of share / units as at 31 March 2025	No. of share / units as at 31 March 2024	As at 31 March 2025	As at 31 March 2024
Aditya Birla Sun Life Short Term Fund - Direct Plan - Growth	15,03,685	7,01,471	756.06	272.15
Axis Short Term Fund - Direct Growth	27,53,388	21,41,030	905.94	324.09
ICICI Prudential Short Term Fund - Direct Plan - Growth	14,17,850	11,03,584	908.29	647.18
Kotak Bond Fund (Short Term) - Direct Plan - Growth	12,57,245	12,57,245	704.64	650.37
Nippon India Short Term Fund - Direct Growth Plan - Growth Option	16,20,879	12,60,923	907.07	647.77
SBI Short Term Debt Fund - Direct Plan - Growth	21,04,886	21,04,886	701.16	648.16
Aditya Birla Sun Life Arbitrage Fund - Direct Plan - Growth	42,00,578	23,36,300	1,181.06	645.77
HDFC Arbitrage Fund - Direct Plan - Wholesale Plan - Growth	58,54,765	50,78,119	1,160.88	608.16
ICICI Prudential Equity Arbitrage Fund - Direct Plan - Growth	50,00,101	42,84,289	1,807.46	932.65
Invesco India Arbitrage Fund - Direct Plan - Growth	50,89,249	35,63,612	1,725.86	1,434.56
Kotak Equity Arbitrage fund - Direct Plan - Growth	1,06,89,446	85,62,387	4,206.59	1,117.94
Nippon India Arbitrage Fund - Direct Growth Plan - Growth Option	49,78,419	54,51,493	1,403.74	3,115.53
SBI Arbitrage Opportunities Fund - Direct Plan - Growth	58,96,072	64,80,485	2,082.08	1,424.81
Tata Arbitrage Fund - Direct Plan - Growth	79,61,074	44,28,525	1,181.47	2,121.31
ICICI PrudentiaL Money Market fund - Direct Plan - Growth	95,359	-	359.18	608.15
Nippon India Liquid Fund- Growth Plan- Growth Option	19,168	-	1,201.59	-
HDFC Corporate Bond Fund - Direct Plan - Growth Option	6,20,867	-	202.04	-
HDFC Liquid Fund- Growth	19,945	-	1,005.21	-
HDFC Money Market Fund - Direct Plan - Growth Option	6,284	-	359.23	-
HDFC Short Term Debt Fund- Direct Growth	18,73,315	-	604.81	-
Axis Money Market Fund Direct Growth	21,955	-	310.87	-
Kotak Money Market Fund- Direct Growth	6,922	-	307.71	-
TATA Money Market Fund - Direct Plan - Growth	13,074	-	616.61	-
Total Investments at FVTPL- Current			**31,654.48**	**24,370.19**
Aggregate carrying value of quoted investments			31,654.48	24,370.19
Aggregate market value of quoted investments			31,654.48	24,370.19

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

9 OTHER FINANCIAL ASSETS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Unsecured, considered good unless otherwise stated		
Non Current		
Security deposits	277.27	215.82
Production Linked Incentive Receivable [Refer Note (iii) below]	110.17	110.17
Bank deposits with maturity more than 12 months [Refer Note (i) below]	1,603.60	99.25
Interest accrued but not due on deposits	-	5.74
Other receivables		
Considered Good	65.37	65.97
Considered Doubtful	226.95	226.95
Less: Loss allowance on other receivables [Refer note (ii) below]	(226.95)	(226.95)
Net Other receivables	65.37	65.97
Total	**2,056.41**	**496.95**

Notes:

(i) Out of total Bank deposits of ₹ 1603.60 lakhs, term deposits amounting to ₹ 1198.09 lakhs (as at 31 March 2024 ₹ 98.16 lakhs) are lodged as margin money against Bank Guarantees and other Commitments.

(ii) Loss allowance of ₹ 226.95 lakhs is made for incentive receivable under Market Access Initiative Scheme(MAI scheme).

(iii) The Company had a short receipt of ₹ 110.17 Lakhs for claim of FY 22-23. The management has written to the respective authority for clarification. The management believes that the said amount is fully recoverable.

10 OTHER NON CURRENT ASSETS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Unsecured, considered good unless otherwise stated		
Prepaid expenses	513.57	-
Capital advances	746.50	797.99
Total	**1,260.07**	**797.99**

11 INVENTORIES*

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
(At lower of Cost and Net Realizable Value)		
(a) Raw materials	7,997.87	6,330.47
(b) Work-in-progress	13,383.01	12,348.02
(c) Finished goods - Including Goods in transit (C.Y. 46.32 Lakhs , P.Y. 162.47 Lakhs)	894.24	402.95
(d) Fuel	78.84	69.75
(e) Stores & Spares	403.54	387.36
(f) Stock in Trade Including Goods in transit (C.Y. 2.49 Lakhs , P.Y. Nil)	1,209.22	1,256.83
Total	**23,966.72**	**20,795.38**

(i)* Inventories are given as security for borrowings as disclosed under note 18(ii).

(il) Finished goods -Inventory write down are accounted, considering the nature of inventory, ageing and net realisable value for ₹ 610.60 Lakhs (as at 31 March 2024 ₹ 678.20 Lakhs). The changes in write downs are recognised as an expense in the statement of Profit and loss.

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

12 TRADE RECEIVABLES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Trade receivables considered good- Unsecured	52,368.47	34,960.89
Trade receivables -credit impaired	114.19	139.07
Less:- Loss Allowance	(317.51)	(139.07)
Total	**52,165.15**	**34,960.89**

(i) The Company's exposure to credit and currency risk, and loss allowances are disclosed in Note 38.

(ii) Includes receivables from related parties [refer note 39 (c)].

(iii) Movements in the expected credit loss allowance:

(₹ in Lakhs)

Particulars	Year ended 31 March 2025	Year ended 31 March 2024
Opening balance	139.07	87.30
Add / (less) : Loss allowance measured at expected credit losses	178.44	51.77
Less: Provision used during the year	-	-
Closing balance	**317.51**	**139.07**

(iv) Trade receivables are given as security for borrowings as disclosed under note 18(ii).

(v) Trade receivables Ageing Schedule:

(₹ in Lakhs)

Particulars	Outstanding for following periods from due date of payment						Total
	Not Due	Less than 6 months	6 months to 1 year	1 to 2 years	2 to 3 years	More than 3 years	
(i) Undisputed Trade Receivables - considered good	34,700.47	14,362.65	1,685.18	736.87	868.62	14.68	52,368.47
(ii) Undisputed Trade Receivables - credit impaired	-	-	-	0.01	3.23	110.95	114.19
Less Loss Allowance	(72.62)	(45.66)	(31.15)	(23.76)	(18.98)	(125.34)	(317.51)
As at 31 March 2025	**34,627.85**	**14,316.98**	**1,654.04**	**713.11**	**852.87**	**0.30**	**52,165.15**
Weighted average loss rate	**0.21%**	**0.32%**	**1.85%**	**3.23%**	**2.18%**	**99.76%**	**0.60%**

(₹ in Lakhs)

Particulars	Outstanding for following periods from due date of payment						Total
	Not Due	Less than 6 months	6 months to 1 year	1 to 2 years	2 to 3 years	More than 3 years	
(i) Undisputed Trade Receivables - considered good	25,727.18	7,084.88	1,649.35	459.59	11.43	28.46	34,960.89
(ii) Undisputed Trade Receivables - credit impaired	-	-	-	57.19	13.36	68.52	139.07
Less Loss Allowance	-	-	-	(57.19)	(13.36)	(68.52)	(139.07)
As at 31 March 2024	**25,727.18**	**7,084.88**	**1,649.35**	**459.59**	**11.43**	**28.46**	**34,960.89**
Weighted average loss rate	**0.00%**	**0.00%**	**0.00%**	**11.07%**	**53.87%**	**70.66%**	**0.40%**

The average credit period on sales of goods is 60-90 days. No interest is charged on outstanding trade receivables.

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

13 CASH AND BANK BALANCES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
(a) Cash and cash equivalents		
Cash on hand	1.89	2.73
Balance with Banks		
In Current accounts	88.56	1,511.48
Total	**90.45**	**1,514.21**
(b) Bank Balances other than cash and cash equivalents		
Bank Deposits with Maturity more than 3 months but less than 12 months [Refer note below]	27.86	2,620.70
Share Escrow Account (Refer note 44)	-	567.53
Total	**27.86**	**3,188.23**

(i) Out of total Bank deposits of ₹ 27.86 Lakhs, Term deposits amounting to ₹ 13.49 Lakhs (as at 31 March 2024 ₹ 338.55 Lakhs) are lodged as margin money against Bank Guarantees and other Commitments.

14 OTHER FINANCIAL ASSETS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Unsecured, considered good unless otherwise stated		
Current		
Subsidy receivable [Refer Note (i) below]	95.93	99.14
Interest Accrued but not due on deposits	-	122.71
Derivative financial instruments	35.78	12.12
Deposits with original maturity over 12 months -Current	1,784.54	-
Insurance claims	10.03	48.18
Security Deposit	309.73	307.42
Export Taxable Under Rebate Claim	670.22	-
Production Linked Incentive Receivable [Refer Note (ii) below]	1,000.00	1,000.00
Export Incentive Receivable	125.84	-
Other Receivables [Refer Note (iii) below]	51.12	355.31
Total	**4,083.19**	**1,944.88**

(i) Company is eligible to get various incentives namely – Capital subsidy, interest subsidy, incentive on power tariff, employment generation incentive subsidy etc. from GSBTM (Gujarat State Biotechnology Mission) under Biotechnology Policy of Gujarat for establishing new API Plant at Limbasi. Company has received claims of subsidies on timely manner from GSBTM. As at 31 March 2025, the Company has outstanding receivable on account of various subsidies as follows - Power Tariff Subsidy ₹ 79.48 Lakhs, Employment Generation Incentive ₹ 16.45 Lakhs (as at 31 March 2024 Interest Subsidy ₹ 14.96 lakhs for interest paid on term loan, Power Tariff Subsidy ₹ 68.59 lakhs , Employment Generation Incentive ₹ 15.59 lakhs).

(ii) The Company is eligible for claiming benefits under the Production Linked Incentive (PLI) Scheme of the Government of India and recognised the PLI income in accordance with the conditions prescribed in the PLI scheme.

(iii) Other receivable includes Nil (as at 31 March 2024 ₹ 336.72 lakhs) of amount recoverable from customer towards bank guarantees invoked.

15 OTHER CURRENT ASSETS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Unsecured, considered good unless otherwise stated		
Advance to Supplier	157.71	765.72
Balances with government authorities	480.65	1,032.98

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

Prepaid expenses	739.12	733.12
Export Incentive Receivable	151.44	311.23
Advances to Employees	7.45	6.28
Total	**1,536.37**	**2,849.33**

16 EQUITY SHARE CAPITAL

(₹ in Lakhs, except per share data)

Particulars	As at 31 March 2025	As at 31 March 2024
Authorised		
11,00,00,000 (Previous Year - 11,00,00,000) equity shares of ₹ 1/- each and 31 March, 2024 ₹ 1/-) [Refer note below]	1,100.00	1,100.00
	1,100.00	**1,100.00**
Issued, Subscribed and fully paid-up		
10,46,16,204 (as at 31 March 2024 - 10,46,16,204) equity shares of ₹ 1/- (as at 31 March 2024 ₹ 1/-) each fully paid up [Refer Note (v) below]	1,046.16	1,046.16
	1,046.16	**1,046.16**

(i) Reconciliation of equity shares outstanding at the beginning and at the end of the reporting year:

(₹ in Lakhs, except per share data)

	As at 31 March 2025		As at 31 March 2024	
Particulars	**Number of Shares**	**in Lakhs**	**Number of Shares**	**in Lakhs**
As at the beginning of the year	10,46,16,204	1,046.16	10,46,16,204	1,046.16
Outstanding at the end of the year	**10,46,16,204**	**1,046.16**	**10,46,16,204**	**1,046.16**

(ii) Terms/rights attached to equity shares with voting rights:

The Company has only one class of equity shares having a par value of ₹ 1 per share. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of the equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts, if any. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

(iii) Details of shareholders holding more than 5% shares in the Company:

(₹ in Lakhs, except per share data)

	As at 31 March 2025		As at 31 March 2024	
Particulars	**No. of shares**	**% of total Shares**	**No. of shares**	**% of total Shares**
Equity Shares of 1 each fully paid				
Mr. Sudhir Jairam Vaid	3,01,69,524	28.84%	3,01,69,524	28.84%
Mrs. Manju Sudhir Vaid	99,87,636	9.55%	99,87,384	9.55%
Nishtha Jhunjhunwala Disc Trust	83,99,732	8.03%	83,99,732	8.03%
Aryavir Jhunjhunwala Disc Trust	83,99,754	8.03%	83,99,754	8.03%
Aryaman Jhunjhunwala Disc Trust	83,99,754	8.03%	83,99,754	8.03%
M/s. Ontario Inc.	20,92,325	2.00%	56,40,536	5.39%

(iv) Shares held by Promoters & Promoters group at the end of the Year:

(₹ in Lakhs, except per share data)

Particulars	As at 31 March 2025		As at 31 March 2024		% of change during the year
	No. of Shares	**% of total Shares**	**No. of Shares**	**% of total Shares**	
Promoters					
Mr. Sudhir Vaid	3,01,69,524	28.84%	3,01,69,524	28.84%	-
Mr. Ankur Vaid	5,86,520	0.56%	5,86,520	0.56%	-

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

Particulars	As at 31 March 2025		As at 31 March 2024		% of change during the year
	No. of Shares	% of total Shares	No. of Shares	% of total Shares	
Promoters Group					
Mrs. Manju Sudhir Vaid	99,87,636	9.55%	99,87,384	9.55%	-
Mrs. Megha Vaid	5,47,008	0.52%	5,47,008	0.52%	-
Mrs. Sonal Kumra	73,920	0.07%	73,920	0.07%	-
Sudman Consultants LLP	47,52,000	4.54%	47,52,000	4.54%	-

(v) Pursuant to the approval of the shareholders at the Extra Ordinary General Meeting of the Company held on 8 July 2022, each equity share of face value of ₹ 10/- per share was sub-divided into 10 equity shares of face value of ₹ 1/- per share and approved the issuance of 1 bonus shares of face value ₹ 1 each for every 10 existing fully paid-up equity share of face value ₹ 1 each and accordingly 95,10,564 bonus shares were issued and allotted on 20 July 2022 out of securities premium.

(vi) No equity shares are issued for consideration other than cash or have been bought back in previous five financial years.

17 OTHER EQUITY

(₹ in Lakhs, except per share data)

Particulars	As at 31 March 2025	As at 31 March 2024
Reserve and Surplus		
Retained Earnings	1,69,106.70	1,40,499.50
General Reserve	2,921.79	2,921.79
Securities premium	8,197.10	8,197.10
Total	**1,80,225.59**	**1,51,618.39**

Nature and purpose of reserves:

(i) General reserve:

The general reserve is used from time to time to transfer profits from retained earnings for appropriation purposes. There is no policy of regular transfer. Items included under General Reserve shall not be reclassified back into the Statement of Profit & Loss.

(ii) Retained Earnings:

Retained Earnings are the profits that the Company has earned till date less any transfer to general reserve, dividends , other distributions to shareholder and remeasurements of definied benefit obligations comprising acturial gains or losses and return on plan assets considering interest income.

(iii) Securities Premium:

This reserve represents Security Premium received at the time of issuance of Equity Shares.

18 BORROWINGS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Non-current		
Secured - at amortised cost		
Term Loan [Refer Note (i) below]	-	622.98
Less: Current maturities of term Loan	-	(622.98)
Total	**-**	**-**
Current borrowing		
Secured - at amortised cost		
Cash Credit Facility [Refer Note (ii) and (iii) below]	38.11	-
Current maturities of long term liabilities	-	622.98
Total	**38.11**	**622.98**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

(i) The Company had availed Term Loan from State Bank of India. Term Loan of ₹ 10,000 lakhs (outstanding amounting as at 31 March 2025 ₹ Nil lakhs, 31 March 2024 ₹ 622.98 lakhs) secured by first charge on Factory Land & Building and Plant & Machinery of Unit-III at Limbasi, Dist. Kheda, (Survey No. 666,667,668 and 84 at Village Malavada and Survey No. 94A,94B,119,120,126,135 and 136 at Ranasar) and charge on the same has been created. Interest rate is 3 months MCLR + 0.20% p.a and loan is repayable in 16 quarterly instalments of ₹ 625 lakhs each starting from October, 2020.

(ii) Short term Borrowings from banks are in nature of working capital facilities which are secured by first pari passu charge on entire current assets of the Company. Interest rate is MCLR + 0.05% and this borrowing is repayable on demand.

(iii) The Company has Fund-based and Non-fund-based limits of Working Capital from Banks. For the said facility,the company is not required to submit quarterly returns with the bank as per sanction letter provided.

19 PROVISIONS

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Non-current		
Employee Benefits		
Provisions for compensated absences (Refer note 36)	281.99	195.61
Total	**281.99**	**195.61**
Current		
Employee Benefits		
Provision for Compensated Absences (Refer note 36)	258.39	184.68
Provision for Gratuity (Refer Note 36)	58.03	42.70
Others		
Provision for Sales Return [Refer note (i) below]	237.58	162.81
Total	**554.00**	**390.19**

Note:

(i) Provision for Sales Returns:

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Opening Balance	162.81	2,542.05
Add: Provision made during the period	215.05	2,853.11
Less: Provision utilised during the period	(140.28)	(5,232.35)
Closing Balance	**237.58**	**162.81**

20 INCOME TAXES

The major component of income tax expense for the years ended 31 March 2025 and 31 March 2024 are as follows:

(₹ in Lakhs)

Particulars	Year ended 31 March 2025	Year ended 31 March 2024
Statement of Profit and Loss		
Current tax	11,896.14	9,983.39
Deferred tax	394.96	462.79
Income tax expense in the Statement of Profit and Loss	**12,291.10**	**10,446.18**
Statement to Other comprehensive income (OCI)		
Income tax relating to fair valuation of investments measured at FVOCI	215.09	-
Income tax relating to re-measurement gain/ (loss) on defined benefit plans	(14.34)	(0.24)
Income tax charge/(credit) recognised in OCI	**200.75**	**(0.24)**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

(a) Reconciliation of tax expense and the accounting profit multiplied by tax rate for the year ended 31 March 2025 and 31 March 2024.

(₹ in Lakhs)

Particulars	Year ended 31 March 2025	Year ended 31 March 2024
Accounting profit before tax	**49,455.33**	**41,256.50**
Tax Rate	25.168%	25.168%
Income tax expense calculated at corporate tax rate	12,446.92	10,383.44
Adjustment		
Tax impact on income charged under capital gain	(324.75)	(8.94)
Tax impact on expenditure not deductible under tax	189.43	148.75
Changes in temporary differences of earlier years	-	3.32
Others	(20.50)	4.46
Total	**12,291.10**	**10,531.03**
Effective tax rate	**24.85%**	**25.53%**

(b) Deferred tax:

The major components of Deferred tax liabilities /(assets) arising on account of timing differences are as follows:

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Deferred tax liabilities		
Property, plant and equipment and intangible assets	3,125.17	2,609.32
Fair Valuation of Investments measured at FVTPL	417.69	442.29
Fair valuation of investments measured at FVOCI	215.09	-
Right of use assets	57.47	-
Total	**3,815.42**	**3,051.61**
Deferred tax assets		
Employee benefit obligations	178.29	120.69
Loss Allowance for trade receivables & other financial assets	140.87	95.97
Provision for expenses allowed for tax purpose on payment basis	28.97	22.35
Lease liabilities	65.12	6.15
Total	**413.25**	**245.16**
Deferred Tax liabilities (Net)	3,402.17	2,806.45
Total	**3,402.17**	**2,806.45**

Movement of deferred tax liabilities / (assets) during the year:

(₹ in Lakhs)

Particulars	For the Year ended 31 March 2025	For the Year ended 31 March 2024
Deferred tax liabilities / (assets) in relation to:		
Property, plant and equipment and intangible assets	514.38	222.26
Fair Valuation of Investments measured at FVTPL	(24.60)	267.12
Fair valuation of investments measured at FVOCI	215.09	-
Lease liabilities	58.97	-
Right of use assets	(58.97)	(4.87)
Employee benefit obligations	(57.61)	(4.24)
Loss Allowance for trade receivables & other financial assets	(44.91)	(16.88)
Provision for expenses allowed for tax purpose on payment basis	(6.63)	(0.84)
Total	**595.72**	**462.55**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

(I) There are certain income-tax related legal proceedings which are pending against the Company. Potential liabilities, if any have been adequately provided for, and the Company does not currently estimate any probable material incremental tax liabilities in respect of these matters. Refer note 34 (b).

(ii) The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

(iii) The Tax rate used for Financial Year 2024-25 and 2023-24, in reconciliation above is the corporate tax rate of 25.168% payable by corporate entity in India on taxable profits under the Indian Tax Law.

(C) Non-Current tax asset / (Current tax Liabilities)

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Provision for Income Tax	(11,957.55)	(29,344.46)
Advance payment of Tax	11,122.53	29,062.20
Total	**(835.02)**	**(282.26)**

(D) Income Tax Balances (Net)

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Income tax assets (Net)	177.66	267.12
Current tax liabilities (net)	1,012.68	549.38
Total	**(835.02)**	**(282.26)**

21 TRADE PAYABLES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Total outstanding dues of micro enterprises and small enterprises	595.24	961.54
Total outstanding dues of creditors other than micro enterprises and small enterprises	10,708.74	8,481.99
Total	**11,303.98**	**9,443.53**

(a) Trade Payables Ageing Schedule:

(₹ in Lakhs)

Particulars	Not Due	Outstanding for following periods from due date of payment				Total
		Less than 1 Year	1 to 2 years	2 to 3 years	More than 3 years	
(i) MSME	463.83	17.56	48.34	34.25	31.26	595.24
(ii) Others	7,137.95	3,109.77	275.33	157.45	28.24	10,708.74
(iii) Disputed Dues MSME	-	-	-	-	-	-
(iv) Disputed Dues -Other	-	-	-	-	-	-
As at 31 March 2025	**7,601.77**	**3,127.33**	**323.67**	**191.70**	**59.50**	**11,303.98**

(₹ in Lakhs)

Particulars	Not Due	Outstanding for following periods from due date of payment				Total
		Less than 1 Year	1 to 2 years	2 to 3 years	More than 3 years	
(i) MSME	926.96	34.58	-	-	-	961.54
(ii) Others	7,218.80	1,159.85	13.83	13.16	76.35	8,481.99
(iii) Disputed Dues MSME	-	-	-	-	-	-
(iv) Disputed Dues -Other	-	-	-	-	-	-
As at 31 March 2024	**8,145.76**	**1,194.43**	**13.83**	**13.16**	**76.35**	**9,443.53**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

(b) Disclosure under the Micro, Small and Medium Enterprises Development Act (MSMED), 2006

(₹ in Lakhs)

Particulars		Year Ended 31 March 2025	Year Ended 31 March 2024
(i)	Principal amount and the interest due thereon remaining unpaid to each supplier at the end of each accounting year (but within due date as per the MSMED Act)		
	- Principal amount due to micro and small enterprise	597.20	848.82
	- Interest due on above	1.86	3.08
(ii)	Interest paid by the Company in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along-with the amount of the payment made to the supplier beyond the appointed day during the period.	-	-
(iii)	Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the period) but without adding interest specified under the Micro, Small and Medium Enterprises Act, 2006.	112.72	109.64
(iv)	The amount of interest accrued and remaining unpaid at the end of each accounting year.	114.58	112.72
(v)	Interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises.	114.58	112.72

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Company. This has been relied upon by the auditors.

22 OTHER FINANCIAL LIABILITIES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Interest accrued but not due on borrowings	-	10.39
Payables for employee benefits	1,312.84	1,183.71
Security Deposits	10.00	10.00
Payable to customers	2,251.35	-
Unpaid Dividend	5.26	-
Payable to selling shareholders and others (Refer note 44)	-	714.19
Payable on purchase of Property, Plant and Equipment *	590.34	502.34
Total	**4,169.79**	**2,420.63**

Payable on purchase of Property, Plant and Equipment includes total outstanding dues of Micro enterprise and samll enterprises of ₹ 116.54 lakhs(as at 31 March 2024 Nil)

23 OTHER CURRENT LIABILITIES

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Payable to Statutory and other authorities	291.39	260.59
Contract liabilities	840.47	366.16
Total	**1,131.86**	**626.75**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

24 REVENUE FROM OPERATIONS

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Revenue From contracts with customers		
Sale of Goods (at point in time)	1,17,840.33	99,532.52
Sale of Services (at point in time)	141.45	273.21
	1,17,981.78	**99,805.73**
Other Operating Revenue		
Export benefits	1,026.91	888.19
Production Linked Incentive Income [Refer note 14 (ii)]	1,000.00	1,000.00
	2,026.91	**1,888.19**
Total	**1,20,008.69**	**1,01,693.92**

(a) Disaggregate revenues from contracts with customers :

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Domestic	66,183.16	53,420.94
Exports	53,825.53	48,272.98
Total	**1,20,008.69**	**1,01,693.92**

(b) Disaggregate revenues from contracts with customers based on products:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Active Pharmaceutical Ingredient (API)	94,009.07	82,802.78
Formulations	25,999.62	18,891.14
Total	**1,20,008.69**	**1,01,693.92**

There are no transactions with a single customer which amounts to 10% or more of the Company's revenue.

(c) Reconciliation of Revenue from operations with contract price:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Contract Price	1,20,399.39	1,04,568.26
Less : Adjustment made to contract price on account of:		
Provision for Sales Return	(215.05)	(2,853.11)
Others - rate difference	(175.65)	(21.23)
Total	**1,20,008.69**	**1,01,693.92**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

(d) Contract Balances

The following table provides information about receivables,contract assets and contract liabilities from contracts with customers

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Receivables, which are included in 'trade receivables'	**52,165.15**	**34,960.89**
Contract assets	-	-
Contract liabilities	840.47	366.16

The amount of 366.16 lakhs as at 31 March 2024 has been recognised as revenue during the year ended 31 March 2025. (31 March 2024 ₹ 155.51 lakhs)

(e) Unsatisfied or partially satisfied performance obligation

Revenue to be recognised in future related to the performance obligations that are unsatisfied or partially satisfied as at 31st March, 2025 and expected to be recognised within one year is of ₹ 840.47 lakhs and for more than one year is Nil.

25 OTHER INCOME

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Interest income		
From Bank (under the effective interest method)	164.33	304.11
On income tax refund	6.19	-
On investment	0.49	-
Other Gain and Losses		
Net gain on sale of investments	1,360.57	345.14
Net gain on Investments in Mutual Funds measured at FVTPL	865.80	1,061.33
Net foreign exchange gain	819.84	648.05
Other Non Operating Income		
Subsidy income	791.94	764.69
Insurance claim Received	0.09	14.14
Net profit on sale of Property, plant & equipment	-	1.19
Testing Fees Income	-	111.43
Excess provision no longer required written back	273.24	3.81
Miscellaneous income	162.18	124.11
Total	**4,444.67**	**3,378.00**

26 COST OF MATERIALS CONSUMED

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Raw materials including packing materials at the beginning of the year	6,330.47	8,042.87
Add: Purchases	28,098.66	16,741.31
	34,429.13	**24,784.18**
Less: Raw materials including packing materials at the end of the year	7,997.87	6,330.47
Total	**26,431.26**	**18,453.71**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

27 CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Opening stock		
Finished goods	402.95	548.49
Stock-in-trade	1,256.83	931.70
Work-in-progress	12,348.02	11,319.82
	14,007.80	**12,800.01**
Less : Closing stock		
Finished goods	894.24	402.95
Stock-in-trade	1,209.22	1,256.83
Work-in-progress	13,383.01	12,348.02
	15,486.47	**14,007.80**
Total changes in inventories of finished goods, work-in-progress and stock-in-trade		
Finished goods	(491.29)	145.54
Stock-in-trade	47.61	(325.13)
Work-in-progress	(1,034.99)	(1,028.20)
Total changes in inventories of finished goods, work-in-progress and stock-in-trade	**(1,478.67)**	**(1,207.79)**

28 EMPLOYEE BENEFITS EXPENSE:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Salaries, wages and bonus	13,007.78	11,479.16
Contribution to provident and other funds	684.92	632.39
Staff welfare expenses	200.66	193.12
Total	**13,893.36**	**12,304.67**

29 FINANCE COSTS

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
(a) Interest expense on borrowings		
- Term Loan	9.30	183.90
- Cash Credit/Over Draft	5.38	21.41
(b) Interest on lease liabilities (Refer Note 7)	38.25	44.08
Total interest expense for financial liabilities carried at amortized cost	**52.93**	**249.39**
Interest on Income tax	-	5.80
Total	**52.93**	**255.19**

30 DEPRECIATION AND AMORTIZATION

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Depreciation of property, plant and equipment (Refer Note 5)	5,230.65	5,156.13
Amortisation of intangible assets (Refer Note 6)	31.36	33.88
Depreciation of right of use assets (Refer Note 7)	175.34	169.14
Total	**5,437.35**	**5,359.15**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

31 OTHER EXPENSES

(₹ in Lakhs)

Particulars		Year Ended 31 March 2025	Year Ended 31 March 2024
(a)	**Power & Fuel**		
	Power & Fuel Consumed	11,223.02	10,496.87
Total		**11,223.02**	**10,496.87**
(b)	**Others**		
	Consumption of stores and spare parts	1,219.25	1,241.19
	Laboratory Charges & Testing Expenses	2,117.04	1,881.88
	Repairs & Maintenance	1,398.26	1,558.56
	Rent, Rates & Taxes	1,102.98	855.81
	Insurance Expense	253.62	312.94
	Bank Charges	51.24	63.21
	Travelling and conveyance	1,105.65	994.04
	Communication, IT and Stationery Expenses	259.60	223.28
	Payment to Auditors (Refer Note-33)	30.55	46.19
	Legal & Professional Fees	744.84	530.46
	Directors Sitting Fee	24.10	30.50
	Selling, Distribution and Advertisement Expenses	3,455.18	3,310.96
	Net loss on sale of Property, plant & equipment	22.47	-
	Loss allowance	178.44	51.77
	Corporate Social Responsibilities Expense (Refer Note 35)	620.11	590.33
	Membership & Subscription	69.60	64.76
	Security Service Charges	212.64	217.45
	Effluent Treatment Plant Charges	537.39	616.30
	Safety & Environment Charges	17.38	23.13
	Miscellaneous Expense	287.51	204.10
Total		**13,707.85**	**12,816.86**

32 EARNINGS PER SHARE (EPS)

(₹ in Lakhs)

Particulars		Year Ended 31 March 2025	Year Ended 31 March 2024
Basic and Diluted EPS			
(A)	Net profit after tax before other comprehensive income as per standalone statement of profit and loss (₹ in lakhs) (A)	37,164.23	30,810.32
(B)	Weighted average number of equity shares considered for calculation of EPS	10,46,16,204	10,46,16,204
(C)	Basic and Diluted Earning Per Share (₹) (A/B)	35.52	29.45
(D)	Nominal Value of equity share (₹)	1.00	1.00

33 PAYMENT TO AUDITORS

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
For Audit Fees	24.25	37.55
For Certification fees	5.00	7.71
For Other fees	0.85	-
For Reimbursement of expense	0.45	0.93
Total	**30.55**	**46.19**

Company has paid fees of ₹ Nil (as at 31 March 2024 ₹ 77.25 Lakhs) for issuing various reports and certificates in connection with the completed initial public offering (IPO) during the previous year. This expenses have been recovered from the selling shareholders and are not included in the above information.

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

34 COMMITMENTS AND CONTINGENCIES

(a) Commitments

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Estimated amount of contracts remaining to be executed on capital account and not provided for in respect of the Property, Plant & Equipment (Net of Advances)	2,276.01	1,244.29
Total	**2,276.01**	**1,244.29**

(b) Contingent liabilities

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Claims against the Company / disputed liabilities not acknowledged as debts:		
Disputed demand of Excise duty for which an appeal has been preferred	376.37	376.37
- The Company has preferred Appeal to Income Tax Appellate Tribunal (ITAT) against order received from Assessing officer in respect of short payment of Excise duty, non reversal of input credit		
Disputed demand of Income Tax in which company has preferred Appeal or filed rectification with Department :	14.61	1,054.56
- The Company has preferred Appeal to CIT(A) against order received from Assessing officer in respect of disallowance of additional depreciation in A.Y. 2013-14. Appeal order was received but effect order is pending		
- The Company has preferred Appeal to CIT(A) against order received from Assessing officer in respect of Penalty imposed u/s 271(1)(C) in A.Y. 2015-16 & 2016-17. Appeal order was received but effect order is pending		
- The Company has preferred Appeal to CIT(A) against order received from Assessing officer in respect of disallowance of Purchase of Raw Material in A.Y. 2016-17		
- The Company has preferred Appeal to CIT(A) against order received from Assessing officer in respect of disallowance of u/s 35(2)(AB) and Rule 8D r.w.s 14A in A.Y. 2018-19. Appeal order was received but effect order is pending		
- The Company has filed rectification with Assessing officer against intimation received from CPC regarding payment of Dividend Distribution Tax for A.Y. 2020-21. The Company has also filed Appeal to CIT(A) against order received from Assessing officer in respect of disallowance u/s Rule 8D r.w.s 14A in A.Y. 2020-21 and regarding not granting credit of payment of Dividend Distribution Tax. Appeal order was received but effect order is pending.		
Total	**390.98**	**1,430.93**

(i) It is not practicable for the Company to estimate the timing of cash outflows, if any, in respect of the above pending litigations of the respective proceedings.

(ii) The Company does not expect any reimbursements in respect of the above contingent liabilities.

(iii) The Company believes that the ultimate outcome of these proceedings will not have a material adverse effect on the Company's financial position and results of operations. These demands are with respect to income tax and service tax matters for which appeals have been filed.

(iv) The Company has ongoing disputes with various tax authorities (income tax,and excise) in India. The Company have disclosed contingent liability as above, respectively, in respect of various tax demands, which are being contested by the Company based on the management evaluation and advice of tax consultants.

(v) The amounts as assessed contingent liability do not include interest and penalty that could be claimed by counter parties.

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

35 CORPORATE SOCIAL RESPONSIBILITIES

Amount spent towards CSR activities during the year are as follows:

(₹ in Lakhs)

Particulars		Year Ended 31 March 2025	Year Ended 31 March 2024
(i)	Gross Amount required to be spent by the Company during the year	631.59	572.30
(ii)	Amount approved by the board to be spent during the year	631.59	572.30
(iii)	Amount spent during the year on	620.11	590.33
	(a) Construction or acquisation of any asset	-	-
	(b) On purpose other than (a) above	620.11	590.33
(iv)	Excess spent on CSR activities up to immediately preceeding three financial years	21.33	
(v)	Excess / (Shortfall) at the end of the year	9.85	18.03
(vi)	Total of previous years shortfall	-	-
(vii)	Reason for shortfall	Not Applicable	Not Applicable
(viii)	Nature of CSR activities	Medical, Educational, Environmental sustainability, Promoting sports, Social, Rural Development	Medical, Educational, Environmental sustainability, Promoting sports, Social, Rural Development
(ix)	details of related party transactions, e.g., contribution to a trust controlled by the Company in relation to CSR expenditure as per relevant Accounting Standard	Not Applicable	Not Applicable
(x)	where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year shall be shown separately.	Not Applicable	Not Applicable

36 EMPLOYEE BENEFITS PLANS:

(a) Defined contribution plans:

The Company makes contributions towards provident fund, a defined contribution retirement benefit plan for qualifying employees. The provident fund is operated by the Regional Provident Fund Commissioner. The Company recognized ₹ 549.45 Lakhs (Previous Year ₹ 500.34 Lakhs) for provident fund contributions in the Statement of Profit and Loss. The contributions payable to these plans by the company are at rates specified in the rules of the scheme.

(b) Defined benefit plans:

The Company makes annual contributions to the Employee's Group Gratuity cash accumulation scheme of the LIC, a funded defined benefit plan for qualifying employees. The Scheme provides for payment to vested employees at retirement/death while in employment or on termination of employment as per the provisions of the Payment of Gratuity Act, 1972. Vesting occurs on completion of 5 years of service. The present value of the defined benefit obligation and the related current service cost are measured using the Projected Unit Credit Method as per actuarial valuation carried out at the balance sheet date.

Characteristics of Defined Benefit Plans and risk associated with them:

Valuation of defined benefit plan are performed on certain basic set of pre-determined assumptions and other regulatory framework, which may vary over time. Thus, Company is exposed to various risks in providing the above benefit plans which are as follows:

(i) Interest rate risk:

The plan exposes the Company to the risk of fall in interest rates. A fall in interest rates will result in an increase in the ultimate cost of providing the above benefit and will thus result in an increase in the value of the liability (i.e. value of defined benefit obligation).

(ii) Salary escalation risk:

The present value of the defined benefit plan is calculated with the assumption of salary increase rate of plan particulars in future. Deviation in the rate of increase of salary in future for plan participants from the rate of increase in salary used to determine the present value of obligation will have a bearing on the plan's liability.

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

(iii) Demographic risk:

The Company has used certain mortality and attrition assumptions in valuation of the liability. The Company is exposed to the risk of actual experience turning out to be worse compared to the assumptions.

(iv) Investment risk:

The Company has funded with LIC fund, there is no significant investment risk. Further the present value of the defined benefit plan liability is calculated using a discount rate which is determined by reference to market yields at the end of the reporting period on government bonds. If the return on plan asset is below this rate, it will create a plan deficit. Currently, for the plan in India, it has a relatively balanced mix of investments in government securities, and other debt instruments.

The following table sets out the status of the gratuity plan as required under Ind AS-19 and the amounts recognized in the Company's financial statements as at 31 March 2025:

(₹ in Lakhs)

Particulars		As at 31 March 2025	As at 31 March 2024
i.	**Reconciliation of Opening and Closing Balances of defined benefit obligation:**		
	Liability at the beginning of the Year	877.91	760.15
	Current Service Cost	124.13	119.88
	Interest Cost	62.95	55.87
	Benefits paid	(82.83)	(52.77)
	Actuarial (Gains)/Losses on Obligations - Due to Change in Demographic Assumptions	(33.53)	(26.97)
	Actuarial (Gains)/Losses on Obligations - Due to Change in Financial Assumptions	20.22	6.20
	Actuarial (Gains)/Losses on Obligations - Due to Experience	66.94	15.56
	Liability at the end of the Year	**1,035.79**	**877.91**
ii.	**Reconciliation of Opening and Closing Balances of the Fair value of Plan assets:**		
	Plan assets at the beginning of the Year, at Fair value	835.21	702.48
	Expected return on plan assets	59.88	51.63
	Contributions	168.84	140.06
	Benefit paid	(82.83)	(52.77)
	Actuarial gain/(loss) on plan assets	(3.34)	(6.19)
	Plan assets at the end of the Year, at Fair Value	**977.76**	**835.21**
iii.	**Present value of defined benefit obligation and Fair value of plan assets:**		-
	Obligations at the end of the Year	1,035.79	877.91
	Plan assets at the end of the Year, at Fair value	(977.76)	(835.21)
	Liability recognized in balance sheet at the end of the Year	**58.03**	**42.70**
iv.	**Expense recognised in the statement of profit and loss for the year**		
	Current Service Cost	124.13	119.88
	Interest Cost	62.95	55.87
	Expected returns on plan assets	(59.88)	(51.63)
	Total	**127.19**	**124.12**
v.	**Expense recognised in the other comprehensive income for the year**		
	Actuarial (gain)/loss on obligation for the period	53.63	(5.22)
	Return on planned asset, excluding Interest Income	3.34	6.19
	Total	**56.98**	**0.97**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

vi.	Actuarial Assumptions		
	Discount Rate (per annum)*	6.54%	7.17%
	Expected rate of return on plan assets**	6.54%	7.17%
	Salary Escalation***	9.00%	9.00%
	Attrition Rate	22.00%	16.70%
	Weighted average duration of defined benefit obligation	5 Years	5 Years
	Retirement Age	58 Years	58 Years
	Mortality Rate	Indian Assured Lives Mortality (2012-14) Urban	**Indian Assured Lives Mortality (2012-14) Urban**

* The discount rate is based on the prevailing market yields of government of India securities as at the balance sheet date for the estimated term of the obligations.

**Expected rate of return on plan assets is determined based on the nature of assets and prevailing economic scenario.

*** The estimate of future salary increases considered, takes into account inflation, seniority, promotion, increments and other relevant factors.

vii. Sensitivity Analysis for each significant actuarial assumption:

The significant actuarial assumptions for the determination of the defined benefit obligations are discount rate and expected salary increase. The sensitivity analysis below have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Projected Benefit Obligation on Current Assumptions	**1,035.79**	**877.91**
Impact of increase in discount rate by 1 %	(31.66)	(33.22)
Impact of decrease in discount rate by 1 %	34.12	36.30
Impact of increase in salary escalation rate by 1 %	30.75	32.99
Impact of decrease in salary escalation rate by 1 %	(29.21)	(30.91)
Impact of increase in employee turnover rate by 1 %	(6.61)	(5.33)
Impact of decrease in employee turnover rate by 1 %	6.91	5.60

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligations as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the defined benefit obligations has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

viii. Investment details of plan assets:

The plan assets are managed by Insurance Company viz Life Insurance Corporation of India who has invested the funds substantially as under:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Insurance Fund - investment in LIC policy	977.76	835.21

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

ix. Balance Sheet Reconciliation

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Opening Net Liability	**42.70**	**57.67**
Expense Recognized in Statement in profit or Loss	127.19	124.12
Expenses Recognized in OCI	56.98	0.97
Employer Contribution	(168.84)	(140.06)
Net Liability/(Asset) recognised in the balance sheet	**58.03**	**42.70**

x. Maturity Profile

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
1st Following Year	218.48	158.30
2nd Following Year	171.91	126.81
3rd Following Year	161.53	122.08
4th Following Year	156.93	109.16
5th Following Year	121.98	116.08
Sum of Years 6 to 10	332.37	344.01
Sum of Years 11 and above	155.81	261.58

xi. Expected contribution during the next annual reporting period

The Company's best expected contribution during the next year is ₹ 186.47 Lakhs.

(c) Compensated absences:

Actuarial Valuation for Compensated Absences is done as at the year end and the provision is made based on leave balances derived as per Company's Rules with corresponding charge to the Statement of Profit and Loss amounting to ₹ 260.99 Lakhs (as at 31 March 2024 ₹ 55.25 Lakhs) and it covers all regular employees. Major drivers in actuarial assumptions, typically, are years of service and employee compensation.

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Actuarial Assumptions		
Discount Rate (per annum)*	6.54%	7.17%
Salary Escalation***	9.00%	9.00%
Attrition Rate	22.00%	16.70%

37 The Company has taken various derivatives to hedge its risk associated with foreign exchange fluctuations. These transactions have been undertaken to act as economic hedges for the Company's exposures to various risks in foreign exchange markets. Forward exchange contracts (being derivative instruments), which are not intended for trading or speculative purposes but for hedge purposes are entered, which are available at the settlement date of certain payables and receivables.

(₹ in Lakhs)

Particulars	As at 31 March 2025		As at 31 March 2024	
	Amount (in Lakhs)	Amount (in Lakhs)	Amount (in Lakhs)	Amount (in Lakhs)
Hedging of Trade Receivables	-	-	-	-
Forward Contracts	USD 41.08	3,510.29	USD 72.46	6,041.35

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

The details of foreign currency exposures not hedged by derivative instruments are as under:

(₹ in Lakhs)

Particulars	As at 31 March 2025		As at 31 March 2024	
	Amount (in Lakhs)	Amount (in Lakhs)	Amount (in Lakhs)	Amount (in Lakhs)
Trade Receivables	USD 170.06	14,531.60	USD 81.07	6,759.21
	EURO 11.37	1,049.66	EURO 11.04	992.00
	JPY 2411.64	1,374.15	JPY 1231.99	678.16
	RUB 12.60	12.97	RUB 114.13	100.16
	CAD 0.01	0.74	CAD 0.01	0.75
	AED 8.90	207.12	-	-
Trade Payables	USD 53.40	4,563.01	USD 15.27	1,273.14

38 FINANCIAL INSTRUMENTS: FAIR VALUE AND RISK MANAGEMENT

(i) Categories of Financial instruments: Financial assets and liabilities

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Financial Assets :		
Amortised cost		
Trade receivables	52,165.15	34,960.89
Cash and Cash equivalents	90.45	1,514.21
Bank Balances other than cash and cash equivalents	27.86	3,188.23
Other Financial Assets	6,103.82	2,429.71
Fair value through profit or loss		
Non-current Investment - Investments in Clean Max Everglades Pvt Ltd	73.68	-
Current Investment - Investments in Mutual Funds	31,654.48	24,370.19
Derivative instruments	35.78	12.12
Fair value through other comprehensive income		
Non-current Investment - Investments in Palvella Therapeutics Inc	1,725.22	-
Total	**91,876.44**	**66,475.35**
Financial Liabilities :		
Amortised cost		
Borrowings (including current maturities)	38.11	622.98
Lease Liability	258.82	350.78
Trade payables	11,303.98	9,443.53
Other Financial Liabilities	4,169.79	2,420.63
Fair value through profit or loss		
Derivative instruments	-	-
Total	**15,770.70**	**12,837.92**

(ii) Fair value hierarchy :

The fair values of the financial assets and liabilities are determined based on the price that would be received to sell an asset or paid to transfer a liability at the reporting date considering the fair value hierarchy as under:

Level 1: It includes financial instruments measured using quoted prices. This includes listed equity instruments that have quoted price. The fair value of all equity instruments which are traded in the stock exchanges is valued using the closing price as at the reporting period.

Level 2: The fair value of financial instruments that are not traded in an active market (for example, traded bonds, over-the counter derivatives) is determined using valuation techniques which maximize the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities, contingent consideration and indemnification asset included in level 3.

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

38 FINANCIAL INSTRUMENTS: FAIR VALUE AND RISK MANAGEMENT: (CONTINUED..)

Fair value hierarchy

The following tables categorise the financial assets and liabilities held at fair value by the valuation methodology applied in determining their fair value.

(₹ in Lakhs)

As at 31 March 2025	Level 1	Level 2	Level 3	Total
Financial Assets :				
Investment in Mutual Funds	31,654.48	-	-	31,654.48
Investment - Investments in Palvella Therapeutics Inc	1,725.22	-	-	1,725.22
Investment - Investments in Clean Max Everglades Pvt Ltd			73.68	73.68
Derivative financial assets	-	35.78	-	35.78

(₹ in Lakhs)

As at 31 March 2024	Level 1	Level 2	Level 3	Total
Financial Assets :				
Investment in Mutual Funds	24,370.19	-	-	24,370.19
Derivative financial assets	-	12.12	-	12.12

Determination of fair values:

Basis of assumptions used to estimated the fair value of financial assets and liabilities that are measured at fair value on recurring basis :

Investment in Mutual Funds: The fair values represent net asset value as stated by the issuers of these mutual fund units in the published statements. Net asset values represent the price at which the issuer will issue further units in the mutual fund and the price at which issuers will redeem such units from the investors.

Derivative instruments: For forward contracts, future cash flows are estimated based on forward exchange rates and forward interest rates (from observable forward exchange rates / yield curves at the end of the reporting period) and contract forward exchange rates and forward interest rates, discounted at a rate that reflects the credit risk of various counterparties.

Derivative instruments are financial contracts that derive their value from an underlying asset. Their main purpose is to mitigate financial risk and protect against price volatility. Given the uncertainties associated with export revenue from the sale of goods, company has engaged into derivative instruments, to hedge their risk against price fluctuations and safeguard their financial stability.

(iii) Financial Risk Management

The Company's activities are exposed to variety of financial risks. These risks include market risk (including foreign currency risk, interest rate risks and price risk), credit risks and liquidity risk. The Company's overall risk management program seeks to minimize potential adverse effects on the financial performance of the Company through established policies and processes which are laid down to ascertain the extent of risks, setting appropriate limits, controls, continuous monitoring and its compliance.

A Market Risk :

Market risk refers to the possibility that changes in the market rates may have impact on the Company's profits or the value of its holding of financial instruments. The Company is exposed to market risks on account of foreign currency rates, interest rates and underlying equity prices.

A1 Foreign currency risk :

The Company's foreign currency risk arises from its foreign currency transactions and foreign currency borrowings. The fluctuation in foreign currency exchange rates may have potential impact on the income statement and equity, where any transaction references more than one currency or where assets/liabilities are denominated in a currency other than the functional currency of the company.

The overall objective of the foreign currency risk management is to minimize the short term currency impact on its revenue and cash-flow in order to improve the predictability of the financial performance.

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

38 FINANCIAL INSTRUMENTS: FAIR VALUE AND RISK MANAGEMENT: (CONTINUED..)

The major foreign currency exposures for the Company are denominated in USD. Additionally, there are transactions which are entered into in other currencies and are not significant in relation to the total volume of the foreign currency exposures. The Company hedges some trade receivables and future cash flows upto a maximum of 6 months forward based on historical trends, budgets and monthly sales estimates.

The following table sets forth information relating to foreign currency exposure:

(₹ in Lakhs)

As at 31 March 2025	US Dollars	Others*	Total
Assets :			
Trade and other receivables	18,041.89	2,644.64	20,686.52
Total	**18,041.89**	**2,644.64**	**20,686.52**
Liabilities :			
Trade and other payables	4,563.01	-	4,563.01
Total	**4,563.01**	**-**	**4,563.01**
Net Balance (Assets - Liabilities)	**13,478.87**	**2,644.64**	**16,123.51**

(₹ in Lakhs)

As at 31 March 2024	US Dollars	Others*	Total
Assets :			
Trade and other receivables	12,800.56	1,771.07	14,571.63
Total	**12,800.56**	**1,771.07**	**14,571.63**
Liabilities :			
Trade and other payables	1,273.14	-	1,273.14
Total	**1,273.14**	**-**	**1,273.14**
Net Balance (Assets - Liabilities)	**11,527.42**	**1,771.07**	**13,298.49**

*Others mainly includes currencies namely Ruble, Euro and Japanese Yen.

Foreign currency sensitivity

The following tables demonstrate the sensitivity to a reasonably possible change in USD rates to the functional currency of entity, with all other variables held constant. The Company's exposure to foreign currency changes for all other currencies is not material. The impact on the Company's profit after tax is due to changes in the fair value of monetary assets and liabilities.

(₹ in Lakhs)

Particulars	Effect on profit before tax	Changes in USD rate	Equity effect net of tax
As at 31 March 2025	199.37	+2%	149.19
	(199.37)	-2%	(149.19)
As at 31 March 2024	109.72	+2%	82.11
	(109.72)	-2%	(82.11)

A2 Interest rate risk :

Interest rate risk refers to the possibility that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rate. The Company is exposed to fluctuations in interest rates in respect of term loan carrying a floating rate of interest. In respect of term loan, the Company has outstanding borrowing of ₹ 38.11 lakhs as at 31 March, 2025 (As at 31 March 2024: ₹ 622.98 lakhs) The following table demonstrates the sensitivity to a reasonable possible change on interest rates on that position of borrowing affected. with all other variables held constant, the Company's profit before tax is affected through the impact on floating rate of borrowing as follows:

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

38 FINANCIAL INSTRUMENTS: FAIR VALUE AND RISK MANAGEMENT: (CONTINUED..)

(₹ in Lakhs)

Particulars	Effect on profit before tax	Equity effect net of tax
As at 31 March 2025		
Increase by 50 basis points	-	-
Decrease by 50 basis points	-	-
As at 31 March 2024		
Increase by 50 basis points	(3.11)	(2.33)
Decrease by 50 basis points	3.11	2.33

A3 Price Risk :

Price risk is the risk that the value of the financial instrument will fluctuate as a result of changes in market prices which arises on account of movement in interest rates, liquidity and credit quality of underlying securities. The primary goal of the Company's investment in mutual funds is to hold investments for short term for strategic purpose. Management monitors their performance and they are managed on fair value basis. Further there is no price risk for investment in Clean Max Everglades Pvt Ltd.

(₹ in Lakhs)

Particulars	Effect on profit before tax	Equity effect net of tax
As at 31 March 2025		
Increase by 2% in prices of investment	667.59	499.57
Decrease by 2% in prices of investment	(667.59)	(499.57)
As at 31 March 2024		
Increase by 2% in prices of investment	487.40	364.73
Decrease by 2% in prices of investment	(487.40)	(364.73)

B Credit Risk :

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its operating activities (primarily trade receivables) and from its financing activities, including deposits with banks and financial institutions and other financial instruments.

The Company establishes a loss allowance that represents its estimate of expected losses in respect of trade receivables. The maximum exposure to credit risk as at reporting date is from trade receivables amounting to ₹ 317.51 Lakhs (March 31, 2024: ₹ 139.07 Lakhs). The movement in loss allowance in respect of trade receivables during the year was as follows:

(₹ in Lakhs)

Movement in expected credit loss allowance on trade receivable	Year Ended 31 March 2025	Year Ended 31 March 2024
Opening Balance	139.07	87.30
Add:- Loss Allowance	178.44	51.77
Closing Balance	**317.51**	**139.07**

There are no trade receivables accounting for more than 10% of the Company's total trade receivables as at 31 March 2025 and 31 March 2024. Refer note 12 for ageing of trade receivables.

(₹ in Lakhs)

Movement in expected credit loss allowance on trade receivable	Year Ended 31 March 2025	Year Ended 31 March 2024
Opening Balance	226.95	226.95
Add:- Loss Allowance	-	-
Closing Balance	**226.95**	**226.95**

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

38 FINANCIAL INSTRUMENTS: FAIR VALUE AND RISK MANAGEMENT: (CONTINUED..)

(₹ in Lakhs)

Movement in expected credit loss allowance on trade receivable	As on 31 March 2025	As on 31 March 2024
Not due	34,627.85	25,727.18
0-6 months	14,316.98	7,084.88
6 months-1 year	1,654.04	1,649.35
1-2 year	713.11	459.59
2-3 years	852.87	11.43
Greater than 3 years	0.30	28.46
Expected credit Losses rate	**0.60%**	**0.40%**
Amount of expected credit loss provided for	**317.51**	**139.07**

C Liquidity Risk :

Liquidity risk refers to the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company generates cash flows from operations to meet its financial obligations, maintains adequate liquid assets in the form of cash & cash equivalents and has undrawn short term line of credits from banks to ensure necessary liquidity.

Contractual maturities of significant financial liabilities are as below:

(₹ in Lakhs)

As at 31 March 2025	Less than 1 year	Between 1-2 years	Between 2 - 5 years	More than 5 years	Total
Borrowings	38.11	-	-	-	38.11
Lease Liabilities	195.84	62.98	-	-	258.82
Trade payables	11,303.98	-	-	-	11,303.98
Other financial Liabilities	4,169.79	-	-	-	4,169.79
Total	**15,707.72**	**62.98**	**-**	**-**	**15,770.70**

(₹ in Lakhs)

As at 31 March 2024	Less than 1 year	Between 1-2 years	Between 2 - 5 years	More than 5 years	Total
Borrowings	622.98	-	-	-	622.98
Lease Liabilities	162.08	187.55	1.15	-	350.78
Trade payables	9,443.53	-	-	-	9,443.53
Other financial Liabilities	2,420.63	-	-	-	2,420.63
Total	**12,649.22**	**187.55**	**1.15**	**-**	**12,837.92**

(iv) Capital Management

The capital structure of the Company consists of equity and debt. The Company's objective for capital management is to maintain the capital structure which will support the Company's strategy to maximize shareholder's value, safeguarding the business continuity and help in supporting the growth of the Company.

The Company monitors capital using gearing ratio, which is net debt (total debt less Cash and cash equivalents) divided by total equity.

Gearing Ratio

(₹ in Lakhs)

Particulars	As at 31 March 2025	As at 31 March 2024
Total borrowings (Refer Note 18)	38.11	622.98
Less: Cash and cash equivalents [Refer Note 13(a)]	90.45	1,514.21
Net Debt (A)	**(52.34)**	**(891.23)**
Total Equity (B)	**1,81,271.75**	**1,52,664.55**
Gearing Ratio (C=A/B)	**-0.03%**	**-0.58%**

39 RELATED PARTY TRANSACTIONS

(a) List of related parties and relationship

(₹ in Lakhs)

Key Management Personnel (KMP):	Mr. Sudhir Vaid, Chairman & Managing Director	Mr. Amitabh Thakore, Independent Director
	Mr. Ankur Vaid, Joint Managing Director & CEO	Mrs. Bharti Khanna, Independent Director
	Mr. Utpal Sheth, Non-executive Director (upto 30 Sept, 2023)	Mr. Anil Katyal, Independent Director (Upto 25 August, 2023)
	Mr. Amit Varma, Non-executive Director (Upto 19 August, 2023)	Mr. Arvind Agarwal, Independent Director
	Mr. Rajiv Ambrish Agarwal, Non-executive Director	Mr. Jayaram Easwaran, Independent Director
	Mr. Ravi Kapoor, Non-executive Director	Mr. Mandayam Chakravarthy Sriraman, Independent Director
	Mr. Lalit Sethi, Chief Financial Officer	
	Mr. Prakash Sajnani, AVP - Finance & Company Secretary	
Relative of Key Management Personnel:	Mrs. Manju Vaid	Mrs. Megha Vaid
	Col. S. K. Vaid	Mrs. Sonal Kumra
Enterprises controlled by / under significantly influenced by Directors and/or their relatives:	Sudman Consultants LLP	Ravi Kapoor & Associates
Joint Venture:	Concord Biotech Japan K.K.	

(b) Transaction with related parties:

(₹ in Lakhs)

Types of Transactions	Key Management Personnel		Relatives of Key Management Personnel		Joint Venture		Enterprises controlled by / under significantly influenced by Directors and/or their relatives:		Total	
	Year Ended 31 March 2025	Year Ended 31 March 2024	Year Ended 31 March 2025	Year Ended 31 March 2024	Year Ended 31 March 2025	Year Ended 31 March 2024	Year Ended 31 March 2025	Year Ended 31 March 2024	Year Ended 31 March 2025	Year Ended 31 March 2024
Remuneration Paid:										
Mrs. Megha Vaid	-	-	87.50	76.76	-	-	-	-	87.50	76.76
Mrs. Sonal Kumra	-	-	96.66	84.79	-	-	-	-	96.66	84.79
Total	**-**	**-**	**184.16**	**161.55**	**-**	**-**	**-**	**-**	**184.16**	**161.55**
Compensation to Key Managerial Person:										
Short term benefits	1,113.76	920.49							1,113.76	920.49
Post employment benefits	106.93	-							106.93	-
Total	**1,220.69**	**920.49**	**-**	**-**	**-**	**-**	**-**	**-**	**1,220.69**	**920.49**

Professional Fees:										
Ravi Kapoor & Associates	-	-	-	-	-	-	27.50	27.95	27.50	27.95
Col. S. K. Vaid	-	-	55.42	55.42	-	-	-	-	55.42	55.42
Total	**-**	**-**	**55.42**	**55.42**	**-**	**-**	**27.50**	**27.95**	**82.92**	**83.37**
Rent paid:										
Mr. Sudhir Vaid	139.22	130.11	-	-	-	-	-	-	139.22	130.11
Mrs. Manju Vaid	-	-	44.67	41.74	-	-	-	-	44.67	41.74
Total	**139.22**	**130.11**	**44.67**	**41.74**	**-**	**-**	**-**	**-**	**183.89**	**171.85**
Sale of Products:										
Concord Biotech Japan K.K.	-	-	-	-	3,035.14	4,305.98	-	-	3,035.14	4,305.98
Total	**-**	**-**	**-**	**-**	**3,035.14**	**4,305.98**			**3,035.14**	**4,305.98**
Dividend Paid:										
Mr. Sudhir Vaid	2,639.83	2,060.58	-	-	-	-	-	-	2,639.83	2,060.58
Mrs. Manju Vaid	-	-	873.90	682.14	-	-	-	-	873.90	682.14
Mr. Ankur Vaid	51.32	40.06	-	-	-	-	-	-	51.32	40.06
Mrs. Megha Vaid	-	-	47.86	37.36	-	-	-	-	47.86	37.36
Mrs. Sonal Kumra		-	6.47	5.05	-	-	-	-	6.47	5.05
Mr. Ravi Kapoor	18.38	15.03	-	-	-	-	-	-	18.38	15.03
Mr. Rajiv Ambrish Agarwal	11.42	8.91	-	-	-	-	-	-	11.42	8.91
Mr. Prakash Sajnani	1.93	1.50	-	-	-	-	-	-	1.93	1.50
Sudman Consultants LLP	-	-	-	-	-	-	415.80	324.56	415.80	324.56
Mr. Arvind Agarwal	0.10	-	-	-	-	-	-	-	0.10	-
Total	**2,722.97**	**2,126.08**	**928.23**	**724.55**	**-**	**-**	**415.80**	**324.56**	**4,067.00**	**3,175.19**

(c) Outstanding Balances with related parties

(₹ in Lakhs)

Types of Transactions	Key Management Personnel		Relatives of Key Management Personnel		Joint Venture		Enterprises controlled by / under significantly influenced by Directors and/or their relatives:		Total	
	As at 31 March 2025	As at 31 March 2024	As at 31 March 2025	As at 31 March 2024	As at 31 March 2025	As at 31 March 2024	As at 31 March 2025	As at 31 March 2024	As at 31 March 2025	As at 31 March 2024
Payables for employee benefits:										
Mrs. Megha Vaid	-	-	3.71	3.45	-	-	-	-	3.71	3.45
Mrs. Sonal Kumra	-	-	3.94	3.39	-	-	-	-	3.94	3.39
Total	**-**	**-**	**7.65**	**6.84**	**-**	**-**	**-**	**-**	**7.65**	**6.84**
Amount Payables (in respect to Compensation to Key Managerial Person)										
Short term benefits	49.71	40.65	-	-	-	-	-	-	49.71	40.65
Post employment benefits	106.93	-	-	-	-	-	-	-	106.93	-
Total	**156.64**	**40.65**	**-**	**-**	**-**	**-**	**-**	**-**	**156.64**	**40.65**
Trade Payables:										
Ravi Kapoor & Associates	-	-	-	-	-	-	-	2.06	-	2.06
Col. S. K. Vaid	-	-	4.99	4.99	-	-	-	-	4.99	4.99
Total	**-**	**-**	**4.99**	**4.99**	**-**	**-**	**-**	**2.06**	**4.99**	**7.05**
Trade receivables:										
Concord Biotech Japan K.K.	-	-	-	-	1,374.15	678.15	-	-	1,374.15	678.15
Total	**-**	**-**	**-**	**-**	**1,374.15**	**678.15**	**-**	**-**	**1,374.15**	**678.15**

1. Outstanding balance at the year end are unsecured and interest free and settlement occurs through bank.
2. Company has not provided any commitment to the related party as at 31 March 2025 (P.Y -Nil)
3. The Company has neither made any provision nor written off / written back any balances pertaining to related parties.
4. All above transactions are in the normal course of business and are made on terms equivalent to those that prevail arm's length transactions.

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

40 OPERATING SEGMENT

The chief operational decision maker monitors the operating results of its Business segment separately for the purpose of making decision about resource allocation and performance assessment. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the financial statements. Operating segment have been identified on the basis of nature of products and other quantitative criteria specified in the Ind AS 108.

The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment for the purpose of making decision on allocation of resources and assessing its performance.

Geographical segment

Geographical segment is considered based on sales within India and outside India. In outside India, company separately disclosed sales to America and Others.

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
i) Segment Revenue		
Revenue from Operations [*]		
(a) Within India	66,183.16	53,420.94
(b) Outside India		
(i) United States of America	13,797.36	10,798.23
(ii) Others	40,028.17	37,474.75
Total Revenue from Operations	**1,20,008.69**	**1,01,693.92**
ii) Non Current operating assets [**]:		
(a) Within India	87,593.21	79,477.81
(b) Outside India	-	-
(i) United States of America	-	-
(ii) Others	-	-
(c) Unallocable [***]	66.52	**66.52**
Total Non Current operating assets	**87,659.73**	**79,544.33**

[*] The revenue information above is based on the locations of the customers.

[**] Non Current Operating Assets for this purpose consist of property, plant and equipment, capital work-in-progress, intangible assets, right-of use assets and investment in joint venture, Investment in Palvella Therapeutics Inc and Clean Max Everglades Pvt Ltd.

[***] Non Current Investment in Concord Biotech Japan K.K. is considered as unallocable.

Information about major customers:

There are no customers accounting for more than 10% of the Revenue in the year ended 31 March 2025 and Previous year 31 March 2024.

41 RESEARCH & DEVELOPMENT

The Company's facility is approved for Research & Development by Department of Science & Industrial Research (DSIR). The Company has incurred expenditure of revenue nature on Research & Development, details of which are as under:

(₹ in Lakhs)

Particulars	Year Ended 31 March 2025	Year Ended 31 March 2024
Cost of Materials Consumed	493.25	391.21
Salaries & Wages	1,171.27	1,088.43
Power & Fuel	198.25	90.57
Depreciation	163.04	162.96
Other Expenses	688.07	528.20
Total	**2,713.87**	**2,261.37**

Notes to the **Consolidated Financial Statements** for the year ended 31 March 2025

42 DISCLOSURE REQUIREMENT AS PER SCHEDULE III

(i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

(ii) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

(iii) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

(iv) The Company has not advanced or loaned or invested funds to any other person(s) or entity(is), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

(v) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(vi) The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

(vii) The Company is not declared as wilful defaulter by any bank or financial institution (as defined under the Companies Act, 2013) or consortium thereof or other lender in accordance with the guidelines on wilful defaulters issued by the Reserve Bank of India.

(viii) The Company has not revalued any of its Property, Plant and Equipment (including Right-of-Use Assets) during the year.

(ix) The Company doesn't have any co-owned properties or the properties (including properties for which the lease agreement executed and disclosed as 'Right-of-Use Assets' in restated consolidated financial information) title deed of which are held by the others.

(x) The Company has not granted any Loans or Advances in the nature of loans to promoters, Directors, KMPs and the related parties (as defined under Companies Act, 2013), either severally or jointly with any other person.

(xi) The Company has used the borrowings from the banks for its intended purpose during the financial year.

(xii) The Company did not have any transaction with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the current and previous financial year.

(xiii) The Company has complied with number of layers prescribed under the Companies Act,2013.

(xiv) The Company has not entered in to any scheme of arrangement which has an accounting impact on current or previous financial year.

(xv) Ratio Analysis

(₹ in Lakhs)

Name		Numerator	Denominator	Year Ended 31 March 2025	Year Ended 31 March 2024	% Variance	Reason
(a)	Current Ratio (in times)	Total current assets	Total current liabilities	6.17	6.30	-2.09%	-
(c)	Debt Service Coverage Ratio (DSCR) (in times)	Earning for Debt Service = Net Profit after taxes + Depreciation and Amortisation expenses + Interest	Debt service = Interest and lease payments + Principal repayments	59.84	13.52	342.57%	DSCR has increased due to increase in profitability for the year and repayment of entire borrowings in current year.
(d)	Return on Equity / Return on Net worth Ratio (in %)	Profit for the year	Average total equity	22.00%	22.00%	0.00%	-
(e)	Inventory turnover ratio (in times)	Cost of goods sold	Average inventory	1.37	1.09	26.33%	Due to increase in cost of goods sold and corresponding increase in sales let to increase in inventory turnover ratio.
(f)	Trade Receivables turnover ratio (in times)	Revenue from contract with customers	Average trade receivables	2.71	3.20	(15.20%)	-
(g)	Trade payables turnover ratio (in times)	Purchases of materials and & purchase of stock-in-trade	Average trade payables	3.25	2.38	36.55%	Due to improvement in payment cycle in current year.
(h)	Net capital turnover ratio (in times)	Revenue from operations	Average working capital (i.e. Total current assets less Total current liabilities)	1.26	1.35	(6.67%)	-
(i)	Net profit ratio (in %)	Profit for the year	Revenue from operations	31.00%	30.00%	3.33%	-
(j)	Return on Capital employed (in %)	Profit before tax and finance costs (excl. Interest expense on lease liabilities)	Capital employed = Tangible Net worth + Total Borrowings + Deferred tax liabilities	27.00%	27.00%	0.00%	-
(k)	Return on investment (in %)	Income generated from invested funds	Average invested funds in treasury investments	8.00%	8.00%	0.00%	

Notes to the Consolidated Financial Statements for the year ended 31 March 2025

43 The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment had released draft rules for the Code on Social Security, 2020 on November 13, 2020, and invited suggestions from stakeholders which are under consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified. The Company will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.

44 During the previous year ended March 31, 2024, the Company's equity shares had been listed on National Stock Exchange ("NSE") and on BSE Limited ("BSE") on August 18, 2023, by completing Initial Public Offering ("IPO") through offer for sale ("OFS") of 2,09,25,652 equity shares of face value of ₹ 1 each at an issue price of ₹ 741 per equity share by Helix Investment Holdings Pte Limited, Singapore ("selling shareholder").

The Company had received proceeds in the share escrow account amounting to ₹ 1,55,052.08 Lakhs out of which ₹ 1,48,814.66 Lakhs paid to selling shareholders and ₹ 5,669.89 Lakhs to various parties for initial public offer expenses. The company has paid all dues to the parties for initial public offer expenses.

The Company has receivable balance of share issue expenses in connection with the public offer of equity shares amounting to ₹ NIL (as at March 2024 : ₹ NIL). As per the Offer Agreement entered between the Company and the selling shareholders, the selling shareholders shall reimburse the share issue expenses except for the listing fees which has been solely borne by the Company. Accordingly, the Company has recovered the expenses incurred in connection with the Issue on completion of IPO during the current year.

The Company's payable balance to selling shareholders and various parties for initial public offer expenses has been disclosed under the Note 22 Other financial liabilities as "Payable to selling shareholders and others".

Being 100% offer for sale, the Company has not presented the utilization of the proceeds of IPO. There is no unutilised amount as on March 31, 2025.

45 DISCLOSURE FOR MAINTENANCE OF BOOKS OF ACCOUNTS WITH AUDIT TRAIL

The Ministry of Corporate Affairs (MCA) has issued a notification dated 24 March 2021 (Companies(Accounts) Amendments Rules, 2021) which is effective from 1 April 2023, states that every Company which uses accounting software for maintaining its books of account shall use only such accounting software which has a feature of recording audit trail of each and every transaction, and further creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled.

In respect of accounting software, the Company has advanced version of the accounting software having feature of recording audit trail of each and every transaction, and creating an edit log of each change made along with the date when such changes were made and also audit trail cannot be disabled. Further, other than the period where audit trail was not enabled in the previous year, the audit trail has been preserved by the Company as per the statutory requirements for record retention.

46 EVENTS AFTER THE REPORTING PERIOD:

(₹ in Lakhs)

Sr No.	Name of Entity	Country of Incorporation	Activities	% of Ownership Interest As at 31 March 2024	% of Ownership Interest As at 31 March 2023	Accounting Method	Carrying Amounts	
							As at 31 March 2025	As at 31 March 2024
	Joint Venture							
1	Concord Biotech Japan K.K.	Japan	Pharmaceutical	50%	50%	Equity Method	73.65	**205.86**

*There is no contingent liability in the books of Concord Biotech Japan K.K.

47 ADDITIONAL INFORMATION PURSUANT TO SCHEDULE III OF COMPANIES ACT, 2013

(₹ in Lakhs)

Name of Entity	For the financial year ending on as at 31 March 2025							
	Net Assets i.e. Total Assets minus Total Liabilities		Share in Profit or (loss)		Share in other Comprehensive Income		Share in Total Comprehensive Income	
	As a % of consolidated net assets	Amount	As a % of consolidated profit / (loss)	Amount	As a % of consolidated OCI	Amount	As a % of consolidated Total Comprehensive Income / (loss)	Amount
Parent								
Concord Biotech Limited	100.00%	1,81,271.75	100.36%	37,296.43	100.00%	596.89	100.35%	37,893.32
Joint Venture								
Concord Biotech Japan K.K	0.00%	-	-0.36%	-132.21	0.00%	-	-0.35%	(132.21)
Grand Total	**100.00%**	**1,81,271.75**	**100.00%**	**37,164.23**	**100.00%**	**596.89**	**100.00%**	**37,761.11**

(₹ in Lakhs)

Name of Entity	For the financial year ending on as at 31 March 2024							
	Net Assets i.e. Total Assets minus Total Liabilities		Share in Profit or (loss)		Share in other Comprehensive Income		Share in Total Comprehensive Income	
	As a % of consolidated net assets	Amount	As a % of consolidated profit / (loss)	Amount	As a % of consolidated OCI	Amount	As a % of consolidated Total Comprehensive Income / (loss)	Amount
Parent								
Concord Biotech Limited	100.00%	1,52,664.55	98.91%	30,473.18	100.00%	(0.73)	98.91%	30,472.46
Joint Venture								
Concord Biotech Japan K.K	0.00%	-	1.09%	337.13	0.00%	-	1.09%	337.13
Grand Total	**100.00%**	**1,52,664.55**	**100.00%**	**30,810.32**	**100.00%**	**(0.73)**	**100.00%**	**30,809.59**

Notes to the **Consolidated Financial Statements** for the year ended 31 March 2025

48 EVENTS AFTER THE REPORTING PERIOD:

The board of directors have recommended final dividend of ₹ 10.70/- per fully paid up equity share of ₹ 1/- each for financial year ended March 31, 2025 on outstanding paid up share capital of the company as on date, in its board meeting held on May 29, 2025, subject to approval of shareholders at ensuing annual general meeting of the Company.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No : 101248W/W-100022

Rupen Shah
Partner
Membership No. : 116240

Place: Ahmedabad
Date: 29 May 2025

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Ankur Vaid
Joint Managing Director & CEO
DIN: 01857225

Lalit Sethi
Chief Financial Officer

Prakash Sajnani
Asst. Vice President - Finance & Company Secretary

Place: Ahmedabad
Date: 29 May 2025

NOTES

CONCORD BIOTECH

Biotech for Mankind...

Concord Biotech Limited
16th Floor, B-Wing, Mondeal Heights
Iscon Cross Road, S.G. Highway
Ahmedabad - 380015, Gujarat, India

P: +91 79 68138700
F: +91 2714 222504
E: complianceofficer@concordbiotech.com